Orange Book Cumulative Supplement 7 July 2017

CUMULATIVE SUPPLEMENT 7 JULY 2017

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

Department of Health and Human Services Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy

2017

Prepared By Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

Cumulative Supplement 7 July 2017

CONTENTS

PAGE

1.0 INTRODUCTION ...... v 1.1 How to use the Cumulative Supplement ...... v 1.2 Cumulative Supplement Content ...... vi 1.3 Applicant Name Changes ...... vii 1.4 Levothyroxine Sodium...... vii 1.5 Availability of the Edition ...... viii 1.6 Report of Counts for the Prescription Drug Product List ...... ix 1.7 Cumulative Supplement Legend ...... x

DRUG PRODUCT LISTS Prescription Drug Product List ...... 1-1 OTC Drug Product List ...... 2-1 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List ...... 3-1 Orphan Product Designations and Approvals List ...... 4-1 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ...... 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Patent and Exclusivity Lists ...... A-1 B. Patent and Exclusivity Terms ...... B-1

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

CUMULATIVE SUPPLEMENT 7 July 2017

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons. The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists. Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.) Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List. New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item. New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item. The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

• Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

• All product changes received and processed as of the date of publication. o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

• New Drug Application (NDA) approvals appear in the CS month they were approved.

• Patent information, also updated daily in the EOB, is current to the date of publication.

• Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [email protected].

mail to: FDA/CDER Orange Book Staff Office of Generic Drugs 7620 Standish Place Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME NEW APPLICANT NAME (FORMER ABBREVIATED NAME) (NEW ABBREVIATED NAME)

JAI PHARMA LTD MYLAN LABORATORIES LTD (JAI PHARMA LTD) (MYLAN LABS LTD)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

vii

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharmas NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name Applicant Strength TE Code Appl No Product No UNITHROID STEVENS J 0.025MG AB1 021210 001 LEVOTHYROXINE MYLAN 0.025MG AB1 076187 001 SODIUM LEVOXYL KING PHARMS 0.025MG AB1 021301 001 SYNTHROID ABBVIE 0.025MG AB1 021402 001 LEVO-T ALARA PHARM 0.025MG AB1 021342 001

SYNTHROID ABBVIE 0.025MG AB2 021402 001 LEVOTHYROXINE MYLAN 0.025MG AB2 076187 001 SODIUM LEVO-T ALARA PHARM 0.025MG AB2 021342 001 UNITHROID STEVENS J 0.025MG AB2 021210 001

LEVOXYL KING PHARMS 0.025MG AB3 021301 001 LEVO-T ALARA PHARM 0.025MG AB3 021342 001 UNITHROID STEVENS J 0.025MG AB3 021210 001 LEVOTHYROXINE MYLAN 0.025MG AB3 076187 001 SODIUM

LEVOTHYROXINE MYLAN 0.025MG AB4 076187 001 SODIUM

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

viii

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED DEC 2016 MAR 2017 JUN 2017 SEP 2017 DEC 2017

DRUG PRODUCTS 18130 18391 18711 LISTED SINGLE 2646 2688 2708 SOURCE (14.6%) (14.6%) (14.5%) MULTISOURCE 15484 15703 16003

(85.4%) (85.4%) (85.5%)

THERAPEUTICALLY 15335 15581 15882

EQUIVALENT (84.7%) (84.7%) (84.9%)

NOT THERAPEUTICALLY 129 122 121

EQUIVALENT (0.7%) (0.7%) (0.6%)

1 EXCEPTIONS 73 73 73

(0.4%) (0.4%) (0.4%)

NEW MOLECULAR 7 14 17 ENTITIES APPROVED

NUMBER OF 1051 1053 1050 APPLICANTS

1Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA New drug product approval usually in the supplement month. CAHN** Applicant holder firm name has changed. CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. CDFR Change. Dosage Form; Route of Administration. CFTG Change. A first time generic for the innovator product. A TE Code is added. CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status. CMS1 Change. Miscellaneous addition to list. CMS2 Change. Miscellaneous deletion from list. CPOT Change. Potency amount/unit. CRLD Change. Reference Listed Drug. CHRS Change. Reference Standard. CTEC Change. Therapeutic Equivalence Code. CTNA Change. Trade Name. DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note: The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

PRESCRIPTION DRUG PRODUCT LIST - 37TH EDITION RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -1

ABACAVIR SULFATE; LAMIVUDINE TABLET;ORAL ABACAVIR SULFATE AND LAMIVUDINE AB AUROBINDO PHARMA LTD EQ 600MG BASE;300MG A 206151 001 Mar 28, 2017 Mar NEWA AB CIPLA LTD EQ 600MG BASE;300MG A 091144 001 Mar 28, 2017 Mar NEWA AB LUPIN LTD EQ 600MG BASE;300MG A 204990 001 Mar 28, 2017 Mar NEWA

ABALOPARATIDE SOLUTION;SUBCUTANEOUS TYMLOS +! RADIUS HEALTH INC 3.12MG/1.56ML (2MG/ML) N 208743 001 Apr 28, 2017 Apr NEWA

ABIRATERONE ACETATE TABLET;ORAL ZYTIGA + JANSSEN BIOTECH 500MG N 202379 002 Apr 14, 2017 May NEWA

ACAMPROSATE CALCIUM TABLET, DELAYED RELEASE;ORAL ACAMPROSATE CALCIUM AB ZYDUS PHARMS USA INC 333MG A 205995 001 May 26, 2017 May NEWA

ACETAMINOPHEN SOLUTION;IV (INFUSION) ACETAMINOPHEN AP CUSTOPHARM INC 1GM/100ML (10MG/ML) A 202605 001 Jun 13, 2016 Jan CAHN

ACETAMINOPHEN; BUTALBITAL TABLET;ORAL BUTALBITAL AND ACETAMINOPHEN AA TEDOR PHARMA INC 300MG;50MG A 207635 001 Jun 05, 2017 May NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AB TEDOR PHARMA INC 300MG;50MG;40MG A 206615 001 Aug 04, 2017 Jul NEWA TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE AA ACTAVIS LABS UT INC 325MG;50MG;40MG A 088616 001 Nov 09, 1984 Apr CTNA AA MALLINCKRODT INC 325MG;50MG;40MG A 087804 001 Jan 24, 1985 Mar CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> @ ALLIED PHARMA INC 120MG/5ML;12MG/5ML A 086366 001 Jul CAHN >D> @ ROXANE 120MG/5ML;12MG/5ML A 086366 001 Jul CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN AA ABHAI LLC 300MG;5MG A 209036 001 Jun 21, 2017 Jun NEWA AA 300MG;7.5MG A 209036 002 Jun 21, 2017 Jun NEWA AA 300MG;10MG A 209036 003 Jun 21, 2017 Jun NEWA AA 325MG;5MG A 209037 001 Jun 21, 2017 Jun NEWA AA 325MG;7.5MG A 209037 002 Jun 21, 2017 Jun NEWA AA 325MG;10MG A 209037 003 Jun 21, 2017 Jun NEWA AA AMNEAL PHARMS NY 300MG;5MG A 206869 001 Jun 23, 2017 Jun NEWA AA LANNETT HOLDINGS INC 300MG;5MG A 207171 001 Jun 20, 2017 Jun NEWA AA 300MG;7.5MG A 207171 002 Jun 20, 2017 Jun NEWA AA 300MG;10MG A 207171 003 Jun 20, 2017 Jun NEWA AA 325MG;5MG A 207172 001 Jun 22, 2017 Jun NEWA AA 325MG;7.5MG A 207172 002 Jun 22, 2017 Jun NEWA AA 325MG;10MG A 207172 003 Jun 22, 2017 Jun NEWA AA MALLINCKRODT INC 300MG;5MG A 206718 001 Mar 31, 2017 Mar NEWA AA 300MG;7.5MG A 206718 002 Mar 31, 2017 Mar NEWA AA 300MG;10MG A 206718 003 Mar 31, 2017 Mar NEWA AA ! MIKART 300MG;7.5MG A 040658 002 Mar 24, 2006 May CHRS AA 300MG;7.5MG A 040658 002 Mar 24, 2006 Apr CMS1 AA ! 300MG;10MG A 040658 003 Jun 23, 2004 May CHRS AA 300MG;10MG A 040658 003 Jun 23, 2004 Apr CMS1 RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -2

TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN AA UPSHER-SMITH LABS 325MG;5MG A 206484 001 Mar 24, 2017 Jun CAHN AA 325MG;5MG A 206484 001 Mar 24, 2017 Mar NEWA AA 325MG;7.5MG A 206484 002 Mar 24, 2017 Jun CAHN AA 325MG;7.5MG A 206484 002 Mar 24, 2017 Mar NEWA AA 325MG;10MG A 206484 003 Mar 24, 2017 Jun CAHN AA 325MG;10MG A 206484 003 Mar 24, 2017 Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE TABLET;ORAL OXYCODONE AND ACETAMINOPHEN AA AMNEAL PHARMS 325MG;5MG A 040777 001 Nov 27, 2007 May CAHN AA ASCENT PHARMS INC 325MG;2.5MG A 207419 001 Mar 22, 2017 Mar NEWA AA 325MG;5MG A 207419 002 Mar 22, 2017 Mar NEWA AA 325MG;7.5MG A 207419 003 Mar 22, 2017 Mar NEWA AA 325MG;10MG A 207419 004 Mar 22, 2017 Mar NEWA AA NOVEL LABS INC 325MG;2.5MG A 204407 001 Feb 24, 2017 Feb NEWA AA 325MG;5MG A 204407 002 Feb 24, 2017 Feb NEWA AA 325MG;7.5MG A 204407 003 Feb 24, 2017 Feb NEWA AA 325MG;10MG A 204407 004 Feb 24, 2017 Feb NEWA PERCOCET AA ! VINTAGE PHARMS LLC 325MG;7.5MG A 040330 003 Nov 23, 2001 Jan CMS1 AA ! 325MG;10MG A 040330 004 Nov 23, 2001 Jan CMS1

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE TABLET;ORAL TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN AB AUROBINDO PHARMA LTD 325MG;37.5MG A 207152 001 Mar 22, 2017 Mar NEWA AB MACLEODS PHARMS LTD 325MG;37.5MG A 206885 001 May 02, 2017 Apr NEWA

ACETAZOLAMIDE TABLET;ORAL ACETAZOLAMIDE >A> AB SUN PHARM INDS 125MG A 089753 002 Jun 22, 1988 Jul CMS1

ACETAZOLAMIDE SODIUM INJECTABLE;INJECTION ACETAZOLAMIDE SODIUM AP PAR STERILE PRODUCTS EQ 500MG BASE/VIAL A 205358 001 Jun 20, 2017 Jun NEWA

ACETIC ACID, GLACIAL SOLUTION;IRRIGATION, URETHRAL ACETIC ACID 0.25% IN PLASTIC CONTAINER AT ICU MEDICAL INC 250MG/100ML N 017656 001 Feb CAHN

ACETOHEXAMIDE TABLET;ORAL ACETOHEXAMIDE @ WATSON LABS TEVA 250MG A 071893 001 Nov 25, 1987 May CAHN @ 500MG A 071894 001 Nov 25, 1987 May CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE CAPSULE;ORAL SEMPREX-D +! AUXILIUM PHARMS LLC 8MG;60MG N 019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR CAPSULE;ORAL ACYCLOVIR AB BOSCOGEN 200MG A 075090 001 Jan 26, 1999 May CAHN @ CHARTWELL MOLECULES 200MG A 074872 001 Apr 22, 1997 Jan CAHN @ MYLAN 200MG A 074727 001 Apr 22, 1997 Jun DISC ZOVIRAX AB +! MYLAN PHARMS INC 200MG N 018828 001 Jan 25, 1985 Jan CAHN OINTMENT;TOPICAL ACYCLOVIR >A> AB GLENMARK PHARMS LTD 5% A 205510 001 Jul 31, 2017 Jul NEWA >A> AB TOLMAR 5% A 206437 001 Jul 31, 2017 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -3

SUSPENSION;ORAL ZOVIRAX AB +! MYLAN PHARMS INC 200MG/5ML N 019909 001 Dec 22, 1989 Jan CAHN TABLET;BUCCAL SITAVIG +! EPI HLTH 50MG N 203791 001 Apr 12, 2013 Jun CAHN TABLET;ORAL ACYCLOVIR @ CHARTWELL MOLECULES 400MG A 074834 001 Apr 24, 1997 Jan CAHN @ 800MG A 074834 002 Apr 24, 1997 Jan CAHN AB HERITAGE PHARMS INC 400MG A 074891 001 Oct 31, 1997 Apr CMFD AB 800MG A 074891 002 Oct 31, 1997 Apr CMFD AB MYLAN PHARMS INC 400MG A 075211 001 Sep 28, 1998 Mar CAHN AB 800MG A 075211 002 Sep 28, 1998 Mar CAHN ZOVIRAX AB + MYLAN PHARMS INC 400MG N 020089 001 Apr 30, 1991 Jan CAHN AB +! 800MG N 020089 002 Apr 30, 1991 Jan CAHN

ACYCLOVIR SODIUM INJECTABLE;INJECTION ACYCLOVIR SODIUM @ ATHENEX INC EQ 500MG BASE/VIAL A 074596 002 Apr 22, 1997 Mar CAHN @ EQ 1GM BASE/VIAL A 074596 001 Apr 22, 1997 Mar CAHN AP ! HIKMA PHARMS EQ 1GM BASE/VIAL A 205771 002 Feb 29, 2016 Mar CTEC AP MYLAN LABS LTD EQ 500MG BASE/VIAL A 203927 001 Mar 29, 2017 Mar NEWA AP EQ 1GM BASE/VIAL A 203927 002 Mar 29, 2017 Mar NEWA AP ZYDUS PHARMS USA INC EQ 500MG BASE/VIAL A 206606 001 Jun 13, 2017 May NEWA AP EQ 1GM BASE/VIAL A 206606 002 Jun 13, 2017 May NEWA

ADENOSINE INJECTABLE;INJECTION ADENOSINE AP WEST-WARD PHARMS INT 3MG/ML A 076404 001 Jun 16, 2004 Jan CAHN AP 3MG/ML A 076500 001 Jun 16, 2004 Jan CAHN @ 3MG/ML A 076501 001 Jun 16, 2004 Jan CAHN

ALBENDAZOLE TABLET;ORAL ALBENZA +! IMPAX LABS INC 200MG N 020666 001 Jun 11, 1996 Jun CAHN

ALBUTEROL SULFATE AEROSOL, METERED;INHALATION PROVENTIL-HFA BX +! 3M DRUG DELIVERY EQ 0.09MG BASE/INH N 020503 001 Aug 15, 1996 May CAHN SOLUTION;INHALATION ALBUTEROL SULFATE >A> AN SUN PHARMA GLOBAL EQ 0.083% BASE A 207857 001 Jul 21, 2017 Jul NEWA

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE SOLUTION;INHALATION ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE >A> AN SUN PHARMA GLOBAL EQ 0.083% BASE;0.17% A 207875 001 Aug 07, 2017 Jul NEWA AN WATSON LABS TEVA EQ 0.083% BASE;0.017% A 077063 001 Dec 31, 2007 Feb CAHN

ALENDRONATE SODIUM TABLET;ORAL ALENDRONATE SODIUM @ UPSHER-SMITH LABS EQ 5MG BASE A 075871 001 Apr 22, 2009 Jun CAHN @ EQ 10MG BASE A 075871 002 Apr 22, 2009 Jun CAHN @ EQ 35MG BASE A 075871 004 Apr 22, 2009 Jun CAHN @ EQ 40MG BASE A 075871 003 Apr 22, 2009 Jun CAHN @ EQ 70MG BASE A 075871 005 Apr 22, 2009 Jun CAHN

ALLOPURINOL TABLET;ORAL ZYLOPRIM >A> AB + CASPER PHARMA LLC 100MG N 016084 001 Jul CAHN >A> AB +! 300MG N 016084 002 Jul CAHN >D> AB + SEBELA IRELAND LTD 100MG N 016084 001 Jul CAHN >D> AB +! 300MG N 016084 002 Jul CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -4

ALOSETRON HYDROCHLORIDE TABLET;ORAL ALOSETRON HYDROCHLORIDE AB AMNEAL PHARMS EQ 0.5MG BASE A 206647 001 Dec 22, 2016 May CAHN AB EQ 1MG BASE A 206647 002 Dec 22, 2016 May CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K INJECTABLE;INJECTION INFUVITE ADULT +! SANDOZ INC 2 IU/ML;40MG/ML;12MCG/ML;40 N 021163 001 May 18, 2000 May CAHN IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG /ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;66 0 IU/ML;0.03MG/ML INJECTABLE;IV (INFUSION) INFUVITE ADULT +! SANDOZ INC 2 IU/ML;40MG/ML;12MCG/ML;40 N 021559 001 Jun 16, 2003 May CAHN IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG /ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;66 0 IU/ML;30MCG/ML

ALPRAZOLAM TABLET;ORAL ALPRAZOLAM AB ACTAVIS ELIZABETH 0.25MG A 074342 001 Oct 31, 1993 Apr CAHN AB 0.5MG A 074342 002 Oct 31, 1993 Apr CAHN AB 1MG A 074342 003 Oct 31, 1993 Apr CAHN AB 2MG A 074342 004 Oct 31, 1993 Apr CAHN TABLET, EXTENDED RELEASE;ORAL ALPRAZOLAM AB AUROBINDO PHARMA LTD 0.5MG A 090871 001 Jun 07, 2011 Jan CAHN AB 1MG A 090871 002 Jun 07, 2011 Jan CAHN AB 2MG A 090871 003 Jun 07, 2011 Jan CAHN AB 3MG A 090871 004 Jun 07, 2011 Jan CAHN

ALPROSTADIL INJECTABLE;INJECTION EDEX @ AUXILIUM PHARMS LLC 0.005MG/VIAL N 020649 001 Jun 12, 1997 May CAHN AP + 0.01MG/VIAL N 020649 002 Jun 12, 1997 May CAHN +! 0.01MG/VIAL N 020649 005 Jul 30, 1998 May CAHN AP + 0.02MG/VIAL N 020649 003 Jun 12, 1997 May CAHN +! 0.02MG/VIAL N 020649 006 Jul 30, 1998 May CAHN AP +! 0.04MG/VIAL N 020649 004 Jun 12, 1997 May CAHN +! 0.04MG/VIAL N 020649 007 Jul 30, 1998 May CAHN SUPPOSITORY;URETHRAL MUSE +! MYLAN SPECIALITY LP 0.125MG N 020700 001 Nov 19, 1996 Mar CAHN +! 0.25MG N 020700 002 Nov 19, 1996 Mar CAHN +! 0.5MG N 020700 003 Nov 19, 1996 Mar CAHN +! 1MG N 020700 004 Nov 19, 1996 Mar CAHN

AMANTADINE HYDROCHLORIDE CAPSULE;ORAL AMANTADINE HYDROCHLORIDE AB ALEMBIC PHARMS LTD 100MG A 208966 001 Jun 21, 2017 Jun NEWA AB HERITAGE PHARMA 100MG A 209171 001 Jun 12, 2017 May NEWA AB LANNETT HOLDINGS INC 100MG A 209221 001 Jun 15, 2017 May NEWA AB STRIDES PHARMA 100MG A 209047 001 Jun 07, 2017 May NEWA AB USL PHARMA 100MG A 070589 001 Aug 05, 1986 Jun CAHN SYRUP;ORAL AMANTADINE HYDROCHLORIDE AA ! CMP PHARMA INC 50MG/5ML A 075819 001 Sep 11, 2002 Apr CAHN AA ! PHARM ASSOC 50MG/5ML A 074509 001 Jul 17, 1995 May CAHN SYMMETREL + @ ENDO PHARMS 50MG/5ML N 016023 002 Jan CRLD TABLET;ORAL AMANTADINE HYDROCHLORIDE AB NEWGEN PHARMS LLC 100MG A 207571 001 Jan 31, 2017 Jan NEWA AB STRIDES PHARMA 100MG A 209035 001 Jun 09, 2017 May NEWA AB ! USL PHARMA 100MG A 076186 001 Dec 16, 2002 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -5

AMCINONIDE CREAM;TOPICAL CYCLOCORT + @ ASTELLAS 0.025% N 018116 001 Jun CRLD + @ 0.1% N 018116 002 Jun CRLD LOTION;TOPICAL CYCLOCORT + @ ASTELLAS 0.1% N 019729 001 Jun 13, 1988 Jun CRLD OINTMENT;TOPICAL CYCLOCORT + @ ASTELLAS 0.1% N 018498 001 Jun CRLD

AMIFOSTINE INJECTABLE;INJECTION AMIFOSTINE >A> AP MYLAN LABS LTD 500MG/VIAL A 204363 001 Jul 17, 2017 Jul NEWA AP SUN PHARMA GLOBAL 500MG/VIAL A 077126 001 Mar 14, 2008 Apr CAHN

AMILORIDE HYDROCHLORIDE TABLET;ORAL AMILORIDE HYDROCHLORIDE >A> AB WINDLAS HLTHCARE 5MG A 204180 001 Aug 07, 2015 Jul CAHN >D> AB ZYDUS PHARMS USA INC 5MG A 204180 001 Aug 07, 2015 Jul CAHN

AMINO ACIDS INJECTABLE;INJECTION AMINOSYN 10% ICU MEDICAL INC 10% (10GM/100ML) N 017673 003 Feb CAHN AMINOSYN 10% (PH6) ICU MEDICAL INC 10% (10GM/100ML) N 017673 008 Nov 18, 1985 Feb CAHN AMINOSYN 3.5% ICU MEDICAL INC 3.5% (3.5GM/100ML) N 017789 004 Feb CAHN AMINOSYN 5% ICU MEDICAL INC 5% (5GM/100ML) N 017673 001 Feb CAHN AMINOSYN 7% ICU MEDICAL INC 7% (7GM/100ML) N 017673 002 Feb CAHN AMINOSYN 7% (PH6) ICU MEDICAL INC 7% (7GM/100ML) N 017673 006 Nov 18, 1985 Feb CAHN AMINOSYN 8.5% ICU MEDICAL INC 8.5% (8.5GM/100ML) N 017673 004 Feb CAHN AMINOSYN 8.5% (PH6) ICU MEDICAL INC 8.5% (8.5GM/100ML) N 017673 007 Nov 18, 1985 Feb CAHN AMINOSYN II 10% ICU MEDICAL INC 10% (10GM/100ML) N 019438 005 Apr 03, 1986 Feb CAHN AMINOSYN II 10% IN PLASTIC CONTAINER ICU MEDICAL INC 10% (10GM/100ML) N 020015 001 Dec 19, 1991 Feb CAHN AMINOSYN II 15% IN PLASTIC CONTAINER ICU MEDICAL INC 15% (15GM/100ML) N 020041 001 Dec 19, 1991 Feb CAHN AMINOSYN II 3.5% @ ICU MEDICAL INC 3.5% (3.5GM/100ML) N 019438 001 Apr 03, 1986 Feb CAHN AMINOSYN II 5% @ ICU MEDICAL INC 5% (5GM/100ML) N 019438 002 Apr 03, 1986 Feb CAHN AMINOSYN II 7% ICU MEDICAL INC 7% (7GM/100ML) N 019438 003 Apr 03, 1986 Feb CAHN AMINOSYN II 8.5% ICU MEDICAL INC 8.5% (8.5GM/100ML) N 019438 004 Apr 03, 1986 Feb CAHN AMINOSYN-HBC 7% ICU MEDICAL INC 7% (7GM/100ML) N 019374 001 Jul 12, 1985 Feb CAHN AMINOSYN-HF 8% ICU MEDICAL INC 8% (8GM/100ML) A 020345 001 Apr 04, 1996 Jun CAHN AMINOSYN-PF 10% ICU MEDICAL INC 10% (10GM/100ML) N 019492 002 Oct 17, 1986 Feb CAHN AMINOSYN-PF 7% ICU MEDICAL INC 7% (7GM/100ML) N 019398 001 Sep 06, 1985 Feb CAHN AMINOSYN-RF 5.2% ICU MEDICAL INC 5.2% (5.2GM/100ML) N 018429 001 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -6

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE INJECTABLE;INJECTION AMINOSYN 3.5% M ICU MEDICAL INC 3.5%;21MG/100ML;40MG/100ML;128MG/1 N 017789 003 Feb CAHN 00ML;234MG/100ML

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE INJECTABLE;INJECTION AMINOSYN 3.5% M @ ICU MEDICAL INC 3.5%;21MG/100ML;128MG/100ML;234MG/ N 017789 005 Feb CAHN 100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE INJECTABLE;INJECTION AMINOSYN II 10% W/ ELECTROLYTES ICU MEDICAL INC 10%;102MG/100ML;45MG/100ML;522MG/1 N 019437 004 Apr 03, 1986 Apr CAHN 00ML;410MG/100ML AMINOSYN II 7% W/ ELECTROLYTES @ ICU MEDICAL INC 7%;102MG/100ML;45MG/100ML;522MG/10 N 019437 006 Apr 03, 1986 Apr CAHN 0ML;410MG/100ML AMINOSYN II 8.5% W/ ELECTROLYTES ICU MEDICAL INC 8.5%;102MG/100ML;45MG/100ML;522MG/ N 019437 005 Apr 03, 1986 Apr CAHN 100ML;410MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE INJECTABLE;INJECTION AMINOSYN II 3.5% M @ ICU MEDICAL INC 3.5%;30MG/100ML;97MG/100ML;120MG/1 N 019437 007 Apr 03, 1986 Apr CAHN 00ML;49MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE INJECTABLE;INJECTION AMINOSYN 7% W/ ELECTROLYTES ICU MEDICAL INC 7%;102MG/100ML;522MG/100ML;410MG/1 N 017789 002 Feb CAHN 00ML AMINOSYN 8.5% W/ ELECTROLYTES ICU MEDICAL INC 8.5%;102MG/100ML;522MG/100ML;410MG N 017673 005 Feb CAHN /100ML

AMINOLEVULINIC ACID HYDROCHLORIDE FOR SOLUTION;ORAL GLEOLAN +! NXDC 1.5GM/VIAL N 208630 001 Jun 06, 2017 Jun NEWA

AMIODARONE HYDROCHLORIDE TABLET;ORAL AMIODARONE HYDROCHLORIDE AB MAYNE PHARMA INC 200MG A 075389 001 Jan 25, 2001 Jan CAHN @ MYLAN 200MG A 075188 001 Feb 24, 1999 Mar DISC AB ! SANDOZ 200MG A 075315 001 Dec 23, 1998 Mar CHRS AB TARO PHARM 100MG A 075424 002 Dec 18, 2002 Mar CAHN AB 200MG A 075424 001 Mar 30, 2001 Mar CAHN 300MG A 076362 002 Dec 02, 2003 Mar CAHN AB 400MG A 076362 001 Nov 29, 2002 Mar CAHN CORDARONE + @ WYETH PHARMS INC 200MG N 018972 001 Dec 24, 1985 Jan DISC PACERONE AB UPSHER-SMITH LABS 100MG A 075135 002 Apr 12, 2005 Jun CAHN AB 200MG A 075135 001 Apr 30, 1998 Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE TABLET;ORAL ELAVIL + @ ASTRAZENECA 10MG N 012703 001 Mar CRLD + @ 25MG N 012703 003 Mar CRLD + @ 50MG N 012703 004 Mar CRLD + @ 75MG N 012703 005 Mar CRLD + @ 100MG N 012703 006 Mar CRLD + @ 150MG N 012703 007 Mar CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -7

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE TABLET;ORAL CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE @ WATSON LABS TEVA EQ 12.5MG BASE;5MG A 072052 001 Dec 16, 1988 May CAHN

AMLODIPINE BESYLATE TABLET;ORAL AMLODIPINE BESYLATE AB MYLAN PHARMS INC EQ 2.5MG BASE A 076418 001 Oct 03, 2005 Mar CAHN @ EQ 2.5MG BASE A 078224 001 Feb 27, 2008 May DISC AB EQ 5MG BASE A 076418 002 Oct 03, 2005 Mar CAHN @ EQ 5MG BASE A 078224 002 Feb 27, 2008 May DISC AB EQ 10MG BASE A 076418 003 Oct 03, 2005 Mar CAHN @ EQ 10MG BASE A 078224 003 Feb 27, 2008 May DISC AB UPSHER-SMITH LABS EQ 2.5MG BASE A 077759 001 Jul 09, 2007 Jun CAHN AB EQ 5MG BASE A 077759 002 Jul 09, 2007 Jun CAHN AB EQ 10MG BASE A 077759 003 Jul 09, 2007 Jun CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL TABLET;ORAL AMLODIPINE AND OLMESARTAN MEDOXOMIL >A> AB ALEMBIC PHARMS LTD EQ 5MG BASE;20MG A 207073 001 Jul 17, 2017 Jul NEWA >A> AB EQ 5MG BASE;40MG A 207073 002 Jul 17, 2017 Jul NEWA >A> AB EQ 10MG BASE;20MG A 207073 003 Jul 17, 2017 Jul NEWA >A> AB EQ 10MG BASE;40MG A 207073 004 Jul 17, 2017 Jul NEWA >A> AB ALKEM LABS LTD EQ 5MG BASE;20MG A 209042 001 Aug 14, 2017 Jul NEWA >A> AB EQ 5MG BASE;40MG A 209042 002 Aug 14, 2017 Jul NEWA >A> AB EQ 10MG BASE;20MG A 209042 003 Aug 14, 2017 Jul NEWA >A> AB EQ 10MG BASE;40MG A 209042 004 Aug 14, 2017 Jul NEWA AB AUROBINDO PHARMA LTD EQ 5MG BASE;20MG A 206906 001 May 15, 2017 May NEWA AB EQ 5MG BASE;40MG A 206906 002 May 15, 2017 May NEWA AB EQ 10MG BASE;20MG A 206906 003 May 15, 2017 May NEWA AB EQ 10MG BASE;40MG A 206906 004 May 15, 2017 May NEWA AB GLENMARK PHARMS LTD EQ 5MG BASE;20MG A 207807 001 Jul 05, 2017 Jun NEWA AB EQ 5MG BASE;40MG A 207807 002 Jul 05, 2017 Jun NEWA AB EQ 10MG BASE;20MG A 207807 003 Jul 05, 2017 Jun NEWA AB EQ 10MG BASE;40MG A 207807 004 Jul 05, 2017 Jun NEWA AB JUBILANT GENERICS EQ 5MG BASE;20MG A 207450 001 May 15, 2017 May NEWA AB EQ 5MG BASE;40MG A 207450 002 May 15, 2017 May NEWA AB EQ 10MG BASE;20MG A 207450 003 May 15, 2017 May NEWA AB EQ 10MG BASE;40MG A 207450 004 May 15, 2017 May NEWA AB TORRENT PHARMS LTD EQ 5MG BASE;20MG A 202933 001 Nov 25, 2016 Apr CAHN AB EQ 5MG BASE;40MG A 202933 002 Nov 25, 2016 Apr CAHN AB EQ 10MG BASE;20MG A 202933 003 Nov 25, 2016 Apr CAHN AB EQ 10MG BASE;40MG A 202933 004 Nov 25, 2016 Apr CAHN

AMMONIA N-13 INJECTABLE;INTRAVENOUS AMMONIA N 13 AP GEN HOSP 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A 207025 001 Feb 03, 2016 May CAHN

AMMONIUM LACTATE LOTION;TOPICAL LAC-HYDRIN + @ RANBAXY EQ 12% BASE N 019155 001 Apr 24, 1985 Jan CRLD

AMOXAPINE TABLET;ORAL AMOXAPINE @ UPSHER-SMITH LABS 25MG A 072943 001 Jun 28, 1991 Jun CAHN @ 50MG A 072944 001 Jun 28, 1991 Jun CAHN @ 100MG A 072878 001 Jun 28, 1991 Jun CAHN @ 150MG A 072879 001 Jun 28, 1991 Jun CAHN @ WATSON PHARMS TEVA 25MG A 072418 001 May 11, 1989 Feb CAHN @ 50MG A 072419 001 May 11, 1989 Feb CAHN @ 100MG A 072420 001 May 11, 1989 Feb CAHN @ 150MG A 072421 001 May 11, 1989 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -8

AMOXICILLIN FOR SUSPENSION;ORAL AMOXIL @ DR REDDYS LABS INC 200MG/5ML N 050760 001 Apr 15, 1999 Feb DISC @ 400MG/5ML N 050760 002 Apr 15, 1999 Feb DISC TABLET;ORAL AMOXIL + @ DR REDDYS LABS INC 500MG N 050754 002 Jul 10, 1998 Mar DISC + @ 875MG N 050754 001 Jul 10, 1998 Mar DISC TABLET, CHEWABLE;ORAL AMOXICILLIN TEVA 125MG A 064013 002 Sep 11, 1995 Feb CTEC ! 250MG A 064013 001 Dec 22, 1992 Feb CTEC AMOXIL + @ DR REDDYS LABS INC 125MG N 050542 002 Feb DISC + @ 250MG N 050542 001 Feb DISC

AMOXICILLIN; CLAVULANATE POTASSIUM FOR SUSPENSION;ORAL AUGMENTIN '200' + @ DR REDDYS LABS INC 200MG/5ML;EQ 28.5MG BASE/5ML N 050725 001 May 31, 1996 Feb DISC AUGMENTIN '400' + @ DR REDDYS LABS INC 400MG/5ML;EQ 57MG BASE/5ML N 050725 002 May 31, 1996 Feb DISC AUGMENTIN ES-600 + @ DR REDDYS LABS INC 600MG/5ML;EQ 42.9MG BASE/5ML N 050755 001 Jun 22, 2001 Feb DISC TABLET;ORAL AMOXICILLIN AND CLAVULANATE POTASSIUM AB ! SANDOZ 250MG;EQ 125MG BASE A 065189 001 Aug 23, 2005 Feb CHRS AB ! SANDOZ INC 500MG;EQ 125MG BASE A 065117 001 Nov 27, 2002 Feb CHRS AUGMENTIN '250' + @ DR REDDYS LABS INC 250MG;EQ 125MG BASE N 050564 001 Aug 06, 1984 Feb DISC AUGMENTIN '500' + @ DR REDDYS LABS INC 500MG;EQ 125MG BASE N 050564 002 Aug 06, 1984 Feb DISC TABLET, CHEWABLE;ORAL AMOXICILLIN AND CLAVULANATE POTASSIUM TEVA 200MG;EQ 28.5MG BASE A 065205 001 Feb 09, 2005 Feb CTEC ! 400MG;EQ 57MG BASE A 065205 002 Feb 09, 2005 Feb CTEC AUGMENTIN '200' + @ DR REDDYS LABS INC 200MG;EQ 28.5MG BASE N 050726 001 May 31, 1996 Feb DISC AUGMENTIN '400' + @ DR REDDYS LABS INC 400MG;EQ 57MG BASE N 050726 002 May 31, 1996 Feb DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL MYDAYIS + SHIRE DEV LLC 3.125MG;3.125MG;3.125MG;3.125MG N 022063 001 Jun 20, 2017 Jun NEWA + 6.25MG;6.25MG;6.25MG;6.25MG N 022063 002 Jun 20, 2017 Jun NEWA + 9.375MG;9.375MG;9.375MG;9.375MG N 022063 003 Jun 20, 2017 Jun NEWA + 12.5MG;12.5MG;12.5MG;12.5MG N 022063 004 Jun 20, 2017 Jun NEWA TABLET;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE >A> AB ALVOGEN MALTA 1.25MG;1.25MG;1.25MG;1.25MG A 207388 001 Jul 28, 2017 Jul NEWA >A> AB 1.875MG;1.875MG;1.875MG;1.875MG A 207388 002 Jul 28, 2017 Jul NEWA >A> AB 2.5MG;2.5MG;2.5MG;2.5MG A 207388 003 Jul 28, 2017 Jul NEWA >A> AB 3.125MG;3.125MG;3.125MG;3.125MG A 207388 004 Jul 28, 2017 Jul NEWA >A> AB 3.75MG;3.75MG;3.75MG;3.75MG A 207388 005 Jul 28, 2017 Jul NEWA >A> AB 5MG;5MG;5MG;5MG A 207388 006 Jul 28, 2017 Jul NEWA >A> AB 7.5MG;7.5MG;7.5MG;7.5MG A 207388 007 Jul 28, 2017 Jul NEWA AB EPIC PHARMA LLC 1.25MG;1.25MG;1.25MG;1.25MG A 040444 001 Jun 19, 2002 May CAHN AB 1.875MG;1.875MG;1.875MG;1.875MG A 040444 005 Nov 03, 2014 May CAHN AB 2.5MG;2.5MG;2.5MG;2.5MG A 040444 002 Jun 19, 2002 May CAHN AB 3.125MG;3.125MG;3.125MG;3.125MG A 040444 006 Nov 03, 2014 May CAHN AB 3.75MG;3.75MG;3.75MG;3.75MG A 040444 007 Nov 03, 2014 May CAHN AB 5MG;5MG;5MG;5MG A 040444 003 Jun 19, 2002 May CAHN AB 7.5MG;7.5MG;7.5MG;7.5MG A 040444 004 Jun 19, 2002 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -9

AMPICILLIN SODIUM INJECTABLE;INJECTION AMPICILLIN SODIUM @ WEST-WARD PHARMS INT EQ 125MG BASE/VIAL A 062692 001 Jun 24, 1986 Jan CAHN @ EQ 250MG BASE/VIAL A 062692 002 Jun 24, 1986 Jan CAHN @ EQ 500MG BASE/VIAL A 062692 003 Jun 24, 1986 Jan CAHN @ EQ 1GM BASE/VIAL A 062692 004 Jun 24, 1986 Jan CAHN @ EQ 2GM BASE/VIAL A 062692 005 Jun 24, 1986 Jan CAHN @ EQ 10GM BASE/VIAL A 062692 006 Jun 24, 1986 Jan CAHN PENBRITIN-S + @ WYETH AYERST EQ 125MG BASE/VIAL N 050072 001 Jun CRLD + @ EQ 250MG BASE/VIAL N 050072 002 Jun CRLD + @ EQ 500MG BASE/VIAL N 050072 003 Jun CRLD + @ EQ 1GM BASE/VIAL N 050072 004 Jun CRLD + @ EQ 2GM BASE/VIAL N 050072 005 Jun CRLD + @ EQ 4GM BASE/VIAL N 050072 006 Jun CRLD

AMPICILLIN SODIUM; SULBACTAM SODIUM INJECTABLE;INJECTION AMPICILLIN AND SULBACTAM >A> AP ANTIBIOTICE EQ 1GM BASE/VIAL;EQ 500MG A 201406 001 Dec 07, 2015 Jul CAHN BASE/VIAL >A> AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL A 201406 002 Dec 07, 2015 Jul CAHN >D> AP ANTIBIOTICS SA EQ 1GM BASE/VIAL;EQ 500MG A 201406 001 Dec 07, 2015 Jul CAHN BASE/VIAL >D> AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL A 201406 002 Dec 07, 2015 Jul CAHN AP WEST-WARD PHARMS INT EQ 1GM BASE/VIAL;EQ 500MG A 065074 001 Mar 19, 2002 Jan CAHN BASE/VIAL AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL A 065074 002 Mar 19, 2002 Jan CAHN AP EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL A 065076 001 Mar 19, 2002 Jan CAHN

ANAGRELIDE HYDROCHLORIDE CAPSULE;ORAL ANAGRELIDE HYDROCHLORIDE @ MYLAN PHARMS INC EQ 0.5MG BASE A 076811 001 Apr 18, 2005 May DISC AB EQ 0.5MG BASE A 076811 001 Apr 18, 2005 Mar CAHN @ EQ 0.5MG BASE A 077613 001 Jun 27, 2006 May DISC @ EQ 1MG BASE A 076811 002 Apr 18, 2005 May DISC AB EQ 1MG BASE A 076811 002 Apr 18, 2005 Mar CAHN @ EQ 1MG BASE A 077613 002 Jun 27, 2006 May DISC AB TORRENT PHARMS LTD EQ 0.5MG BASE A 209151 001 Jun 30, 2017 Jun NEWA AB EQ 1MG BASE A 209151 002 Jun 30, 2017 Jun NEWA @ UPSHER-SMITH LABS EQ 0.5MG BASE A 076683 001 Apr 18, 2005 Jun CAHN @ EQ 1MG BASE A 076683 002 Apr 18, 2005 Jun CAHN

ANASTROZOLE TABLET;ORAL ANASTROZOLE @ WATSON LABS TEVA 1MG A 078984 001 Jun 28, 2010 May CAHN ARIMIDEX AB +! ASTRAZENECA PHARMS 1MG N 020541 001 Dec 27, 1995 May CAHN

ARGATROBAN INJECTABLE;INJECTION ARGATROBAN +! HIKMA PHARM CO LTD 50MG/50ML (1MG/ML) N 203049 002 Sep 30, 2016 Feb NEWA AP +! NOVARTIS PHARMS CORP 250MG/2.5ML (100MG/ML) N 020883 001 Jun 30, 2000 Jun CAHN INJECTABLE;IV (INFUSION) ARGATROBAN IN SODIUM CHLORIDE AP GLAND PHARMA LTD 125MG/125ML (1MG/ML) A 205570 001 May 22, 2017 May NEWA AP +! SANDOZ 125MG/125ML (1MG/ML) N 022485 001 May 09, 2011 May CFTG

ARIPIPRAZOLE TABLET;ORAL ARIPIPRAZOLE AB ORCHID HLTHCARE 2MG A 202683 001 May 23, 2017 May NEWA AB 5MG A 202683 002 May 23, 2017 May NEWA AB 10MG A 202683 003 May 23, 2017 May NEWA AB 15MG A 202683 004 May 23, 2017 May NEWA AB 20MG A 202683 005 May 23, 2017 May NEWA AB 30MG A 202683 006 May 23, 2017 May NEWA AB SANTOS BIOTECH 2MG A 091279 001 Jan 09, 2017 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -10

TABLET;ORAL ARIPIPRAZOLE AB 5MG A 091279 002 Jan 09, 2017 May CAHN AB 10MG A 091279 003 Jan 09, 2017 May CAHN AB 15MG A 091279 004 Jan 09, 2017 May CAHN AB 20MG A 091279 005 Jan 09, 2017 May CAHN AB 30MG A 091279 006 Jan 09, 2017 May CAHN

ARIPIPRAZOLE LAUROXIL SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR ARISTADA + ALKERMES INC 1064MG/3.9ML (272.82MG/ML) N 207533 004 Jun 05, 2017 Jun NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE INJECTABLE;INJECTION SEPTOCAINE AP +! DEPROCO 4%;EQ 0.0085MG BASE/1.7ML (4%;EQ N 022010 001 Mar 30, 2006 Jun CFTG 0.005MG BASE/ML) ULTACAN AP HANSAMED INC 4%;EQ 0.0085MG BASE/1.7ML (4%; EQ A 201751 001 Jul 11, 2017 Jun NEWA 0.005MG BASE/ML) ULTACAN FORTE AP HANSAMED INC 4%;EQ 0.017MG BASE/1.7ML (4%; EQ A 201750 001 Jul 11, 2017 Jun NEWA 0.01MG BASE/ML)

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K INJECTABLE;IV (INFUSION) INFUVITE PEDIATRIC +! SANDOZ INC 80MG/VIAL;0.02MG/VIAL;400 N 021265 001 Feb 21, 2001 May CAHN IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE) +! SANDOZ INC 80MG/VIAL;0.02MG/VIAL;400 N 021646 001 Jan 29, 2004 May CAHN IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL

ASPIRIN; BUTALBITAL; CAFFEINE TABLET;ORAL FIORINAL + @ ALLERGAN SALES LLC 325MG;50MG;40MG N 017534 003 Apr 16, 1986 Jan CRLD

ASPIRIN; DIPYRIDAMOLE CAPSULE, EXTENDED RELEASE;ORAL ASPIRIN AND DIPYRIDAMOLE AB AMNEAL PHARMS 25MG;200MG A 206392 001 Mar 08, 2016 May CAHN AB IMPAX LABS INC 25MG;200MG A 206964 001 Jan 18, 2017 Jan NEWA AB PAR PHARM INC 25MG;200MG A 207944 001 Jan 18, 2017 Jan NEWA AB SANDOZ INC 25MG;200MG A 206739 001 Jan 18, 2017 Jan NEWA

ATENOLOL TABLET;ORAL ATENOLOL @ WATSON LABS TEVA 100MG A 073353 001 Dec 27, 1991 May CAHN

ATOMOXETINE HYDROCHLORIDE CAPSULE;ORAL ATOMOXETINE HYDROCHLORIDE AB APOTEX INC 10MG A 078983 001 May 30, 2017 May NEWA AB 18MG A 078983 002 May 30, 2017 May NEWA AB 25MG A 078983 003 May 30, 2017 May NEWA AB 40MG A 078983 004 May 30, 2017 May NEWA AB 60MG A 078983 005 May 30, 2017 May NEWA AB 80MG A 078983 006 May 30, 2017 May NEWA AB 100MG A 078983 007 May 30, 2017 May NEWA AB AUROBINDO PHARMA LTD 10MG A 079016 001 May 30, 2017 May NEWA AB 18MG A 079016 002 May 30, 2017 May NEWA AB 25MG A 079016 003 May 30, 2017 May NEWA AB 40MG A 079016 004 May 30, 2017 May NEWA AB 60MG A 079016 005 May 30, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -11

CAPSULE;ORAL ATOMOXETINE HYDROCHLORIDE AB 80MG A 079016 006 May 30, 2017 May NEWA AB 100MG A 079016 007 May 30, 2017 May NEWA AB GLENMARK PHARMS LTD 10MG A 079019 001 May 30, 2017 May NEWA AB 18MG A 079019 002 May 30, 2017 May NEWA AB 25MG A 079019 003 May 30, 2017 May NEWA AB 40MG A 079019 004 May 30, 2017 May NEWA AB 60MG A 079019 005 May 30, 2017 May NEWA AB 80MG A 079019 006 May 30, 2017 May NEWA AB 100MG A 079019 007 May 30, 2017 May NEWA AB TEVA PHARMS USA 10MG A 079022 001 May 30, 2017 May NEWA AB 18MG A 079022 002 May 30, 2017 May NEWA AB 25MG A 079022 003 May 30, 2017 May NEWA AB 40MG A 079022 004 May 30, 2017 May NEWA AB 60MG A 079022 005 May 30, 2017 May NEWA AB 80MG A 079022 006 May 30, 2017 May NEWA AB 100MG A 079022 007 May 30, 2017 May NEWA STRATTERA AB + LILLY 10MG N 021411 002 Nov 26, 2002 May CFTG AB + 18MG N 021411 003 Nov 26, 2002 May CFTG AB + 25MG N 021411 004 Nov 26, 2002 May CFTG AB + 40MG N 021411 005 Nov 26, 2002 May CFTG AB +! 60MG N 021411 006 Nov 26, 2002 May CFTG AB + 80MG N 021411 007 Feb 14, 2005 May CFTG AB + 100MG N 021411 008 Feb 14, 2005 May CFTG

ATORVASTATIN CALCIUM TABLET;ORAL ATORVASTATIN CALCIUM AB TEVA PHARMS USA EQ 10MG BASE A 205300 001 Mar 27, 2017 Mar NEWA AB EQ 20MG BASE A 205300 002 Mar 27, 2017 Mar NEWA AB EQ 40MG BASE A 205300 003 Mar 27, 2017 Mar NEWA AB EQ 80MG BASE A 205300 004 Mar 27, 2017 Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE TABLET;ORAL EZETIMIBE AND ATORVASTATIN CALCIUM WATSON LABS TEVA EQ 10MG BASE;10MG A 206084 001 Apr 26, 2017 Apr NEWA EQ 20MG BASE;10MG A 206084 002 Apr 26, 2017 Apr NEWA EQ 40MG BASE;10MG A 206084 003 Apr 26, 2017 Apr NEWA ! EQ 80MG BASE;10MG A 206084 004 Apr 26, 2017 Apr NEWA

ATOVAQUONE SUSPENSION;ORAL ATOVAQUONE AB PADDOCK LLC 750MG/5ML A 207833 001 Apr 28, 2017 Apr NEWA

ATRACURIUM BESYLATE INJECTABLE;INJECTION ATRACURIUM BESYLATE AP MYLAN LABS LTD 10MG/ML A 206096 001 Jun 22, 2017 Jun NEWA @ WATSON PHARMS TEVA 10MG/ML A 074945 001 Jul 28, 1998 Feb CAHN ATRACURIUM BESYLATE PRESERVATIVE FREE AP MYLAN LABS LTD 10MG/ML A 206001 001 Apr 07, 2017 Mar NEWA TRACRIUM + @ HOSPIRA 10MG/ML N 018831 002 Jun 20, 1985 Apr CMS1 TRACRIUM PRESERVATIVE FREE + @ HOSPIRA 10MG/ML N 018831 001 Nov 23, 1983 Apr CMS1

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE TABLET;ORAL DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE AA ANI PHARMS INC 0.025MG;2.5MG A 086727 001 Jun CMFD

AVIBACTAM SODIUM; CEFTAZIDIME POWDER;IV (INFUSION) AVYCAZ +! CEREXA EQ 0.5GM BASE;2GM/VIAL N 206494 001 Feb 25, 2015 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -12

AZACITIDINE POWDER;IV (INFUSION), SUBCUTANEOUS AZACITIDINE AP ACTAVIS LLC 100MG/VIAL N 208216 001 Apr 29, 2016 Mar CTEC AP DR REDDYS LABS LTD 100MG/VIAL A 201537 001 Sep 16, 2013 Mar CDFR AP MYLAN INSTITUTIONAL 100MG/VIAL A 204949 001 Apr 28, 2016 Mar CDFR AP NATCO PHARMA LTD 100MG/VIAL A 207234 001 Jun 23, 2017 Jun NEWA AP SHILPA MEDICARE 100MG/VIAL A 207518 001 Sep 29, 2016 Mar CDFR VIDAZA AP +! CELGENE 100MG/VIAL N 050794 001 May 19, 2004 Mar CDFR

AZATHIOPRINE SODIUM INJECTABLE;INJECTION IMURAN >A> + @ CASPER PHARMA LLC EQ 100MG BASE/VIAL N 017391 001 Jul CAHN >D> + @ SEBELA IRELAND LTD EQ 100MG BASE/VIAL N 017391 001 Jul CAHN

AZELASTINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC AZELASTINE HYDROCHLORIDE AT SANDOZ INC 0.05% A 202305 001 May 31, 2012 Feb CAHN OPTIVAR AT +! MYLAN SPECIALITY LP 0.05% N 021127 001 May 22, 2000 Mar CAHN SPRAY, METERED;NASAL ASTELIN AB +! MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY N 020114 001 Nov 01, 1996 Mar CAHN ASTEPRO @ MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY N 022203 001 Oct 15, 2008 Mar CAHN AB +! EQ 0.1876MG BASE/SPRAY N 022203 002 Aug 31, 2009 Mar CAHN AZELASTINE HYDROCHLORIDE AB BRECKENRIDGE PHARM EQ 0.125MG BASE/SPRAY A 090176 001 Jul 28, 2015 Feb CAHN AB UPSHER-SMITH LABS EQ 0.125MG BASE/SPRAY A 202609 001 Mar 17, 2017 Jun CAHN AB EQ 0.125MG BASE/SPRAY A 202609 001 Mar 17, 2017 Mar NEWA >A> AB ZYDUS PHARMS USA INC EQ 0.125MG BASE/SPRAY A 091409 001 Aug 14, 2017 Jul NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE SPRAY, METERED;NASAL AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE AB APOTEX INC EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY A 207712 001 Apr 28, 2017 Apr NEWA DYMISTA AB +! MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY N 202236 001 May 01, 2012 Apr CFTG +! EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY N 202236 001 May 01, 2012 Mar CAHN

AZITHROMYCIN INJECTABLE;INJECTION AZITHROMYCIN AP MYLAN LABS LTD EQ 500MG BASE/VIAL A 204732 001 Jan 26, 2017 Jan NEWA TABLET;ORAL AZITHROMYCIN @ MYLAN EQ 250MG BASE A 065365 001 May 30, 2007 Jun DISC @ EQ 500MG BASE A 065366 001 May 30, 2007 May DISC ZITHROMAX AB + PFIZER EQ 250MG BASE N 050711 001 Jul 18, 1996 Apr CRLD AB + EQ 500MG BASE N 050784 001 May 24, 2002 Apr CRLD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE OINTMENT;TOPICAL CORTISPORIN +! MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG N 050168 002 May 04, 1984 Feb CAHN BASE/GM;5,000 UNITS/GM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE OINTMENT;OPHTHALMIC NEOSPORIN AT + CASPER PHARMA LLC 400 UNITS/GM;EQ 3.5MG N 050417 001 Apr CMFD BASE/GM;10,000 UNITS/GM RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -13

BACLOFEN INJECTABLE;INTRATHECAL BACLOFEN AP EMERALD INTL LTD 0.05MG/ML A 091193 001 May 03, 2016 Mar CAHN AP 0.5MG/ML A 091193 002 May 03, 2016 Mar CAHN AP 2MG/ML A 091193 003 May 03, 2016 Mar CAHN GABLOFEN +! MALLINCKRODT INC 1MG/ML N 022462 004 Jun 22, 2012 Mar CRLD AP PIRAMAL CRITICAL 0.05MG/ML N 022462 001 Nov 19, 2010 Apr CAHN AP 0.5MG/ML N 022462 002 Nov 19, 2010 Apr CAHN +! 1MG/ML N 022462 004 Jun 22, 2012 Apr CAHN AP 2MG/ML N 022462 003 Nov 19, 2010 Apr CAHN TABLET;ORAL BACLOFEN MY LAN@ MYLAN@ 10MG A 077181 001 Jul 29, 2005 May DISC AB OXFORD PHARMS 10MG A 077088 002 Oct 31, 2007 Apr CMS1 AB USL PHARMA 10MG A 074584 001 Aug 19, 1996 Jun CAHN AB 20MG A 074584 002 Aug 19, 1996 Jun CAHN

BALSALAZIDE DISODIUM CAPSULE;ORAL BALSALAZIDE DISODIUM >D> BX WEST-WARD PHARMS INT 750MG A 077806 001 Dec 28, 2007 Jul CTEC >A> AB 750MG A 077806 001 Dec 28, 2007 Jul CTEC BX 750MG A 077806 001 Dec 28, 2007 Apr CTEC

BARIUM SULFATE FOR SUSPENSION;ORAL E-Z-HD +! BRACCO 98% (334GM/BOTTLE) N 208036 001 Jan 11, 2016 Apr CPOT E-Z-PAQUE +! BRACCO 96% (169GM/BOTTLE) N 208036 002 Apr 07, 2017 Apr NEWA SUSPENSION;ORAL LIQUID E-Z-PAQUE +! BRACCO 60% (213GM/355ML) N 208143 003 Mar 01, 2017 Mar NEWA VARIBAR NECTAR >A> +! BRACCO 40% (96GM/240ML) N 208143 004 Jul 07, 2017 Jul NEWA

BENAZEPRIL HYDROCHLORIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE AB AMNEAL PHARMS 5MG A 076820 001 Feb 03, 2006 Apr CAHN AB 10MG A 076820 002 Feb 03, 2006 Apr CAHN AB 20MG A 076820 003 Feb 03, 2006 Apr CAHN AB 40MG A 076820 004 Feb 03, 2006 Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE TABLET;ORAL LOTENSIN HCT + @ US PHARMS HOLDINGS I 5MG;6.25MG N 020033 001 May 19, 1992 May DISC

BENDROFLUMETHIAZIDE; NADOLOL TABLET;ORAL CORZIDE AB + KING PHARMS LLC 5MG;40MG N 018647 001 May 25, 1983 Mar CAHN AB +! 5MG;80MG N 018647 002 May 25, 1983 Mar CAHN

BENZONATATE CAPSULE;ORAL TESSALON AA + PFIZER 100MG N 011210 001 Apr CRLD

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE GEL;TOPICAL CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE AB TOLMAR 5%;EQ 1% BASE A 204087 001 Jun 27, 2017 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -14

BENZPHETAMINE HYDROCHLORIDE TABLET;ORAL BENZPHETAMINE HYDROCHLORIDE @ EPIC PHARMA LLC 50MG A 040714 001 Oct 29, 2007 May CAHN AA TWI PHARMS INC 50MG A 040578 001 Apr 17, 2006 Mar CAHN

BENZTROPINE MESYLATE TABLET;ORAL BENZTROPINE MESYLATE AA EPIC PHARMA LLC 0.5MG A 072264 001 Feb 27, 1989 May CAHN AA 1MG A 072265 001 Feb 27, 1989 May CAHN AA 2MG A 072266 001 Feb 27, 1989 May CAHN OXFORD PHARMS 0.5MG A 040706 002 Feb 14, 2008 May CMS1 1MG A 040706 003 Feb 14, 2008 May CMS1 AA ! UPSHER-SMITH LABS 0.5MG A 040103 001 Dec 12, 1996 Feb CAHN AA ! 1MG A 040103 002 Dec 12, 1996 Feb CAHN AA ! 2MG A 040103 003 Dec 12, 1996 Feb CAHN AA ! USL PHARMA 0.5MG A 040103 001 Dec 12, 1996 Jun CAHN AA ! 1MG A 040103 002 Dec 12, 1996 Jun CAHN AA ! 2MG A 040103 003 Dec 12, 1996 Jun CAHN

BETAINE HYDROCHLORIDE FOR SOLUTION;ORAL CYSTADANE >A> +! ORPHAN EUROPE 1GM/SCOOPFUL N 020576 001 Oct 25, 1996 Jul CAHN >D> +! RARE DIS THERAP 1GM/SCOOPFUL N 020576 001 Oct 25, 1996 Jul CAHN

BETAMETHASONE DIPROPIONATE LOTION;TOPICAL BETAMETHASONE DIPROPIONATE AB ! FOUGERA PHARMS INC EQ 0.05% BASE A 070275 001 Aug 12, 1985 Jan CAHN TA RO@ TARO@ EQ 0.05% BASE A 074272 001 Sep 30, 1994 Apr CAHN DIPROSONE + @ SCHERING EQ 0.05% BASE N 017781 001 Jan CRLD OINTMENT;TOPICAL BETAMETHASONE DIPROPIONATE AB TARO EQ 0.05% BASE A 074271 001 Sep 15, 1994 Apr CAHN

BETAMETHASONE VALERATE AEROSOL, FOAM;TOPICAL BETAMETHASONE VALERATE AB PERRIGO UK FINCO 0.12% A 078337 001 Nov 26, 2012 Apr CAHN AB RICONPHARMA LLC 0.12% A 207144 001 May 24, 2017 May NEWA AB TARO PHARM 0.12% A 208204 001 May 24, 2017 May NEWA LUXIQ AB +! MYLAN PHARMS INC 0.12% N 020934 001 Feb 28, 1999 Jan CAHN

BETAXOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC BETAXOLOL HYDROCHLORIDE AT TELIGENT EQ 0.5% BASE A 075630 001 Apr 12, 2001 Apr CAHN

BETHANECHOL CHLORIDE TABLET;ORAL BETHANECHOL CHLORIDE @ IMPAX LABS 5MG A 040721 001 Nov 01, 2006 Jan CMS1 @ 10MG A 040721 002 Nov 01, 2006 Jan CMS1 @ 25MG A 040721 003 Nov 01, 2016 Jan CMS1 AA LANNETT HOLDINGS INC 5MG A 040677 002 Mar 27, 2008 May CMS1 AA 10MG A 040677 003 Mar 27, 2008 May CMS1 AA 25MG A 040677 004 Mar 27, 2008 May CMS1 AA UPSHER-SMITH LABS 5MG A 040633 001 Jun 01, 2005 Jun CAHN AA 10MG A 040634 001 Jun 01, 2005 Jun CAHN AA 25MG A 040635 001 Jun 01, 2005 Jun CAHN AA 50MG A 040636 001 Jun 01, 2005 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -15

BETRIXABAN CAPSULE;ORAL BEVYXXA + PORTOLA PHARMS INC 40MG N 208383 001 Jun 23, 2017 Jun NEWA +! 80MG N 208383 002 Jun 23, 2017 Jun NEWA

BICALUTAMIDE TABLET;ORAL BICALUTAMIDE AB SANTOS BIOTECH 50MG A 091011 001 Jun 10, 2015 May CAHN AB WATSON LABS TEVA 50MG A 078634 001 Aug 28, 2009 May CAHN CASODEX AB +! ASTRAZENECA PHARMS 50MG N 020498 001 Oct 04, 1995 May CAHN

BIMATOPROST SOLUTION/DROPS;OPHTHALMIC BIMATOPROST AT SANDOZ INC 0.03% A 202565 001 May 05, 2015 Mar CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE TABLET, CHEWABLE, TABLET, CAPSULE;ORAL HELIDAC >A> + @ CASPER PHARMA LLC 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N 050719 001 Aug 15, 1996 Jul CAHN N/A,500MG >D> + @ SEBELA IRELAND LTD 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N 050719 001 Aug 15, 1996 Jul CAHN N/A,500MG

BISOPROLOL FUMARATE TABLET;ORAL BISOPROLOL FUMARATE AB ORIT LABS LLC 5MG A 204891 001 Jan 11, 2017 Jan NEWA AB 10MG A 204891 002 Jan 11, 2017 Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE TABLET;ORAL BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE @ WATSON LABS TEVA 2.5MG;6.25MG A 075469 001 Sep 25, 2000 May CAHN @ 5MG;6.25MG A 075469 002 Sep 25, 2000 May CAHN @ 10MG;6.25MG A 075469 003 Sep 25, 2000 May CAHN ZIAC AB + TEVA BRANDED PHARM 2.5MG;6.25MG N 020186 003 Mar 26, 1993 Jan CAHN AB + 5MG;6.25MG N 020186 001 Mar 26, 1993 Jan CAHN AB +! 10MG;6.25MG N 020186 002 Mar 26, 1993 Jan CAHN

BIVALIRUDIN INJECTABLE;INTRAVENOUS BIVALIRUDIN AP APOTEX INC 250MG/VIAL A 204876 001 Jul 06, 2017 Jun NEWA AP DR REDDYS LABS LTD 250MG/VIAL A 201577 001 May 26, 2017 May NEWA

BRETYLIUM TOSYLATE INJECTABLE;INJECTION BRETYLIUM TOSYLATE @ WEST-WARD PHARMS INT 50MG/ML A 070545 001 May 14, 1986 Jan CAHN

BRIGATINIB TABLET;ORAL ALUNBRIG + ARIAD 30MG N 208772 001 Apr 28, 2017 Apr NEWA +! 90MG N 208772 002 Apr 28, 2017 Apr NEWA

BRIMONIDINE TARTRATE SOLUTION/DROPS;OPHTHALMIC BRIMONIDINE TARTRATE AT SANDOZ INC 0.2% A 076254 001 Sep 16, 2003 Feb CAHN AT 0.2% A 078075 001 Jan 30, 2008 Mar CAHN QOLIANA AT SANDOZ INC 0.15% N 021764 001 May 22, 2006 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -16

BROMFENAC SODIUM SOLUTION/DROPS;OPHTHALMIC BROMFENAC SODIUM AT1 AMRING PHARMS EQ 0.09% ACID A 202030 001 Jan 09, 2013 Mar CAHN AT1 ! APOTEX INC EQ 0.09% ACID A 202435 001 Jun 19, 2014 Feb CHRS AT2 ! HI-TECH PHARMACAL EQ 0.09% ACID A 203395 001 Jan 22, 2014 Mar CHRS

BROMPHENIRAMINE MALEATE TABLET;ORAL BROMPHENIRAMINE MALEATE @ UPSHER-SMITH LABS 4MG A 083215 001 Jun CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE SYRUP;ORAL BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE AA TARO PHARM 2MG/5ML;10MG/5ML;30MG/5ML A 205112 001 Feb 27, 2017 Feb NEWA

BUDESONIDE CAPSULE;ORAL BUDESONIDE >A> AB AMNEAL PHARMS 3MG A 206200 001 Jul 31, 2017 Jul NEWA AB APPCO PHARMA LLC 3MG A 207367 001 Apr 07, 2017 Mar NEWA AB ZYDUS PHARMS USA INC 3MG A 206134 001 May 04, 2017 Apr NEWA

BUMETANIDE INJECTABLE;INJECTION BUMETANIDE AP ! ATHENEX INC 0.25MG/ML A 074441 001 Jan 27, 1995 Mar CAHN AP WEST-WARD PHARMS INT 0.25MG/ML A 079196 001 Apr 30, 2008 Jan CAHN BUMEX + @ VALIDUS PHARMS 0.25MG/ML N 018226 001 Feb 28, 1983 Jun CAHN TABLET;ORAL BUMEX AB + VALIDUS PHARMS 0.5MG N 018225 002 Feb 28, 1983 Jun CAHN AB + 1MG N 018225 001 Feb 28, 1983 Jun CAHN AB + 2MG N 018225 003 Jun 14, 1985 Jun CAHN

BUPRENORPHINE HYDROCHLORIDE FILM;BUCCAL BELBUCA + BDSI EQ 0.075MG BASE N 207932 001 Oct 23, 2015 Jan CAHN + EQ 0.15MG BASE N 207932 002 Oct 23, 2015 Jan CAHN + EQ 0.3MG BASE N 207932 003 Oct 23, 2015 Jan CAHN + EQ 0.45MG BASE N 207932 004 Oct 23, 2015 Jan CAHN + EQ 0.6MG BASE N 207932 005 Oct 23, 2015 Jan CAHN + EQ 0.75MG BASE N 207932 006 Oct 23, 2015 Jan CAHN +! EQ 0.9MG BASE N 207932 007 Oct 23, 2015 Jan CAHN TABLET;SUBLINGUAL BUPRENORPHINE HYDROCHLORIDE AB RHODES PHARMS EQ 2MG BASE A 207276 001 Mar 27, 2017 Mar NEWA AB EQ 8MG BASE A 207276 002 Mar 27, 2017 Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE TABLET;SUBLINGUAL BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE AB AMNEAL PHARMS EQ 8MG BASE;EQ 2MG BASE A 203136 002 Feb 22, 2013 May CAHN BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE AB AMNEAL PHARMS EQ 2MG BASE;EQ 0.5MG BASE A 203136 001 Feb 22, 2013 May CAHN ZUBSOLV + OREXO US INC EQ 5.7MG BASE;EQ 1.4MG BASE N 204242 002 Jul 03, 2013 Jan CHRS +! EQ 11.4MG BASE;EQ 2.9MG BASE N 204242 004 Dec 11, 2014 Jan CHRS

BUPROPION HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL BUPROPION HYDROCHLORIDE AB3 ANBISON LAB CO LTD 150MG A 207224 001 Jun 30, 2017 Jun NEWA AB3 300MG A 207224 002 Jun 30, 2017 Jun NEWA AB3 JUBILANT GENERICS 150MG A 207459 001 Jun 30, 2017 Jun NEWA AB3 300MG A 207459 002 Jun 30, 2017 Jun NEWA AB3 LUPIN LTD 150MG A 090693 001 Apr 06, 2017 Mar NEWA AB3 300MG A 090693 002 Apr 06, 2017 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -17

TABLET, EXTENDED RELEASE;ORAL BUPROPION HYDROCHLORIDE AB3 SCIEGEN PHARMS INC 150MG A 207479 001 Apr 12, 2017 Mar NEWA AB3 300MG A 207479 002 Apr 12, 2017 Mar NEWA FORFIVO XL +! ALVOGEN 450MG N 022497 001 Nov 10, 2011 Jan CAHN

BUSPIRONE HYDROCHLORIDE TABLET;ORAL BUSPIRONE HYDROCHLORIDE AB AMNEAL PHARMS CO 5MG A 208829 001 May 24, 2017 May NEWA AB 7.5MG A 208829 002 May 24, 2017 May NEWA AB 10MG A 208829 003 May 24, 2017 May NEWA AB 15MG A 208829 004 May 24, 2017 May NEWA AB 30MG A 208829 005 May 24, 2017 May NEWA @ MYLAN 5MG A 075467 001 Feb 28, 2002 Jun DISC @ 10MG A 075467 003 Feb 28, 2002 Jun DISC @ 15MG A 075467 004 Feb 28, 2002 Jun DISC AB STRIDES PHARMA 5MG A 202330 001 Aug 25, 2014 Apr CAHN AB 10MG A 202330 002 Aug 25, 2014 Apr CAHN AB 15MG A 202330 003 Aug 25, 2014 Apr CAHN AB 30MG A 202330 004 Aug 25, 2014 Apr CAHN

BUSULFAN INJECTABLE;INJECTION BUSULFAN AP PHARMASCIENCE INC 6MG/ML A 207050 001 Mar 24, 2017 Mar NEWA AP SANDOZ INC 6MG/ML A 205106 001 Jul 07, 2017 Jun NEWA

BUTABARBITAL SODIUM TABLET;ORAL BUTISOL SODIUM @ MYLAN SPECIALITY LP 15MG N 000793 002 Mar CAHN +! 30MG N 000793 004 Mar CAHN @ 50MG N 000793 003 Mar CAHN @ 100MG N 000793 005 Mar CAHN

BUTORPHANOL TARTRATE INJECTABLE;INJECTION BUTORPHANOL TARTRATE PRESERVATIVE FREE AP WEST-WARD PHARMS INT 1MG/ML A 075045 001 Aug 12, 1998 Jan CAHN AP 2MG/ML A 075045 002 Aug 12, 1998 Jan CAHN

CALCIPOTRIENE AEROSOL, FOAM;TOPICAL SORILUX +! MAYNE PHARMA 0.005% N 022563 001 Oct 06, 2010 Jan CAHN OINTMENT;TOPICAL CALCIPOTRIENE ! GLENMARK PHARMS INC 0.005% A 090633 001 Mar 24, 2010 May CAHN

CALCITONIN SALMON SPRAY, METERED;NASAL CALCITONIN-SALMON AB ! APOTEX INC 200 IU/SPRAY A 076396 001 Nov 17, 2008 Apr CHRS MIACALCIN + @ MYLAN IRELAND LTD 200 IU/SPRAY N 020313 002 Aug 17, 1995 Apr DISC

CALCITONIN SALMON RECOMBINANT SPRAY, METERED;NASAL FORTICAL @ UPSHER-SMITH LABS 200 IU/SPRAY N 021406 001 Aug 12, 2005 Jun CAHN

CALCITRIOL CAPSULE;ORAL CALCITRIOL AB AMNEAL PHARMS 0.25MCG A 203289 002 Jun 14, 2017 May NEWA AB 0.5MCG A 203289 001 Jun 14, 2017 May NEWA INJECTABLE;INJECTION CALCIJEX + ABBVIE@ 0.001MG/ML N 018874 001 Sep 25, 1986 May CRLD + @ 0.002MG/ML N 018874 002 Sep 25, 1986 May CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -18

INJECTABLE;INJECTION CALCITRIOL ! AKORN 0.001MG/ML A 078066 001 Jan 29, 2008 May CHRS

CALCIUM ACETATE CAPSULE;ORAL CALCIUM ACETATE AB CHARTWELL RX 667MG A 091312 001 Jun 01, 2012 Mar CAHN TABLET;ORAL CALCIUM ACETATE AB ! PADDOCK LLC 667MG A 091561 001 Apr 13, 2011 Apr CHRS ELIPHOS AB CYPRESS PHARM 667MG A 078502 001 Nov 25, 2008 Apr CHRS

CALCIUM CHLORIDE INJECTABLE;INJECTION CALCIUM CHLORIDE 10% >A> AP LUITPOLD PHARMS INC 100MG/ML A 209088 001 Jul 27, 2017 Jul NEWA CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER >D> +! HOSPIRA 100MG/ML N 021117 001 Jan 28, 2000 Jul CFTG >A> AP +! 100MG/ML N 021117 001 Jan 28, 2000 Jul CFTG

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE INJECTABLE;INJECTION DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER AP ICU MEDICAL INC 20MG/100ML;5GM/100ML;30MG/100ML;60 N 017608 001 Feb CAHN 0MG/100ML;310MG/100ML POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;104MG/100ML;6 N 019685 005 Oct 17, 1988 Feb CAHN 00MG/100ML;310MG/100ML @ 20MG/100ML;5GM/100ML;179MG/100ML;6 N 019685 006 Oct 17, 1988 Feb CAHN 00MG/100ML;310MG/100ML POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;254MG/100ML;6 N 019685 007 Oct 17, 1988 Feb CAHN 00MG/100ML;310MG/100ML POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER AP ICU MEDICAL INC 20MG/100ML;5GM/100ML;179MG/100ML;6 N 019685 002 Oct 17, 1988 Feb CAHN 00MG/100ML;310MG/100ML AP 20MG/100ML;5GM/100ML;328MG/100ML;6 N 019685 008 Oct 17, 1988 Feb CAHN 00MG/100ML;310MG/100ML POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;254MG/100ML;6 N 019685 003 Oct 17, 1988 Feb CAHN 00MG/100ML;310MG/100ML POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER AP ICU MEDICAL INC 20MG/100ML;5GM/100ML;328MG/100ML;6 N 019685 004 Oct 17, 1988 Feb CAHN 00MG/100ML;310MG/100ML POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;104MG/100ML;6 N 019685 001 Oct 17, 1988 Feb CAHN 00MG/100ML;310MG/100ML

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE INJECTABLE;INJECTION RINGER'S IN PLASTIC CONTAINER AP ICU MEDICAL INC 33MG/100ML;30MG/100ML;860MG/100ML N 018251 001 Feb CAHN SOLUTION;IRRIGATION RINGER'S IN PLASTIC CONTAINER AT ICU MEDICAL INC 33MG/100ML;30MG/100ML;860MG/100ML N 017635 001 Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE INJECTABLE;INJECTION LACTATED RINGER'S IN PLASTIC CONTAINER AP ICU MEDICAL INC 20MG/100ML;30MG/100ML;600MG/100ML; N 017641 001 Feb CAHN 310MG/100ML SOLUTION;IRRIGATION LACTATED RINGER'S IN PLASTIC CONTAINER AT +! ICU MEDICAL INC 20MG/100ML;30MG/100ML;600MG/100ML; N 019416 001 Jan 17, 1986 Feb CAHN 310MG/100ML RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -19

CALCIUM GLUCONATE SOLUTION;IV (INFUSION) CALCIUM GLUCONATE +! FRESENIUS KABI USA 1GM/10ML (100MG/ML) N 208418 001 Jun 15, 2017 Jun NEWA +! 5GM/50ML (100MG/ML) N 208418 002 Jun 15, 2017 Jun NEWA +! 10GM/100ML (100MG/ML) N 208418 003 Jun 15, 2017 Jun NEWA

CANDESARTAN CILEXETIL TABLET;ORAL CANDESARTAN CILEXETIL AB ALEMBIC PHARMS LTD 32MG A 209119 001 Jun 20, 2017 Jun NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE TABLET;ORAL CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE AB MYLAN PHARMS INC 16MG;12.5MG A 090704 001 Dec 04, 2012 May CAHN AB 32MG;12.5MG A 090704 002 Dec 04, 2012 May CAHN AB 32MG;25MG A 090704 003 Dec 04, 2012 May CAHN

CAPECITABINE TABLET;ORAL CAPECITABINE AB AMNEAL PHARMS 150MG A 204741 001 Feb 28, 2017 Feb NEWA AB 500MG A 204741 002 Feb 28, 2017 Feb NEWA

CAPTOPRIL TABLET;ORAL CAPTOPRIL @ BOSCOGEN 12.5MG A 074677 004 May 30, 1997 May CAHN @ 25MG A 074677 002 May 30, 1997 May CAHN @ 50MG A 074677 001 May 30, 1997 May CAHN @ 100MG A 074677 003 May 30, 1997 May CAHN AB MYLAN PHARMS INC 12.5MG A 074434 001 Feb 13, 1996 Mar CAHN AB 25MG A 074434 002 Feb 13, 1996 Mar CAHN AB 50MG A 074434 003 Feb 13, 1996 Mar CAHN AB ! 100MG A 074434 004 Feb 13, 1996 Mar CAHN

CARBAMAZEPINE CAPSULE, EXTENDED RELEASE;ORAL EQUETRO + VALIDUS PHARMS 100MG N 021710 001 Dec 10, 2004 Jun CAHN + 200MG N 021710 002 Dec 10, 2004 Jun CAHN +! 300MG N 021710 003 Dec 10, 2004 Jun CAHN SOLUTION;IV (INFUSION) CARNEXIV +! LUNDBECK PHARMS LLC 200MG/20ML (10MG/ML) N 206030 001 Oct 07, 2016 Jan CAHN SUSPENSION;ORAL TERIL AB TARO PHARM 100MG/5ML A 076729 001 Sep 20, 2004 Mar CAHN

CARBIDOPA; LEVODOPA TABLET;ORAL CARBIDOPA AND LEVODOPA >A> IDT AUSTRALIA LTD 10MG;100MG A 073587 002 Jun 29, 1995 Jul CMS1 >A> 25MG;250MG A 073587 003 Jun 29, 1995 Jul CMS1

CARBOPLATIN INJECTABLE;INJECTION CARBOPLATIN @ WATSON LABS TEVA 50MG/VIAL A 076162 001 Oct 14, 2004 May CAHN @ 150MG/VIAL A 076162 002 Oct 14, 2004 May CAHN @ 450MG/VIAL A 076162 003 Oct 14, 2004 May CAHN INJECTABLE;IV (INFUSION) CARBOPLATIN AP ACCORD HLTHCARE 50MG/5ML (10MG/ML) A 206775 001 Feb 09, 2017 Jan NEWA AP 150MG/15ML (10MG/ML) A 206775 002 Feb 09, 2017 Jan NEWA AP 450MG/45ML (10MG/ML) A 206775 003 Feb 09, 2017 Jan NEWA AP 600MG/60ML (10MG/ML) A 206775 004 Feb 09, 2017 Jan NEWA AP GLAND PHARMA LTD 50MG/5ML (10MG/ML) A 207324 001 Feb 15, 2017 Jan NEWA AP 150MG/15ML (10MG/ML) A 207324 002 Feb 15, 2017 Jan NEWA AP 450MG/45ML (10MG/ML) A 207324 003 Feb 15, 2017 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -20

INJECTABLE;IV (INFUSION) CARBOPLATIN AP 600MG/60ML (10MG/ML) A 207324 004 Feb 15, 2017 Jan NEWA AP INGENUS PHARMS LLC 50MG/5ML (10MG/ML) A 208487 001 Apr 26, 2017 Apr NEWA AP 150MG/15ML (10MG/ML) A 208487 002 Apr 26, 2017 Apr NEWA AP 450MG/45ML (10MG/ML) A 208487 003 Apr 26, 2017 Apr NEWA AP 600MG/60ML (10MG/ML) A 208487 004 Apr 26, 2017 Apr NEWA

CARISOPRODOL CAPSULE;ORAL SOMA @ MYLAN SPECIALITY LP 250MG N 011792 003 Mar CAHN TABLET;ORAL CARISOPRODOL @ EPIC PHARMA LLC 350MG A 040397 001 Sep 21, 2000 May CAHN AA HIKMA INTL PHARMS 350MG A 040124 001 Jan 24, 1996 Apr CMFD AB NOSTRUM LABS INC 250MG A 207237 001 May 11, 2017 Apr NEWA @ WATSON LABS TEVA 350MG A 086179 001 May CAHN SOMA AB +! MYLAN SPECIALITY LP 250MG N 011792 004 Sep 13, 2007 Mar CAHN AA + 350MG N 011792 001 Mar CAHN

CARTEOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC CARTEOLOL HYDROCHLORIDE AT ! SANDOZ INC 1% A 075476 001 Jan 03, 2000 May CHRS AT 1% A 075476 001 Jan 03, 2000 Mar CAHN OCUPRESS + @ NOVARTIS 1% N 019972 001 May 23, 1990 May DISC

CARVEDILOL TABLET;ORAL CARVEDILOL >D> AB PLIVA HRVATSKA DOO 3.125MG A 078240 001 Oct 30, 2007 Jul DISC >A> @ 3.125MG A 078240 001 Oct 30, 2007 Jul DISC >D> AB 6.25MG A 078240 002 Oct 30, 2007 Jul DISC >A> @ 6.25MG A 078240 002 Oct 30, 2007 Jul DISC >D> AB 12.5MG A 078240 003 Oct 30, 2007 Jul DISC >A> @ 12.5MG A 078240 003 Oct 30, 2007 Jul DISC >D> AB 25MG A 078240 004 Oct 30, 2007 Jul DISC >A> @ 25MG A 078240 004 Oct 30, 2007 Jul DISC

CASPOFUNGIN ACETATE POWDER;IV (INFUSION) CANCIDAS AP +! MERCK 50MG/VIAL N 021227 001 Jan 26, 2001 Mar CDFR AP +! 70MG/VIAL N 021227 002 Jan 26, 2001 Mar CDFR

CEFADROXIL/CEFADROXIL HEMIHYDRATE CAPSULE;ORAL CEFADROXIL >A> AB CSPC OUYI PHARM CO EQ 500MG BASE A 205072 001 Jul 28, 2017 Jul NEWA

CEFDINIR CAPSULE;ORAL OMNICEF + @ ABBVIE 300MG N 050739 001 Dec 04, 1997 Jan CRLD FOR SUSPENSION;ORAL OMNICEF + @ ABBVIE 125MG/5ML N 050749 001 Dec 04, 1997 Jan CRLD + @ 250MG/5ML N 050749 002 Jul 29, 2004 Jan CRLD

CEFIXIME FOR SUSPENSION;ORAL CEFIXIME AB BELCHER PHARMS LLC 100MG/5ML A 206938 001 Feb 06, 2017 Jan NEWA AB 200MG/5ML A 206938 002 Feb 06, 2017 Jan NEWA AB 500MG/5ML A 206939 001 Feb 06, 2017 Jan NEWA SUPRAX AB +! LUPIN LTD 500MG/5ML N 202091 001 Feb 20, 2013 Jan CFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -21

CEFOTETAN DISODIUM INJECTABLE;INJECTION CEFOTAN AP + TELIGENT EQ 1GM BASE/VIAL N 050588 001 Dec 27, 1985 Apr CAHN AP + EQ 2GM BASE/VIAL N 050588 002 Dec 27, 1985 Apr CAHN @ EQ 10GM BASE/VIAL N 050588 003 Apr 25, 1988 Apr CAHN CEFOTAN IN PLASTIC CONTAINER @ TELIGENT EQ 20MG BASE/ML N 050694 002 Jul 30, 1993 Apr CAHN @ EQ 40MG BASE/ML N 050694 001 Jul 30, 1993 Apr CAHN

CEFOXITIN SODIUM INJECTABLE;INJECTION CEFOXITIN AP WEST-WARD PHARMS INT EQ 1GM BASE/VIAL A 065051 001 Sep 11, 2000 Jan CAHN AP EQ 2GM BASE/VIAL A 065051 002 Sep 11, 2000 Jan CAHN AP EQ 10GM BASE/VIAL A 065050 001 Sep 11, 2000 Jan CAHN

CEFPROZIL TABLET;ORAL CEFPROZIL AB AUROBINDO PHARMA LTD 250MG A 065340 001 May 24, 2007 Jan CAHN AB 500MG A 065340 002 May 24, 2007 Jan CAHN

CEFTAZIDIME INJECTABLE;INJECTION FORTAZ AP +! TELIGENT 500MG/VIAL N 050578 001 Jul 19, 1985 Apr CAHN AP +! 1GM/VIAL N 050578 002 Jul 19, 1985 Apr CAHN AP +! 2GM/VIAL N 050578 003 Jul 19, 1985 Apr CAHN AP +! 6GM/VIAL N 050578 004 Jul 19, 1985 Apr CAHN

CEFTAZIDIME SODIUM INJECTABLE;INJECTION FORTAZ IN PLASTIC CONTAINER @ TELIGENT EQ 10MG BASE/ML N 050634 001 Apr 28, 1989 May CAHN +! EQ 20MG BASE/ML N 050634 002 Apr 28, 1989 May CAHN +! EQ 40MG BASE/ML N 050634 003 Apr 28, 1989 May CAHN

CEFTRIAXONE SODIUM INJECTABLE;INJECTION CEFTRIAXONE SODIUM AP SAGENT PHARMS EQ 10GM BASE/VIAL A 091117 001 Jan 20, 2017 Jan NEWA ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER + @ HOFFMANN LA ROCHE EQ 10MG BASE/ML N 050624 001 Feb 11, 1987 Jan CRLD + @ EQ 20MG BASE/ML N 050624 002 Feb 11, 1987 Jan CRLD + @ EQ 40MG BASE/ML N 050624 003 Feb 11, 1987 Jan CRLD

CEFUROXIME AXETIL TABLET;ORAL CEFUROXIME AXETIL AB AUROBINDO PHARMA LTD EQ 125MG BASE A 065308 001 Mar 29, 2006 Jan CAHN AB EQ 250MG BASE A 065308 002 Mar 29, 2006 Jan CAHN AB EQ 500MG BASE A 065308 003 Mar 29, 2006 Jan CAHN

CEFUROXIME SODIUM INJECTABLE;INJECTION ZINACEF AP +! TELIGENT EQ 1.5GM BASE/VIAL N 050558 003 Oct 19, 1983 May CAHN AP +! EQ 7.5GM BASE/VIAL N 050558 004 Oct 23, 1986 May CAHN ZINACEF IN PLASTIC CONTAINER @ TELIGENT EQ 15MG BASE/ML N 050643 001 Apr 28, 1989 May CAHN +! EQ 30MG BASE/ML N 050643 002 Apr 28, 1989 May CAHN INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ZINACEF AB +! TELIGENT EQ 750MG BASE/VIAL N 050558 002 Oct 19, 1983 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -22

CELECOXIB CAPSULE;ORAL CELECOXIB AB JUBILANT GENERICS 50MG A 207061 001 Apr 04, 2017 Mar NEWA AB 100MG A 207061 002 Apr 04, 2017 Mar NEWA AB 200MG A 207061 003 Apr 04, 2017 Mar NEWA AB 400MG A 207061 004 Apr 04, 2017 Mar NEWA

CEPHALEXIN CAPSULE;ORAL CEPHALEXIN AB AUROBINDO PHARMA LTD EQ 250MG BASE A 065253 001 Nov 16, 2005 Jan CAHN AB EQ 500MG BASE A 065253 002 Nov 16, 2005 Jan CAHN

CEPHAPIRIN SODIUM INJECTABLE;INJECTION CEPHAPIRIN SODIUM @ WEST-WARD PHARMS INT EQ 500MG BASE/VIAL A 062720 001 Jul 02, 1987 Jan CAHN @ EQ 1GM BASE/VIAL A 062720 002 Jul 02, 1987 Jan CAHN @ EQ 2GM BASE/VIAL A 062720 003 Jul 02, 1987 Jan CAHN @ EQ 20GM BASE/VIAL A 062720 004 Jul 02, 1987 Jan CAHN

CETIRIZINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC ZERVIATE +! NICOX OPHTHALMICS EQ 0.24% BASE N 208694 001 May 30, 2017 May NEWA SYRUP;ORAL CETIRIZINE HYDROCHLORIDE AA ALLIED PHARMA INC 5MG/5ML A 090191 001 Nov 12, 2009 Apr CAHN

CEVIMELINE HYDROCHLORIDE CAPSULE;ORAL CEVIMELINE HYDROCHLORIDE AB RISING PHARMS INC 30MG A 203775 001 Jun 04, 2014 May CAHN

CHENODIOL TABLET;ORAL CHENIX + @ LEADIANT BIOSCI INC 250MG N 018513 002 Jul 28, 1983 Feb CAHN

CHLORAMPHENICOL SODIUM SUCCINATE INJECTABLE;INJECTION CHLOROMYCETIN + @ PARKEDALE EQ 1GM BASE/VIAL N 050155 001 Mar CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE CAPSULE;ORAL CHLORDIAZEPOXIDE HYDROCHLORIDE @ UPSHER-SMITH LABS 5MG A 084678 001 Jun CAHN @ 10MG A 084041 001 Jun CAHN @ 25MG A 084679 002 Jun CAHN @ USL PHARMA 10MG A 084623 001 Apr DISC

CHLORHEXIDINE GLUCONATE SOLUTION;DENTAL PERIOGARD AT COLGATE PALMOLIVE CO 0.12% A 073695 001 Jan 14, 1994 May CAHN

CHLORPHENESIN CARBAMATE TABLET;ORAL MAOLATE @ PAMLAB LLC 400MG N 014217 002 Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE SOLUTION;ORAL HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE AA ACELLA PHARMS LLC 4MG/5ML;5MG/5ML A 206891 001 Jun 09, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -23

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE SOLUTION;ORAL HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE AA BIO-PHARM INC 4MG/5ML;5MG/5ML;60MG/5ML A 206660 001 May 15, 2017 May NEWA

CHLORPROMAZINE HYDROCHLORIDE TABLET;ORAL CHLORPROMAZINE HYDROCHLORIDE USL PHARMA 10MG A 083386 001 Jun CAHN 10MG A 083386 001 May CTEC ! 25MG A 084112 001 Jun CAHN ! 25MG A 084112 001 May CHRS 50MG A 084113 001 Jun CAHN 50MG A 084113 001 May CTEC ! 100MG A 084114 001 Jun CAHN ! 100MG A 084114 001 May CHRS 200MG A 084115 001 Jun CAHN 200MG A 084115 001 May CTEC THORAZINE @ GLAXOSMITHKLINE 10MG N 009149 002 May CRLD @ 25MG N 009149 007 May CRLD @ 50MG N 009149 013 May CRLD @ 100MG N 009149 018 May CRLD @ 200MG N 009149 020 May CRLD

CHLORPROPAMIDE TABLET;ORAL CHLORPROPAMIDE @ ANI PHARMS INC 250MG A 087353 001 Jan CAHN @ WATSON LABS TEVA 100MG A 088852 001 Sep 26, 1984 May CAHN @ 250MG A 088826 001 Sep 26, 1984 May CAHN GLUCAMIDE >D> @ ANI PHARMS INC 250MG A 088641 001 Oct 11, 1984 Jul CMFD >A> AB 250MG A 088641 001 Oct 11, 1984 Jul CMFD

CHLORTHALIDONE TABLET;ORAL CHLORTHALIDONE AB RICONPHARMA LLC 25MG A 206904 001 Mar 30, 2017 Mar NEWA AB 50MG A 206904 002 Mar 30, 2017 Mar NEWA

CHOLESTYRAMINE POWDER;ORAL CHOLESTYRAMINE AB ZYDUS PHARMS USA INC EQ 4GM RESIN/SCOOPFUL A 202902 001 Apr 25, 2017 Apr NEWA PREVALITE AB UPSHER-SMITH LABS EQ 4GM RESIN/PACKET A 073263 001 Feb 22, 1996 Jun CAHN AB EQ 4GM RESIN/SCOOPFUL A 073263 002 Oct 30, 1997 Jun CAHN

CHOLINE C-11 INJECTABLE;INTRAVENOUS CHOLINE C-11 >D> AP UNIV TX MD ANDERSON 4-33.1mCi/ML A 205690 001 Oct 29, 2015 Jul CPOT >A> 4-100mCi/ML A 205690 001 Oct 29, 2015 Jul CPOT

CHOLINE FENOFIBRATE CAPSULE, DELAYED RELEASE;ORAL FENOFIBRIC ACID AB ALEMBIC PHARMS LTD EQ 45MG FENOFIBRIC ACID A 208705 001 May 12, 2017 May NEWA AB EQ 135MG FENOFIBRIC ACID A 208705 002 May 12, 2017 May NEWA

CICLESONIDE AEROSOL, METERED;INHALATION ALVESCO >A> +! ASTRAZENECA PHARMS 0.08MG/INH N 021658 002 Jan 10, 2008 Jul CAHN >A> +! 0.16MG/INH N 021658 003 Jan 10, 2008 Jul CAHN >D> +! TAKEDA GMBH 0.08MG/INH N 021658 002 Jan 10, 2008 Jul CAHN >D> +! 0.16MG/INH N 021658 003 Jan 10, 2008 Jul CAHN AEROSOL, METERED;NASAL ZETONNA >A> +! ASTRAZENECA PHARMS 0.037MG/INH N 202129 001 Jan 20, 2012 Jul CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -24

AEROSOL, METERED;NASAL ZETONNA >D> +! TAKEDA GMBH 0.037MG/INH N 202129 001 Jan 20, 2012 Jul CAHN SPRAY, METERED;NASAL OMNARIS >A> +! ASTRAZENECA PHARMS 0.05MG/INH N 022004 001 Oct 20, 2006 Jul CAHN >D> +! TAKEDA GMBH 0.05MG/INH N 022004 001 Oct 20, 2006 Jul CAHN

CICLOPIROX CREAM;TOPICAL CICLOPIROX AB PERRIGO NEW YORK 0.77% A 077364 001 Mar 03, 2006 Apr CAHN SHAMPOO;TOPICAL CICLOPIROX AT PERRIGO CO 1% A 078594 001 Feb 16, 2010 Apr CAHN

CILOSTAZOL TABLET;ORAL CILOSTAZOL @ EPIC PHARMA LLC 50MG A 077150 001 Mar 11, 2005 May CAHN @ 100MG A 077022 001 Nov 23, 2004 May CAHN MY LAN@ MYLAN@ 50MG A 077323 002 Apr 20, 2006 May DISC @ 100MG A 077323 001 Apr 20, 2006 May DISC @ MYLAN PHARMS INC 50MG A 077019 001 Nov 23, 2004 Mar DISC @ 100MG A 077019 002 Nov 23, 2004 Mar DISC @ PLIVA HRVATSKA DOO 50MG A 077898 001 Oct 29, 2007 Mar DISC @ 100MG A 077898 002 Oct 29, 2007 Mar DISC PLETAL + OTSUKA@ 50MG N 020863 001 Jan 15, 1999 Jan CRLD + @ 100MG N 020863 002 Jan 15, 1999 Jan CRLD

CIMETIDINE TABLET;ORAL CIMETIDINE @ CHARTWELL MOLECULES 200MG A 074281 001 May 17, 1994 Jan CAHN @ 300MG A 074281 002 May 17, 1994 Jan CAHN @ 400MG A 074281 003 May 17, 1994 Jan CAHN @ 800MG A 074329 001 May 17, 1994 Jan CAHN @ SANDOZ INC 200MG A 074250 001 Jun 29, 1995 Mar CAHN @ 300MG A 074250 002 Jun 29, 1995 Mar CAHN @ 400MG A 074250 003 Jun 29, 1995 Mar CAHN @ 800MG A 074250 004 Jun 29, 1995 Mar CAHN @ UPSHER-SMITH LABS 200MG A 074506 001 Jan 24, 1996 Jun CAHN @ 300MG A 074506 002 Jan 24, 1996 Jun CAHN @ 400MG A 074506 003 Jan 24, 1996 Jun CAHN @ 800MG A 074506 004 Jan 24, 1996 Jun CAHN

CIMETIDINE HYDROCHLORIDE SOLUTION;ORAL CIMETIDINE HYDROCHLORIDE AA PHARM ASSOC EQ 300MG BASE/5ML A 074553 001 Jan 27, 1997 May CAHN

CIPROFLOXACIN INJECTABLE;INJECTION CIPRO + @ BAYER HLTHCARE 400MG/40ML (10MG/ML) N 019847 001 Dec 26, 1990 Feb DISC + @ 200MG/20ML (10MG/ML) N 019847 002 Dec 26, 1990 Feb DISC CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER + @ BAYER HLTHCARE 200MG/100ML N 019857 001 Dec 26, 1990 Feb DISC + @ 400MG/200ML N 019857 002 Dec 26, 1990 Feb DISC CIPROFLOXACIN AP ! CLARIS 200MG/20ML (10MG/ML) A 078062 001 Apr 29, 2008 Feb CHRS AP ! 400MG/40ML (10MG/ML) A 078062 002 Apr 29, 2008 Feb CHRS CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER AP ! HOSPIRA 200MG/100ML A 077753 001 Mar 18, 2008 Feb CHRS AP ! 400MG/200ML A 077753 002 Mar 18, 2008 Feb CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -25

CIPROFLOXACIN HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC CIPROFLOXACIN HYDROCHLORIDE AT AMRING PHARMS EQ 0.3% BASE A 078598 001 Jan 16, 2008 Mar CAHN AT TELIGENT EQ 0.3% BASE A 076754 001 Jun 09, 2004 Apr CAHN TABLET;ORAL CIPROFLOXACIN HYDROCHLORIDE AB TARO PHARM EQ 100MG BASE A 076912 001 Feb 18, 2005 Mar CAHN AB EQ 250MG BASE A 076912 002 Oct 06, 2004 Mar CAHN AB EQ 500MG BASE A 076912 003 Oct 06, 2004 Mar CAHN AB EQ 750MG BASE A 076912 004 Oct 06, 2004 Mar CAHN

CISATRACURIUM BESYLATE INJECTABLE;INJECTION CISATRACURIUM BESYLATE AP ACCORD HLTHCARE EQ 2MG BASE/ML A 205873 001 Jun 16, 2017 Jun NEWA CISATRACURIUM BESYLATE PRESERVATIVE FREE AP ACCORD HLTHCARE EQ 2MG BASE/ML A 205872 001 Jun 16, 2017 Jun NEWA AP EQ 10MG BASE/ML A 205872 002 Jun 16, 2017 Jun NEWA AP JIANGSU HENGRUI MED EQ 2MG BASE/ML A 204960 001 Jan 27, 2017 Jan NEWA

CISPLATIN INJECTABLE;INJECTION CISPLATIN AP GLAND PHARMA LTD 1MG/ML A 207323 001 Mar 17, 2017 Mar NEWA AP + HQ SPCLT PHARMA 1MG/ML N 018057 004 Nov 08, 1988 Mar CRLD PLATINOL + @ HQ SPCLT PHARMA 10MG/VIAL N 018057 001 Mar CRLD + @ 50MG/VIAL N 018057 002 Mar CRLD PLATINOL-AQ + @ HQ SPCLT PHARMA 0.5MG/ML N 018057 003 Jul 18, 1984 Mar CRLD

CITALOPRAM HYDROBROMIDE CAPSULE;ORAL CITALOPRAM HYDROBROMIDE @ MYLAN PHARMS INC EQ 10MG BASE A 077668 001 Feb 28, 2007 Mar DISC @ EQ 20MG BASE A 077668 002 Feb 28, 2007 Mar DISC @ EQ 40MG BASE A 077668 003 Feb 28, 2007 Mar DISC SOLUTION;ORAL CITALOPRAM HYDROBROMIDE AA AUROBINDO PHARMA LTD EQ 10MG BASE/5ML A 077812 001 Aug 28, 2006 Jan CAHN TABLET;ORAL CITALOPRAM HYDROBROMIDE @ EPIC PHARMA LLC EQ 10MG BASE A 077036 001 Oct 28, 2004 May CAHN @ EQ 20MG BASE A 077036 002 Oct 28, 2004 May CAHN @ EQ 40MG BASE A 077036 003 Oct 28, 2004 May CAHN MY LAN@ MYLAN@ EQ 10MG BASE A 077039 001 Feb 03, 2005 Jun DISC @ EQ 20MG BASE A 077039 002 Feb 03, 2005 Jun DISC @ EQ 40MG BASE A 077039 003 Feb 03, 2005 Jun DISC @ MYLAN PHARMS INC EQ 10MG BASE A 077037 001 Nov 05, 2004 May DISC @ EQ 20MG BASE A 077037 002 Nov 05, 2004 May DISC @ EQ 40MG BASE A 077037 003 Nov 05, 2004 May DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE FOR SOLUTION;ORAL PREPOPIK +! FERRING PHARMS INC 12GM/PACKET;3.5GM/PACKET;10MG/PACK N 202535 001 Jul 16, 2012 Mar CAHN ET

CLARITHROMYCIN TABLET;ORAL CLARITHROMYCIN @ MYLAN 250MG A 065195 001 Mar 11, 2005 May DISC @ 500MG A 065195 002 Mar 11, 2005 May DISC

CLEMASTINE FUMARATE TABLET;ORAL CLEMASTINE FUMARATE @ SANDOZ 2.68MG A 073459 001 Oct 31, 1993 Feb DISC ! TEVA 2.68MG A 073283 001 Jan 31, 1992 Feb CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -26

CLINDAMYCIN HYDROCHLORIDE CAPSULE;ORAL CLINDAMYCIN HYDROCHLORIDE AB EPIC PHARMA LLC EQ 150MG BASE A 065194 001 Mar 22, 2004 May CAHN AB EQ 300MG BASE A 065194 002 Mar 22, 2004 May CAHN @ MYLAN PHARMS INC EQ 75MG BASE A 091225 001 May 31, 2011 May DISC @ EQ 150MG BASE A 091225 002 May 31, 2011 May DISC @ EQ 300MG BASE A 091225 003 May 31, 2011 May DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR SOLUTION;ORAL CLINDAMYCIN PALMITATE HYDROCHLORIDE AA INVAGEN PHARMS EQ 75MG BASE/5ML A 206958 001 May 05, 2017 Apr NEWA AA ORIT LABS LLC EQ 75MG BASE/5ML A 206958 001 May 05, 2017 Jun CAHN AA PADDOCK LLC EQ 75MG BASE/5ML A 090902 001 Jul 07, 2010 Apr CAHN

CLINDAMYCIN PHOSPHATE AEROSOL, FOAM;TOPICAL EVOCLIN AT +! MYLAN PHARMS INC 1% N 050801 001 Oct 22, 2004 Jan CAHN INJECTABLE;INJECTION CLINDAMYCIN PHOSPHATE AP SAGENT PHARMS EQ 150MG BASE/ML A 090109 001 Sep 30, 2011 Apr CAHN AP WEST-WARD PHARMS INT EQ 150MG BASE/ML A 065206 001 Sep 24, 2004 Jan CAHN CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER >A> AP BAXTER HLTHCARE CORP EQ 6MG BASE/ML A 208084 001 Jun 28, 2017 Jul CAHN >A> AP EQ 12MG BASE/ML A 208084 002 Jun 28, 2017 Jul CAHN >A> AP EQ 18MG BASE/ML A 208084 003 Jun 28, 2017 Jul CAHN >D> AP CELERITY PHARMS EQ 6MG BASE/ML A 208084 001 Jun 28, 2017 Jul CAHN AP EQ 6MG BASE/ML A 208084 001 Jun 28, 2017 Jun NEWA >D> AP EQ 12MG BASE/ML A 208084 002 Jun 28, 2017 Jul CAHN AP EQ 12MG BASE/ML A 208084 002 Jun 28, 2017 Jun NEWA >D> AP EQ 18MG BASE/ML A 208084 003 Jun 28, 2017 Jul CAHN AP EQ 18MG BASE/ML A 208084 003 Jun 28, 2017 Jun NEWA SOLUTION;IV (INFUSION) CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE +! BAXTER HLTHCARE CORP EQ 300MG BASE/50ML (EQ 6MG N 208083 001 Apr 20, 2017 May CAHN BASE/ML) +! EQ 600MG BASE/50ML (EQ 12MG N 208083 002 Apr 20, 2017 May CAHN BASE/ML) +! EQ 900MG BASE/50ML (EQ 18MG N 208083 003 Apr 20, 2017 May CAHN BASE/ML) +! CELERITY PHARMS EQ 300MG BASE/50ML (EQ 6MG N 208083 001 Apr 20, 2017 Apr NEWA BASE/ML) +! EQ 600MG BASE/50ML (EQ 12MG N 208083 002 Apr 20, 2017 Apr NEWA BASE/ML) +! EQ 900MG BASE/50ML (EQ 18MG N 208083 003 Apr 20, 2017 Apr NEWA BASE/ML) SOLUTION;TOPICAL CLINDAMYCIN PHOSPHATE AT FOUGERA PHARMS INC EQ 1% BASE A 064159 001 Jun 05, 1997 Jan CAHN SWAB;TOPICAL CLINDETS AT PERRIGO CO EQ 1% BASE A 064136 001 Sep 30, 1996 Apr CAHN

CLOBAZAM SUSPENSION;ORAL ONFI +! LUNDBECK PHARMS LLC 2.5MG/ML N 203993 001 Dec 14, 2012 Jan CAHN TABLET;ORAL ONFI @ LUNDBECK PHARMS LLC 5MG N 202067 001 Oct 21, 2011 Jan CAHN + 10MG N 202067 002 Oct 21, 2011 Jan CAHN +! 20MG N 202067 003 Oct 21, 2011 Jan CAHN

CLOBETASOL PROPIONATE AEROSOL, FOAM;TOPICAL CLOBETASOL PROPIONATE >A> AB1 INGENUS PHARMS LLC 0.05% A 206805 001 Jul 31, 2017 Jul NEWA OLUX AB1 +! MYLAN PHARMS INC 0.05% N 021142 001 May 26, 2000 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -27

AEROSOL, FOAM;TOPICAL OLUX E AB2 +! MYLAN PHARMS INC 0.05% N 022013 001 Jan 12, 2007 Jan CAHN CREAM;TOPICAL CLOBETASOL PROPIONATE AB1 FOUGERA PHARMS INC 0.05% A 074392 001 Sep 30, 1996 Jan CAHN AB1 MYLAN PHARMS INC 0.05% A 075338 001 Feb 09, 2001 May CMFD @ 0.05% A 075338 001 Feb 09, 2001 Jan CAHN AB1 TARO 0.05% A 074249 001 Jul 08, 1996 Apr CAHN GEL;TOPICAL CLOBETASOL PROPIONATE AB PERRIGO CO 0.05% A 075027 001 Oct 31, 1997 Apr CAHN AB TARO 0.05% A 075279 001 May 28, 1999 Apr CAHN AB TELIGENT PHARMA INC 0.05% A 208881 001 Mar 06, 2017 Feb NEWA OINTMENT;TOPICAL CLOBETASOL PROPIONATE AB GLENMARK PHARMS 0.05% A 208933 001 Mar 20, 2017 Mar NEWA AB1 MYLAN PHARMS INC 0.05% A 075057 001 Aug 12, 1998 May CMFD @ 0.05% A 075057 001 Aug 12, 1998 Jan CAHN AB TARO 0.05% A 074248 001 Jul 12, 1996 Apr CAHN TEMOVATE + @ FOUGERA PHARMS 0.05% N 019323 001 Dec 27, 1985 Jan CRLD SOLUTION;TOPICAL CLOBETASOL PROPIONATE AT TARO 0.05% A 075224 001 Nov 16, 1998 Apr CAHN SPRAY;TOPICAL CLOBETASOL PROPIONATE AT AKORN 0.05% A 207218 001 Apr 28, 2017 Apr NEWA AT ZYDUS PHARMS USA INC 0.05% A 206378 001 Feb 16, 2017 Feb NEWA

CLOFARABINE INJECTABLE;IV (INFUSION) CLOFARABINE AP ABON PHARMS LLC 20MG/20ML (1MG/ML) A 204029 001 May 09, 2017 Apr NEWA CLOLAR AP +! GENZYME 20MG/20ML (1MG/ML) N 021673 001 Dec 28, 2004 Apr CFTG

CLOFIBRATE CAPSULE;ORAL CLOFIBRATE @ USL PHARMA 500MG A 070531 001 Jun 16, 1986 Jun CAHN

CLOMIPRAMINE HYDROCHLORIDE CAPSULE;ORAL CLOMIPRAMINE HYDROCHLORIDE AB SANDOZ 25MG A 074953 001 Jun 25, 1997 Feb CMFD AB 50MG A 074953 002 Jun 25, 1997 Feb CMFD AB 75MG A 074953 003 Jun 25, 1997 Feb CMFD

CLONAZEPAM TABLET;ORAL CLONAZEPAM @ MYLAN PHARMS INC 0.5MG A 074940 001 Oct 30, 1997 Mar DISC @ 1MG A 074940 002 Oct 30, 1997 Mar DISC @ 2MG A 074940 003 Oct 30, 1997 Mar DISC AB PRINSTON INC 0.5MG A 077856 001 Jun 28, 2006 Feb CAHN AB 1MG A 077856 002 Jun 28, 2006 Feb CAHN AB 2MG A 077856 003 Jun 28, 2006 Feb CAHN

CLONIDINE HYDROCHLORIDE TABLET;ORAL CLONIDINE HYDROCHLORIDE >A> CHARTWELL MOLECULES 0.1MG A 071785 002 Apr 05, 1988 Jul CMS1 >A> 0.2MG A 071785 003 Apr 05, 1988 Jul CMS1 @ 0.3MG A 071785 001 Apr 05, 1988 Feb CAHN AB PRINSTON INC 0.1MG A 077901 001 Mar 09, 2007 Feb CAHN AB 0.2MG A 077901 002 Mar 09, 2007 Feb CAHN AB 0.3MG A 077901 003 Mar 09, 2007 Feb CAHN TABLET, EXTENDED RELEASE;ORAL CLONIDINE HYDROCHLORIDE AB2 ACTAVIS ELIZABETH 0.1MG A 202792 001 May 15, 2015 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -28

TABLET, EXTENDED RELEASE;ORAL CLONIDINE HYDROCHLORIDE AB1 0.1MG A 203320 001 May 15, 2015 Apr CAHN @ 0.2MG A 202792 002 May 15, 2015 Apr CAHN @ 0.2MG A 203320 002 May 15, 2015 Apr CAHN

CLOPIDOGREL BISULFATE TABLET;ORAL CLOPIDOGREL BISULFATE >A> AB ACME LABS EQ 75MG BASE A 078004 001 May 17, 2012 Jul CAHN >D> AB ALLIED PHARMA INC EQ 75MG BASE A 078004 001 May 17, 2012 Jul CAHN AB EQ 75MG BASE A 078004 001 May 17, 2012 Mar CAHN AB CSPC OUYI PHARM CO EQ 75MG BASE A 204359 001 Feb 02, 2017 Jan NEWA

CLORAZEPATE DIPOTASSIUM TABLET;ORAL CLORAZEPATE DIPOTASSIUM AB TARO PHARM 3.75MG A 075731 003 Apr 27, 2000 Mar CAHN AB 7.5MG A 075731 002 Apr 27, 2000 Mar CAHN AB 15MG A 075731 001 Apr 27, 2000 Mar CAHN

CLOTRIMAZOLE SOLUTION;TOPICAL CLOTRIMAZOLE AT ! TARO 1% A 074580 001 Jul 29, 1996 Apr CAHN LOTRIMIN >D> @ SCHERING PLOUGH 1% N 017613 001 Jul CRLD >A> + @ 1% N 017613 001 Jul CRLD

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE @ PHARM ASSOC 10MG/5ML;6.25MG/5ML A 089647 001 Dec 22, 1988 May CAHN

CODEINE SULFATE SOLUTION;ORAL CODEINE SULFATE @ WEST-WARD PHARMS INT 30MG/5ML N 202245 001 Jun 30, 2011 Jan CAHN TABLET;ORAL CODEINE SULFATE AB + WEST-WARD PHARMS INT 15MG N 022402 001 Jul 16, 2009 Jan CAHN AB + 30MG N 022402 002 Jul 16, 2009 Jan CAHN AB +! 60MG N 022402 003 Jul 16, 2009 Jan CAHN

CORTICOTROPIN INJECTABLE;INJECTION PURIFIED CORTROPHIN GEL @ ANI PHARMS INC 40 UNITS/ML N 008975 001 May CAHN @ 80 UNITS/ML N 008975 002 May CAHN

CORTICOTROPIN-ZINC HYDROXIDE INJECTABLE;INJECTION CORTROPHIN-ZINC @ ANI PHARMS INC 40 UNITS/ML N 009854 001 May CAHN

CORTISONE ACETATE TABLET;ORAL CORTONE + @ MERCK 25MG N 007750 003 Mar CRLD

COSYNTROPIN SOLUTION;INTRAVENOUS COSYNTROPIN @ SANDOZ INC 0.25MG/ML (0.25MG/ML) N 022028 001 Feb 21, 2008 May CAHN

CROMOLYN SODIUM CONCENTRATE;ORAL GASTROCROM AA +! MYLAN SPECIALITY LP 100MG/5ML N 020479 001 Feb 29, 1996 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -29

SOLUTION;INHALATION CROMOLYN SODIUM >D> AN BAUSCH AND LOMB 10MG/ML A 075585 001 Dec 21, 2000 Jul DISC >A> @ 10MG/ML A 075585 001 Dec 21, 2000 Jul DISC AN 10MG/ML A 075585 001 Dec 21, 2000 Feb CAHN INTAL @ KING PHARMS LLC 10MG/ML N 018596 001 May 28, 1982 May CAHN

CYANOCOBALAMIN INJECTABLE;INJECTION CYANOCOBALAMIN AP MYLAN LABS LTD 1MG/ML A 204829 001 Jun 05, 2017 May NEWA DODEX @ ACCORD HLTHCARE 1MG/ML A 083022 001 Jun CAHN

CYCLOBENZAPRINE HYDROCHLORIDE TABLET;ORAL CYCLOBENZAPRINE HYDROCHLORIDE AB OXFORD PHARMS 5MG A 077209 002 Feb 03, 2006 May CMS1 AB PRINSTON INC 5MG A 077797 001 Feb 28, 2007 Feb CAHN AB 10MG A 077797 002 Feb 28, 2007 Feb CAHN AB RUBICON RES PVT LTD 5MG A 208170 001 May 31, 2017 May NEWA AB 7.5MG A 208170 002 May 31, 2017 May NEWA AB 10MG A 208170 003 May 31, 2017 May NEWA @ UPSHER-SMITH LABS 5MG A 072854 002 Feb 03, 2006 Jun CAHN @ 10MG A 072854 001 Nov 19, 1991 Jun CAHN

CYCLOPHOSPHAMIDE CAPSULE;ORAL CYCLOPHOSPHAMIDE + WEST-WARD PHARMS INT 25MG N 203856 001 Sep 16, 2013 Jan CAHN +! 50MG N 203856 002 Sep 16, 2013 Jan CAHN INJECTABLE;INJECTION CYTOXAN (LYOPHILIZED) + @ BAXTER HLTHCARE 500MG/VIAL N 012142 003 Feb CRLD + @ 1GM/VIAL N 012142 004 Aug 30, 1982 Feb CRLD + @ 2GM/VIAL N 012142 005 Aug 30, 1982 Feb CRLD

CYPROHEPTADINE HYDROCHLORIDE SYRUP;ORAL CYPROHEPTADINE HYDROCHLORIDE >A> AA SILARX PHARMS INC 2MG/5ML A 203191 001 Jul 13, 2017 Jul NEWA PERIACTIN + @ MERCK 2MG/5ML N 013220 002 Jan CRLD TABLET;ORAL CYPROHEPTADINE HYDROCHLORIDE AA APNAR PHARMA LP 4MG A 207555 001 Jan 31, 2017 Jan NEWA AA IMPAX LABS INC 4MG A 040537 001 Sep 30, 2003 Feb CAHN AA SANTOS BIOTECH 4MG A 040644 001 May 30, 2006 May CAHN AA ZYDUS PHARMS USA INC 4MG A 208938 001 May 19, 2017 May NEWA

CYSTEAMINE BITARTRATE CAPSULE, DELAYED RELEASE;ORAL PROCYSBI + HORIZON PHARMA USA EQ 25MG BASE N 203389 001 Apr 30, 2013 Mar CAHN +! EQ 75MG BASE N 203389 002 Apr 30, 2013 Mar CAHN

CYSTEAMINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC CYSTARAN +! LEADIANT BIOSCI INC EQ 0.44% BASE N 200740 001 Oct 02, 2012 Feb CAHN

CYTARABINE INJECTABLE;INJECTION CYTARABINE AP MYLAN LABS LTD 20MG/ML A 200915 001 Dec 13, 2011 Mar CAHN WEST-WARD PHARMS INT 100MG/VIAL A 071471 001 Aug 02, 1989 Mar CTEC ! 500MG/VIAL A 071472 001 Aug 02, 1989 Mar CHRS ! 1GM/VIAL A 074245 001 Aug 31, 1994 Mar CHRS ! 2GM/VIAL A 074245 002 Aug 31, 1994 Mar CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -30

INJECTABLE;INJECTION CYTOSAR-U @ TEVA PHARMS USA 100MG/VIAL A 075206 001 Dec 30, 1998 Mar DISC @ 500MG/VIAL A 075206 002 Dec 30, 1998 Mar DISC @ 1GM/VIAL A 075206 004 Dec 30, 1998 Mar DISC @ 2GM/VIAL A 075206 003 Dec 30, 1998 Mar DISC

DACARBAZINE INJECTABLE;INJECTION DACARBAZINE AP ! FRESENIUS KABI USA 100MG/VIAL A 075371 001 Aug 27, 1999 Feb CHRS AP ! 200MG/VIAL A 075371 002 Aug 27, 1999 Feb CHRS DTIC-DOME + @ BAYER HLTHCARE 100MG/VIAL N 017575 001 Apr DISC + @ 200MG/VIAL N 017575 002 Apr DISC

DALFAMPRIDINE TABLET, EXTENDED RELEASE;ORAL AMPYRA AB +! ACORDA 10MG N 022250 001 Jan 22, 2010 Jan CFTG DALFAMPRIDINE AB ACTAVIS LABS FL INC 10MG A 206836 001 Jan 23, 2017 Jan NEWA AB AUROBINDO PHARMA LTD 10MG A 206811 001 Jan 23, 2017 Jan NEWA

DANTROLENE SODIUM INJECTABLE;INJECTION DANTROLENE SODIUM AP HIKMA PHARMS 20MG/VIAL A 204762 001 Jun 19, 2017 Jun NEWA

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL XIGDUO XR >A> + ASTRAZENECA AB EQ 2.5MG BASE;1GM N 205649 005 Jul 28, 2017 Jul NEWA

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL QTERN +! ASTRAZENECA AB EQ 10MG BASE;EQ 5MG BASE N 209091 001 Feb 27, 2017 Feb NEWA

DAPSONE TABLET;ORAL DAPSONE AB ACTAVIS LLC 25MG A 204380 001 Mar 23, 2017 Mar NEWA AB 100MG A 204380 002 Mar 23, 2017 Mar NEWA

DARIFENACIN HYDROBROMIDE TABLET, EXTENDED RELEASE;ORAL DARIFENACIN >A> AB MACLEODS PHARMS LTD EQ 7.5MG BASE A 207302 001 Jul 28, 2017 Jul NEWA >A> AB EQ 15MG BASE A 207302 002 Jul 28, 2017 Jul NEWA

DECITABINE INJECTABLE;INTRAVENOUS DECITABINE AP ACCORD HLTHCARE 50MG/VIAL A 203475 001 Feb 27, 2017 Feb NEWA AP PHARMASCIENCE INC 50MG/VIAL A 204607 001 May 31, 2017 May NEWA

DEFERASIROX GRANULE;ORAL JADENU SPRINKLE + NOVARTIS PHARMS CORP 90MG N 207968 001 May 18, 2017 May NEWA + 180MG N 207968 002 May 18, 2017 May NEWA +! 360MG N 207968 003 May 18, 2017 May NEWA

DEFLAZACORT SUSPENSION;ORAL EMFLAZA +! MARATHON PHARMS LLC 22.75MG/ML N 208685 001 Feb 09, 2017 Feb NEWA +! PTC THERAP 22.75MG/ML N 208685 001 Feb 09, 2017 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -31

TABLET;ORAL EMFLAZA + MARATHON PHARMS LLC 6MG N 208684 001 Feb 09, 2017 Feb NEWA + 18MG N 208684 002 Feb 09, 2017 Feb NEWA + 30MG N 208684 003 Feb 09, 2017 Feb NEWA +! 36MG N 208684 004 Feb 09, 2017 Feb NEWA + PTC THERAP 6MG N 208684 001 Feb 09, 2017 Apr CAHN + 18MG N 208684 002 Feb 09, 2017 Apr CAHN + 30MG N 208684 003 Feb 09, 2017 Apr CAHN +! 36MG N 208684 004 Feb 09, 2017 Apr CAHN

DELAFLOXACIN MEGLUMINE POWDER;IV (INFUSION) BAXDELA +! MELINTA THERAPS INC EQ 300MG BASE/VIAL N 208611 001 Jun 19, 2017 Jun NEWA TABLET;ORAL BAXDELA +! MELINTA THERAPS INC EQ 450MG BASE N 208610 001 Jun 19, 2017 Jun NEWA

DESIPRAMINE HYDROCHLORIDE TABLET;ORAL DESIPRAMINE HYDROCHLORIDE AB IMPAX LABS INC 10MG A 205153 001 Oct 28, 2016 Feb CAHN AB 25MG A 205153 002 Oct 28, 2016 Feb CAHN AB 50MG A 205153 003 Oct 28, 2016 Feb CAHN AB 75MG A 205153 004 Oct 28, 2016 Feb CAHN AB 100MG A 205153 005 Oct 28, 2016 Feb CAHN AB 150MG A 205153 006 Oct 28, 2016 Feb CAHN

DESMETHYL PIROXICAM CAPSULE;ORAL PIROXICAM SUN PHARM INDS 10MG A 073536 002 Jan 23, 2008 Mar CMS1

DESMOPRESSIN ACETATE INJECTABLE;INJECTION DESMOPRESSIN ACETATE >D> AP HOSPIRA 0.004MG/ML A 075220 001 Aug 28, 2000 Jul DISC >A> @ 0.004MG/ML A 075220 001 Aug 28, 2000 Jul DISC >D> AP TEVA PHARMS USA 0.004MG/ML A 074888 001 Oct 15, 1997 Jul DISC >A> @ 0.004MG/ML A 074888 001 Oct 15, 1997 Jul DISC SPRAY, METERED;NASAL NOCTIVA + SERENITY PHARMS LLC 0.00083MG/SPRAY N 201656 001 Mar 03, 2017 Mar NEWA +! 0.00166MG/SPRAY N 201656 002 Mar 03, 2017 Mar NEWA STIMATE @ FERRING PHARMS INC 0.15MG/SPRAY N 020355 001 Mar 07, 1994 Jun CAHN STIMATE (NEEDS NO REFRIGERATION) +! FERRING PHARMS INC 0.15MG/SPRAY N 020355 002 Oct 24, 2007 Jun CAHN TABLET;ORAL DESMOPRESSIN ACETATE AB HERITAGE PHARMA 0.1MG A 207880 001 May 26, 2017 May NEWA AB 0.1MG A 207880 001 May 26, 2017 May CAHN AB 0.2MG A 207880 002 May 26, 2017 May NEWA AB 0.2MG A 207880 002 May 26, 2017 May CAHN

DESOGESTREL; ETHINYL ESTRADIOL TABLET;ORAL-28 DESOGESTREL AND ETHINYL ESTRADIOL AB ACCORD HLTHCARE 0.15MG,N/A;0.02MG,0.01MG A 209170 001 Jun 05, 2017 May NEWA AB AUROBINDO PHARMA LTD 0.15MG,N/A;0.02MG,0.01MG A 206853 001 Mar 22, 2017 Mar NEWA KALLIGA AB AUROBINDO PHARMA LTD 0.15MG;0.03MG A 207081 001 May 17, 2017 May NEWA

DESONIDE CREAM;TOPICAL DESONIDE >A> AB GLENMARK PHARMS 0.05% A 209729 001 Jul 24, 2017 Jul NEWA OINTMENT;TOPICAL DESONIDE AB HI-TECH PHARMACAL 0.05% A 208836 001 Mar 27, 2017 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -32

DESOXIMETASONE CREAM;TOPICAL TOPICORT AB ! TARO 0.05% A 073210 001 Nov 30, 1990 Apr CAHN AB ! 0.25% A 073193 001 Nov 30, 1990 Apr CAHN + @ 0.25% N 017856 001 May CAHN TOPICORT LP + TARO@ 0.05% N 018309 001 May CAHN GEL;TOPICAL DESOXIMETASONE AB RISING PHARMS INC 0.05% A 204675 001 Aug 12, 2016 May CAHN TOPICORT AB ! TARO 0.05% A 074904 001 Jul 14, 1998 Apr CAHN + @ 0.05% N 018586 001 Mar 29, 1982 May CAHN + @ TARO PHARMS NORTH 0.05% N 018586 001 Mar 29, 1982 Jan CRLD OINTMENT;TOPICAL DESOXIMETASONE AB RISING PHARMS INC 0.25% A 204272 001 Nov 30, 2016 May CAHN TOPICORT AB +! TARO 0.05% N 018594 001 Jan 17, 1985 May CAHN AB ! 0.25% A 074286 001 Jun 07, 1996 Apr CAHN + @ 0.25% N 018763 001 Sep 30, 1983 May CAHN SPRAY;TOPICAL DESOXIMETASONE AT PERRIGO ISRAEL 0.25% A 206441 001 Jan 20, 2017 Jan NEWA TOPICORT AT +! TARO 0.25% N 204141 001 Apr 11, 2013 Jan CFTG

DESVENLAFAXINE SUCCINATE TABLET, EXTENDED RELEASE;ORAL DESVENLAFAXINE SUCCINATE AB ACTAVIS LABS FL EQ 25MG BASE A 204065 001 Jul 29, 2016 May CAHN AB EQ 50MG BASE A 204065 002 Jul 29, 2016 May CAHN AB EQ 100MG BASE A 204065 003 Jul 29, 2016 May CAHN

DEUTETRABENAZINE TABLET;ORAL AUSTEDO + TEVA BRANDED PHARM 6MG N 208082 001 Apr 03, 2017 Apr NEWA + 9MG N 208082 002 Apr 03, 2017 Apr NEWA +! 12MG N 208082 003 Apr 03, 2017 Apr NEWA

DEXAMETHASONE TABLET;ORAL DEXAMETHASONE >A> AB LARKEN LABS INC 1.5MG A 201270 001 Jul 17, 2017 Jul NEWA >D> BP PAR PHARM 1.5MG A 088237 001 Apr 28, 1983 Jul CAHN BP 6MG A 088481 001 Nov 28, 1983 May CHRS @ UPSHER SMITH 0.75MG A 087534 001 Jun CAHN @ 1.5MG A 087533 001 Jun CAHN >A> BP XSPIRE PHARMA 1.5MG A 088237 001 Apr 28, 1983 Jul CAHN

DEXAMETHASONE ACETATE INJECTABLE;INJECTION DEXAMETHASONE ACETATE @ WATSON LABS TEVA EQ 16MG BASE/ML A 087711 001 May 24, 1982 May CAHN

DEXAMETHASONE SODIUM PHOSPHATE SOLUTION/DROPS;OPHTHALMIC, OTIC DEXAMETHASONE SODIUM PHOSPHATE AT ! SANDOZ INC EQ 0.1% PHOSPHATE A 088771 001 Jan 16, 1985 Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE SUSPENSION/DROPS;OPHTHALMIC MAXITROL AT SANDOZ INC 0.1%;EQ 3.5MG BASE/ML;10,000 A 062341 001 May 22, 1984 Feb CAHN UNITS/ML RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -33

DEXLANSOPRAZOLE CAPSULE, DELAYED RELEASE;ORAL DEXILANT AB +! TAKEDA PHARMS USA 60MG N 022287 002 Jan 30, 2009 Apr CFTG DEXLANSOPRAZOLE AB PAR PHARM INC 60MG A 202294 001 Apr 19, 2017 Apr NEWA

DEXMEDETOMIDINE HYDROCHLORIDE INJECTABLE;INJECTION DEXMEDETOMIDINE HYDROCHLORIDE AP ACCORD HLTHCARE EQ 200MCG BASE/2ML (EQ 100MCG A 204023 001 Feb 09, 2016 Mar CAHN BASE/ML) AP LUITPOLD PHARMS INC EQ 200MCG BASE/2ML (EQ 100MCG A 203773 001 May 12, 2017 May CAHN BASE/ML) AP PHARMAFORCE EQ 200MCG BASE/2ML (EQ 100MCG A 203773 001 May 12, 2017 May NEWA BASE/ML) AP WEST-WARD PHARMS INT EQ 200MCG BASE/2ML (EQ 100MCG A 205046 001 Apr 26, 2017 Apr NEWA BASE/ML)

DEXMETHYLPHENIDATE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL DEXMETHYLPHENIDATE HYDROCHLORIDE AB IMPAX LABS INC 25MG A 203614 001 Jul 05, 2017 Jun NEWA AB 35MG A 203614 002 Jul 05, 2017 Jun NEWA AB TEVA PHARMS USA 25MG A 202731 001 Jul 05, 2017 Jun NEWA AB 35MG A 202731 004 Jul 05, 2017 Jun NEWA

DEXTROAMPHETAMINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL DEXTROAMPHETAMINE SULFATE AB NESHER PHARMS 5MG A 209111 001 Jun 27, 2017 Jun NEWA AB 10MG A 209111 002 Jun 27, 2017 Jun NEWA AB 15MG A 209111 003 Jun 27, 2017 Jun NEWA TABLET;ORAL DEXTROAMPHETAMINE SULFATE @ EPIC PHARMA LLC 5MG A 090652 001 Mar 07, 2014 May CAHN @ 10MG A 090652 002 Mar 07, 2014 May CAHN

DEXTROSE INJECTABLE;INJECTION DEXTROSE 10% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 10GM/100ML N 018080 001 Feb CAHN DEXTROSE 20% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 20GM/100ML N 018564 001 Mar 23, 1982 Feb CAHN DEXTROSE 30% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 30GM/100ML N 019345 001 Jan 26, 1985 Feb CAHN DEXTROSE 40% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 40GM/100ML N 018562 001 Mar 23, 1982 May CAHN DEXTROSE 5% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 50MG/ML N 016367 002 Feb CAHN DEXTROSE 50% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 50GM/100ML N 018563 001 Mar 23, 1982 Feb CAHN @ 50GM/100ML N 019894 001 Dec 26, 1989 Jun CAHN DEXTROSE 70% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 70GM/100ML N 018561 001 Mar 23, 1982 Apr CAHN AP +! 70GM/100ML N 019893 001 Dec 26, 1989 Feb CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE INJECTABLE;INJECTION NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;21MG/100ML;128MG/100ML;2 N 017610 001 Feb CAHN 34MG/100ML

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS INJECTABLE;INJECTION IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;30MG/100ML;141MG/100ML;1 N 019513 001 May 08, 1986 Feb CAHN 5MG/100ML;260MG/100ML;25MG/100ML RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -34

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE INJECTABLE;INJECTION NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;30MG/100ML;37MG/100ML;22 N 017609 001 Feb CAHN 2MG/100ML;526MG/100ML;502MG/100ML

DEXTROSE; POTASSIUM CHLORIDE INJECTABLE;INJECTION POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;149MG/100ML N 018371 001 Apr CAHN POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;224MG/100ML N 018371 003 Apr CAHN POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;298MG/100ML N 018371 002 Apr CAHN

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE INJECTABLE;INJECTION POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;225MG/100ML N 018365 002 Jul 05, 1983 Feb CAHN 5GM/100ML;149MG/100ML;225MG/100ML N 018365 006 Mar 28, 1988 Feb CAHN POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;300MG/100ML N 018876 001 Jan 17, 1986 Jun CAHN 5GM/100ML;149MG/100ML;300MG/100ML N 018876 006 Mar 28, 1988 Jun CAHN POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;450MG/100ML N 018362 005 Mar 28, 1988 Feb CAHN AP 5GM/100ML;74.5MG/100ML;450MG/100ML N 018362 009 Jul 05, 1983 Feb CAHN POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;900MG/100ML N 019691 002 Mar 24, 1988 Apr CAHN AP 5GM/100ML;149MG/100ML;900MG/100ML N 019691 004 Mar 24, 1988 Apr CAHN POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;224MG/100ML;225MG/100ML N 018365 008 Mar 28, 1988 Feb CAHN POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;224MG/100ML;300MG/100ML N 018876 007 Mar 28, 1988 Jun CAHN POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML N 018362 006 Mar 28, 1988 Feb CAHN POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML N 019691 006 Mar 24, 1988 Apr CAHN POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;149MG/100ML;225MG/100ML N 018365 001 Feb CAHN 5GM/100ML;298MG/100ML;225MG/100ML N 018365 009 Mar 28, 1988 Feb CAHN POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;298MG/100ML;300MG/100ML N 018876 008 Mar 28, 1988 Jun CAHN POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;149MG/100ML;450MG/100ML N 018362 010 Jul 05, 1983 Feb CAHN AP 5GM/100ML;298MG/100ML;450MG/100ML N 018362 007 Mar 28, 1988 Feb CAHN POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;149MG/100ML;900MG/100ML N 019691 005 Mar 24, 1988 Apr CAHN AP 5GM/100ML;298MG/100ML;900MG/100ML N 019691 008 Mar 24, 1988 Apr CAHN POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;149MG/100ML;300MG/100ML N 018876 002 Jan 17, 1986 Jun CAHN POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;224MG/100ML;225MG/100ML N 018365 003 Jul 05, 1983 Feb CAHN POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;224MG/100ML;300MG/100ML N 018876 003 Jan 17, 1986 Jun CAHN POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML N 018362 002 Feb CAHN POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML N 019691 007 Mar 24, 1988 Apr CAHN POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;298MG/100ML;225MG/100ML N 018365 004 Jul 05, 1983 Feb CAHN POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;298MG/100ML;300MG/100ML N 018876 004 Mar 28, 1988 Jun CAHN POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;298MG/100ML;450MG/100ML N 018362 003 Feb CAHN POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;298MG/100ML;900MG/100ML N 019691 009 Mar 24, 1988 Apr CAHN POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;225MG/100ML N 018365 005 Mar 28, 1988 Feb CAHN 5GM/100ML;149MG/100ML;225MG/100ML N 018365 007 Mar 28, 1988 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -35

INJECTABLE;INJECTION POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;300MG/100ML N 018876 005 Mar 28, 1988 Jun CAHN 5GM/100ML;149MG/100ML;300MG/100ML N 018876 009 Mar 28, 1988 Jun CAHN POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;450MG/100ML N 018362 008 Mar 28, 1988 Feb CAHN AP 5GM/100ML;149MG/100ML;450MG/100ML N 018362 004 Mar 28, 1988 Feb CAHN POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;900MG/100ML N 019691 001 Mar 24, 1988 Apr CAHN AP 5GM/100ML;149MG/100ML;900MG/100ML N 019691 003 Mar 24, 1988 Apr CAHN

DEXTROSE; SODIUM CHLORIDE INJECTABLE;INJECTION DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER +! ICU MEDICAL INC 5GM/100ML;225MG/100ML N 017606 001 Feb CAHN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER +! ICU MEDICAL INC 5GM/100ML;300MG/100ML N 017799 001 Feb CAHN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;450MG/100ML N 017607 001 Feb CAHN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML;900MG/100ML N 017585 001 Feb CAHN

DIAZEPAM TABLET;ORAL DIAZEPAM @ UPSHER-SMITH LABS 2MG A 070302 001 Dec 20, 1985 Jun CAHN @ 5MG A 070303 001 Dec 20, 1985 Jun CAHN @ 10MG A 070304 001 Dec 20, 1985 Jun CAHN @ VIRTUS PHARMS 2MG A 070462 001 Feb 25, 1986 Feb CAHN @ 5MG A 070463 001 Feb 25, 1986 Feb CAHN @ 10MG A 070464 001 Feb 25, 1986 Feb CAHN

DICLOFENAC POTASSIUM TABLET;ORAL DICLOFENAC POTASSIUM @ WATSON LABS TEVA 50MG A 075152 001 Nov 27, 1998 May CAHN

DICLOFENAC SODIUM SOLUTION;TOPICAL DICLOFENAC SODIUM AT ACTAVIS LABS UT INC 2% A 207238 001 May 15, 2017 May NEWA >D> AT APOTEX INC 1.5% A 202027 001 May 27, 2014 Jul CHRS >A> AT ! 1.5% A 202027 001 May 27, 2014 Jul CHRS >A> AT RICONPHARMA LLC 1.5% A 206715 001 Aug 07, 2017 Jul NEWA AT TWI PHARMS INC 1.5% A 202393 001 Nov 24, 2014 Mar CAHN PENNSAID AT +! HORIZON PHARMA 2% N 204623 001 Jan 16, 2014 May CFTG + @ NUVO PHARMS INC 1.5% N 020947 001 Nov 04, 2009 Apr CAHN + @ NUVO RES INC 1.5% N 020947 001 Nov 04, 2009 Feb DISC SOLUTION/DROPS;OPHTHALMIC DICLOFENAC SODIUM AT SANDOZ INC 0.1% A 078031 001 Feb 06, 2008 Feb CAHN TABLET, DELAYED RELEASE;ORAL DICLOFENAC SODIUM @ ALLIED PHARMA INC 50MG A 074986 001 Feb 26, 1999 Apr CAHN @ 75MG A 074986 002 Feb 26, 1999 Apr CAHN TABLET, EXTENDED RELEASE;ORAL DICLOFENAC SODIUM @ ACTAVIS ELIZABETH 100MG A 075910 001 Jan 07, 2002 Apr DISC AB ! DEXCEL LTD 100MG A 076201 001 Nov 06, 2002 Apr CHRS VOLTAREN-XR >D> @ NOVARTIS 100MG N 020254 001 Mar 08, 1996 Jul CRLD >A> + @ 100MG N 020254 001 Mar 08, 1996 Jul CRLD

DICLOFENAC SODIUM; MISOPROSTOL TABLET, DELAYED RELEASE;ORAL DICLOFENAC SODIUM AND MISOPROSTOL AB EAGLE PHARMS 50MG;0.2MG A 200540 001 Mar 14, 2014 Jan CAHN AB 75MG;0.2MG A 200540 002 Mar 14, 2014 Jan CAHN AB EXELA HOLDINGS 50MG;0.2MG A 200540 001 Mar 14, 2014 Mar CAHN AB 75MG;0.2MG A 200540 002 Mar 14, 2014 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -36

DICYCLOMINE HYDROCHLORIDE INJECTABLE;INJECTION DICYCLOMINE HYDROCHLORIDE AP LUITPOLD PHARMS INC 10MG/ML A 208353 001 Feb 17, 2017 Feb NEWA

DIDANOSINE CAPSULE, DELAYED REL PELLETS;ORAL DIDANOSINE @ MYLAN PHARMS INC 125MG A 090788 001 Apr 08, 2010 May DISC @ 200MG A 090788 002 Apr 08, 2010 May DISC @ 250MG A 090788 003 Apr 08, 2010 May DISC @ 400MG A 090788 004 Apr 08, 2010 May DISC FOR SOLUTION;ORAL >D> DIDANOSINE >D> AA AUROBINDO PHARMA 10MG/ML A 078112 001 Mar 08, 2007 Jul DISC >A> @ 10MG/ML A 078112 001 Mar 08, 2007 Jul DISC VIDEX >D> AA +! BRISTOL MYERS SQUIBB 10MG/ML N 020156 001 Oct 09, 1991 Jul CTEC >A> +! BRISTOL-MYERS SQUIBB 10MG/ML N 020156 001 Oct 09, 1991 Jul CTEC >D> TABLET, FOR SUSPENSION;ORAL >D> DIDANOSINE >D> AUROBINDO 100MG A 077275 001 Aug 14, 2012 Jul DISC >A> @ 100MG A 077275 001 Aug 14, 2012 Jul DISC >D> 150MG A 077275 002 Aug 14, 2012 Jul DISC >A> @ 150MG A 077275 002 Aug 14, 2012 Jul DISC >D> ! 200MG A 077275 003 Aug 14, 2012 Jul DISC >A> @ 200MG A 077275 003 Aug 14, 2012 Jul DISC

DIENOGEST; ESTRADIOL VALERATE TABLET;ORAL NATAZIA +! BAYER HLTHCARE N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1M N 022252 001 May 06, 2010 Apr CTEC G,N/A

DIETHYLPROPION HYDROCHLORIDE TABLET;ORAL DIETHYLPROPION HYDROCHLORIDE @ EPIC PHARMA LLC 25MG A 040828 001 Nov 05, 2008 May CAHN

DIFLORASONE DIACETATE OINTMENT;TOPICAL DIFLORASONE DIACETATE AB RICONPHARMA LLC 0.05% A 207440 001 Feb 27, 2017 Feb NEWA AB ! TARO 0.05% A 075331 001 May 14, 1999 Apr CAHN PSORCON + @ PHARMACIA AND UPJOHN 0.05% N 019260 001 Aug 28, 1985 Mar CRLD

DIFLUNISAL TABLET;ORAL DIFLUNISAL >A> @ ALLIED PHARMA INC 250MG A 073562 001 Nov 27, 1992 Jul CAHN >A> @ 500MG A 073563 001 Nov 27, 1992 Jul CAHN >D> @ ROXANE 250MG A 073562 001 Nov 27, 1992 Jul CAHN >D> @ 500MG A 073563 001 Nov 27, 1992 Jul CAHN AB ZYDUS PHARMS USA INC 500MG A 203547 001 Jun 16, 2017 Jun NEWA

DIGOXIN ELIXIR;ORAL DIGOXIN +! WEST-WARD PHARMS INT 0.05MG/ML N 021648 001 Aug 26, 2004 Jan CAHN INJECTABLE;INJECTION DIGOXIN >D> AP EUROHLTH INTL SARL 0.25MG/ML A 083391 001 Jul CAHN AP SANDOZ INC 0.25MG/ML A 040481 001 Aug 21, 2003 Mar CAHN >A> AP WEST-WARD PHARMS INT 0.25MG/ML A 083391 001 Jul CAHN LANOXIN AP +! COVIS PHARMA BV 0.25MG/ML N 009330 002 May CAHN LANOXIN PEDIATRIC +! COVIS PHARMA BV 0.1MG/ML N 009330 004 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -37

DIHYDROERGOTAMINE MESYLATE INJECTABLE;INJECTION DIHYDROERGOTAMINE MESYLATE AP WEST-WARD PHARMS INT 1MG/ML A 040453 001 Jun 09, 2003 Jan CAHN

DILTIAZEM HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL DILTIAZEM HYDROCHLORIDE AB3 SUN PHARM INDS LTD 120MG A 203023 001 Jun 08, 2017 May NEWA AB3 180MG A 203023 002 Jun 08, 2017 May NEWA AB3 240MG A 203023 003 Jun 08, 2017 May NEWA AB3 300MG A 203023 004 Jun 08, 2017 May NEWA AB3 360MG A 203023 005 Jun 08, 2017 May NEWA >A> AB3 ZYDUS PHARMS USA INC 120MG A 206534 001 Aug 08, 2017 Jul NEWA >A> AB4 120MG A 206641 001 Aug 11, 2017 Jul NEWA >A> AB3 180MG A 206534 002 Aug 08, 2017 Jul NEWA >A> AB4 180MG A 206641 002 Aug 11, 2017 Jul NEWA >A> AB3 240MG A 206534 003 Aug 08, 2017 Jul NEWA >A> AB4 240MG A 206641 003 Aug 11, 2017 Jul NEWA >A> AB3 300MG A 206534 004 Aug 08, 2017 Jul NEWA >A> AB4 300MG A 206641 004 Aug 11, 2017 Jul NEWA >A> AB3 360MG A 206534 005 Aug 08, 2017 Jul NEWA >A> AB4 360MG A 206641 005 Aug 11, 2017 Jul NEWA >A> AB4 420MG A 206641 006 Aug 11, 2017 Jul NEWA INJECTABLE;INJECTION DILTIAZEM HYDROCHLORIDE AP ! ATHENEX INC 5MG/ML A 074617 001 Feb 28, 1996 Mar CAHN AP WEST-WARD PHARMS INT 5MG/ML A 078538 001 Dec 17, 2008 Jan CAHN TABLET;ORAL DILTIAZEM HYDROCHLORIDE @ CHARTWELL MOLECULES 30MG A 074093 001 Nov 05, 1992 Feb CAHN @ 60MG A 074093 002 Nov 05, 1992 Feb CAHN @ 90MG A 074093 003 Nov 05, 1992 Feb CAHN @ 120MG A 074093 004 Nov 05, 1992 Feb CAHN

DIMENHYDRINATE INJECTABLE;INJECTION DIMENHYDRINATE @ WATSON LABS TEVA 50MG/ML A 080615 001 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE ELIXIR;ORAL DIPHENHYDRAMINE HYDROCHLORIDE ! PHARM ASSOC 12.5MG/5ML A 087513 001 Feb 10, 1982 May CAHN INJECTABLE;INJECTION DIPHENHYDRAMINE HYDROCHLORIDE @ WATSON LABS TEVA 10MG/ML A 080873 001 May CAHN @ 50MG/ML A 080873 002 May CAHN DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE @ WATSON LABS TEVA 50MG/ML A 080873 003 May CAHN

DIPYRIDAMOLE INJECTABLE;INJECTION DIPYRIDAMOLE AP ! ATHENEX INC 5MG/ML A 074939 001 Apr 13, 1998 Mar CAHN

DISULFIRAM TABLET;ORAL DISULFIRAM AB CHARTWELL MOLECULES 250MG A 091563 001 Dec 31, 2012 Jan CAHN AB 500MG A 091563 002 Dec 31, 2012 Jan CAHN @ WATSON LABS TEVA 500MG A 086890 001 May CAHN

DIVALPROEX SODIUM TABLET, DELAYED RELEASE;ORAL DIVALPROEX SODIUM AB PRINSTON INC EQ 125MG VALPROIC ACID A 090210 001 Nov 30, 2009 Feb CAHN AB EQ 250MG VALPROIC ACID A 090210 002 Nov 30, 2009 Feb CAHN AB EQ 500MG VALPROIC ACID A 090210 003 Nov 30, 2009 Feb CAHN AB UPSHER-SMITH LABS EQ 125MG VALPROIC ACID A 078182 001 Jul 29, 2008 Jun CAHN AB EQ 250MG VALPROIC ACID A 078182 002 Jul 29, 2008 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -38

TABLET, DELAYED RELEASE;ORAL DIVALPROEX SODIUM AB EQ 500MG VALPROIC ACID A 078182 003 Jul 29, 2008 Jun CAHN

DOCETAXEL INJECTABLE;INJECTION DOCETAXEL AP ACTAVIS LLC 20MG/ML (20MG/ML) N 203551 001 Apr 12, 2013 Feb CAHN AP 80MG/4ML (20MG/ML) N 203551 002 Apr 12, 2013 Feb CAHN 140MG/7ML (20MG/ML) N 203551 003 Apr 12, 2013 Feb CAHN AP DFB ONCOLOGY LTD 20MG/ML (20MG/ML) A 206177 001 Jan 20, 2017 Jan NEWA AP 80MG/4ML (20MG/ML) A 206177 002 Jan 20, 2017 Jan NEWA 200MG/10ML (20MG/ML) A 206177 003 Jan 20, 2017 Jan NEWA + HOSPIRA INC 160MG/8ML (20MG/ML) N 022234 007 Jan 24, 2017 Jan NEWA >A> AP JIANGSU HENGRUI MED 20MG/ML (20MG/ML) A 207252 001 Aug 09, 2017 Jul NEWA ! 40MG/ML A 203170 001 Feb 15, 2017 Jan NEWA >A> AP 80MG/4ML (20MG/ML) A 207252 002 Aug 09, 2017 Jul NEWA >A> AP 160MG/8ML (20MG/ML) A 207252 003 Aug 09, 2017 Jul NEWA @ PFIZER LABS 20MG/2ML (10MG/ML) N 202356 001 Mar 13, 2014 Jan DISC @ 80MG/8ML (10MG/ML) N 202356 002 Mar 13, 2014 Jan DISC @ 130MG/13ML (10MG/ML) N 202356 003 Mar 13, 2014 Jan DISC @ 200MG/20ML (10MG/ML) N 202356 004 Mar 13, 2014 Jan DISC

DOFETILIDE CAPSULE;ORAL DOFETILIDE AB MAYNE PHARMA INC 0.125MG A 207058 001 Jun 06, 2016 Feb CAHN AB 0.25MG A 207058 002 Jun 06, 2016 Feb CAHN AB 0.5MG A 207058 003 Jun 06, 2016 Feb CAHN

DONEPEZIL HYDROCHLORIDE TABLET;ORAL DONEPEZIL HYDROCHLORIDE AB ACI HEALTHCARE LTD 5MG A 078662 001 May 31, 2011 Jun CAHN AB 10MG A 078662 002 May 31, 2011 Jun CAHN AB ALLIED PHARMA INC 5MG A 078662 001 May 31, 2011 Mar CAHN AB 10MG A 078662 002 May 31, 2011 Mar CAHN AB ZHEJIANG HISUN PHARM 23MG A 202410 001 Mar 24, 2017 Mar NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE AB AMNEAL PHARMS 10MG;14MG A 208328 001 Jan 27, 2017 Jan NEWA AB 10MG;28MG A 208328 002 Jan 27, 2017 Jan NEWA NAMZARIC AB + FOREST LABS LLC 10MG;14MG N 206439 001 Dec 23, 2014 Jan CFTG AB +! 10MG;28MG N 206439 002 Dec 23, 2014 Jan CFTG

DOPAMINE HYDROCHLORIDE INJECTABLE;INJECTION DOPAMINE HYDROCHLORIDE @ TELIGENT 40MG/ML N 018656 001 Jun 28, 1983 May CAHN

DORZOLAMIDE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC DORZOLAMIDE HYDROCHLORIDE AT SANDOZ INC EQ 2% BASE A 078748 001 Nov 06, 2008 Mar CAHN AT EQ 2% BASE A 078981 001 Apr 13, 2009 Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE SOLUTION/DROPS;OPHTHALMIC DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE AT SANDOZ INC EQ 2% BASE;EQ 0.5% BASE A 090604 001 Nov 18, 2009 Mar CAHN

DOXAPRAM HYDROCHLORIDE INJECTABLE;INJECTION DOXAPRAM HYDROCHLORIDE AP ATHENEX INC 20MG/ML A 076266 001 Jan 10, 2003 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -39

DOXAZOSIN MESYLATE TABLET;ORAL DOXAZOSIN MESYLATE AB ZYDUS PHARMS USA INC EQ 1MG BASE A 208719 001 Jul 07, 2017 Jun NEWA AB EQ 2MG BASE A 208719 002 Jul 07, 2017 Jun NEWA AB EQ 4MG BASE A 208719 003 Jul 07, 2017 Jun NEWA AB EQ 8MG BASE A 208719 004 Jul 07, 2017 Jun NEWA

DOXEPIN HYDROCHLORIDE CAPSULE;ORAL DOXEPIN HYDROCHLORIDE AB AMNEAL PHARMS CO EQ 10MG BASE A 207482 001 Jun 28, 2017 Jun NEWA AB EQ 25MG BASE A 207482 002 Jun 28, 2017 Jun NEWA AB EQ 50MG BASE A 207482 003 Jun 28, 2017 Jun NEWA AB EQ 75MG BASE A 207482 004 Jun 28, 2017 Jun NEWA AB EQ 100MG BASE A 207482 005 Jun 28, 2017 Jun NEWA @ WATSON LABS TEVA EQ 50MG BASE A 072987 001 Mar 29, 1991 May CAHN CREAM;TOPICAL ZONALON +! MYLAN PHARMS INC 5% N 020126 001 Apr 01, 1994 Jan CAHN

DOXERCALCIFEROL INJECTABLE;INJECTION DOXERCALCIFEROL AP AMNEAL PHARMS CO 2MCG/ML (2MCG/ML) A 208974 001 May 24, 2017 May NEWA AP 4MCG/2ML (2MCG/ML) A 208974 002 May 24, 2017 May NEWA AP 4MCG/2ML (2MCG/ML) A 208975 001 May 24, 2017 May NEWA

DOXORUBICIN HYDROCHLORIDE INJECTABLE;INJECTION DOXORUBICIN HYDROCHLORIDE AP AMNEAL PHARMS CO 20MG/VIAL A 208888 001 Feb 17, 2017 Feb NEWA AP 50MG/VIAL A 208888 002 Feb 17, 2017 Feb NEWA >A> AP GLAND PHARMA LTD 2MG/ML A 209825 001 Aug 11, 2017 Jul NEWA INJECTABLE, LIPOSOMAL;INJECTION DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) AB DR REDDYS LABS LTD 20MG/10ML (2MG/ML) A 208657 001 May 15, 2017 May NEWA AB 50MG/25ML (2MG/ML) A 208657 002 May 15, 2017 May NEWA

DOXYCYCLINE CAPSULE;ORAL DOXYCYCLINE >A> AB ALEMBIC PHARMS LTD EQ 75MG BASE A 209165 001 Jul 28, 2017 Jul NEWA >A> AB EQ 100MG BASE A 209165 002 Jul 28, 2017 Jul NEWA

DOXYCYCLINE HYCLATE >D> CAPSULE, DELAYED RELEASE;ORAL >D> DOXYCYCLINE HYCLATE >D> MEDICIS EQ 75MG BASE A 065281 001 Dec 21, 2005 Jul DISC >A> @ EQ 75MG BASE A 065281 001 Dec 21, 2005 Jul DISC >D> ! EQ 100MG BASE A 065281 002 Dec 21, 2005 Jul DISC >A> @ EQ 100MG BASE A 065281 002 Dec 21, 2005 Jul DISC INJECTABLE;INJECTION VIBRAMYCIN + PFIZER@ EQ 100MG BASE/VIAL N 050442 002 Jan CRLD + @ EQ 200MG BASE/VIAL N 050442 001 Jan CRLD TABLET;ORAL ACTICLATE AB + AQUA PHARMS LLC EQ 75MG BASE N 205931 001 Jul 25, 2014 Jun CFTG AB +! EQ 150MG BASE N 205931 002 Jul 25, 2014 Jun CFTG DOXYCYCLINE HYCLATE CARIBE HOLDINGS EQ 50MG BASE A 062269 003 Mar CMFD @ EQ 50MG BASE A 062269 003 Jan CAHN AB EQ 100MG BASE A 062269 002 Nov 08, 1982 Jan CAHN @ EPIC PHARMA LLC EQ 20MG BASE A 065182 001 May 13, 2005 May CAHN AB MAYNE PHARMA INC EQ 75MG BASE A 208765 001 Jun 14, 2017 May NEWA AB EQ 150MG BASE A 208765 002 Jun 14, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -40

DRONABINOL SOLUTION;ORAL SYNDROS +! INSYS DEV CO INC 5MG/ML N 205525 001 Mar 23, 2017 Mar NEWA

DROSPIRENONE; ETHINYL ESTRADIOL TABLET;ORAL DROSPIRENONE AND ETHINYL ESTRADIOL >A> AB PII 3MG;0.02MG A 203291 001 Jul 18, 2017 Jul NEWA

DULOXETINE HYDROCHLORIDE CAPSULE, DELAYED REL PELLETS;ORAL DULOXETINE HYDROCHLORIDE AB MACLEODS PHARMS LTD EQ 20MG BASE A 204815 001 Mar 23, 2017 Mar NEWA AB EQ 30MG BASE A 204815 002 Mar 23, 2017 Mar NEWA AB EQ 60MG BASE A 204815 003 Mar 23, 2017 Mar NEWA AB PRINSTON INC EQ 20MG BASE A 206653 001 May 18, 2017 May NEWA AB EQ 30MG BASE A 206653 002 May 18, 2017 May NEWA AB EQ 60MG BASE A 206653 003 May 18, 2017 May NEWA AB ZYDUS HLTHCARE EQ 20MG BASE A 090739 001 Jan 08, 2014 Apr CAHN AB EQ 30MG BASE A 090739 002 Jan 08, 2014 Apr CAHN AB EQ 60MG BASE A 090739 003 Jan 08, 2014 Apr CAHN

DUTASTERIDE CAPSULE;ORAL DUTASTERIDE AB AMNEAL PHARMS 0.5MG A 203118 001 Nov 20, 2015 May CAHN AB MARKSANS PHARMA 0.5MG A 204376 001 Apr 07, 2017 Mar NEWA

DYPHYLLINE TABLET;ORAL LUFYLLIN @ MYLAN SPECIALITY LP 200MG A 084566 001 Mar CAHN @ 400MG A 084566 002 Mar CAHN

ECONAZOLE NITRATE AEROSOL, FOAM;TOPICAL ECOZA +! CHEMO RESEARCH SL 1% N 205175 001 Oct 24, 2013 May CAHN CREAM;TOPICAL SPECTAZOLE + @ ALVOGEN MALTA 1% N 018751 001 Dec 23, 1982 Mar CMS1

EDARAVONE SOLUTION;IV (INFUSION) RADICAVA +! MITSUBISHI TANABE 30MG/100ML (0.3MG/ML) N 209176 001 May 05, 2017 May NEWA

EDROPHONIUM CHLORIDE INJECTABLE;INJECTION TENSILON + @ TELIGENT 10MG/ML N 007959 001 Apr CAHN TENSILON PRESERVATIVE FREE + @ TELIGENT 10MG/ML N 007959 002 Apr CAHN

ELETRIPTAN HYDROBROMIDE TABLET;ORAL ELETRIPTAN HYDROBROMIDE >A> AB MYLAN PHARMS INC EQ 20MG BASE A 205152 001 Aug 11, 2017 Jul NEWA >A> AB EQ 40MG BASE A 205152 002 Aug 11, 2017 Jul NEWA AB TEVA PHARMS USA EQ 20MG BASE A 202040 001 Jun 27, 2017 Jun NEWA AB EQ 40MG BASE A 202040 002 Jun 27, 2017 Jun NEWA AB ZYDUS PHARMS USA INC EQ 20MG BASE A 206409 001 Jun 16, 2017 Jun NEWA AB EQ 40MG BASE A 206409 002 Jun 16, 2017 Jun NEWA RELPAX AB + PFIZER IRELAND EQ 20MG BASE N 021016 001 Dec 26, 2002 Jun CFTG AB +! EQ 40MG BASE N 021016 002 Dec 26, 2002 Jun CFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -41

ELVITEGRAVIR TABLET;ORAL VITEKTA + @ GILEAD SCIENCES INC 85MG N 203093 001 Sep 24, 2014 May DISC + @ 150MG N 203093 002 Sep 24, 2014 May DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE AB TEVA PHARMS USA 200MG;300MG A 090894 001 Jun 08, 2017 May NEWA TRUVADA AB +! GILEAD 200MG;300MG N 021752 001 Aug 02, 2004 May CFTG

ENALAPRIL MALEATE SOLUTION;ORAL EPANED >D> SILVERGATE PHARMS 1MG/ML N 208686 001 Sep 20, 2016 Jul CRLD >A> +! 1MG/ML N 208686 001 Sep 20, 2016 Jul CRLD

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE TABLET;ORAL ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE @ UPSHER-SMITH LABS 5MG;12.5MG A 076116 001 Sep 19, 2001 Jun CAHN @ 10MG;25MG A 076116 002 Sep 19, 2001 Jun CAHN

ENALAPRILAT INJECTABLE;INJECTION ENALAPRILAT AP ! ATHENEX INC 1.25MG/ML A 075634 001 Aug 22, 2000 Mar CAHN VASOTEC + @ BIOVAIL LABS INTL 1.25MG/ML N 019309 001 Feb 09, 1988 Mar CRLD

ENTACAPONE TABLET;ORAL ENTACAPONE AB MACLEODS PHARMS LTD 200MG A 207210 001 Jun 05, 2017 May NEWA @ MYLAN PHARMS INC 200MG A 202394 001 May 13, 2013 May DISC

ENTECAVIR TABLET;ORAL ENTECAVIR AB SANDOZ INC 0.5MG A 206672 001 May 11, 2017 May NEWA AB 1MG A 206672 002 May 11, 2017 May NEWA AB ZYDUS PHARMS USA INC 0.5MG A 206745 001 Jun 23, 2017 Jun NEWA AB 1MG A 206745 002 Jun 23, 2017 Jun NEWA

EPHEDRINE SULFATE SOLUTION;INTRAVENOUS AKOVAZ AP +! FLAMEL IRELAND LTD 50MG/ML (50MG/ML) N 208289 001 Apr 29, 2016 Mar CTEC EPHEDRINE SULFATE AP AKORN INC 50MG/ML (50MG/ML) N 208609 001 Mar 01, 2017 Mar NEWA SOLUTION;IV (INFUSION) CORPHEDRA PAR STERILE PRODUCTS 50MG/ML (50MG/ML) N 208943 001 Jan 27, 2017 Jan NEWA

EPINASTINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC EPINASTINE HYDROCHLORIDE AT AKORN 0.05% A 204055 001 May 05, 2017 Apr NEWA AT SANDOZ INC 0.05% A 203384 001 Dec 07, 2016 Mar CAHN

EPINEPHRINE INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS ADRENACLICK BX +! IMPAX LABS INC EQ 0.15MG/DELIVERY N 020800 003 Nov 25, 2009 Jun CAHN BX +! EQ 0.3MG/DELIVERY N 020800 004 Nov 25, 2009 Jun CAHN TWINJECT 0.15 @ IMPAX LABS INC EQ 0.15MG/DELIVERY N 020800 002 May 28, 2004 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -42

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS TWINJECT 0.3 @ IMPAX LABS INC EQ 0.3MG/DELIVERY N 020800 001 May 30, 2003 Jun CAHN SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS SYMJEPI +! ADAMIS PHARMS CORP 0.3MG/ML (0.3MG/ML) N 207534 001 Jun 15, 2017 Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE INJECTABLE;INJECTION LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE @ BELMORA LLC 0.01MG/ML;2% A 080504 004 Oct 19, 1983 Feb CAHN @ 0.02MG/ML;2% A 080504 005 Oct 19, 1983 Feb CAHN @ WEST-WARD PHARMS INT 0.01MG/ML;1% A 080406 001 Mar CAHN @ 0.01MG/ML;2% A 080406 002 Mar CAHN

EPLERENONE TABLET;ORAL EPLERENONE >A> AB ACCORD HLTHCARE 25MG A 206922 001 Jul 13, 2017 Jul NEWA >A> AB 50MG A 206922 002 Jul 13, 2017 Jul NEWA AB MYLAN PHARMS INC 25MG A 203896 001 Feb 02, 2017 Jan NEWA AB 50MG A 203896 002 Feb 02, 2017 Jan NEWA

EPTIFIBATIDE INJECTABLE;INJECTION EPTIFIBATIDE AP AKORN 2MG/ML A 204589 001 Apr 18, 2017 Apr NEWA AP 75MG/100ML A 204589 002 Apr 18, 2017 Apr NEWA AP AMNEAL PHARMS 2MG/ML A 205581 001 Dec 08, 2016 May CAHN AP 75MG/100ML A 205581 002 Dec 08, 2016 May CAHN

ERGOLOID MESYLATES TABLET;ORAL ERGOLOID MESYLATES ! SUN PHARM INDS 1MG A 081113 001 Oct 31, 1991 May CHRS HYDERGINE + @ NOVARTIS 1MG N 017993 001 May DISC

ERYTHROMYCIN GEL;TOPICAL E-GLADES @ MYLAN PHARMS INC 2% A 065009 001 Mar 18, 2002 Jan CAHN ERYGEL AT +! MYLAN PHARMS INC 2% N 050617 001 Oct 21, 1987 Jan CAHN ERYTHROMYCIN AT PERRIGO CO 2% A 063211 001 Jan 29, 1993 Apr CAHN >A> AT TELIGENT PHARMA INC 2% A 208154 001 Jul 19, 2017 Jul NEWA SOLUTION;TOPICAL A/T/S @ TARO 2% A 062405 001 Nov 18, 1982 Apr CAHN SWAB;TOPICAL ERYTHROMYCIN @ MYLAN PHARMS INC 2% A 064128 001 Jul 03, 1996 Jan CAHN AT ! PERRIGO CO 2% A 064126 001 Jul 03, 1996 Apr CAHN

>D> ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL >D> GRANULE;ORAL >D> ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL >D> ! BARR EQ 200MG BASE/5ML;EQ 600MG A 062759 001 May 20, 1988 Jul DISC BASE/5ML >A> @ EQ 200MG BASE/5ML;EQ 600MG A 062759 001 May 20, 1988 Jul DISC BASE/5ML

ESCITALOPRAM OXALATE TABLET;ORAL ESCITALOPRAM OXALATE AB AMNEAL PHARMS EQ 5MG BASE A 205619 001 May 17, 2017 May NEWA AB EQ 10MG BASE A 205619 002 May 17, 2017 May NEWA AB EQ 20MG BASE A 205619 003 May 17, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -43

ESOMEPRAZOLE MAGNESIUM FOR SUSPENSION, DELAYED RELEASE;ORAL NEXIUM + ASTRAZENECA PHARMS EQ 10MG BASE/PACKET N 022101 001 Feb 27, 2008 May CRLD

ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS ESOMEPRAZOLE SODIUM AP ! AUROBINDO PHARMA LTD EQ 20MG BASE/VIAL A 204657 001 Aug 10, 2016 May CHRS AP ! EQ 40MG BASE/VIAL A 204657 002 Aug 10, 2016 May CHRS AP DEVA HOLDING AS EQ 40MG BASE/VIAL A 207181 001 Mar 06, 2017 Feb NEWA AP MYLAN LABS LTD EQ 20MG BASE/VIAL A 202686 001 May 17, 2017 May NEWA AP EQ 40MG BASE/VIAL A 202686 002 May 17, 2017 May NEWA NEXIUM IV + @ ASTRAZENECA PHARMS EQ 20MG BASE/VIAL N 021689 001 Mar 31, 2005 May DISC + @ EQ 40MG BASE/VIAL N 021689 002 Mar 31, 2005 May DISC

ESTRADIOL FILM, EXTENDED RELEASE;TRANSDERMAL ESTRADERM + @ NOVARTIS 0.05MG/24HR N 019081 002 Sep 10, 1986 May DISC + @ 0.1MG/24HR N 019081 003 Sep 10, 1986 May DISC VIVELLE @ NOVARTIS 0.05MG/24HR N 020323 002 Oct 28, 1994 May DISC @ 0.1MG/24HR N 020323 004 Oct 28, 1994 May DISC GEL, METERED;TRANSDERMAL ELESTRIN +! MYLAN SPECIALITY LP 0.06% (0.87GM/ACTIVATION) N 021813 001 Dec 15, 2006 Mar CAHN SPRAY;TRANSDERMAL EVAMIST +! PERRIGO PHARMA INTL 1.53MG/SPRAY N 022014 001 Jul 27, 2007 May CAHN TABLET;VAGINAL ESTRADIOL >A> AB TEVA PHARMS USA 10MCG A 206388 001 Jul 21, 2017 Jul NEWA

ESTRADIOL ACETATE TABLET;ORAL FEMTRACE + @ APIL 0.45MG N 021633 001 Aug 20, 2004 Jun DISC + @ 0.9MG N 021633 002 Aug 20, 2004 Jun DISC + @ 1.8MG N 021633 003 Aug 20, 2004 Jun DISC

ESTRADIOL VALERATE INJECTABLE;INJECTION ESTRADIOL VALERATE @ SANDOZ INC 10MG/ML A 040628 001 Oct 04, 2007 Apr CAHN @ 20MG/ML A 040628 002 Oct 04, 2007 Apr CAHN @ 40MG/ML A 040628 003 Oct 04, 2007 Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE TABLET;ORAL ESTRADIOL AND NORETHINDRONE ACETATE AB MYLAN LABS LTD 0.5MG;0.1MG A 207261 001 Feb 10, 2017 Jan NEWA AB 1MG;0.5MG A 207261 002 Feb 10, 2017 Jan NEWA

ESTROGENS, CONJUGATED SYNTHETIC B TABLET;ORAL ENJUVIA TEVA BRANDED PHARM 0.3MG N 021443 001 Dec 20, 2004 Apr CAHN 0.45MG N 021443 002 Dec 20, 2004 Apr CAHN @ 0.625MG N 021443 003 May 10, 2004 Apr CAHN 0.9MG N 021443 005 Apr 27, 2007 Apr CAHN @ 1.25MG N 021443 004 May 10, 2004 Apr CAHN

ESTROGENS, ESTERIFIED TABLET;ORAL MENEST MONARCH PHARMS 0.3MG A 084951 001 Jun CAHN 0.625MG A 084948 001 Jun CAHN 1.25MG A 084950 001 Jun CAHN ! 2.5MG A 084949 001 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -44

ESTRONE INJECTABLE;INJECTION ESTRONE @ WATSON LABS TEVA 5MG/ML A 085239 001 May CAHN

ESTROPIPATE TABLET;ORAL ESTROPIPATE @ BARR 0.75MG A 040135 001 Nov 27, 1996 May DISC @ 1.5MG A 040135 002 Nov 27, 1996 May DISC @ 3MG A 040135 003 Nov 27, 1996 May DISC ! WATSON LABS TEVA 3MG A 081215 001 Sep 23, 1993 May CHRS AB 3MG A 081215 001 Sep 23, 1993 Feb CAHN OGEN .625 @ PHARMACIA AND UPJOHN 0.75MG A 083220 001 May DISC OGEN 1.25 @ PHARMACIA AND UPJOHN 1.5MG A 083220 002 May DISC OGEN 2.5 @ PHARMACIA AND UPJOHN 3MG A 083220 003 May DISC

ETELCALCETIDE SOLUTION;INTRAVENOUS PARSABIV +! KAI PHARMS INC 2.5MG/0.5ML (2.5MG/0.5ML) N 208325 001 Feb 07, 2017 Feb NEWA +! 5MG/ML (5MG/ML) N 208325 002 Feb 07, 2017 Feb NEWA +! 10MG/2ML (5MG/ML) N 208325 003 Feb 07, 2017 Feb NEWA

ETHACRYNIC ACID TABLET;ORAL ETHACRYNIC ACID >A> AB PAR PHARM INC 25MG A 208501 001 Jul 21, 2017 Jul NEWA AB WEST-WARD PHARMS INT 25MG A 207262 001 Feb 23, 2017 Feb NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE TABLET;ORAL-21 ZOVIA 1/35E-21 @ WATSON PHARMS TEVA 0.035MG;1MG A 072720 001 Dec 30, 1991 Mar CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL TABLET;ORAL LO SIMPESSE AB AUROBINDO PHARMA LTD 0.02MG,0.01MG;0.01MG,N/A A 206852 001 Apr 28, 2017 Apr NEWA SIMPESSE AB AUROBINDO PHARMA LTD 0.03MG,0.01MG;0.15MG,N/A A 206851 001 Apr 07, 2017 Mar NEWA TABLET;ORAL-28 ELIFEMME AB LABS LEON FARMA 0.03MG,0.04MG,0.03MG;0.05MG,0.075M A 202507 001 Dec 04, 2015 Feb CAHN G,0.125MG

ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE;TRANSDERMAL XULANE AB ! MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A 200910 001 Apr 16, 2014 Mar CAHN

ETHINYL ESTRADIOL; NORETHINDRONE TABLET;ORAL-21 NORETHIN 1/35E-21 @ WATSON PHARMS TEVA 0.035MG;1MG A 071480 001 Apr 12, 1988 Mar CAHN NORETHINDRONE AND ETHINYL ESTRADIOL @ WATSON PHARMS TEVA 0.035MG;1MG A 070685 001 Jan 29, 1987 Mar CAHN NORETHINDRONE AND ETHINYL ESTRADIOL (7/14) @ WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG A 071041 001 Sep 24, 1991 May CAHN TABLET;ORAL-28 NORETHINDRONE AND ETHINYL ESTRADIOL AB ACCORD HLTHCARE 0.035MG;1MG A 206864 001 Apr 28, 2017 Apr NEWA AB WATSON LABS TEVA 0.035MG;1MG A 070687 001 Jan 29, 1987 May CAHN NORETHINDRONE AND ETHINYL ESTRADIOL (10/11) WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG A 071044 001 Apr 01, 1988 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -45

TABLET, CHEWABLE;ORAL NEXESTA FE AB AUROBINDO PHARMA LTD 0.035MG;0.4MG A 207535 001 Feb 02, 2017 Jan NEWA NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE AB ACCORD HLTHCARE 0.035MG;0.4MG A 207066 001 Mar 29, 2017 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE TABLET;ORAL AUROVELA 24 FE AB AUROBINDO PHARMA LTD 0.02MG;1MG A 207504 001 Jun 15, 2017 Jun NEWA NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AB MYLAN LABS LTD 0.0025MG;0.5MG A 207260 001 Feb 02, 2017 Jan NEWA TABLET;ORAL-21 AUROVELA 1.5/30 AB AUROBINDO PHARMA LTD 0.03MG;1.5MG A 207581 001 Jun 26, 2017 Jun NEWA AUROVELA 1/20 AB AUROBINDO PHARMA LTD 0.02MG;1MG A 207506 001 Jun 16, 2017 Jun NEWA TABLET;ORAL-28 AUROVELA FE 1.5/30 AB AUROBINDO PHARMA LTD 0.03MG;1.5MG A 207580 001 Jun 15, 2017 May NEWA AUROVELA FE 1/20 AB AUROBINDO PHARMA LTD 0.02MG;1MG A 207505 001 Jun 16, 2017 Jun NEWA LOESTRIN FE 1/20 >D> AB APIL 0.02MG;1MG N 017354 001 Jul CRLD >A> AB + 0.02MG;1MG N 017354 001 Jul CRLD

ETHINYL ESTRADIOL; NORGESTREL TABLET;ORAL-28 NORGESTREL AND ETHINYL ESTRADIOL AB MYLAN LABS LTD 0.05MG;0.5MG A 202875 001 May 08, 2017 Apr NEWA OGESTREL 0.5/50-28 AB ! WATSON LABS 0.05MG;0.5MG A 075406 002 Dec 15, 1999 May CTEC

ETHOSUXIMIDE SYRUP;ORAL ETHOSUXIMIDE AA PHARM ASSOC 250MG/5ML A 040253 001 Nov 22, 2000 May CAHN ZARONTIN AA ! PARKE-DAVIS 250MG/5ML A 080258 001 Mar CAHN

ETIDRONATE DISODIUM TABLET;ORAL DIDRONEL + @ APIL 200MG N 017831 001 Jun DISC + @ 400MG N 017831 002 Jun DISC ETIDRONATE DISODIUM MYLAN 200MG A 075800 001 Jan 24, 2003 Jun CTEC ! 400MG A 075800 002 Jan 24, 2003 Jun CHRS

ETODOLAC CAPSULE;ORAL ETODOLAC @ CHARTWELL MOLECULES 200MG A 074842 001 Jul 17, 1997 Mar CAHN @ 300MG A 074842 002 Jul 17, 1997 Mar CAHN @ CHARTWELL PHARMS LLC 200MG A 074842 001 Jul 17, 1997 Jan CAHN @ 300MG A 074842 002 Jul 17, 1997 Jan CAHN @ ECI PHARMS LLC 300MG A 074929 001 Jan 30, 1998 Apr CAHN LODINE >D> @ WYETH PHARMS INC 300MG N 018922 003 Jan 31, 1991 Jul CRLD >A> + @ 300MG N 018922 003 Jan 31, 1991 Jul CRLD TABLET;ORAL ETODOLAC @ CHARTWELL MOLECULES 400MG A 074841 001 Jun 27, 1997 Jan CAHN @ MYLAN PHARMS INC 400MG A 075104 001 Feb 06, 1998 May DISC AB 400MG A 075104 001 Feb 06, 1998 Mar CAHN @ 500MG A 075104 002 Nov 20, 1998 May DISC AB 500MG A 075104 002 Nov 20, 1998 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -46

ETOMIDATE INJECTABLE;INJECTION ETOMIDATE AP AUROBINDO PHARMA LTD 2MG/ML A 206126 001 Feb 24, 2017 Feb NEWA AP GLAND PHARMA LTD 2MG/ML A 209058 001 Apr 18, 2017 Apr NEWA AP MYLAN LABS LTD 2MG/ML A 201044 001 Feb 07, 2017 Jan NEWA AP WEST-WARD PHARMS INT 2MG/ML A 074593 001 Nov 04, 1996 Jan CAHN

EXEMESTANE TABLET;ORAL EXEMESTANE AB MYLAN PHARMS INC 25MG A 203315 001 Mar 10, 2017 Feb NEWA >A> AB UPSHER-SMITH LABS 25MG A 209208 001 Jul 26, 2017 Jul NEWA

EZETIMIBE TABLET;ORAL EZETIMIBE AB AMNEAL PHARMS CO 10MG A 208803 001 Jun 12, 2017 May NEWA AB APOTEX INC 10MG A 208332 001 Jun 12, 2017 May NEWA AB OHM LABS INC 10MG A 207311 001 Jun 12, 2017 May NEWA AB SANDOZ INC 10MG A 203931 001 Jun 12, 2017 May NEWA AB TEVA PHARMS USA 10MG A 078724 001 Jun 12, 2017 May NEWA AB WATSON LABS INC 10MG A 200831 001 Jun 12, 2017 May NEWA AB ZYDUS PHARMS USA INC 10MG A 204331 001 Jun 12, 2017 May NEWA

EZETIMIBE; SIMVASTATIN TABLET;ORAL EZETIMIBE AND SIMVASTATIN AB DR REDDYS LABS INTL 10MG;10MG A 200909 001 Apr 26, 2017 Apr NEWA AB 10MG;20MG A 200909 002 Apr 26, 2017 Apr NEWA AB 10MG;40MG A 200909 003 Apr 26, 2017 Apr NEWA AB 10MG;80MG A 200909 004 Apr 26, 2017 Apr NEWA AB DR REDDYS LABS SA 10MG;10MG A 200909 001 Apr 26, 2017 May CAHN AB 10MG;20MG A 200909 002 Apr 26, 2017 May CAHN AB 10MG;40MG A 200909 003 Apr 26, 2017 May CAHN AB 10MG;80MG A 200909 004 Apr 26, 2017 May CAHN AB IMPAX LABS INC 10MG;10MG A 201890 001 Apr 26, 2017 Apr NEWA AB 10MG;20MG A 201890 002 Apr 26, 2017 Apr NEWA AB 10MG;40MG A 201890 003 Apr 26, 2017 Apr NEWA AB 10MG;80MG A 201890 004 Apr 26, 2017 Apr NEWA AB WATSON LABS INC 10MG;10MG A 202968 001 Apr 26, 2017 Apr NEWA AB 10MG;20MG A 202968 002 Apr 26, 2017 Apr NEWA AB 10MG;40MG A 202968 003 Apr 26, 2017 Apr NEWA AB 10MG;80MG A 202968 004 Apr 26, 2017 Apr NEWA VYTORIN AB + MSD INTL 10MG;10MG N 021687 001 Jul 23, 2004 Apr CFTG AB + 10MG;20MG N 021687 002 Jul 23, 2004 Apr CFTG AB + 10MG;40MG N 021687 003 Jul 23, 2004 Apr CFTG AB +! 10MG;80MG N 021687 004 Jul 23, 2004 Apr CFTG

FAMCICLOVIR TABLET;ORAL FAMCICLOVIR AB ! TEVA PHARMS 500MG A 077487 003 Aug 24, 2007 Jan CHRS FAMVIR + @ NOVARTIS 125MG N 020363 003 Dec 11, 1995 Jan DISC + @ 250MG N 020363 001 Apr 26, 1996 Jan DISC + @ 500MG N 020363 002 Jun 29, 1994 Jan DISC

FAMOTIDINE INJECTABLE;INJECTION FAMOTIDINE AP ATHENEX INC 10MG/ML A 075651 001 Apr 16, 2001 Mar CAHN AP 10MG/ML A 075684 001 Apr 16, 2001 Mar CAHN FAMOTIDINE PRESERVATIVE FREE AP ATHENEX INC 10MG/ML A 075622 001 Apr 16, 2001 Mar CAHN AP 10MG/ML A 075825 001 Apr 17, 2001 Mar CAHN TABLET;ORAL FAMOTIDINE AB PERRIGO R AND D 20MG A 077352 002 Jul 27, 2005 Apr CAHN AB 40MG A 077352 001 Jul 27, 2005 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -47

FELBAMATE SUSPENSION;ORAL FELBAMATE AB TARO PHARM 600MG/5ML A 206314 001 Jun 16, 2017 Jun NEWA FELBATOL AB +! MYLAN SPECIALITY LP 600MG/5ML N 020189 003 Jul 29, 1993 Mar CAHN TABLET;ORAL FELBAMATE AB IMPAX LABS INC 400MG A 202284 001 Nov 04, 2015 Feb CAHN AB 600MG A 202284 002 Nov 04, 2015 Feb CAHN AB TARO PHARM 400MG A 207093 001 Apr 20, 2017 Apr NEWA AB 600MG A 207093 002 Apr 20, 2017 Apr NEWA AB ZYDUS PHARMS USA INC 400MG A 208970 001 May 30, 2017 May NEWA AB 600MG A 208970 002 May 30, 2017 May NEWA FELBATOL AB + MYLAN SPECIALITY LP 400MG N 020189 001 Jul 29, 1993 Mar CAHN AB +! 600MG N 020189 002 Jul 29, 1993 Mar CAHN

FENOFIBRATE CAPSULE;ORAL FENOFIBRATE (MICRONIZED) AB GLENMARK PHARMS LTD 67MG A 205566 001 Apr 07, 2017 Mar NEWA AB 134MG A 205566 002 Apr 07, 2017 Mar NEWA AB 200MG A 205566 003 Apr 07, 2017 Mar NEWA AB ! IMPAX LABS 200MG A 075868 003 Oct 27, 2003 Jun CHRS AB INVAGEN PHARMS 67MG A 207378 001 Mar 28, 2017 Mar NEWA AB 134MG A 207378 002 Mar 28, 2017 Mar NEWA AB 200MG A 207378 003 Mar 28, 2017 Mar NEWA AB RHODES PHARMS 200MG A 075753 003 Apr 09, 2002 Jun CHRS TABLET;ORAL FENOFIBRATE AB ! IMPAX LABS 160MG A 076509 002 Mar 26, 2008 Mar CHRS AB RHODES PHARMS 160MG A 076433 002 May 13, 2005 Mar CHRS

FENOLDOPAM MESYLATE INJECTABLE;INJECTION FENOLDOPAM MESYLATE AP SANDOZ INC EQ 10MG BASE/ML A 077155 001 Feb 15, 2005 Mar CAHN

FENOPROFEN CALCIUM TABLET;ORAL FENOPROFEN CALCIUM @ WATSON LABS TEVA EQ 600MG BASE A 072407 001 Aug 17, 1988 May CAHN

FENTANYL FILM, EXTENDED RELEASE;TRANSDERMAL FENTANYL-100 AB 3M DRUG DELIVERY 100MCG/HR A 202097 005 Nov 04, 2016 Mar CAHN AB ACTAVIS LABS UT INC 100MCG/HR A 076709 004 Aug 20, 2007 Mar CAHN AB MAYNE PHARMA 100MCG/HR A 077062 004 Aug 20, 2007 Mar CAHN FENTANYL-12 AB 3M DRUG DELIVERY 12.5MCG/HR A 202097 001 Nov 04, 2016 Mar CAHN FENTANYL-25 AB 3M DRUG DELIVERY 25MCG/HR A 202097 002 Nov 04, 2016 Mar CAHN AB ACTAVIS LABS UT INC 25MCG/HR A 076709 001 Aug 20, 2007 Mar CAHN AB MAYNE PHARMA 25MCG/HR A 077062 001 Aug 20, 2007 Mar CAHN FENTANYL-50 AB 3M DRUG DELIVERY 50MCG/HR A 202097 003 Nov 04, 2016 Mar CAHN AB ACTAVIS LABS UT INC 50MCG/HR A 076709 002 Aug 20, 2007 Mar CAHN AB MAYNE PHARMA 50MCG/HR A 077062 002 Aug 20, 2007 Mar CAHN FENTANYL-75 AB 3M DRUG DELIVERY 75MCG/HR A 202097 004 Nov 04, 2016 Mar CAHN AB ACTAVIS LABS UT INC 75MCG/HR A 076709 003 Aug 20, 2007 Mar CAHN AB MAYNE PHARMA 75MCG/HR A 077062 003 Aug 20, 2007 Mar CAHN SPRAY;SUBLINGUAL SUBSYS + INSYS DEV CO INC 0.1MG N 202788 001 Jan 04, 2012 May CAHN + 0.2MG N 202788 002 Jan 04, 2012 May CAHN +! 0.4MG N 202788 003 Jan 04, 2012 May CAHN + 0.6MG N 202788 004 Jan 04, 2012 May CAHN + 0.8MG N 202788 005 Jan 04, 2012 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -48

SPRAY;SUBLINGUAL SUBSYS + 1.2MG N 202788 006 Aug 30, 2012 May CAHN + 1.6MG N 202788 007 Aug 30, 2012 May CAHN

FESOTERODINE FUMARATE TABLET, EXTENDED RELEASE;ORAL FESOTERODINE FUMARATE AB AUROBINDO PHARMA LTD 4MG A 205007 001 Feb 17, 2017 Feb NEWA AB 8MG A 205007 002 Feb 17, 2017 Feb NEWA

FINASTERIDE TABLET;ORAL FINASTERIDE AB ACCORD HLTHCARE 1MG A 091643 001 Nov 05, 2013 Mar CAHN AB ACTAVIS TOTOWA TEVA 5MG A 077914 001 Mar 28, 2007 May CAHN

FLUCONAZOLE FOR SUSPENSION;ORAL FLUCONAZOLE AB AUROBINDO PHARMA LTD 50MG/5ML A 079150 001 Sep 18, 2009 Jan CAHN AB 200MG/5ML A 079150 002 Sep 18, 2009 Jan CAHN INJECTABLE;INJECTION DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER + @ PFIZER 200MG/100ML (2MG/ML) N 019950 003 Sep 29, 1992 Mar DISC + @ 400MG/200ML (2MG/ML) N 019950 005 Jul 08, 1994 Mar DISC DIFLUCAN IN SODIUM CHLORIDE 0.9% + @ PFIZER 200MG/100ML (2MG/ML) N 019950 001 Jan 29, 1990 Mar DISC + @ 400MG/200ML (2MG/ML) N 019950 006 Jan 29, 1990 Mar DISC DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER + @ PFIZER 200MG/100ML (2MG/ML) N 019950 002 Jan 29, 1990 Mar DISC + @ 400MG/200ML (2MG/ML) N 019950 004 Jan 29, 1990 Mar DISC FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER AP ! HOSPIRA 200MG/100ML (2MG/ML) A 076304 001 Jul 29, 2004 Mar CHRS AP ! 400MG/200ML (2MG/ML) A 076304 002 Jul 29, 2004 Mar CHRS FLUCONAZOLE IN SODIUM CHLORIDE 0.9% WEST-WARD PHARMS INT 100MG/50ML (2MG/ML) A 076087 002 Sep 26, 2008 Jan CAHN AP 200MG/100ML (2MG/ML) A 076087 001 Jul 29, 2004 Jan CAHN AP 400MG/200ML (2MG/ML) A 076087 003 Jul 29, 2004 Jan CAHN FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ! ACS DOBFAR INFO SA 200MG/100ML (2MG/ML) A 079104 001 Jul 30, 2009 Mar CHRS AP ! 400MG/200ML (2MG/ML) A 079104 002 Jul 30, 2009 Mar CHRS AP WEST-WARD PHARMS INT 200MG/100ML (2MG/ML) A 078107 001 Jul 30, 2008 Jan CAHN AP 400MG/200ML (2MG/ML) A 078107 002 Jul 30, 2008 Jan CAHN TABLET;ORAL FLUCONAZOLE AB UNIQUE PHARM LABS 150MG A 076957 004 Feb 27, 2017 Feb NEWA AB ZYDUS PHARMS USA INC 50MG A 208963 001 Feb 16, 2017 Feb NEWA AB 100MG A 208963 002 Feb 16, 2017 Feb NEWA AB 150MG A 208963 003 Feb 16, 2017 Feb NEWA AB 200MG A 208963 004 Feb 16, 2017 Feb NEWA

FLUCYTOSINE CAPSULE;ORAL FLUCYTOSINE AB NOVEL LABS INC 250MG A 204652 001 Jul 07, 2017 Jun NEWA AB 500MG A 204652 002 Jul 07, 2017 Jun NEWA

FLUDARABINE PHOSPHATE INJECTABLE;INJECTION FLUDARABINE PHOSPHATE AP ACTAVIS LLC 50MG/2ML (25MG/ML) A 203738 001 Feb 28, 2017 Feb NEWA

FLUMAZENIL INJECTABLE;INJECTION FLUMAZENIL AP SANDOZ INC 0.5MG/5ML (0.1MG/ML) A 077071 001 May 03, 2005 Apr CAHN AP 1MG/10ML (0.1MG/ML) A 077071 002 May 03, 2005 Apr CAHN AP WEST-WARD PHARMS INT 0.5MG/5ML (0.1MG/ML) A 076256 002 Oct 12, 2004 Jan CAHN AP 0.5MG/5ML (0.1MG/ML) A 076787 002 Oct 12, 2004 Jan CAHN AP 1MG/10ML (0.1MG/ML) A 076256 001 Oct 12, 2004 Jan CAHN AP 1MG/10ML (0.1MG/ML) A 076787 001 Oct 12, 2004 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -49

FLUNISOLIDE AEROSOL, METERED;INHALATION AEROSPAN HFA +! MYLAN SPECIALITY LP 0.078MG/INH N 021247 001 Jan 27, 2006 Mar CAHN

FLUOCINOLONE ACETONIDE CREAM;TOPICAL FLUOCINOLONE ACETONIDE AT FOUGERA PHARMS INC 0.01% A 088170 001 Dec 16, 1982 Jan CAHN AT 0.025% A 088169 001 Dec 16, 1982 Jan CAHN @ TARO 0.01% A 040035 001 Oct 31, 1994 Apr CAHN @ 0.025% A 040042 001 Oct 31, 1994 Apr CAHN OIL/DROPS;OTIC FLUOCINOLONE ACETONIDE >A> AT PERRIGO ISRAEL 0.01% A 202849 001 Jul 17, 2017 Jul NEWA OINTMENT;TOPICAL FLUOCINOLONE ACETONIDE AT FOUGERA PHARMS INC 0.025% A 088168 001 Dec 16, 1982 Jan CAHN AT TARO 0.025% A 040041 001 Sep 15, 1994 Apr CAHN SOLUTION;TOPICAL FLUOCINOLONE ACETONIDE AT FOUGERA PHARMS INC 0.01% A 088167 001 Dec 16, 1982 Jan CAHN

FLUOCINONIDE CREAM;TOPICAL FLUOCINONIDE AB1 FOUGERA PHARMS INC 0.05% A 073030 001 Oct 17, 1994 Jan CAHN AB PERRIGO ISRAEL 0.1% A 090256 001 Jan 14, 2014 Apr CAHN AB1 TARO 0.05% A 071500 001 Jun 10, 1987 Mar CMFD FLUOCINONIDE EMULSIFIED BASE AB2 G AND W LABS INC 0.05% A 074204 001 Jun 13, 1995 May CMFD GEL;TOPICAL FLUOCINONIDE AB FOUGERA PHARMS INC 0.05% A 072933 001 Dec 30, 1994 Jan CAHN AB ! TARO 0.05% A 074935 001 Jul 29, 1997 Apr CAHN OINTMENT;TOPICAL FLUOCINONIDE >A> AB NOVEL LABS INC 0.05% A 207538 001 Jul 31, 2017 Jul NEWA AB ! TARO 0.05% A 075008 001 Jun 30, 1999 Apr CAHN SOLUTION;TOPICAL FLUOCINONIDE >A> AT NOVEL LABS INC 0.05% A 206003 001 Jul 21, 2017 Jul NEWA AT ! TARO 0.05% A 074799 001 Dec 31, 1996 Apr CAHN LIDEX AT + CNTY LINE PHARMS 0.05% N 018849 001 Apr 06, 1984 Mar CRLD

FLUOROURACIL CREAM;TOPICAL FLUOROURACIL AB MYLAN PHARMS INC 0.5% A 203122 001 Apr 20, 2015 Jun CAHN INJECTABLE;INJECTION FLUOROURACIL AP SAGENT PHARMS 500MG/10ML (50MG/ML) A 203608 001 May 11, 2017 May NEWA AP 1GM/20ML (50MG/ML) A 203608 002 May 11, 2017 May NEWA >D> AP SANDOZ 2.5GM/50ML (50MG/ML) A 091299 001 May 02, 2011 Jul DISC >A> @ 2.5GM/50ML (50MG/ML) A 091299 001 May 02, 2011 Jul DISC >D> AP 5GM/100ML (50MG/ML) A 091299 002 May 02, 2011 Jul DISC >A> @ 5GM/100ML (50MG/ML) A 091299 002 May 02, 2011 Jul DISC + @ SPECTRUM PHARMS 500MG/10ML (50MG/ML) N 012209 001 Jan CRLD SOLUTION;TOPICAL FLUOROURACIL AT TARO PHARM 2% A 076526 001 Nov 05, 2003 Mar CAHN AT 5% A 076526 002 Nov 05, 2003 Mar CAHN

FLUOXETINE HYDROCHLORIDE CAPSULE;ORAL FLUOXETINE HYDROCHLORIDE @ MYLAN EQ 10MG BASE A 075207 001 Jan 30, 2002 Jun DISC @ EQ 20MG BASE A 075207 002 Jan 30, 2002 Jun DISC @ EQ 40MG BASE A 075207 003 May 25, 2007 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -50

SOLUTION;ORAL FLUOXETINE HYDROCHLORIDE AA AUROBINDO PHARMA LTD EQ 20MG BASE/5ML A 079209 001 Mar 20, 2009 Jan CAHN AA ! PHARM ASSOC EQ 20MG BASE/5ML A 076015 001 Jan 30, 2002 May CAHN TABLET;ORAL FLUOXETINE HYDROCHLORIDE AB ALEMBIC PHARMS LTD EQ 10MG BASE A 208698 001 Apr 05, 2017 Mar NEWA AB EQ 20MG BASE A 208698 002 Apr 05, 2017 Mar NEWA +! ALVOGEN EQ 60MG BASE N 202133 001 Oct 06, 2011 Jan CAHN

FLUOXYMESTERONE TABLET;ORAL FLUOXYMESTERONE ! USL PHARMA 10MG A 088342 001 Oct 21, 1983 Jun CAHN

FLUPHENAZINE HYDROCHLORIDE CONCENTRATE;ORAL FLUPHENAZINE HYDROCHLORIDE @ ANI PHARMS INC 5MG/ML A 073058 001 Aug 30, 1991 Jan CAHN ! PHARM ASSOC 5MG/ML A 074725 001 Sep 16, 1996 May CAHN ELIXIR;ORAL FLUPHENAZINE HYDROCHLORIDE ! PHARM ASSOC 2.5MG/5ML A 040146 001 Aug 21, 1996 May CAHN

FLURANDRENOLIDE CREAM;TOPICAL FLURANDRENOLIDE AT CINTEX SVCS 0.05% A 205342 001 Apr 13, 2016 Jun CAHN LOTION;TOPICAL FLURANDRENOLIDE AT CINTEX SVCS 0.05% A 205343 001 Dec 22, 2016 Jun CAHN

FLURAZEPAM HYDROCHLORIDE CAPSULE;ORAL FLURAZEPAM HYDROCHLORIDE @ AUROLIFE PHARMA LLC 15MG A 071717 002 Jul 31, 1991 Jan CMS1

FLUTAMIDE CAPSULE;ORAL FLUTAMIDE @ MYLAN 125MG A 076224 001 May 09, 2003 Jun DISC

FLUTICASONE PROPIONATE POWDER;INHALATION ARMONAIR RESPICLICK + TEVA PHARM 0.055MG/INH N 208798 001 Jan 27, 2017 Jan NEWA + 0.113MG/INH N 208798 002 Jan 27, 2017 Jan NEWA +! 0.232MG/INH N 208798 003 Jan 27, 2017 Jan NEWA SPRAY, METERED;NASAL FLONASE >D> @ GLAXOSMITHKLINE 0.05MG/SPRAY N 020121 001 Oct 19, 1994 Jul CRLD >A> + @ 0.05MG/SPRAY N 020121 001 Oct 19, 1994 Jul CRLD FLUTICASONE PROPIONATE >D> AB WEST-WARD PHARMS INT 0.05MG/SPRAY A 076504 001 Feb 22, 2006 Jul CHRS >A> AB ! 0.05MG/SPRAY A 076504 001 Feb 22, 2006 Jul CHRS

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE POWDER;INHALATION AIRDUO RESPICLICK + TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH N 208799 001 Jan 27, 2017 Jan NEWA + 0.113MG/INH;EQ 0.014MG BASE/INH N 208799 002 Jan 27, 2017 Jan NEWA +! 0.232MG/INH;EQ 0.014MG BASE/INH N 208799 003 Jan 27, 2017 Jan NEWA

FLUVASTATIN SODIUM CAPSULE;ORAL FLUVASTATIN SODIUM AB ! MYLAN PHARMS INC EQ 40MG BASE A 090595 002 Apr 11, 2012 May CHRS LESCOL + @ NOVARTIS EQ 20MG BASE N 020261 001 Dec 31, 1993 May DISC + @ EQ 40MG BASE N 020261 002 Dec 31, 1993 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -51

FLUVOXAMINE MALEATE CAPSULE, EXTENDED RELEASE;ORAL FLUVOXAMINE MALEATE AB ! ACTAVIS ELIZABETH 150MG A 091482 002 Nov 18, 2013 Apr CHRS LUVOX CR + @ JAZZ PHARMS 100MG N 022033 001 Feb 28, 2008 Apr DISC + @ 150MG N 022033 002 Feb 28, 2008 Apr DISC TABLET;ORAL FLUVOXAMINE MALEATE @ ECI PHARMS LLC 25MG A 075900 001 Feb 23, 2006 May CAHN @ 50MG A 075900 002 Feb 23, 2006 May CAHN @ 100MG A 075900 003 Feb 23, 2006 May CAHN @ UPSHER-SMITH LABS 25MG A 075887 001 Jan 05, 2001 Jun CAHN AB 25MG A 075888 001 Nov 29, 2000 Jun CAHN @ 50MG A 075887 002 Jan 05, 2001 Jun CAHN AB 50MG A 075888 002 Nov 29, 2000 Jun CAHN @ 100MG A 075887 003 Jan 05, 2001 Jun CAHN AB ! 100MG A 075888 003 Nov 29, 2000 Jun CAHN

FOLIC ACID TABLET;ORAL FOLIC ACID @ CONTRACT PHARMACAL 1MG A 085061 001 Mar DISC

FORMOTEROL FUMARATE POWDER;INHALATION FORADIL + @ NOVARTIS 0.012MG/INH N 020831 001 Feb 16, 2001 Feb DISC

FORMOTEROL FUMARATE; GLYCOPYRROLATE AEROSOL, METERED;INHALATION BEVESPI AEROSPHERE +! ASTRAZENECA PHARMS 0.0048MG/INH;0.0090MG/INH N 208294 001 Apr 25, 2016 Mar CAHN

FOSINOPRIL SODIUM TABLET;ORAL FOSINOPRIL SODIUM @ UPSHER-SMITH LABS 10MG A 076188 001 Oct 08, 2004 Jun CAHN AB 10MG A 076483 001 Apr 23, 2004 Jun CAHN @ 20MG A 076188 002 Oct 08, 2004 Jun CAHN AB 20MG A 076483 002 Apr 23, 2004 Jun CAHN @ 40MG A 076188 003 Oct 08, 2004 Jun CAHN AB 40MG A 076483 003 Apr 23, 2004 Jun CAHN MONOPRIL + @ BRISTOL MYERS SQUIBB 10MG N 019915 002 May 16, 1991 Jan CRLD + @ 20MG N 019915 003 May 16, 1991 Jan CRLD + @ 40MG N 019915 004 Mar 28, 1995 Jan CRLD

FOSPHENYTOIN SODIUM INJECTABLE;INJECTION FOSPHENYTOIN SODIUM AP FRESENIUS KABI USA EQ 50MG PHENYTOIN NA/ML A 078052 001 Aug 06, 2007 Jun CMFD @ HOSPIRA EQ 50MG PHENYTOIN NA/ML A 078158 001 Aug 06, 2007 Mar DISC AP WEST-WARD PHARMS INT EQ 50MG PHENYTOIN NA/ML A 077481 001 Aug 06, 2007 Jan CAHN AP EQ 50MG PHENYTOIN NA/ML A 077989 001 Aug 06, 2007 Jan CAHN

FUROSEMIDE INJECTABLE;INJECTION FUROSEMIDE @ ACCORD HLTHCARE 10MG/ML A 070017 001 Dec 15, 1986 Jun CAHN TABLET;ORAL FUROSEMIDE BX IPCA LABS LTD 20MG A 078010 001 Sep 18, 2006 Apr CTEC BX 40MG A 078010 002 Sep 18, 2006 Apr CTEC BX 80MG A 078010 003 Sep 18, 2006 Apr CTEC AB PRINSTON INC 20MG A 076796 001 Mar 26, 2004 Feb CAHN AB 40MG A 076796 002 Mar 26, 2004 Feb CAHN AB 80MG A 076796 003 Mar 26, 2004 Feb CAHN @ SUN PHARM INDS INC 20MG A 091258 001 Apr 01, 2014 May DISC @ 40MG A 091258 002 Apr 01, 2014 May DISC @ 80MG A 091258 003 Apr 01, 2014 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -52

TABLET;ORAL FUROSEMIDE @ WATSON LABS TEVA 20MG A 070449 001 Nov 22, 1985 May CAHN @ 80MG A 070528 001 Jan 07, 1986 May CAHN AB WEST-WARD PHARMS INT 20MG N 018823 001 Nov 10, 1983 Jan CAHN AB 40MG N 018823 002 Nov 10, 1983 Jan CAHN

GABAPENTIN CAPSULE;ORAL GABAPENTIN AB AUROBINDO PHARMA LTD 100MG A 078787 001 Jan 31, 2008 Jan CAHN AB 300MG A 078787 002 Jan 31, 2008 Jan CAHN AB 400MG A 078787 003 Jan 31, 2008 Jan CAHN AB EPIC PHARMA LLC 100MG A 207099 001 Mar 24, 2017 Mar NEWA AB 300MG A 207099 002 Mar 24, 2017 Mar NEWA AB 400MG A 207099 003 Mar 24, 2017 Mar NEWA TABLET;ORAL GABAPENTIN AB GLENMARK PHARMS LTD 600MG A 077662 001 Aug 18, 2006 May CAHN AB 800MG A 077662 002 Aug 18, 2006 May CAHN AB TEVA PHARMS USA 600MG A 205807 001 Mar 10, 2017 Feb NEWA AB 800MG A 205807 002 Mar 10, 2017 Feb NEWA

GALANTAMINE HYDROBROMIDE TABLET;ORAL GALANTAMINE HYDROBROMIDE >D> @ YABAO PHARM EQ 4MG BASE A 077604 001 Feb 06, 2009 Jul CMFD >A> AB EQ 4MG BASE A 077604 001 Feb 06, 2009 Jul CMFD >D> @ EQ 8MG BASE A 077604 002 Feb 06, 2009 Jul CMFD >A> AB EQ 8MG BASE A 077604 002 Feb 06, 2009 Jul CMFD >D> @ EQ 12MG BASE A 077604 003 Feb 06, 2009 Jul CMFD >A> AB EQ 12MG BASE A 077604 003 Feb 06, 2009 Jul CMFD

GANCICLOVIR SOLUTION;IV (INFUSION) GANCICLOVIR +! EXELA PHARMA SCS LLC 500MG/250ML (2MG/ML) N 209347 001 Feb 17, 2017 Feb NEWA

GATIFLOXACIN SOLUTION/DROPS;OPHTHALMIC GATIFLOXACIN AT SANDOZ INC 0.5% A 204227 001 Jul 11, 2016 Feb CAHN

GEMCITABINE HYDROCHLORIDE INJECTABLE;INJECTION GEMCITABINE HYDROCHLORIDE AP APOTEX INC 200MG/5.26ML (38MG/ML) A 206776 001 May 23, 2017 May NEWA AP 1GM/26.3ML (38MG/ML) A 206776 002 May 23, 2017 May NEWA AP 2GM/52.6ML (38MG/ML) A 206776 003 May 23, 2017 May NEWA

GEMFIBROZIL TABLET;ORAL GEMFIBROZIL AB CARIBE HOLDINGS 600MG A 078012 001 Mar 26, 2007 Jan CAHN

GEMIFLOXACIN MESYLATE TABLET;ORAL FACTIVE AB +! LG CHEM LTD EQ 320MG BASE N 021158 001 Apr 04, 2003 Mar CAHN

GENTAMICIN SULFATE CREAM;TOPICAL GENTAMICIN SULFATE @ FOUGERA PHARMS INC EQ 0.1% BASE A 062531 001 Jul 05, 1984 Jan DISC AT ! PERRIGO NEW YORK EQ 0.1% BASE A 062307 001 Jan CHRS @ TARO EQ 0.1% BASE A 062427 001 May 26, 1983 Jan DISC OINTMENT;TOPICAL GENTAMICIN SULFATE AT FOUGERA PHARMS INC EQ 0.1% BASE A 062533 001 Oct 05, 1984 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -53

SOLUTION/DROPS;OPHTHALMIC GENTAMICIN SULFATE AT SANDOZ INC EQ 0.3% BASE A 062196 001 Mar CAHN

GLIMEPIRIDE TABLET;ORAL GLIMEPIRIDE @ EPIC PHARMA LLC 1MG A 077274 001 Oct 06, 2005 May CAHN @ 2MG A 077274 002 Oct 06, 2005 May CAHN @ 4MG A 077274 003 Oct 06, 2005 May CAHN AB PRINSTON INC 1MG A 077370 001 Dec 23, 2005 Feb CAHN AB 2MG A 077370 002 Dec 23, 2005 Feb CAHN AB 4MG A 077370 003 Dec 23, 2005 Feb CAHN AB 8MG A 077370 004 Dec 23, 2005 Feb CAHN

GLIPIZIDE TABLET;ORAL GLIPIZIDE AB WATSON LABS TEVA 5MG A 074223 001 Feb 27, 1995 May CAHN AB 10MG A 074223 002 Feb 27, 1995 May CAHN TABLET, EXTENDED RELEASE;ORAL GLIPIZIDE AB AUROBINDO PHARMA LTD 2.5MG A 206928 001 May 12, 2017 May NEWA AB 5MG A 206928 002 May 12, 2017 May NEWA AB 10MG A 206928 003 May 12, 2017 May NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE TABLET;ORAL GLIPIZIDE AND METFORMIN HYDROCHLORIDE AB EPIC PHARMA LLC 2.5MG;250MG A 077507 001 Oct 27, 2005 May CAHN AB 2.5MG;500MG A 077507 002 Oct 27, 2005 May CAHN AB 5MG;500MG A 077507 003 Oct 27, 2005 May CAHN METAGLIP + @ BRISTOL MYERS SQUIBB 2.5MG;250MG N 021460 001 Oct 21, 2002 Jan CRLD + @ 2.5MG;500MG N 021460 002 Oct 21, 2002 Jan CRLD + @ 5MG;500MG N 021460 003 Oct 21, 2002 Jan CRLD

>D> GLUTAMINE >D> FOR SOLUTION;ORAL >D> NUTRESTORE >D> +! EMMAUS MEDCL 5GM/PACKET N 021667 001 Jun 10, 2004 Jul CAIN

GLUTETHIMIDE TABLET;ORAL GLUTETHIMIDE @ UPSHER-SMITH LABS 500MG A 083234 002 Jun CAHN

GLYBURIDE TABLET;ORAL GLYBURIDE AB1 EPIC PHARMA LLC 1.25MG A 076257 001 Jun 27, 2002 May CAHN AB1 2.5MG A 076257 002 Jun 27, 2002 May CAHN AB1 5MG A 076257 003 Jun 27, 2002 May CAHN AB2 IMPAX LABS INC 1.25MG A 206079 001 Sep 30, 2015 Feb CAHN AB2 2.5MG A 206079 002 Sep 30, 2015 Feb CAHN AB2 5MG A 206079 003 Sep 30, 2015 Feb CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE TABLET;ORAL GLYBURIDE AND METFORMIN HYDROCHLORIDE @ IMPAX LABS INC 1.25MG;250MG A 076731 001 Nov 19, 2004 Feb CAHN @ 2.5MG;500MG A 076731 002 Nov 19, 2004 Feb CAHN @ 5MG;500MG A 076731 003 Nov 19, 2004 Feb CAHN

GLYCINE SOLUTION;IRRIGATION GLYCINE 1.5% IN PLASTIC CONTAINER AT ICU MEDICAL INC 1.5GM/100ML N 018315 001 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -54

GLYCOPYRROLATE INJECTABLE;INJECTION GLYCOPYRROLATE AP AMNEAL PHARMS CO 0.2MG/ML A 208973 001 Jun 15, 2017 Jun NEWA AP SOMERSET THERAPS LLC 0.2MG/ML A 207639 001 Jun 23, 2017 Jun NEWA POWDER;INHALATION SEEBRI +! SUNOVION PHARMS INC 15.6MCG/INH N 207923 001 Oct 29, 2015 Jan CAHN TABLET;ORAL GLYCOPYRROLATE @ EPIC PHARMA LLC 1MG A 040568 001 Dec 22, 2004 May CAHN @ 2MG A 040568 002 Dec 22, 2004 May CAHN AA SANTOS BIOTECH 1MG A 091182 001 Feb 03, 2014 May CAHN AA 2MG A 091182 002 Feb 03, 2014 May CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE POWDER;INHALATION UTIBRON +! SUNOVION PHARMS INC 15.6MCG/INH;27.5MCG/INH N 207930 001 Oct 29, 2015 Jan CAHN

GONADORELIN HYDROCHLORIDE INJECTABLE;INJECTION FACTREL @ WEST-WARD PHARMS INT EQ 0.1MG BASE/VIAL N 018123 001 Sep 30, 1982 Mar CAHN @ EQ 0.2MG BASE/VIAL N 018123 002 Sep 30, 1982 Mar CAHN @ EQ 0.5MG BASE/VIAL N 018123 003 Sep 30, 1982 Mar CAHN

GONADOTROPIN, CHORIONIC INJECTABLE;INJECTION CHORIONIC GONADOTROPIN +! FERRING 5,000 UNITS/VIAL N 017016 006 Jan CMFD

GOSERELIN ACETATE IMPLANT;IMPLANTATION ZOLADEX +! TERSERA THERAPS LLC EQ 3.6MG BASE N 019726 001 Dec 29, 1989 May CAHN +! EQ 10.8MG BASE N 020578 001 Jan 11, 1996 May CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE SOLUTION/DROPS;OPHTHALMIC NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN AT AMRING PHARMS 0.025MG/ML;EQ 1.75MG A 065187 001 Oct 28, 2005 Mar CAHN BASE/ML;10,000 UNITS/ML NEOSPORIN AT ! MONARCH PHARMS 0.025MG/ML;EQ 1.75MG A 060582 001 Apr CAHN BASE/ML;10,000 UNITS/ML

GRANISETRON HYDROCHLORIDE INJECTABLE;INJECTION GRANISETRON HYDROCHLORIDE AP MYLAN LABS LTD EQ 0.1MG BASE/ML (EQ 0.1MG A 203454 001 Apr 04, 2017 Mar NEWA BASE/ML) AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 203454 002 Apr 04, 2017 Mar NEWA AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 203453 001 Jan 31, 2017 Jan NEWA AP SANDOZ INC EQ 0.1MG BASE/ML (EQ 0.1MG A 078534 001 Apr 30, 2009 Mar CAHN BASE/ML) AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 078531 001 Apr 30, 2009 Mar CAHN AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 078531 002 Apr 30, 2009 Mar CAHN AP WEST-WARD PHARMS INT EQ 0.1MG BASE/ML (EQ 0.1MG A 077913 001 Jun 26, 2008 Jan CAHN BASE/ML) AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 077186 001 Jun 30, 2008 Jan CAHN AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 077187 001 Jun 30, 2008 Jan CAHN AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 077177 001 Dec 31, 2007 Jan CAHN TABLET;ORAL GRANISETRON HYDROCHLORIDE @ EPIC PHARMA LLC EQ 1MG BASE A 078260 001 Dec 31, 2007 May CAHN AB TARO PHARM EQ 1MG BASE A 090817 001 May 28, 2010 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -55

GRISEOFULVIN, MICROSIZE SUSPENSION;ORAL GRISEOFULVIN AB CHARTWELL RX 125MG/5ML A 065200 001 Mar 02, 2005 Jun CAHN

HALOBETASOL PROPIONATE CREAM;TOPICAL HALOBETASOL PROPIONATE AB ! G AND W LABS 0.05% A 078162 001 Apr 24, 2007 Apr CHRS ULTRAVATE AB + SUN PHARM INDS LTD 0.05% N 019967 001 Dec 27, 1990 Apr CHRS AB +! 0.05% N 019967 001 Dec 27, 1990 Mar CAHN OINTMENT;TOPICAL HALOBETASOL PROPIONATE AB ! G AND W LABS 0.05% A 077721 001 Sep 07, 2006 Jun CHRS AB PERRIGO ISRAEL 0.05% A 076872 001 Dec 16, 2004 Apr CAHN ULTRAVATE AB + RANBAXY 0.05% N 019968 001 Dec 17, 1990 Jun CHRS

HALOPERIDOL TABLET;ORAL HALOPERIDOL @ FRONTIDA BIOPHARM 20MG A 071177 001 Jan 07, 1988 Feb CAHN

HALOPERIDOL DECANOATE INJECTABLE;INJECTION HALOPERIDOL DECANOATE AO GLAND PHARMA LTD EQ 50MG BASE/ML A 205241 001 May 12, 2017 May NEWA AO EQ 100MG BASE/ML A 205241 002 May 12, 2017 May NEWA @ SANDOZ INC EQ 50MG BASE/ML A 076463 001 Jun 24, 2005 Mar CAHN @ EQ 100MG BASE/ML A 076463 002 Jun 24, 2005 Mar CAHN

HALOPERIDOL LACTATE CONCENTRATE;ORAL HALOPERIDOL AA PHARM ASSOC EQ 2MG BASE/ML A 073037 001 Feb 26, 1993 May CAHN INJECTABLE;INJECTION HALOPERIDOL @ SANDOZ INC EQ 5MG BASE/ML A 076464 001 Sep 29, 2004 Mar CAHN

HEPARIN SODIUM INJECTABLE;INJECTION HEPARIN SODIUM >D> @ EUROHLTH INTL SARL 1,000 UNITS/ML N 017007 001 Jul CAHN >D> @ 2,500 UNITS/ML N 017007 007 Jul CAHN >D> @ 5,000 UNITS/ML N 017007 002 Jul CAHN >D> @ 5,000 UNITS/0.5ML N 017007 010 Jul CAHN >D> @ 7,500 UNITS/ML N 017007 003 Jul CAHN >D> @ 10,000 UNITS/ML N 017007 004 Jul CAHN >D> @ 15,000 UNITS/ML N 017007 005 Jul CAHN >D> @ 20,000 UNITS/ML N 017007 006 Jul CAHN AP GLAND PHARMA LTD 5,000 UNITS/ML A 205323 001 Feb 06, 2017 Jan NEWA >A> @ WEST-WARD PHARMS INT 1,000 UNITS/ML N 017007 001 Jul CAHN >A> @ 2,500 UNITS/ML N 017007 007 Jul CAHN >A> @ 5,000 UNITS/ML N 017007 002 Jul CAHN >A> @ 5,000 UNITS/0.5ML N 017007 010 Jul CAHN >A> @ 7,500 UNITS/ML N 017007 003 Jul CAHN >A> @ 10,000 UNITS/ML N 017007 004 Jul CAHN >A> @ 15,000 UNITS/ML N 017007 005 Jul CAHN >A> @ 20,000 UNITS/ML N 017007 006 Jul CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE SYRUP;ORAL HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE AA ABHAI LLC 1.5MG/5ML;5MG/5ML A 207487 001 Feb 21, 2017 Feb NEWA AA BIO-PHARM INC 1.5MG/5ML;5MG/5ML A 204765 001 Mar 06, 2017 Feb NEWA AA NOVEL LABS INC 1.5MG/5ML;5MG/5ML A 203535 001 Feb 13, 2017 Jan NEWA AA PADDOCK LLC 1.5MG/5ML;5MG/5ML A 205731 001 Feb 15, 2017 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -56

TABLET;ORAL HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE >A> AA AVANTHI INC 1.5MG;5MG A 207176 001 Aug 07, 2017 Jul NEWA TUSSIGON AA ! KING PHARMS 1.5MG;5MG A 088508 001 Jul 30, 1985 Feb CAHN

HYDRALAZINE HYDROCHLORIDE TABLET;ORAL HYDRALAZINE HYDROCHLORIDE AA SCIEGEN PHARMS INC 10MG A 205236 001 May 26, 2017 May NEWA AA 25MG A 205236 002 May 26, 2017 May NEWA AA 50MG A 205236 003 May 26, 2017 May NEWA AA 100MG A 205236 004 May 26, 2017 May NEWA @ UPSHER-SMITH LABS 10MG A 083241 001 Jun CAHN @ 25MG A 083560 001 Jun CAHN @ 50MG A 083561 001 Jun CAHN

HYDROCHLOROTHIAZIDE CAPSULE;ORAL HYDROCHLOROTHIAZIDE AB PRINSTON INC 12.5MG A 075907 001 Sep 17, 2002 Feb CAHN TABLET;ORAL HYDROCHLOROTHIAZIDE AB PRINSTON INC 25MG A 040412 001 Mar 29, 2002 Feb CAHN AB 50MG A 040412 002 Mar 29, 2002 Feb CAHN @ WATSON LABS TEVA 50MG A 083232 001 May CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN TABLET;ORAL IRBESARTAN AND HYDROCHLOROTHIAZIDE AB ATLAS PHARMS LLC 12.5MG;150MG A 203036 001 Jan 15, 2016 Mar CAHN AB 12.5MG;300MG A 203036 002 Jan 15, 2016 Mar CAHN AB 25MG;300MG A 203036 003 Jan 15, 2016 Mar CAHN AB WEST-WARD PHARMS INT 25MG;300MG A 090351 003 Jun 08, 2017 May NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL TABLET;ORAL LISINOPRIL AND HYDROCHLOROTHIAZIDE AB INVAGEN PHARMS 12.5MG;10MG A 204058 001 May 23, 2017 May NEWA AB 12.5MG;20MG A 204058 002 May 23, 2017 May NEWA AB 25MG;20MG A 204058 003 May 23, 2017 May NEWA PRINZIDE + @ MERCK 12.5MG;10MG N 019778 003 Nov 18, 1993 Jan CRLD + @ 12.5MG;20MG N 019778 001 Feb 16, 1989 Jan CRLD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM TABLET;ORAL LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE >A> AB UNICHEM LABS LTD 12.5MG;50MG A 204832 001 Jul 21, 2017 Jul NEWA >A> AB 12.5MG;100MG A 204832 002 Jul 21, 2017 Jul NEWA >A> AB 25MG;100MG A 204832 003 Jul 21, 2017 Jul NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE TABLET;ORAL MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE @ CHARTWELL RX 12.5MG;7.5MG A 090096 001 Sep 25, 2008 Mar CAHN @ 12.5MG;15MG A 090096 002 Sep 25, 2008 Mar CAHN @ 25MG;15MG A 090096 003 Sep 25, 2008 Mar CAHN AB HERITAGE PHARMS INC 12.5MG;7.5MG A 202150 001 Mar 07, 2014 Jan CMS1 AB 12.5MG;15MG A 202150 002 Mar 07, 2014 Jan CMS1 AB 25MG;15MG A 202150 003 Mar 07, 2014 Jan CMS1

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL TABLET;ORAL OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE AB ALEMBIC PHARMS LTD 12.5MG;20MG A 204233 001 Apr 24, 2017 Apr NEWA AB 12.5MG;40MG A 204233 002 Apr 24, 2017 Apr NEWA AB 25MG;40MG A 204233 003 Apr 24, 2017 Apr NEWA AB AUROBINDO PHARMA LTD 12.5MG;20MG A 205391 001 Apr 24, 2017 Apr NEWA AB 12.5MG;40MG A 205391 002 Apr 24, 2017 Apr NEWA AB 25MG;40MG A 205391 003 Apr 24, 2017 Apr NEWA AB PRINSTON INC 12.5MG;20MG A 207804 001 Apr 24, 2017 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -57

TABLET;ORAL OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE AB 12.5MG;40MG A 207804 002 Apr 24, 2017 Apr NEWA AB 25MG;40MG A 207804 003 Apr 24, 2017 Apr NEWA AB TEVA PHARMS USA 12.5MG;20MG A 200532 001 Apr 24, 2017 Apr NEWA AB 12.5MG;40MG A 200532 002 Apr 24, 2017 Apr NEWA AB 25MG;40MG A 200532 003 Apr 24, 2017 Apr NEWA AB TORRENT PHARMS LTD 12.5MG;20MG A 206515 001 May 03, 2017 Apr NEWA AB 12.5MG;40MG A 206515 002 May 03, 2017 Apr NEWA AB 25MG;40MG A 206515 003 May 03, 2017 Apr NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET;ORAL QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE AB INVAGEN PHARMS 12.5MG;EQ 10MG BASE A 201356 001 Apr 20, 2011 Jun CMS1 AB 12.5MG;EQ 20MG BASE A 201356 002 Apr 20, 2011 Jun CMS1 AB 25MG;EQ 20MG BASE A 201356 003 Apr 20, 2011 Jun CMS1 @ SUN PHARM INDS LTD 12.5MG;EQ 10MG BASE A 078211 001 Mar 04, 2009 Jun DISC @ 12.5MG;EQ 20MG BASE A 078211 002 Mar 04, 2009 Jun DISC @ 25MG;EQ 20MG BASE A 078211 003 Mar 04, 2009 Jun DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE TABLET;ORAL SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE @ UPSHER SMITH 25MG;25MG A 087553 001 Jun CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN TABLET;ORAL TELMISARTAN AND HYDROCHLOROTHIAZIDE >A> AB ZYDUS PHARMS USA INC 12.5MG;40MG A 204221 001 Aug 15, 2017 Jul NEWA >A> AB 12.5MG;80MG A 204221 002 Aug 15, 2017 Jul NEWA >A> AB 25MG;80MG A 204221 003 Aug 15, 2017 Jul NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN TABLET;ORAL VALSARTAN AND HYDROCHLOROTHIAZIDE AB ALEMBIC PHARMS LTD 12.5MG;80MG A 201662 001 Mar 21, 2013 May CAHN AB 12.5MG;160MG A 201662 002 Mar 21, 2013 May CAHN AB 12.5MG;320MG A 201662 003 Mar 21, 2013 May CAHN AB 25MG;160MG A 201662 004 Mar 21, 2013 May CAHN AB 25MG;320MG A 201662 005 Mar 21, 2013 May CAHN AB WATSON LABS TEVA 12.5MG;80MG A 091519 001 Mar 21, 2013 May CAHN AB 12.5MG;160MG A 091519 002 Mar 21, 2013 May CAHN AB 12.5MG;320MG A 091519 003 Mar 21, 2013 May CAHN AB 25MG;160MG A 091519 004 Mar 21, 2013 May CAHN AB 25MG;320MG A 091519 005 Mar 21, 2013 May CAHN

HYDROCODONE BITARTRATE TABLET, EXTENDED RELEASE;ORAL VANTRELA ER + TEVA BRANDED PHARM 15MG N 207975 001 Jan 17, 2017 Jan NEWA + 30MG N 207975 002 Jan 17, 2017 Jan NEWA + 45MG N 207975 003 Jan 17, 2017 Jan NEWA + 60MG N 207975 004 Jan 17, 2017 Jan NEWA + 90MG N 207975 005 Jan 17, 2017 Jan NEWA

HYDROCORTISONE CREAM;TOPICAL HYDROCORTISONE AT ! FOUGERA PHARMS INC 1% A 080693 003 Jan CAHN AT ! 2.5% A 089414 001 Dec 16, 1986 Jan CAHN >D> SYNACORT >D> AT MEDICIS 1% A 087458 001 Jul DISC >A> @ 1% A 087458 001 Jul DISC >D> AT 2.5% A 087457 001 Jul DISC >A> @ 2.5% A 087457 001 Jul DISC LOTION;TOPICAL STIE-CORT @ PERRIGO CO 1% A 089066 001 Nov 25, 1985 Apr CAHN AT 2.5% A 089074 001 Nov 26, 1985 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -58

OINTMENT;TOPICAL HYDROCORTISONE AT ! FOUGERA PHARMS INC 2.5% A 081203 001 May 28, 1993 Jan CAHN HYDROCORTISONE IN ABSORBASE AT CMP PHARMA INC 1% A 088138 001 Sep 06, 1985 Apr CAHN TABLET;ORAL HYDROCORTISONE AB PII 5MG A 207029 001 Apr 27, 2017 Apr NEWA AB 10MG A 207029 002 Apr 27, 2017 Apr NEWA AB 20MG A 207029 003 Apr 27, 2017 Apr NEWA

HYDROCORTISONE ACETATE AEROSOL, METERED;RECTAL CORTIFOAM +! MYLAN SPECIALITY LP 10% N 017351 001 Feb 10, 1982 Mar CAHN

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE CREAM;TOPICAL CORTISPORIN +! MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;10,000 N 050218 001 Aug 09, 1985 Feb CAHN UNITS/GM

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE AEROSOL, METERED;TOPICAL EPIFOAM BX MYLAN SPECIALITY LP 1%;1% A 086457 001 Mar CAHN PROCTOFOAM HC BX MYLAN SPECIALITY LP 1%;1% A 086195 001 Mar CAHN

HYDROCORTISONE VALERATE CREAM;TOPICAL HYDROCORTISONE VALERATE AB ! TARO 0.2% A 075042 001 Aug 25, 1998 Apr CAHN OINTMENT;TOPICAL HYDROCORTISONE VALERATE ! TARO 0.2% A 075043 001 Aug 25, 1998 Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE SOLUTION/DROPS;OTIC CORTISPORIN AT +! MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 N 050479 001 Apr CAHN UNITS/ML NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE AT AMRING PHARMS 1%;EQ 3.5MG BASE/ML;10,000 A 065216 001 Oct 31, 2005 Mar CAHN UNITS/ML AT SANDOZ INC 1%;EQ 3.5MG BASE/ML;10,000 A 062423 001 Aug 25, 1983 Feb CAHN UNITS/ML SUSPENSION/DROPS;OPHTHALMIC CORTISPORIN @ MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 N 050169 001 Apr CAHN UNITS/ML NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE ! SANDOZ INC 1%;EQ 3.5MG BASE/ML;10,000 A 062874 001 May 11, 1988 Feb CAHN UNITS/ML SUSPENSION/DROPS;OTIC NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE AT AMRING PHARMS 1%;EQ 3.5MG BASE/ML;10,000 A 065219 001 May 01, 2006 Mar CAHN UNITS/ML AT SANDOZ INC 1%;EQ 3.5MG BASE/ML;10,000 A 062488 001 Nov 06, 1985 Feb CAHN UNITS/ML

HYDROMORPHONE HYDROCHLORIDE INJECTABLE;INJECTION DILAUDID AP +! FRESENIUS KABI USA 1MG/ML N 019034 003 Apr 30, 2009 Jan CAHN AP +! 2MG/ML N 019034 004 Apr 30, 2009 Jan CAHN AP +! 4MG/ML N 019034 005 Apr 30, 2009 Jan CAHN DILAUDID-HP AP +! FRESENIUS KABI USA 10MG/ML N 019034 001 Jan 11, 1984 Jan CAHN @ 250MG/VIAL N 019034 002 Aug 04, 1994 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -59

SOLUTION;ORAL DILAUDID AA +! RHODES PHARMS 5MG/5ML N 019891 001 Dec 07, 1992 Jun CAHN TABLET;ORAL DILAUDID AB + PURDUE PHARM PRODS 4MG N 019892 002 Nov 09, 2007 May CAHN AB +! 8MG N 019892 001 Dec 07, 1992 May CAHN AB + RHODES PHARMS 2MG N 019892 003 Nov 09, 2007 Jun CAHN AB + 4MG N 019892 002 Nov 09, 2007 Jun CAHN AB +! 8MG N 019892 001 Dec 07, 1992 Jun CAHN

HYDROXOCOBALAMIN INJECTABLE;INJECTION HYDROXOCOBALAMIN ! ACTAVIS LLC 1MG/ML A 085998 001 Feb CAHN

HYDROXYZINE HYDROCHLORIDE INJECTABLE;INJECTION VISTARIL + @ PFIZER 25MG/ML N 011111 001 Jan CRLD + @ 50MG/ML N 011111 002 Jan CRLD TABLET;ORAL HYDROXYZINE HYDROCHLORIDE @ AUROLIFE PHARMA LLC 10MG A 087871 002 Dec 20, 1982 Jan CMS1 @ 25MG A 087871 003 Dec 20, 1982 Jan CMS1 AB NUVO PHARM INC 10MG A 207120 001 Mar 29, 2017 Mar NEWA AB 25MG A 207121 001 Mar 29, 2017 Mar NEWA AB 50MG A 207122 001 Mar 29, 2017 Mar NEWA AB PRINSTON INC 10MG A 040579 001 May 27, 2005 Feb CAHN AB 25MG A 040574 001 May 27, 2005 Feb CAHN AB 50MG A 040580 001 May 27, 2005 Feb CAHN @ SUN PHARM INDS INC 10MG A 040899 001 Jun 10, 2008 Apr DISC @ 25MG A 040899 002 Jun 10, 2008 Apr DISC @ 50MG A 040899 003 Jun 10, 2008 Apr DISC

IBANDRONATE SODIUM TABLET;ORAL IBANDRONATE SODIUM @ MYLAN PHARMS INC EQ 150MG BASE A 078995 001 Mar 19, 2012 May DISC AB WATSON LABS TEVA EQ 150MG BASE A 079003 001 Mar 20, 2012 May CAHN

IBUPROFEN SUSPENSION;ORAL IBUPROFEN AB ! ACTAVIS MID ATLANTIC 100MG/5ML A 074978 001 Mar 25, 1998 May CAHN AB TARO 100MG/5ML A 209204 001 Jun 23, 2017 Jun NEWA MOTRIN + @ MCNEIL CONSUMER 100MG/5ML N 019842 001 Sep 19, 1989 Jan CRLD TABLET;ORAL IBUPROFEN @ MYLAN PHARMS INC 400MG A 070045 001 Sep 24, 1985 Mar CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE TABLET;ORAL OXYCODONE HYDROCHLORIDE AND IBUPROFEN @ WATSON LABS 400MG;5MG A 078394 001 Nov 26, 2007 Jun DISC BX 400MG;5MG A 078394 001 Nov 26, 2007 Apr CTEC

ICOSAPENT ETHYL CAPSULE;ORAL VASCEPA + AMARIN PHARMS 500MG N 202057 002 Feb 16, 2017 Mar NEWA

>D> IDOXURIDINE >D> SOLUTION/DROPS;OPHTHALMIC >D> DENDRID >D> +! ALCON 0.1% N 014169 001 Jul DISC >A> + @ 0.1% N 014169 001 Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -60

IFOSFAMIDE; MESNA INJECTABLE;INTRAVENOUS IFOSFAMIDE/MESNA KIT @ TEVA PHARMS USA 1GM/20ML;1GM/10ML A 075874 001 Feb 26, 2002 Mar DISC (50MG/ML;100MG/ML) @ 3GM/60ML;1GM/10ML A 075874 002 Feb 26, 2002 Mar DISC (50MG/ML;100MG/ML)

IMATINIB MESYLATE TABLET;ORAL IMATINIB MESYLATE AB MYLAN PHARMS INC EQ 100MG BASE A 204644 001 Jun 21, 2017 Jun NEWA AB EQ 400MG BASE A 204644 002 Jun 21, 2017 Jun NEWA

IMIPRAMINE HYDROCHLORIDE TABLET;ORAL IMIPRAMINE HYDROCHLORIDE OXFORD PHARMS 10MG A 040751 003 Feb 28, 2008 May CMS1 25MG A 040751 002 Feb 28, 2008 May CMS1 >D> AB PAR PHARM 10MG A 089422 001 Jul 14, 1987 Jul DISC >A> @ 10MG A 089422 001 Jul 14, 1987 Jul DISC

IMIPRAMINE PAMOATE CAPSULE;ORAL IMIPRAMINE PAMOATE @ MYLAN PHARMS INC EQ 75MG HCL A 202338 001 Jun 28, 2013 Jun DISC @ EQ 100MG HCL A 202338 002 Jun 28, 2013 Jun DISC @ EQ 125MG HCL A 202338 003 Jun 28, 2013 Jun DISC @ EQ 150MG HCL A 202338 004 Jun 28, 2013 Jun DISC

INDACATEROL MALEATE POWDER;INHALATION ARCAPTA NEOHALER +! SUNOVION PHARMS INC EQ 75MCG BASE N 022383 001 Jul 01, 2011 Jan CAHN

INDOMETHACIN CAPSULE;ORAL INDOMETHACIN @ CHARTWELL MOLECULES 25MG N 018829 002 Aug 06, 1984 Feb CAHN @ 50MG A 070651 001 Mar 05, 1986 Apr CAHN @ 50MG N 018829 001 Aug 06, 1984 Feb CAHN CAPSULE, EXTENDED RELEASE;ORAL INDOMETHACIN AB CHARTWELL RX 75MG A 200529 001 Nov 30, 2010 Jun CAHN AB GLENMARK PHARMS LTD 75MG A 203501 001 Jun 22, 2017 Jun NEWA AB NOVAST LABS LTD 75MG A 204853 001 May 08, 2017 Apr NEWA @ WATSON LABS INC 75MG A 202572 001 Dec 09, 2013 Feb DISC

INDOMETHACIN SODIUM INJECTABLE;INJECTION INDOMETHACIN SODIUM >A> AP NAVINTA LLC EQ 1MG BASE/VIAL A 206561 001 Jul 19, 2017 Jul NEWA

IOPAMIDOL INJECTABLE;INJECTION SCANLUX-300 AP MYLAN IRELAND LTD 61% A 090394 001 Jun 18, 2010 Jan CAHN AP SANOCHEMIA CORP USA 61% A 090394 001 Jun 18, 2010 Feb CAHN SCANLUX-370 AP MYLAN IRELAND LTD 76% A 090394 002 Jun 18, 2010 Jan CAHN AP SANOCHEMIA CORP USA 76% A 090394 002 Jun 18, 2010 Feb CAHN

IPRATROPIUM BROMIDE SOLUTION;INHALATION IPRATROPIUM BROMIDE >D> AN BAUSCH AND LOMB INC 0.02% A 075835 001 Oct 15, 2001 Jul DISC >A> @ 0.02% A 075835 001 Oct 15, 2001 Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -61

IRINOTECAN HYDROCHLORIDE INJECTABLE;INJECTION IRINOTECAN HYDROCHLORIDE AP INGENUS PHARMS LLC 40MG/2ML (20MG/ML) A 206935 001 May 26, 2017 May NEWA AP 100MG/5ML (20MG/ML) A 206935 002 May 26, 2017 May NEWA >D> AP SANDOZ INC 40MG/2ML (20MG/ML) A 090137 001 Nov 12, 2009 Jul DISC >A> @ 40MG/2ML (20MG/ML) A 090137 001 Nov 12, 2009 Jul DISC >D> AP 100MG/5ML (20MG/ML) A 090137 002 Nov 12, 2009 Jul DISC >A> @ 100MG/5ML (20MG/ML) A 090137 002 Nov 12, 2009 Jul DISC AP WEST-WARD PHARMS INT 40MG/2ML (20MG/ML) A 078753 001 Dec 24, 2008 Jan CAHN AP 100MG/5ML (20MG/ML) A 078753 002 Dec 24, 2008 Jan CAHN INJECTABLE, LIPOSOMAL;IV (INFUSION) ONIVYDE +! IPSEN INC EQ 43MG BASE/10ML (EQ 4.3MG N 207793 001 Oct 22, 2015 Apr CAHN BASE/ML)

ISONIAZID INJECTABLE;INJECTION ISONIAZID ! SANDOZ INC 100MG/ML A 040648 001 Jul 05, 2005 Mar CAHN SYRUP;ORAL ISONIAZID ! CMP PHARMA INC 50MG/5ML A 088235 001 Nov 10, 1983 Apr CAHN

ISOPROTERENOL HYDROCHLORIDE INJECTABLE;INJECTION ISOPROTERENOL HYDROCHLORIDE >A> AP NEXUS PHARMS 0.2MG/ML A 206961 001 Aug 02, 2017 Jul NEWA ISUPREL >D> +! HOSPIRA 0.2MG/ML N 010515 001 Jul CTEC >A> AP +! 0.2MG/ML N 010515 001 Jul CTEC

ISOSORBIDE DINITRATE TABLET;SUBLINGUAL ISOSORBIDE DINITRATE @ WATSON LABS TEVA 5MG A 086031 001 Sep 29, 1987 May CAHN TABLET, EXTENDED RELEASE;ORAL ISOSORBIDE DINITRATE @ IMPAX LABS INC 40MG A 040723 001 Mar 17, 2008 Feb CAHN

ISRADIPINE CAPSULE;ORAL ISRADIPINE AB WATSON LABS TEVA 2.5MG A 077317 001 Jan 05, 2006 May CAHN AB ! 5MG A 077317 002 Jan 05, 2006 May CAHN

ITRACONAZOLE CAPSULE;ORAL ITRACONAZOLE AB ALKEM LABS LTD 100MG A 208591 001 Jun 12, 2017 May NEWA AB JUBILANT GENERICS 100MG A 203445 001 Feb 23, 2017 Feb NEWA

KANAMYCIN SULFATE INJECTABLE;INJECTION KANAMYCIN @ WEST-WARD PHARMS INT EQ 75MG BASE/2ML A 062324 001 Jan CAHN @ EQ 500MG BASE/2ML A 062324 002 Jan CAHN @ EQ 1GM BASE/3ML A 062324 003 Jan CAHN

KETOCONAZOLE AEROSOL, FOAM;TOPICAL EXTINA AT +! MYLAN PHARMS INC 2% N 021738 001 Jun 12, 2007 Jan CAHN CREAM;TOPICAL NIZORAL + @ JANSSEN PHARMA 2% N 019084 001 Dec 31, 1985 May CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -62

KETOPROFEN CAPSULE;ORAL KETOPROFEN HERITAGE PHARMS INC 25MG A 074014 001 Jan 29, 1993 Feb CAHN AB 50MG A 074014 002 Jan 29, 1993 Feb CAHN AB 75MG A 074014 003 Jan 29, 1993 Feb CAHN

KETOROLAC TROMETHAMINE INJECTABLE;INJECTION KETOROLAC TROMETHAMINE @ SANDOZ INC 15MG/ML A 076271 001 Oct 06, 2004 Mar CAHN AP 30MG/ML A 076271 002 Oct 06, 2004 Mar CAHN SOLUTION/DROPS;OPHTHALMIC KETOROLAC TROMETHAMINE AT SANDOZ INC 0.5% A 076583 001 Nov 05, 2009 Feb CAHN

L-GLUTAMINE >A> FOR SOLUTION;ORAL >A> ENDARI >A> + EMMAUS MEDCL 5GM/PACKET N 208587 001 Jul 07, 2017 Jul NEWA >A> NUTRESTORE >A> +! EMMAUS MEDCL 5GM/PACKET N 021667 001 Jun 10, 2004 Jul CAIN

LABETALOL HYDROCHLORIDE INJECTABLE;INJECTION LABETALOL HYDROCHLORIDE AP SAGENT AGILA LLC 5MG/ML A 079134 001 Feb 03, 2010 Feb CAHN

LACOSAMIDE TABLET;ORAL LACOSAMIDE AB AMNEAL PHARMS 50MG A 204857 001 Sep 09, 2016 May CAHN AB 100MG A 204857 002 Sep 09, 2016 May CAHN AB 150MG A 204857 003 Sep 09, 2016 May CAHN AB 200MG A 204857 004 Sep 09, 2016 May CAHN

LACTULOSE SOLUTION;ORAL LACTULOSE AA PHARM ASSOC 10GM/15ML A 074623 001 Jul 30, 1996 May CAHN

LAMIVUDINE TABLET;ORAL LAMIVUDINE AB CIPLA LTD 150MG A 077221 001 Mar 03, 2017 Feb NEWA AB 300MG A 077221 002 Mar 03, 2017 Feb NEWA

LAMIVUDINE; ZIDOVUDINE TABLET;ORAL LAMIVUDINE AND ZIDOVUDINE AB AUROBINDO PHARMA LTD 150MG;300MG A 077558 001 May 05, 2017 Apr NEWA BX PHARMACARE 150MG;300MG N 022018 001 Mar 17, 2017 Mar NEWA

LAMOTRIGINE TABLET;ORAL LAMOTRIGINE @ MYLAN LABS LTD 25MG A 078443 001 Feb 11, 2009 Mar CAHN @ 100MG A 078443 002 Feb 11, 2009 Mar CAHN @ 150MG A 078443 003 Feb 11, 2009 Mar CAHN @ 200MG A 078443 004 Feb 11, 2009 Mar CAHN TABLET, CHEWABLE;ORAL LAMOTRIGINE AB GLENMARK PHARMS LTD 5MG A 079099 001 Feb 19, 2009 May CAHN AB 25MG A 079099 002 Feb 19, 2009 May CAHN @ MYLAN 5MG A 076630 001 Jan 22, 2009 Jun DISC @ 25MG A 076630 002 Jan 22, 2009 Jun DISC TABLET, EXTENDED RELEASE;ORAL LAMOTRIGINE AB ACTAVIS ELIZABETH 250MG A 203733 001 Nov 13, 2013 Apr CAHN AB HANDA PHARMS LLC 25MG A 202887 001 Jun 17, 2013 Jan CAHN AB 50MG A 202887 002 Jun 17, 2013 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -63

TABLET, EXTENDED RELEASE;ORAL LAMOTRIGINE AB 100MG A 202887 003 Jun 17, 2013 Jan CAHN AB 200MG A 202887 004 Jun 17, 2013 Jan CAHN

LANTHANUM CARBONATE TABLET, CHEWABLE;ORAL FOSRENOL >D> + SHIRE LLC EQ 500MG BASE N 021468 002 Oct 26, 2004 Jul CFTG >A> AB + EQ 500MG BASE N 021468 002 Oct 26, 2004 Jul CFTG >D> + EQ 750MG BASE N 021468 003 Nov 23, 2005 Jul CFTG >A> AB + EQ 750MG BASE N 021468 003 Nov 23, 2005 Jul CFTG >D> +! EQ 1GM BASE N 021468 004 Nov 23, 2005 Jul CFTG >A> AB +! EQ 1GM BASE N 021468 004 Nov 23, 2005 Jul CFTG LANTHANUM CARBONATE >A> AB NATCO PHARMA LTD EQ 500MG BASE A 090978 001 Aug 11, 2017 Jul NEWA >A> AB EQ 750MG BASE A 090978 002 Aug 11, 2017 Jul NEWA >A> AB EQ 1GM BASE A 090978 003 Aug 11, 2017 Jul NEWA

LATANOPROST SOLUTION/DROPS;OPHTHALMIC LATANOPROST AT AMRING PHARMS 0.005% A 200925 001 Mar 22, 2011 Mar CAHN AT SANDOZ INC 0.005% A 091449 001 Mar 22, 2011 Feb CAHN

LETROZOLE TABLET;ORAL LETROZOLE @ KREMERS URBAN PHARMS 2.5MG A 091098 001 Jun 03, 2011 Jun DISC @ LANNETT HOLDINGS INC 2.5MG A 202048 001 Oct 29, 2014 Jun DISC

LETROZOLE; RIBOCICLIB SUCCINATE TABLET, TABLET;ORAL KISQALI FEMARA CO-PACK (COPACKAGED) +! NOVARTIS PHARMS CORP 2.5MG,N/A;N/A,EQ 200MG BASE N 209935 001 May 04, 2017 May NEWA

LEUCOVORIN CALCIUM INJECTABLE;INJECTION LEUCOVORIN CALCIUM PRESERVATIVE FREE AP MYLAN LABS LTD EQ 100MG BASE/VIAL A 203800 001 May 19, 2017 May NEWA AP EQ 200MG BASE/VIAL A 203800 002 May 19, 2017 May NEWA AP EQ 350MG BASE/VIAL A 203800 003 May 19, 2017 May NEWA TABLET;ORAL LEUCOVORIN CALCIUM @ EPIC PHARMA LLC EQ 5MG BASE A 074544 001 Aug 28, 1997 May CAHN @ EQ 25MG BASE A 074544 002 Aug 28, 1997 May CAHN WELLCOVORIN + @ GLAXOSMITHKLINE EQ 5MG BASE N 018342 001 Jul 08, 1983 Jun CRLD + @ EQ 25MG BASE N 018342 002 Jul 08, 1983 Jun CRLD

LEVALBUTEROL HYDROCHLORIDE SOLUTION;INHALATION LEVALBUTEROL HYDROCHLORIDE AN AUROBINDO PHARMA LTD EQ 0.25% BASE A 207628 001 Jan 31, 2017 Jan NEWA

LEVETIRACETAM INJECTABLE;IV (INFUSION) LEVETIRACETAM >A> AP JUBILANT GENERICS 500MG/5ML (100MG/ML) A 206838 001 Jun 02, 2016 Jul CAHN >D> AP JUBILANT LIFE 500MG/5ML (100MG/ML) A 206838 001 Jun 02, 2016 Jul CAHN SOLUTION;ORAL LEVETIRACETAM AA ALLIED PHARMA INC 100MG/ML A 078582 001 Jan 15, 2009 Mar CAHN AA AUROBINDO PHARMA LTD 100MG/ML A 079063 001 Jan 15, 2009 Jan CAHN TABLET;ORAL LEVETIRACETAM AB ACI HEALTHCARE LTD 250MG A 078042 001 Jan 15, 2009 Jun CAHN AB 500MG A 078042 002 Jan 15, 2009 Jun CAHN AB 750MG A 078042 003 Jan 15, 2009 Jun CAHN AB 1GM A 078042 004 Jan 15, 2009 Jun CAHN AB ALLIED PHARMA INC 250MG A 078042 001 Jan 15, 2009 Mar CAHN AB 500MG A 078042 002 Jan 15, 2009 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -64

TABLET;ORAL LEVETIRACETAM AB 750MG A 078042 003 Jan 15, 2009 Mar CAHN AB 1GM A 078042 004 Jan 15, 2009 Mar CAHN ROWEEPRA AB LOTUS PHARM CO LTD 250MG A 090906 002 Oct 31, 2016 Apr NEWA AB 500MG A 090906 001 Nov 05, 2010 Apr CTNA AB 750MG A 090906 003 Oct 31, 2016 Apr NEWA AB 1GM A 090906 004 Oct 31, 2016 Apr NEWA TABLET, EXTENDED RELEASE;ORAL LEVETIRACETAM AB ECI PHARMS LLC 500MG A 204754 001 Aug 26, 2016 Mar CAHN AB 750MG A 204754 002 Aug 26, 2016 Mar CAHN @ MYLAN PHARMS INC 500MG A 200475 001 Dec 19, 2011 Apr DISC @ 750MG A 200475 002 Dec 19, 2011 Apr DISC @ 1GM A 200475 003 Dec 07, 2015 Apr DISC AB PRINSTON INC 500MG A 202533 001 Jul 20, 2012 Feb CAHN AB 750MG A 202533 002 Jul 20, 2012 Feb CAHN AB VIRTUS PHARMS 500MG A 091291 001 Sep 12, 2011 Feb CAHN AB 750MG A 091291 002 Sep 12, 2011 Feb CAHN

LEVOBUNOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC LEVOBUNOLOL HYDROCHLORIDE >D> AT BAUSCH AND LOMB 0.25% A 074307 001 Mar 04, 1994 Jul DISC >A> @ 0.25% A 074307 001 Mar 04, 1994 Jul DISC AT SANDOZ INC 0.5% A 074850 001 Oct 28, 1996 Feb CAHN

LEVOCARNITINE INJECTABLE;INJECTION CARNITOR AP +! LEADIANT BIOSCI INC 200MG/ML N 020182 001 Dec 16, 1992 Mar CAHN SOLUTION;ORAL CARNITOR @ LEADIANT BIOSCI INC 1GM/10ML N 018948 002 Apr 27, 1988 Mar CAHN AA +! 1GM/10ML N 019257 001 Apr 10, 1986 Mar CAHN CARNITOR SF AA + LEADIANT BIOSCI INC 1GM/10ML N 019257 002 Mar 28, 2007 Mar CAHN TABLET;ORAL CARNITOR AB +! LEADIANT BIOSCI INC 330MG N 018948 001 Dec 27, 1985 Mar CAHN LEVOCARNITINE AB IMPAX LABS INC 330MG A 076858 001 Sep 20, 2004 Feb CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE SOLUTION;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE AA SILARX PHARMS INC 2.5MG/ML A 204599 001 May 15, 2017 May NEWA XYZAL >A> AA +! SANOFI-AVENTIS US 2.5MG/5ML N 022157 001 Jan 28, 2008 Jul CAHN >D> AA +! UCB INC 2.5MG/5ML N 022157 001 Jan 28, 2008 Jul CAHN TABLET;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE AB ALLIED PHARMA INC 5MG A 204323 001 Dec 20, 2016 Apr CAHN XYZAL >A> AB +! SANOFI-AVENTIS US 5MG N 022064 001 May 25, 2007 Jul CAHN >D> AB +! UCB INC 5MG N 022064 001 May 25, 2007 Jul CAHN

LEVOFLOXACIN INJECTABLE;INJECTION LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER + @ JANSSEN PHARMS EQ 250MG/50ML (EQ 5MG/ML) N 020635 002 Dec 20, 1996 Jan CRLD + @ EQ 500MG/100ML (EQ 5MG/ML) N 020635 003 Dec 20, 1996 Jan CRLD + @ EQ 750MG/150ML (EQ 5MG/ML) N 020635 005 Dec 20, 1996 Jan CRLD LEVOFLOXACIN AP SAGENT AGILA LLC EQ 500MG/20ML (EQ 25MG/ML) A 200560 001 Jun 20, 2011 Jun CAHN AP EQ 750MG/30ML (EQ 25MG/ML) A 200560 002 Jun 20, 2011 Jun CAHN AP ZYDUS PHARMS USA INC EQ 500MG/20ML (EQ 25MG/ML) A 205968 001 Jun 01, 2017 May NEWA AP EQ 750MG/30ML (EQ 25MG/ML) A 205968 002 Jun 01, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -65

SOLUTION/DROPS;OPHTHALMIC LEVOFLOXACIN AT WATSON LABS TEVA 0.5% A 076826 001 Feb 10, 2011 Feb CAHN TABLET;ORAL LEVOFLOXACIN >D> AB MYLAN 250MG A 076276 001 Jun 20, 2011 Jul DISC >A> @ 250MG A 076276 001 Jun 20, 2011 Jul DISC >D> AB 500MG A 076276 002 Jun 20, 2011 Jul DISC >A> @ 500MG A 076276 002 Jun 20, 2011 Jul DISC @ 750MG A 077097 001 Jun 20, 2011 Jun DISC

LEVOLEUCOVORIN CALCIUM POWDER;IV (INFUSION) LEVOLEUCOVORIN CALCIUM AP ACTAVIS LLC EQ 50MG BASE/VIAL A 206516 001 Feb 13, 2017 Jan NEWA +! EQ 175MG BASE/VIAL N 208723 001 Sep 29, 2016 May CRLD AP AMNEAL PHARMS CO EQ 50MG BASE/VIAL A 207547 001 Feb 13, 2017 Jan NEWA

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE INJECTABLE;INJECTION ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN @ SEPTODONT INC 0.05MG/ML;2% A 084697 001 May CAHN MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN @ BELMORA LLC 0.05MG/ML;2% A 084850 002 Oct 21, 1983 Feb CAHN

LEVOTHYROXINE SODIUM SOLUTION;ORAL TIROSINT-SOL + @ INSTITUT BIOCHIMIQUE 13MCG/ML N 206977 001 Dec 15, 2016 Jun DISC + @ 25MCG/ML N 206977 002 Dec 15, 2016 Jun DISC + @ 50MCG/ML N 206977 003 Dec 15, 2016 Jun DISC + @ 75MCG/ML N 206977 004 Dec 15, 2016 Jun DISC + @ 88MCG/ML N 206977 005 Dec 15, 2016 Jun DISC + @ 100MCG/ML N 206977 006 Dec 15, 2016 Jun DISC + @ 112MCG/ML N 206977 007 Dec 15, 2016 Jun DISC + @ 125MCG/ML N 206977 008 Dec 15, 2016 Jun DISC + @ 137MCG/ML N 206977 009 Dec 15, 2016 Jun DISC + @ 150MCG/ML N 206977 010 Dec 15, 2016 Jun DISC + @ 175MCG/ML N 206977 011 Dec 15, 2016 Jun DISC + @ 200MCG/ML N 206977 012 Dec 15, 2016 Jun DISC

LEVOTHYROXINE SODIUM ** **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL LEVOXYL AB1, + KING PHARMS 0.025MG N 021301 001 May 25, 2001 May CAHN AB3 AB1, + 0.05MG N 021301 002 May 25, 2001 May CAHN AB3 AB1, + 0.075MG N 021301 003 May 25, 2001 May CAHN AB3 AB1, + 0.088MG N 021301 004 May 25, 2001 May CAHN AB3 AB1, + 0.1MG N 021301 005 May 25, 2001 May CAHN AB3 AB1, + 0.112MG N 021301 006 May 25, 2001 May CAHN AB3 AB1, + 0.125MG N 021301 007 May 25, 2001 May CAHN AB3 AB1, + 0.137MG N 021301 008 May 25, 2001 May CAHN AB3 AB1, + 0.15MG N 021301 009 May 25, 2001 May CAHN AB3 AB1, + 0.175MG N 021301 010 May 25, 2001 May CAHN AB3 AB1, +! 0.2MG N 021301 011 May 25, 2001 May CAHN AB3 + @ 0.3MG N 021301 012 May 25, 2001 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -66

LIDOCAINE OINTMENT;TOPICAL LIDOCAINE AT ALKEM LABS LTD 5% A 207810 001 Mar 10, 2017 Feb NEWA AT ! FOUGERA PHARMS INC 5% A 080198 001 Jan CAHN XYLOCAINE + @ ASTRAZENECA 5% N 008048 001 Jan CRLD

LIDOCAINE HYDROCHLORIDE INJECTABLE;INJECTION LIDOCAINE HYDROCHLORIDE @ BELMORA LLC 2% A 080504 001 Feb CAHN

LIDOCAINE; TETRACAINE CREAM;TOPICAL PLIAGLIS +! TARO PHARMS 7%;7% N 021717 001 Jun 29, 2006 May CAHN

LINACLOTIDE CAPSULE;ORAL LINZESS + FOREST LABS LLC 72MCG N 202811 003 Jan 25, 2017 Jan NEWA

LINEZOLID SOLUTION;IV (INFUSION) LINEZOLID AP HQ SPCLT PHARMA 200MG/100ML (2MG/ML) A 207001 001 Jul 07, 2017 Jun NEWA AP 600MG/300ML (2MG/ML) A 207001 002 Jul 07, 2017 Jun NEWA AP SAGENT PHARMS 200MG/100ML (2MG/ML) A 204696 001 Mar 02, 2017 Feb NEWA AP 600MG/300ML (2MG/ML) A 204696 002 Mar 02, 2017 Feb NEWA TABLET;ORAL LINEZOLID AB ZYDUS PHARMS USA INC 600MG A 206097 001 Feb 22, 2017 Feb NEWA

LIOTHYRONINE SODIUM TABLET;ORAL CYTOMEL AB + KING PHARMS EQ 0.005MG BASE N 010379 001 Mar CAHN AB + EQ 0.025MG BASE N 010379 002 Mar CAHN AB +! EQ 0.05MG BASE N 010379 003 Mar CAHN

LISDEXAMFETAMINE DIMESYLATE TABLET, CHEWABLE;ORAL VYVANSE + SHIRE DEV LLC 10MG N 208510 001 Jan 28, 2017 Jan NEWA + 20MG N 208510 002 Jan 28, 2017 Jan NEWA + 30MG N 208510 003 Jan 28, 2017 Jan NEWA + 40MG N 208510 004 Jan 28, 2017 Jan NEWA + 50MG N 208510 005 Jan 28, 2017 Jan NEWA +! 60MG N 208510 006 Jan 28, 2017 Apr CHRS + 60MG N 208510 006 Jan 28, 2017 Jan NEWA

LISINOPRIL TABLET;ORAL LISINOPRIL AB PRINSTON INC 2.5MG A 075743 001 Jul 01, 2002 Feb CAHN AB 5MG A 075743 002 Jul 01, 2002 Feb CAHN AB 10MG A 075743 003 Jul 01, 2002 Feb CAHN AB 20MG A 075743 004 Jul 01, 2002 Feb CAHN AB 30MG A 075743 005 Jul 01, 2002 Feb CAHN AB 40MG A 075743 006 Jul 01, 2002 Feb CAHN

LITHIUM CARBONATE CAPSULE;ORAL LITHIUM CARBONATE AB MYLAN PHARMS INC 150MG A 076243 002 Feb 24, 2003 Jan CAHN AB 300MG A 076243 001 Jun 27, 2002 Jan CAHN AB 600MG A 078763 001 Apr 15, 2008 Jan CAHN AB + WEST-WARD PHARMS INT 150MG N 017812 002 Jan 28, 1987 Jan CAHN AB + 300MG N 017812 001 Jan CAHN AB +! 600MG N 017812 003 Jan 28, 1987 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -67

TABLET;ORAL LITHIUM CARBONATE AB +! WEST-WARD PHARMS INT 300MG N 018558 001 Jan 29, 1982 Jan CAHN TABLET, EXTENDED RELEASE;ORAL LITHIUM CARBONATE AB UNIQUE PHARM LABS 450MG A 205663 001 Jun 05, 2017 May NEWA

LITHIUM CITRATE SYRUP;ORAL LITHIUM CITRATE AA +! WEST-WARD PHARMS INT EQ 300MG CARBONATE/5ML N 018421 001 Jan CAHN

LORAZEPAM INJECTABLE;INJECTION LORAZEPAM AP SAGENT AGILA LLC 2MG/ML A 200217 001 Apr 04, 2017 Mar NEWA AP 2MG/ML A 200542 001 Apr 28, 2017 Apr NEWA AP 4MG/ML A 200217 002 Apr 04, 2017 Mar NEWA AP 4MG/ML A 200542 002 Apr 28, 2017 Apr NEWA @ WEST-WARD PHARMS INT 2MG/ML A 074496 001 Sep 28, 1998 Mar CAHN @ 4MG/ML A 074496 002 Sep 28, 1998 Mar CAHN TABLET;ORAL LORAZEPAM AB SANDOZ 0.5 A 071141 002 Apr 21, 1987 Apr CMS1 AB 1MG A 071141 003 Apr 21, 1987 Apr CMS1

LOSARTAN POTASSIUM TABLET;ORAL LOSARTAN POTASSIUM >D> BX HETERO LABS LTD V 25MG A 203835 001 Aug 12, 2015 Jul CTEC >A> AB 25MG A 203835 001 Aug 12, 2015 Jul CTEC >D> BX 50MG A 203835 002 Aug 12, 2015 Jul CTEC >A> AB 50MG A 203835 002 Aug 12, 2015 Jul CTEC >D> BX 100MG A 203835 003 Aug 12, 2015 Jul CTEC >A> AB 100MG A 203835 003 Aug 12, 2015 Jul CTEC AB UPSHER-SMITH LABS 25MG A 090544 001 Oct 06, 2010 Jun CAHN AB 50MG A 090544 002 Oct 06, 2010 Jun CAHN AB 100MG A 090544 003 Oct 06, 2010 Jun CAHN

LOVASTATIN TABLET;ORAL LOVASTATIN @ MYLAN 10MG A 075935 001 Dec 17, 2001 Mar DISC @ 20MG A 075935 002 Dec 17, 2001 Mar DISC @ 40MG A 075935 003 Dec 17, 2001 Mar DISC TABLET, EXTENDED RELEASE;ORAL ALTOPREV @ COVIS PHARMA BV 10MG N 021316 001 Jun 26, 2002 Apr CAHN + 20MG N 021316 002 Jun 26, 2002 Apr CAHN + 40MG N 021316 003 Jun 26, 2002 Apr CAHN +! 60MG N 021316 004 Jun 26, 2002 Apr CAHN

MAFENIDE ACETATE FOR SOLUTION;TOPICAL MAFENIDE ACETATE >A> AT RICONPHARMA LLC 5% A 206716 001 Jul 31, 2017 Jul NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE INJECTABLE;INJECTION NORMOSOL-R IN PLASTIC CONTAINER ICU MEDICAL INC 30MG/100ML;37MG/100ML;222MG/100ML; N 017586 001 Feb CAHN 526MG/100ML;502MG/100ML SOLUTION;IRRIGATION PHYSIOSOL IN PLASTIC CONTAINER ICU MEDICAL INC 30MG/100ML;37MG/100ML;222MG/100ML; N 017637 002 Jul 08, 1982 Feb CAHN 526MG/100ML;502MG/100ML RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -68

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE SOLUTION;ORAL SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE AA NOVEL LABS INC 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT A 202511 001 Feb 23, 2017 Feb NEWA SUPREP BOWEL PREP KIT AA +! BRAINTREE LABS 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT N 022372 001 Aug 05, 2010 Feb CFTG

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE SOLUTION;ORAL SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE AA NOVEL LABS INC 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT A 202511 001 Feb 23, 2017 May CAIN SUPREP BOWEL PREP KIT AA +! BRAINTREE LABS 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT N 022372 001 Aug 05, 2010 May CAIN

MALATHION LOTION;TOPICAL OVIDE AT +! TARO PHARM 0.5% N 018613 001 Aug 02, 1982 May CAHN

MANNITOL INJECTABLE;INJECTION MANNITOL 10% IN PLASTIC CONTAINER AP ICU MEDICAL INC 10GM/100ML N 019603 002 Jan 08, 1987 Feb CAHN MANNITOL 15% IN PLASTIC CONTAINER AP ICU MEDICAL INC 15GM/100ML N 019603 003 Jan 08, 1990 Feb CAHN MANNITOL 20% IN PLASTIC CONTAINER AP ICU MEDICAL INC 20GM/100ML N 019603 004 Jan 08, 1990 Feb CAHN MANNITOL 5% IN PLASTIC CONTAINER AP ICU MEDICAL INC 5GM/100ML N 019603 001 Jan 08, 1987 Feb CAHN

MANNITOL; SORBITOL SOLUTION;IRRIGATION SORBITOL-MANNITOL IN PLASTIC CONTAINER ICU MEDICAL INC 540MG/100ML;2.7GM/100ML N 018316 001 Feb CAHN

MAPROTILINE HYDROCHLORIDE TABLET;ORAL MAPROTILINE HYDROCHLORIDE @ WATSON LABS TEVA 25MG A 072162 001 Jun 01, 1988 May CAHN @ 50MG A 072163 001 Jun 01, 1988 May CAHN

MEBENDAZOLE TABLET, CHEWABLE;ORAL EMVERM ! IMPAX LABS INC 100MG A 073580 001 Jan 04, 1995 Jun CAHN

MECAMYLAMINE HYDROCHLORIDE TABLET;ORAL MECAMYLAMINE HYDROCHLORIDE ! NEXGEN PHARMA 2.5MG A 204054 001 Mar 19, 2013 May CHRS

MECLIZINE HYDROCHLORIDE TABLET;ORAL MECLIZINE HYDROCHLORIDE AA AMNEAL PHARMS 12.5MG A 201451 001 Feb 23, 2011 May CAHN AA 25MG A 201451 002 Feb 23, 2011 May CAHN @ 50MG A 201451 003 Feb 23, 2011 May CAHN

MECLOFENAMATE SODIUM CAPSULE;ORAL MECLOFENAMATE SODIUM @ WATSON LABS TEVA EQ 100MG BASE A 071469 001 Apr 15, 1987 May CAHN

MEDROXYPROGESTERONE ACETATE INJECTABLE;INJECTION MEDROXYPROGESTERONE ACETATE @ SANDOZ INC 150MG/ML A 078711 001 May 20, 2009 Jun DISC AB 150MG/ML A 078711 001 May 20, 2009 Mar CAHN AB TEVA PHARMS USA 150MG/ML A 076553 001 Jul 28, 2004 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -69

TABLET;ORAL MEDROXYPROGESTERONE ACETATE @ USL PHARMA 10MG A 088484 001 Jul 26, 1984 Jun CAHN

MEFLOQUINE HYDROCHLORIDE TABLET;ORAL MEFLOQUINE HYDROCHLORIDE AB ! BARR 250MG A 076392 001 Dec 29, 2003 Apr CHRS @ SANDOZ 250MG A 076175 001 Feb 20, 2002 Apr DISC

MEGESTROL ACETATE SUSPENSION;ORAL MEGACE + @ BRISTOL MYERS SQUIBB 40MG/ML N 020264 001 Sep 10, 1993 Feb DISC MEGESTROL ACETATE AB HI-TECH PHARMACAL 40MG/ML A 203960 001 Jun 09, 2017 May NEWA AB ! WEST-WARD PHARMS INT 40MG/ML A 075997 001 Feb 15, 2002 Feb CHRS

MELOXICAM TABLET;ORAL MELOXICAM @ SUN PHARM INDS INC 7.5MG A 077937 001 Jul 19, 2006 Apr DISC @ 15MG A 077937 002 Jul 19, 2006 Apr DISC

MELPHALAN TABLET;ORAL ALKERAN AB +! APOTEX INC 2MG N 014691 002 Mar CFTG MELPHALAN AB ALVOGEN MALTA 2MG A 207809 001 Mar 22, 2017 Mar NEWA

MELPHALAN HYDROCHLORIDE INJECTABLE;INJECTION ALKERAN + @ APOTEX INC EQ 50MG BASE/VIAL N 020207 001 Nov 18, 1992 May DISC MELPHALAN HYDROCHLORIDE AP ! MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL A 090270 001 Jun 09, 2009 May CHRS AP SAGENT PHARMS EQ 50MG BASE/VIAL A 201379 001 Feb 28, 2017 Feb NEWA

MEMANTINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL MEMANTINE HYDROCHLORIDE AB AMNEAL PHARMS 7MG A 205825 001 Oct 12, 2016 May CAHN AB 14MG A 205825 002 Oct 12, 2016 May CAHN AB 21MG A 205825 003 Oct 12, 2016 May CAHN AB 28MG A 205825 004 Oct 12, 2016 May CAHN AB ANCHEN PHARMS 7MG A 205784 001 Jun 09, 2017 May NEWA AB 14MG A 205784 002 Jun 09, 2017 May NEWA AB 21MG A 205784 003 Jun 09, 2017 May NEWA AB 28MG A 205784 004 Jun 09, 2017 May NEWA >A> AB ZYDUS PHARMS USA INC 7MG A 203293 001 Aug 03, 2017 Jul NEWA >A> AB 14MG A 203293 002 Aug 03, 2017 Jul NEWA >A> AB 21MG A 203293 003 Aug 03, 2017 Jul NEWA >A> AB 28MG A 203293 004 Aug 03, 2017 Jul NEWA TABLET;ORAL MEMANTINE HYDROCHLORIDE AB AMNEAL PHARMS 5MG A 090041 001 Apr 10, 2015 May CAHN AB 10MG A 090041 002 Apr 10, 2015 May CAHN AB STRIDES PHARMA 5MG A 202350 001 May 23, 2017 May NEWA AB 10MG A 202350 002 May 23, 2017 May NEWA AB UPSHER-SMITH LABS 5MG A 090043 001 Jul 31, 2015 Jun CAHN AB 10MG A 090043 002 Jul 31, 2015 Jun CAHN AB ZYDUS PHARMS USA INC 5MG A 090961 001 Jul 10, 2017 Jun NEWA AB 10MG A 090961 002 Jul 10, 2017 Jun NEWA

MEPERIDINE HYDROCHLORIDE INJECTABLE;INJECTION MEPERIDINE HYDROCHLORIDE AP WEST-WARD PHARMS INT 25MG/ML A 080445 001 Jan CAHN AP 25MG/ML A 080455 007 Jan CAHN AP 50MG/ML A 080445 002 Jan CAHN AP 50MG/ML A 080455 008 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -70

INJECTABLE;INJECTION MEPERIDINE HYDROCHLORIDE AP 75MG/ML A 080445 003 Jan CAHN AP 75MG/ML A 080455 009 Jan CAHN AP 100MG/ML A 080445 004 Jan CAHN AP 100MG/ML A 080455 010 Jan CAHN MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE AP ! ICU MEDICAL INC 10MG/ML A 088432 001 Aug 16, 1984 Apr CAHN @ MALLINCKRODT INC 10MG/ML A 040163 001 May 12, 1997 Mar CAHN AP WEST-WARD PHARMS INT 10MG/ML A 081002 001 Jul 30, 1993 Apr CAHN

MEPIVACAINE HYDROCHLORIDE INJECTABLE;INJECTION ISOCAINE HYDROCHLORIDE AP ! SEPTODONT INC 3% A 080925 001 May CAHN MEPIVACAINE HYDROCHLORIDE @ BELMORA LLC 3% A 083559 001 Feb CAHN

MERCAPTOPURINE TABLET;ORAL MERCAPTOPURINE AB DR REDDYS LABS SA 50MG A 040461 001 Feb 11, 2004 Jun CAHN

MEROPENEM INJECTABLE;INJECTION MEROPENEM AP AUROBINDO PHARMA LTD 500MG/VIAL A 205835 001 Mar 27, 2017 Mar NEWA AP 1GM/VIAL A 205835 002 Mar 27, 2017 Mar NEWA @ SANDOZ 500MG/VIAL A 091201 001 Mar 29, 2011 Jun DISC @ 1GM/VIAL A 091201 002 Mar 29, 2011 Jun DISC MERREM AP +! PFIZER 500MG/VIAL N 050706 003 Jun 21, 1996 Jun CAHN AP +! 1GM/VIAL N 050706 001 Jun 21, 1996 Jun CAHN

MESALAMINE ENEMA;RECTAL ROWASA AB +! MYLAN SPECIALITY LP 4GM/60ML N 019618 001 Dec 24, 1987 Mar CAHN SFROWASA AB + MYLAN SPECIALITY LP 4GM/60ML N 019618 002 Jun 20, 2008 Mar CAHN TABLET, DELAYED RELEASE;ORAL ASACOL HD >D> +! APIL 800MG N 021830 001 May 29, 2008 Jul CFTG >A> AB +! 800MG N 021830 001 May 29, 2008 Jul CFTG LIALDA AB +! SHIRE 1.2GM N 022000 001 Jan 16, 2007 May CFTG MESALAMINE >A> AB ZYDUS PHARMS USA INC 800MG A 203286 001 Jul 21, 2017 Jul NEWA AB 1.2GM A 091640 001 Jun 05, 2017 May NEWA

METAXALONE TABLET;ORAL METAXALONE AB ACTAVIS LABS FL INC 800MG A 203695 001 Jun 15, 2017 Jun NEWA @ EPIC PHARMA LLC 640MG N 022503 001 Jun 01, 2015 May CAHN IMPAX LABS INC 400MG A 040486 001 Feb 27, 2015 Feb CAHN SKELAXIN + @ KING PHARMS 400MG N 013217 001 May CAHN AB +! 800MG N 013217 003 Aug 30, 2002 May CAHN

METFORMIN HYDROCHLORIDE TABLET;ORAL METFORMIN HYDROCHLORIDE @ MYLAN PHARMS INC 500MG A 075969 001 Jan 29, 2002 May DISC @ 850MG A 075969 002 Jan 29, 2002 May DISC @ 1GM A 075969 003 Jan 29, 2002 May DISC @ WATSON LABS FLORIDA 500MG A 075961 001 Jan 25, 2002 Mar DISC @ 850MG A 075961 002 Jan 25, 2002 Mar DISC @ 1GM A 075961 003 Jan 25, 2002 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -71

TABLET, EXTENDED RELEASE;ORAL METFORMIN HYDROCHLORIDE AB1 INTELLIPHARMACEUTICS 500MG A 202306 001 Feb 23, 2017 Feb NEWA AB 750MG A 202306 002 Feb 23, 2017 Feb NEWA AB1 TORRENT PHARMS LTD 500MG A 090014 001 Dec 30, 2009 Apr CAHN

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE TABLET;ORAL ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE TEVA 500MG;EQ 1MG BASE A 077337 005 May 19, 2017 May NEWA

METHADONE HYDROCHLORIDE CONCENTRATE;ORAL METHADOSE AA +! MALLINCKRODT INC 10MG/ML N 017116 002 Apr CAHN POWDER;FOR RX COMPOUNDING METHADONE HYDROCHLORIDE MALLINCKRODT INC 50GM/BOT N 006383 002 Apr CAHN 100GM/BOT N 006383 003 Apr CAHN 500GM/BOT N 006383 004 Apr CAHN SYRUP;ORAL DOLOPHINE HYDROCHLORIDE @ WEST-WARD PHARMS INT 10MG/30ML N 006134 004 Jan CAHN TABLET;ORAL DOLOPHINE HYDROCHLORIDE AA +! WEST-WARD PHARMS INT 5MG N 006134 002 Jan CAHN AA +! 10MG N 006134 010 Jan CAHN METHADONE HYDROCHLORIDE AA EPIC PHARMA LLC 5MG A 090065 001 Aug 18, 2015 May CAHN AA 10MG A 090065 002 Aug 18, 2015 May CAHN TABLET, FOR SUSPENSION;ORAL METHADONE HYDROCHLORIDE AA +! WEST-WARD PHARMS INT 40MG N 017058 001 Jan CAHN

METHENAMINE HIPPURATE TABLET;ORAL METHENAMINE HIPPURATE AB IMPAX LABS INC 1GM A 076411 001 Jun 20, 2003 Feb CAHN

METHIMAZOLE TABLET;ORAL METHIMAZOLE @ ECI PHARMS LLC 15MG A 040619 003 Jul 12, 2005 May CAHN TAPAZOLE AB KING PHARMS LLC 5MG A 040320 001 Mar 31, 2000 Feb CAHN AB 10MG A 040320 002 Mar 31, 2000 Feb CAHN

METHOCARBAMOL SOLUTION;IM-IV METHOCARBAMOL AP LUITPOLD PHARMS INC 1GM/10ML (100MG/ML) A 207496 001 Jun 22, 2017 Jun NEWA AP RENAISSANCE PHARMA 1GM/10ML (100MG/ML) A 208116 001 Jan 19, 2017 Jan NEWA AP RENAISSANCE SSA LLC 1GM/10ML (100MG/ML) A 208116 001 Jan 19, 2017 Mar CAHN >A> AP SAGENT PHARMS 1GM/10ML (100MG/ML) A 205404 001 Jul 18, 2017 Jul NEWA >A> AP SOMERSET THERAPS LLC 1GM/10ML (100MG/ML) A 207522 001 Jul 31, 2017 Jul NEWA TABLET;ORAL METHOCARBAMOL AA ATLAS PHARMS LLC 500MG A 203550 001 Feb 08, 2017 Jan NEWA AA 750MG A 203550 002 Feb 08, 2017 Jan NEWA >A> AA BEXIMCO PHARMS USA 500MG A 208507 001 Jul 21, 2017 Jul NEWA >A> AA 750MG A 208507 002 Jul 21, 2017 Jul NEWA @ UPSHER SMITH 500MG A 087453 001 Jun CAHN @ 750MG A 087454 001 Jun CAHN

METHOTREXATE SOLUTION;SUBCUTANEOUS >A> OTREXUP PFS >A> + ANTARES PHARMA INC 10MG/0.4ML (10MG/0.4ML) N 204824 009 May 31, 2017 Jul NEWA >A> + 15MG/0.6ML (15MG/0.6ML) N 204824 010 May 31, 2017 Jul NEWA >A> + 17.5MG/0.7ML (17.5MG/0.7ML) N 204824 011 May 31, 2017 Jul NEWA >A> + 20MG/0.8ML (20MG/0.8ML) N 204824 012 May 31, 2017 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -72

SOLUTION;SUBCUTANEOUS >A> OTREXUP PFS >A> + 22.5MG/0.9ML (22.5MG/0.9ML) N 204824 013 May 31, 2017 Jul NEWA >A> + 25MG/ML (25MG/ML) N 204824 014 May 31, 2017 Jul NEWA RASUVO @ MEDAC PHARMA INC 27.5MG/0.55ML (27.5MG/0.55ML) N 205776 009 Jul 10, 2014 Jun DISC

METHOTREXATE SODIUM INJECTABLE;INJECTION METHOTREXATE SODIUM PRESERVATIVE FREE AP PHARMACHEMIE BV EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A 040843 002 Jan 11, 2010 Apr CMS1 AP EQ 100MG BASE/4ML (EQ 25MG A 040843 003 Feb 27, 2012 Apr CMS1 BASE/ML) AP EQ 250MG BASE/10ML (EQ 25MG A 040843 004 Jan 11, 2010 Apr CMS1 BASE/ML) SOLUTION;ORAL XATMEP +! SILVERGATE PHARMS EQ 2.5MG BASE/ML N 208400 001 Apr 25, 2017 Apr NEWA TABLET;ORAL METHOTREXATE SODIUM >D> AB HQ SPCLT PHARMA EQ 2.5MG BASE A 201749 001 May 21, 2015 Jul CAHN >A> AB ORION CORP ORION EQ 2.5MG BASE A 201749 001 May 21, 2015 Jul CAHN AB ZYDUS PHARMS USA INC EQ 2.5MG BASE A 207812 001 Jan 13, 2017 Jan NEWA

METHYLDOPATE HYDROCHLORIDE INJECTABLE;INJECTION METHYLDOPATE HYDROCHLORIDE ! LUITPOLD 50MG/ML A 071279 001 Oct 02, 1987 Jan CTEC

METHYLPHENIDATE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL COTEMPLA XR-ODT + NEOS THERAPS INC 8.6MG N 205489 001 Jun 19, 2017 Jun NEWA + 17.3MG N 205489 002 Jun 19, 2017 Jun NEWA + 25.9MG N 205489 003 Jun 19, 2017 Jun NEWA

METHYLPHENIDATE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL METHYLPHENIDATE HYDROCHLORIDE AB2 IMPAX LABS INC 10MG A 205105 001 Jul 28, 2016 Feb CAHN AB2 20MG A 205105 002 Jul 28, 2016 Feb CAHN AB2 30MG A 205105 003 Jul 28, 2016 Feb CAHN AB2 40MG A 205105 004 Jul 28, 2016 Feb CAHN AB2 50MG A 205105 005 Jul 28, 2016 Feb CAHN AB2 60MG A 205105 006 Jul 28, 2016 Feb CAHN ! MAYNE PHARMA 60MG A 078458 004 Jun 23, 2016 Feb CHRS RITALIN LA + @ NOVARTIS 60MG N 021284 005 Oct 27, 2014 Feb DISC TABLET;ORAL METHYLPHENIDATE HYDROCHLORIDE AB ABHAI INC 5MG A 206932 001 May 11, 2017 Apr NEWA AB 10MG A 206932 002 May 11, 2017 Apr NEWA AB 20MG A 206932 003 May 11, 2017 Apr NEWA AB IMPAX LABS INC 5MG A 091159 001 Mar 12, 2014 Feb CAHN AB 10MG A 091159 002 Mar 12, 2014 Feb CAHN AB 20MG A 091159 003 Mar 12, 2014 Feb CAHN AB NOSTRUM LABS INC 5MG A 207587 001 Mar 03, 2017 Feb NEWA AB 10MG A 207587 002 Mar 03, 2017 Feb NEWA AB 20MG A 207587 003 Mar 03, 2017 Feb NEWA TABLET, CHEWABLE;ORAL METHYLPHENIDATE HYDROCHLORIDE AB NOSTRUM LABS INC 2.5MG A 204954 001 Jan 26, 2017 Jan NEWA AB 5MG A 204954 002 Jan 26, 2017 Jan NEWA AB 10MG A 204954 003 Jan 26, 2017 Jan NEWA TABLET, EXTENDED RELEASE;ORAL METHYLPHENIDATE HYDROCHLORIDE >A> AB IMPAX LABS INC 18MG A 208607 001 Jul 14, 2017 Jul NEWA >A> AB 27MG A 208607 002 Jul 14, 2017 Jul NEWA >A> AB 36MG A 208607 003 Jul 14, 2017 Jul NEWA >A> AB 54MG A 208607 004 Jul 14, 2017 Jul NEWA >A> AB OSMOTICA 18MG A 205327 001 Jul 28, 2017 Jul NEWA >A> AB 27MG A 205327 002 Jul 28, 2017 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -73

TABLET, EXTENDED RELEASE;ORAL METHYLPHENIDATE HYDROCHLORIDE >A> AB 36MG A 205327 003 Jul 28, 2017 Jul NEWA >A> AB 54MG A 205327 004 Jul 28, 2017 Jul NEWA >A> 72MG A 205327 005 Jul 28, 2017 Jul NEWA RITALIN-SR AB + NOVARTIS 20MG N 018029 001 Mar 30, 1982 Feb CRLD

METHYLPREDNISOLONE ACETATE INJECTABLE;INJECTION METHYLPREDNISOLONE ACETATE >D> AB SANDOZ 40MG/ML A 040794 001 Mar 05, 2009 Jul CAHN >D> AB 80MG/ML A 040794 002 Mar 05, 2009 Jul CAHN AB SANDOZ INC 40MG/ML A 040719 001 Jan 29, 2009 Mar CAHN >A> AB 40MG/ML A 040794 001 Mar 05, 2009 Jul CAHN AB 80MG/ML A 040719 002 Jan 29, 2009 Mar CAHN >A> AB 80MG/ML A 040794 002 Mar 05, 2009 Jul CAHN

METHYLTESTOSTERONE TABLET;ORAL ANDROID 10 @ VALEANT PHARMS NORTH 10MG A 086450 001 May CAHN

METIPRANOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC METIPRANOLOL AT SANDOZ INC 0.3% A 075720 001 Aug 06, 2001 Feb CAHN

METOCLOPRAMIDE HYDROCHLORIDE SOLUTION;ORAL METOCLOPRAMIDE HYDROCHLORIDE AA PHARM ASSOC EQ 5MG BASE/5ML A 072744 001 May 28, 1991 May CAHN TABLET;ORAL METOCLOPRAMIDE HYDROCHLORIDE @ SUN PHARM INDS EQ 5MG BASE A 071536 002 Jan 16, 1997 May DISC

METOPROLOL SUCCINATE TABLET, EXTENDED RELEASE;ORAL TOPROL-XL AB + ARALEZ PHARMS EQ 25MG TARTRATE N 019962 004 Feb 05, 2001 Jan CAHN AB +! EQ 50MG TARTRATE N 019962 001 Jan 10, 1992 Jan CAHN AB + EQ 100MG TARTRATE N 019962 002 Jan 10, 1992 Jan CAHN AB +! EQ 200MG TARTRATE N 019962 003 Jan 10, 1992 Jan CAHN

METOPROLOL TARTRATE INJECTABLE;INJECTION METOPROLOL TARTRATE AP SANDOZ INC 1MG/ML A 077360 001 Oct 02, 2007 Mar CAHN AP WEST-WARD PHARMS INT 1MG/ML A 076495 001 Jul 07, 2003 Jan CAHN TABLET;ORAL METOPROLOL TARTRATE >A> AB SUN PHARM INDS 50MG A 073654 003 Dec 21, 1993 Jul CMS1

METRONIDAZOLE CAPSULE;ORAL METRONIDAZOLE AB ALEMBIC PHARMS LTD 375MG A 079065 001 Jun 23, 2009 May CAHN GEL;TOPICAL METRONIDAZOLE AB TARO PHARM 1% A 204651 001 Mar 14, 2017 Feb NEWA INJECTABLE;INJECTION METRONIDAZOLE @ WEST-WARD PHARMS INT 500MG/100ML N 018907 001 Mar 30, 1984 May CAHN METRONIDAZOLE IN PLASTIC CONTAINER AP MYLAN LABS LTD 500MG/100ML A 205531 001 May 09, 2017 Apr NEWA TABLET;ORAL METRONIDAZOLE @ CHARTWELL MOLECULES 250MG N 018845 001 Aug 18, 1983 Jun CAHN @ 500MG N 018930 001 Aug 18, 1983 Jun CAHN AB ORIT LABS LLC 250MG A 208681 001 Jun 20, 2017 Jun NEWA AB 500MG A 208681 002 Jun 20, 2017 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -74

TABLET, EXTENDED RELEASE;ORAL METRONIDAZOLE AB ALEMBIC PHARMS LTD 750MG A 090222 001 May 05, 2010 May CAHN

MICONAZOLE NITRATE SUPPOSITORY;VAGINAL MICONAZOLE NITRATE AB ACTAVIS PHARMA 200MG A 073508 001 Nov 19, 1993 May CAHN

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE OINTMENT;TOPICAL VUSION +! MYLAN PHARMS INC 0.25%;81.35%;15% N 021026 001 Feb 16, 2006 Jan CAHN

MIDAZOLAM HYDROCHLORIDE INJECTABLE;INJECTION MIDAZOLAM HYDROCHLORIDE FRESENIUS KABI USA EQ 5MG BASE/ML A 208878 001 Mar 28, 2017 Mar NEWA AP WEST-WARD PHARMS INT EQ 1MG BASE/ML A 075243 001 Jun 20, 2000 Jan CAHN AP EQ 1MG BASE/ML A 075247 002 Jun 23, 2000 Jan CAHN AP EQ 1MG BASE/ML A 075324 001 Jun 20, 2000 Mar CAHN AP EQ 1MG BASE/ML A 075421 002 Jun 20, 2000 Jan CAHN AP EQ 5MG BASE/ML A 075243 002 Jun 20, 2000 Jan CAHN AP EQ 5MG BASE/ML A 075247 001 Jun 23, 2000 Jan CAHN AP EQ 5MG BASE/ML A 075324 002 Jun 20, 2000 Mar CAHN AP EQ 5MG BASE/ML A 075421 001 Jun 20, 2000 Jan CAHN MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE AP SAGENT AGILA LLC EQ 1MG BASE/ML A 090315 001 Nov 29, 2010 May CAHN AP EQ 5MG BASE/ML A 090315 002 Nov 29, 2010 May CAHN SYRUP;ORAL MIDAZOLAM HYDROCHLORIDE @ SUN PHARM INDS LTD EQ 2MG BASE/ML A 076058 001 Mar 15, 2002 May DISC

MIDODRINE HYDROCHLORIDE TABLET;ORAL ORVATEN AB UPSHER-SMITH LABS 2.5MG A 076725 001 Nov 03, 2004 Jun CAHN AB 5MG A 076725 002 Nov 03, 2004 Jun CAHN AB 10MG A 076725 003 Nov 03, 2004 Jun CAHN PROAMATINE + @ SHIRE LLC 2.5MG N 019815 001 Sep 06, 1996 Feb CRLD + @ 5MG N 019815 002 Sep 06, 1996 Feb CRLD + @ 10MG N 019815 003 Mar 20, 2002 Feb CRLD

MIDOSTAURIN CAPSULE;ORAL RYDAPT +! NOVARTIS PHARMS CORP 25MG N 207997 001 Apr 28, 2017 Apr NEWA

MILNACIPRAN HYDROCHLORIDE TABLET;ORAL SAVELLA AB + ALLERGAN SALES LLC 12.5MG N 022256 001 Jan 14, 2009 Feb CAHN AB + 25MG N 022256 002 Jan 14, 2009 Feb CAHN AB +! 50MG N 022256 003 Jan 14, 2009 Feb CAHN AB + 100MG N 022256 004 Jan 14, 2009 Feb CAHN

MILRINONE LACTATE INJECTABLE;INJECTION MILRINONE LACTATE AP WEST-WARD PHARMS INT EQ 1MG BASE/ML A 075530 001 May 28, 2002 Jan CAHN AP EQ 1MG BASE/ML A 075660 001 May 28, 2002 Jan CAHN @ EQ 1MG BASE/ML A 075852 001 May 28, 2002 Mar CAHN MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER @ WEST-WARD PHARMS INT EQ 20MG BASE/100ML (EQ 0.2MG A 075510 001 May 28, 2002 Mar CAHN BASE/ML) AP EQ 20MG BASE/100ML (EQ 0.2MG A 078113 001 May 21, 2008 Jan CAHN BASE/ML) AP EQ 40MG BASE/200ML (EQ 0.2MG A 078113 002 May 21, 2008 Jan CAHN BASE/ML) PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER + @ SANOFI AVENTIS US EQ 10MG BASE/100ML N 020343 001 Aug 09, 1994 Jan CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -75

INJECTABLE;INJECTION PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER + @ EQ 15MG BASE/100ML N 020343 002 Aug 09, 1994 Jan CRLD + @ EQ 20MG BASE/100ML (EQ 0.2MG N 020343 003 Aug 09, 1994 Jan CRLD BASE/ML) + @ EQ 40MG BASE/200ML (EQ 0.2MG N 020343 004 Aug 09, 1994 Jan CRLD BASE/ML)

MINOCYCLINE HYDROCHLORIDE CAPSULE;ORAL MINOCYCLINE HYDROCHLORIDE AB WATSON LABS TEVA EQ 50MG BASE A 063181 001 Dec 30, 1991 May CAHN CAPSULE, EXTENDED RELEASE;ORAL XIMINO SUN PHARM INDS LTD EQ 45MG BASE N 201922 001 Jul 11, 2012 Apr CMFD EQ 90MG BASE N 201922 003 Jul 11, 2012 Apr CMFD EQ 135MG BASE N 201922 005 Jul 11, 2012 Apr CMFD TABLET, EXTENDED RELEASE;ORAL MINOCYCLINE HYDROCHLORIDE @ BARR LABS INC EQ 80MG BASE A 065485 007 Apr 26, 2017 Apr DISC EQ 80MG BASE A 065485 007 Apr 26, 2017 Apr NEWA @ EQ 105MG BASE A 065485 008 Apr 26, 2017 Apr DISC EQ 105MG BASE A 065485 008 Apr 26, 2017 Apr NEWA @ MYLAN PHARMS INC EQ 45MG BASE A 090911 001 Jul 20, 2010 May DISC @ EQ 80MG BASE A 203443 002 Aug 22, 2014 May DISC @ EQ 90MG BASE A 090911 002 Jul 20, 2010 May DISC @ EQ 105MG BASE A 203443 003 Aug 22, 2014 May DISC @ EQ 135MG BASE A 090911 003 Jul 20, 2010 May DISC MINOLIRA DR REDDYS LABS LTD EQ 105MG BASE N 209269 001 May 08, 2017 May NEWA EQ 135MG BASE N 209269 002 May 08, 2017 May NEWA

MIRABEGRON TABLET, EXTENDED RELEASE;ORAL MYRBETRIQ +! APGDI 25MG N 202611 001 Jun 28, 2012 Feb CHRS

MIRTAZAPINE TABLET;ORAL MIRTAZAPINE @ UPSHER-SMITH LABS 15MG A 076189 001 Jun 19, 2003 Jun CAHN AB 15MG A 076219 001 Jun 19, 2003 Jun CAHN @ 30MG A 076189 002 Jun 19, 2003 Jun CAHN AB 30MG A 076219 002 Jun 19, 2003 Jun CAHN @ 45MG A 076189 003 Jun 19, 2003 Jun CAHN AB 45MG A 076219 003 Jun 19, 2003 Jun CAHN TABLET, ORALLY DISINTEGRATING;ORAL MIRTAZAPINE AB AUROBINDO PHARMA LTD 15MG A 077376 002 Dec 08, 2005 Jan CAHN AB 30MG A 077376 003 Dec 08, 2005 Jan CAHN AB 45MG A 077376 004 Feb 28, 2006 Jan CAHN AB ZYDUS PHARMS USA INC 15MG A 205798 001 Jun 01, 2017 May NEWA AB 30MG A 205798 002 Jun 01, 2017 May NEWA AB 45MG A 205798 003 Jun 01, 2017 May NEWA

MITOMYCIN INJECTABLE;INJECTION MITOMYCIN AP WEST-WARD PHARMS INT 5MG/VIAL A 064117 001 Apr 19, 1995 Jan CAHN AP 5MG/VIAL A 064180 001 Dec 23, 1999 Jan CAHN AP 20MG/VIAL A 064117 002 Apr 19, 1995 Jan CAHN AP 20MG/VIAL A 064180 002 Dec 23, 1999 Jan CAHN MUTAMYCIN + @ BRISTOL 5MG/VIAL N 050450 001 Jan CRLD + @ 20MG/VIAL N 050450 002 Jan CRLD

MODAFINIL TABLET;ORAL MODAFINIL AB ALEMBIC PHARMS LTD 100MG A 202700 001 Oct 18, 2012 May CAHN AB 200MG A 202700 002 Oct 18, 2012 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -76

MOEXIPRIL HYDROCHLORIDE TABLET;ORAL MOEXIPRIL HYDROCHLORIDE AB CHARTWELL RX 7.5MG A 077536 001 Nov 30, 2006 Apr CAHN AB 15MG A 077536 002 Nov 30, 2006 Apr CAHN

MOLINDONE HYDROCHLORIDE TABLET;ORAL MOLINDONE HYDROCHLORIDE EPIC PHARMA LLC 5MG A 090453 001 Mar 20, 2015 May CAHN 10MG A 090453 002 Mar 20, 2015 May CAHN ! 25MG A 090453 003 Mar 20, 2015 May CAHN

MOMETASONE FUROATE LOTION;TOPICAL MOMETASONE FUROATE AB PERRIGO ISRAEL 0.1% A 077180 001 Apr 06, 2005 Apr CAHN SPRAY, METERED;NASAL MOMETASONE FUROATE AB AMNEAL PHARMS EQ 0.05MG BASE/SPRAY A 207989 001 Apr 03, 2017 Mar NEWA

MONTELUKAST SODIUM TABLET;ORAL MONTELUKAST SODIUM AB CSPC OUYI PHARM CO EQ 10MG BASE A 209012 001 Apr 24, 2017 Apr NEWA AB PERRIGO R AND D EQ 10MG BASE A 206112 001 Apr 26, 2017 Apr NEWA TABLET, CHEWABLE;ORAL MONTELUKAST SODIUM AB CSPC OUYI PHARM CO EQ 4MG BASE A 209011 001 Apr 18, 2017 Apr NEWA AB EQ 5MG BASE A 209011 002 Apr 18, 2017 Apr NEWA

MORPHINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL MORPHINE SULFATE ACTAVIS ELIZABETH 30MG A 079040 001 Jan 16, 2013 Apr CAHN 45MG A 079040 002 Jan 16, 2013 Apr CAHN 60MG A 079040 003 Jan 16, 2013 Apr CAHN 75MG A 079040 004 Jan 16, 2013 Apr CAHN 90MG A 079040 005 Jan 16, 2013 Apr CAHN ! 120MG A 079040 006 Jan 16, 2013 Apr CAHN AB UPSHER-SMITH LABS 10MG A 202104 001 Jun 03, 2013 Jun CAHN AB 20MG A 202104 002 Jun 03, 2013 Jun CAHN AB 30MG A 202104 003 Jun 03, 2013 Jun CAHN AB 50MG A 202104 004 Jun 03, 2013 Jun CAHN AB 60MG A 202104 005 Jun 03, 2013 Jun CAHN AB 80MG A 202104 006 Jun 03, 2013 Jun CAHN AB 100MG A 202104 007 Jun 03, 2013 Jun CAHN INJECTABLE;INJECTION MORPHINE SULFATE @ ICU MEDICAL INC 0.5MG/ML N 019917 001 Oct 30, 1992 Jun CAHN AP +! 1MG/ML N 019916 001 Oct 30, 1992 Apr CAHN +! 5MG/ML N 019916 002 Oct 27, 2006 Apr CAHN @ MALLINCKRODT INC 1MG/ML N 020631 001 Jul 03, 1996 Apr CAHN @ 2MG/ML N 020631 002 Jul 03, 1996 Apr CAHN SOLUTION;ORAL MORPHINE SULFATE AA HI-TECH PHARMACAL 100MG/5ML A 208809 001 Jul 06, 2017 Jun NEWA AA RHODES PHARMS 10MG/5ML A 206308 001 Jun 22, 2017 Jun NEWA AA 100MG/5ML A 206308 002 Jun 22, 2017 Jun NEWA AA + WEST-WARD PHARMS INT 10MG/5ML N 022195 001 Mar 17, 2008 Jan CAHN AA + 20MG/5ML N 022195 002 Mar 17, 2008 Jan CAHN AA +! 100MG/5ML N 022195 003 Jan 25, 2010 Jan CAHN TABLET;ORAL MORPHINE SULFATE + WEST-WARD PHARMS INT 15MG N 022207 001 Mar 17, 2008 Jan CAHN +! 30MG N 022207 002 Mar 17, 2008 Jan CAHN TABLET, EXTENDED RELEASE;ORAL ARYMO ER + EGALET 15MG N 208603 001 Jan 09, 2017 Jan NEWA + 30MG N 208603 002 Jan 09, 2017 Jan NEWA + 60MG N 208603 003 Jan 09, 2017 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -77

TABLET, EXTENDED RELEASE;ORAL MORPHABOND ER + DAIICHI SANKYO INC 15MG N 206544 001 Oct 02, 2015 Jan CTNA + 30MG N 206544 002 Oct 02, 2015 Jan CTNA + 60MG N 206544 003 Oct 02, 2015 Jan CTNA +! 100MG N 206544 004 Oct 02, 2015 Jan CTNA MORPHINE SULFATE AB ACTAVIS ELIZABETH 15MG A 203849 001 Apr 06, 2015 Apr CAHN AB 30MG A 203849 002 Apr 06, 2015 Apr CAHN AB 60MG A 203849 003 Apr 06, 2015 Apr CAHN AB 100MG A 203849 004 Apr 06, 2015 Apr CAHN AB 200MG A 203849 005 Apr 06, 2015 Apr CAHN AB EPIC PHARMA LLC 15MG A 091357 001 Jun 23, 2016 May CAHN AB 30MG A 091357 002 Jun 23, 2016 May CAHN AB 60MG A 091357 003 Jun 23, 2016 May CAHN AB 100MG A 091357 004 Jun 23, 2016 May CAHN AB 200MG A 091357 005 Jun 23, 2016 May CAHN AB SUN PHARM INDS 15MG A 205634 001 Aug 25, 2016 Mar CAHN AB 30MG A 205634 002 Aug 25, 2016 Mar CAHN AB 60MG A 205634 003 Aug 25, 2016 Mar CAHN AB 100MG A 205634 004 Aug 25, 2016 Mar CAHN AB 200MG A 205634 005 Aug 25, 2016 Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE SOLUTION;IV (INFUSION) AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER AP +! BAYER HLTHCARE 400MG/250ML (1.6MG/ML) N 021277 001 Nov 30, 2001 Apr CFTG MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER AP MYLAN LABS LTD 400MG/250ML (1.6MG/ML) A 205833 001 May 05, 2017 Apr NEWA SOLUTION/DROPS;OPHTHALMIC MOXIFLOXACIN HYDROCHLORIDE AT1 APOTEX INC EQ 0.5% BASE A 090080 001 Jun 30, 2017 Jun NEWA TABLET;ORAL MOXIFLOXACIN HYDROCHLORIDE AB NOVEL LABS INC EQ 400MG BASE A 207285 001 Feb 13, 2017 Jan NEWA

MUPIROCIN OINTMENT;TOPICAL BACTROBAN + @ GLAXOSMITHKLINE 2% N 050591 001 Dec 31, 1987 May DISC MUPIROCIN AB ! PERRIGO NEW YORK 2% A 065123 001 Nov 07, 2003 May CHRS

MUPIROCIN CALCIUM CREAM;TOPICAL MUPIROCIN AB GLENMARK PHARMS INC EQ 2% BASE A 201587 001 Jan 24, 2013 May CAHN

MYCOPHENOLATE MOFETIL HYDROCHLORIDE INJECTABLE;INJECTION MYCOPHENOLATE MOFETIL HYDROCHLORIDE AP AKORN INC 500MG/VIAL A 204043 001 Feb 28, 2017 Feb NEWA AP MYLAN LABS LTD 500MG/VIAL A 203859 001 Mar 31, 2017 Mar NEWA

NABILONE CAPSULE;ORAL CESAMET +! MYLAN SPECIALITY LP 1MG N 018677 001 Dec 26, 1985 Mar CAHN

NADOLOL TABLET;ORAL NADOLOL AB AMNEAL PHARMS CO 20MG A 208832 001 Jun 02, 2017 May NEWA AB 40MG A 208832 002 Jun 02, 2017 May NEWA AB 80MG A 208832 003 Jun 02, 2017 May NEWA >A> AB ZYDUS PHARMS USA INC 20MG A 207761 001 Jul 28, 2017 Jul NEWA >A> AB 40MG A 207761 002 Jul 28, 2017 Jul NEWA >A> AB 80MG A 207761 003 Jul 28, 2017 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -78

NAFTIFINE HYDROCHLORIDE CREAM;TOPICAL NAFTIFINE HYDROCHLORIDE AB TOLMAR 2% A 206960 001 Apr 10, 2017 Mar NEWA

NALDEMEDINE TOSYLATE TABLET;ORAL SYMPROIC +! SHIONOGI INC EQ 0.2MG BASE N 208854 001 Mar 23, 2017 Mar NEWA

NALOXONE HYDROCHLORIDE INJECTABLE;INJECTION NALOXONE @ WEST-WARD PHARMS INT 0.4MG/ML A 070298 001 Sep 24, 1986 Jan CAHN @ 0.4MG/ML A 070496 001 Sep 24, 1986 Jan CAHN NALOXONE HYDROCHLORIDE AP AKORN 0.4MG/ML A 208871 001 Feb 28, 2017 Feb NEWA AP 0.4MG/ML A 208872 001 Mar 14, 2017 Feb NEWA >A> AP SOMERSET THERAPS LLC 0.4MG/ML A 207633 001 Aug 08, 2017 Jul NEWA >A> AP 0.4MG/ML A 207634 001 Jul 26, 2017 Jul NEWA SPRAY, METERED;NASAL NARCAN + ADAPT 2MG/SPRAY N 208411 002 Jan 24, 2017 Jan NEWA

NALTREXONE HYDROCHLORIDE TABLET;ORAL NALTREXONE HYDROCHLORIDE >A> AB APOTEX INC 50MG A 207905 001 Jul 21, 2017 Jul NEWA

NANDROLONE DECANOATE INJECTABLE;INJECTION NANDROLONE DECANOATE ! LUITPOLD PHARMS INC 200MG/ML A 091252 001 Aug 30, 2010 Jun CAHN

NAPROXEN TABLET;ORAL NAPROXEN AB AUROBINDO PHARMA LTD 250MG A 200429 001 Nov 08, 2011 Jan CAHN AB 375MG A 200429 002 Nov 08, 2011 Jan CAHN AB 500MG A 200429 003 Nov 08, 2011 Jan CAHN @ CHARTWELL MOLECULES 250MG A 074410 001 Apr 28, 1995 May CAHN @ 375MG A 074410 002 Apr 28, 1995 May CAHN @ 500MG A 074410 003 Apr 28, 1995 May CAHN @ HIKMA INTL PHARMS 250MG A 076494 001 Jan 14, 2004 May DISC @ 375MG A 076494 002 Jan 14, 2004 May DISC @ 500MG A 076494 003 Jan 14, 2004 May DISC @ WATSON LABS TEVA 250MG A 074163 001 Feb 10, 1995 May CAHN @ 375MG A 074163 002 Feb 10, 1995 May CAHN @ 500MG A 074163 003 Feb 10, 1995 May CAHN

NAPROXEN SODIUM TABLET;ORAL NAPROXEN SODIUM AB GLENMARK PHARMS LTD EQ 250MG BASE A 078314 001 Apr 27, 2007 May CAHN AB EQ 500MG BASE A 078314 002 Apr 27, 2007 May CAHN

NATAMYCIN SUSPENSION;OPHTHALMIC NATACYN +! NOVARTIS PHARMS CORP 5% N 050514 001 Jan CAHN

NEBIVOLOL HYDROCHLORIDE TABLET;ORAL NEBIVOLOL HYDROCHLORIDE @ GLENMARK PHARMS LTD EQ 2.5MG BASE A 203821 001 May 25, 2017 May DISC AB EQ 2.5MG BASE A 203821 001 May 25, 2017 May NEWA @ EQ 5MG BASE A 203821 002 May 25, 2017 May DISC AB EQ 5MG BASE A 203821 002 May 25, 2017 May NEWA @ EQ 10MG BASE A 203821 003 May 25, 2017 May DISC AB EQ 10MG BASE A 203821 003 May 25, 2017 May NEWA @ EQ 20MG BASE A 203821 004 May 25, 2017 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -79

TABLET;ORAL NEBIVOLOL HYDROCHLORIDE AB EQ 20MG BASE A 203821 004 May 25, 2017 May NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN TABLET;ORAL BYVALSON +! FOREST LABS LLC EQ 5MG BASE;80MG N 206302 001 Jun 03, 2016 May CRLD

NEDOCROMIL SODIUM AEROSOL, METERED;INHALATION TILADE >D> @ KING PHARMS 1.75MG/INH N 019660 001 Dec 30, 1992 Jul CAHN >A> @ KING PHARMS LLC 1.75MG/INH N 019660 001 Dec 30, 1992 Jul CAHN

NELFINAVIR MESYLATE POWDER;ORAL VIRACEPT @ AGOURON PHARMS EQ 50MG BASE/SCOOPFUL N 020778 001 Mar 14, 1997 Jan CAHN TABLET;ORAL VIRACEPT +! AGOURON PHARMS EQ 250MG BASE N 020779 001 Mar 14, 1997 Jan CAHN +! EQ 625MG BASE N 021503 001 Apr 30, 2003 Jan CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE SOLUTION;IRRIGATION NEOSPORIN G.U. IRRIGANT AT ! MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML A 060707 001 Apr CAHN

NEOSTIGMINE METHYLSULFATE SOLUTION;INTRAVENOUS NEOSTIGMINE METHYLSULFATE AP PAR STERILE PRODUCTS 5MG/10ML (0.5MG/ML) A 208405 001 Apr 26, 2017 Apr NEWA AP 10MG/10ML (1MG/ML) A 208405 002 Apr 26, 2017 Apr NEWA

>A> NERATINIB MALEATE >A> TABLET;ORAL >A> NERLYNX >A> +! PUMA BIOTECH EQ 40MG BASE N 208051 001 Jul 17, 2017 Jul NEWA

NEVIRAPINE SUSPENSION;ORAL NEVIRAPINE >A> AA CIPLA LTD 50MG/5ML A 207684 001 Aug 03, 2017 Jul NEWA TABLET, EXTENDED RELEASE;ORAL NEVIRAPINE AB AUROBINDO PHARMA LTD 400MG A 207698 001 Feb 28, 2017 Mar CAHN AB AUROBINDO PHARMA USA 400MG A 207698 001 Feb 28, 2017 Feb NEWA >A> AB SCIEGEN PHARMS INC 100MG A 207467 001 Jul 31, 2017 Jul NEWA >A> AB 400MG A 207467 002 Jul 31, 2017 Jul NEWA

NIACIN TABLET;ORAL NIACOR AA ! UPSHER-SMITH LABS 500MG A 040378 001 May 03, 2000 Jun CAHN TABLET, EXTENDED RELEASE;ORAL NIACIN AB LANNETT 500MG A 203899 001 Jun 16, 2017 Jun NEWA AB 1GM A 203899 002 Jun 16, 2017 Jun NEWA

NICARDIPINE HYDROCHLORIDE INJECTABLE;INJECTION NICARDIPINE HYDROCHLORIDE AP WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML) A 078714 001 Dec 28, 2009 Jan CAHN INJECTABLE;INTRAVENOUS NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML) N 022276 002 Apr 07, 2016 Feb NEWA 40MG/200ML (0.2MG/ML) N 022276 003 Apr 07, 2016 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -80

NIFEDIPINE TABLET, EXTENDED RELEASE;ORAL AFEDITAB CR AB1 WATSON LABS TEVA 30MG A 075128 001 Mar 10, 2000 May CAHN NIFEDIPINE @ MYLAN LABS LTD 30MG A 090602 001 Sep 13, 2010 May DISC AB2 30MG A 090602 001 Sep 13, 2010 Mar CAHN @ 60MG A 090602 002 Sep 13, 2010 May DISC AB2 60MG A 090602 002 Sep 13, 2010 Mar CAHN @ 90MG A 090602 003 Sep 13, 2010 May DISC AB2 90MG A 090602 003 Sep 13, 2010 Mar CAHN AB2 OSMOTICA PHARM US 90MG A 077410 001 Oct 03, 2007 Jun CAHN

NIRAPARIB TOSYLATE CAPSULE;ORAL ZEJULA +! TESARO INC EQ 100MG BASE N 208447 001 Mar 27, 2017 Mar NEWA

NISOLDIPINE TABLET, EXTENDED RELEASE;ORAL SULAR AB +! COVIS PHARMA BV 8.5MG N 020356 008 Jan 02, 2008 May CAHN + @ 10MG N 020356 001 Feb 02, 1995 May CAHN AB +! 17MG N 020356 007 Jan 02, 2008 May CAHN + @ 20MG N 020356 002 Feb 02, 1995 May CAHN + @ 25.5MG N 020356 006 Jan 02, 2008 May CAHN + @ 30MG N 020356 003 Feb 02, 1995 May CAHN AB +! 34MG N 020356 005 Jan 02, 2008 May CAHN + @ 40MG N 020356 004 Feb 02, 1995 May CAHN

NITISINONE >A> TABLET;ORAL >A> NITYR >A> + CYCLE PHARMS LTD 2MG N 209449 001 Jul 26, 2017 Jul NEWA >A> + 5MG N 209449 002 Jul 26, 2017 Jul NEWA >A> +! 10MG N 209449 003 Jul 26, 2017 Jul NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE CAPSULE;ORAL NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) AB AMNEAL PHARMS 75MG;25MG A 207372 001 May 15, 2017 May NEWA

NITROGLYCERIN FILM, EXTENDED RELEASE;TRANSDERMAL NITRO-DUR AB1 +! USPHARMA 0.1MG/HR N 020145 001 Apr 04, 1995 Jun CAHN AB1 +! 0.2MG/HR N 020145 002 Apr 04, 1995 Jun CAHN +! 0.3MG/HR N 020145 003 Apr 04, 1995 Jun CAHN AB1 +! 0.4MG/HR N 020145 004 Apr 04, 1995 Jun CAHN AB1 +! 0.6MG/HR N 020145 005 Apr 04, 1995 Jun CAHN +! 0.8MG/HR N 020145 006 Apr 04, 1995 Jun CAHN OINTMENT;TRANSDERMAL NITROGLYCERIN ! FOUGERA PHARMS INC 2% A 087355 001 Jul 08, 1988 Jan CAHN

NOREPINEPHRINE BITARTRATE INJECTABLE;INJECTION NOREPINEPHRINE BITARTRATE AP WEST-WARD PHARMS INT EQ 1MG BASE/ML A 040462 001 Oct 31, 2003 Jan CAHN

NORTRIPTYLINE HYDROCHLORIDE CAPSULE;ORAL NORTRIPTYLINE HYDROCHLORIDE @ MYLAN EQ 10MG BASE A 074234 001 Jul 26, 1993 Jun DISC @ EQ 25MG BASE A 074234 002 Jul 26, 1993 Jun DISC @ EQ 50MG BASE A 074234 003 Jul 26, 1993 Jun DISC @ EQ 75MG BASE A 074234 004 Jul 26, 1993 Jun DISC AB TARO PHARM EQ 10MG BASE A 075520 004 May 08, 2000 Mar CAHN AB EQ 25MG BASE A 075520 003 May 08, 2000 Mar CAHN AB EQ 50MG BASE A 075520 001 May 08, 2000 Mar CAHN AB EQ 75MG BASE A 075520 002 May 08, 2000 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -81

SOLUTION;ORAL NORTRIPTYLINE HYDROCHLORIDE AA ! PHARM ASSOC EQ 10MG BASE/5ML A 075606 001 Aug 28, 2000 May CAHN

NYSTATIN PASTILLE;ORAL MYCOSTATIN @ DELCOR ASSET CORP 200,000 UNITS N 050619 001 Apr 09, 1987 Jun CAHN POWDER;TOPICAL NYSTATIN AT LYNE 100,000 UNITS/GM A 208838 001 May 30, 2017 May NEWA AT NESHER PHARMS 100,000 UNITS/GM A 208581 001 Jun 08, 2017 May NEWA AT UPSHER-SMITH LABS 100,000 UNITS/GM A 065183 001 May 03, 2005 Jun CAHN SUSPENSION;ORAL NYSTATIN >A> @ ALLIED PHARMA INC 100,000 UNITS/ML A 062832 001 Dec 27, 1991 Jul CAHN AA FOUGERA PHARMS INC 100,000 UNITS/ML A 062517 001 Jun 07, 1984 Jan CAHN AA PHARM ASSOC 100,000 UNITS/ML A 203621 001 Jan 07, 2016 May CAHN >D> ROXANE@ 100,000 UNITS/ML A 062832 001 Dec 27, 1991 Jul CAHN AA TARO PHARM 100,000 UNITS/ML A 062876 001 Feb 29, 1988 Apr CAHN TABLET;ORAL NYSTATIN @ USL PHARMA 500,000 UNITS A 062524 001 Nov 26, 1985 Jun CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE CREAM;TOPICAL MYCOLOG-II @ MYLAN PHARMS INC 100,000 UNITS/GM;0.1% A 062606 001 May 15, 1985 Jan CAHN NYSTATIN AND TRIAMCINOLONE ACETONIDE AT FOUGERA PHARMS INC 100,000 UNITS/GM;0.1% A 062599 001 Oct 08, 1985 Jan CAHN >A> AT PERRIGO UK FINCO 100,000 UNITS/GM;0.1% A 208479 001 Aug 14, 2017 Jul NEWA OINTMENT;TOPICAL MYCOLOG-II @ MYLAN PHARMS INC 100,000 UNITS/GM;0.1% A 060572 001 Jun 28, 1985 Jan CAHN NYSTATIN AND TRIAMCINOLONE ACETONIDE >A> AT AKORN 100,000 UNITS/GM;0.1% A 207217 001 Aug 04, 2017 Jul NEWA AT DR REDDYS LABS LTD 100,000 UNITS/GM;0.1% A 207741 001 Jan 31, 2017 Jan NEWA AT FOUGERA PHARMS INC 100,000 UNITS/GM;0.1% A 062602 001 Oct 09, 1985 Jan CAHN

OFLOXACIN SOLUTION/DROPS;OPHTHALMIC OFLOXACIN AT SANDOZ INC 0.3% A 076231 001 May 14, 2004 Feb CAHN SOLUTION/DROPS;OTIC OFLOXACIN AT SANDOZ INC 0.3% A 078222 001 Mar 17, 2008 Feb CAHN

OLANZAPINE TABLET;ORAL OLANZAPINE AB HIKMA PHARMS 2.5MG A 204866 001 Jun 16, 2017 Jun NEWA AB 5MG A 204866 002 Jun 16, 2017 Jun NEWA AB 7.5MG A 204866 003 Jun 16, 2017 Jun NEWA AB 10MG A 204866 004 Jun 16, 2017 Jun NEWA AB 15MG A 204866 005 Jun 16, 2017 Jun NEWA AB 20MG A 204866 006 Jun 16, 2017 Jun NEWA @ MYLAN PHARMS INC 2.5MG A 076866 001 Apr 23, 2012 Jun DISC AB 2.5MG A 076866 001 Apr 23, 2012 Mar CAHN @ 5MG A 076866 002 Apr 23, 2012 Jun DISC AB 5MG A 076866 002 Apr 23, 2012 Mar CAHN @ 7.5MG A 076866 003 Apr 23, 2012 Jun DISC AB 7.5MG A 076866 003 Apr 23, 2012 Mar CAHN @ 10MG A 076866 004 Apr 23, 2012 Jun DISC AB 10MG A 076866 004 Apr 23, 2012 Mar CAHN @ 15MG A 076866 005 Apr 23, 2012 Jun DISC AB 15MG A 076866 005 Apr 23, 2012 Mar CAHN @ 20MG A 076866 006 Apr 23, 2012 Jun DISC AB 20MG A 076866 006 Apr 23, 2012 Mar CAHN TABLET, ORALLY DISINTEGRATING;ORAL OLANZAPINE AB AJANTA PHARMA LTD 5MG A 204320 001 May 30, 2017 May NEWA AB 10MG A 204320 002 May 30, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -82

TABLET, ORALLY DISINTEGRATING;ORAL OLANZAPINE AB 15MG A 204320 003 May 30, 2017 May NEWA AB 20MG A 204320 004 May 30, 2017 May NEWA

OLAPARIB CAPSULE;ORAL LYNPARZA +! ASTRAZENECA PHARMS 50MG N 206162 001 Dec 19, 2014 Mar CRLD

OLIVE OIL; SOYBEAN OIL >D> INJECTABLE;INJECTION >D> CLINOLIPID 20% >D> +! BAXTER HLTHCARE CORP 16%(160GM/1000ML);4% N 204508 001 Oct 03, 2013 Jul DISC (40GM/1000ML) >A> + @ 16%(160GM/1000ML);4% N 204508 001 Oct 03, 2013 Jul DISC (40GM/1000ML)

OLMESARTAN MEDOXOMIL TABLET;ORAL OLMESARTAN MEDOXOMIL AB ACCORD HLTHCARE 5MG A 207662 001 Apr 24, 2017 Apr NEWA AB 20MG A 207662 002 Apr 24, 2017 Apr NEWA AB 40MG A 207662 003 Apr 24, 2017 Apr NEWA AB ALEMBIC PHARMS LTD 5MG A 203012 001 Apr 24, 2017 Apr NEWA AB 20MG A 203012 002 Apr 24, 2017 Apr NEWA AB 40MG A 203012 003 Apr 24, 2017 Apr NEWA AB ALKEM LABS LTD 5MG A 206763 001 Apr 24, 2017 Apr NEWA AB 20MG A 206763 002 Apr 24, 2017 Apr NEWA AB 40MG A 206763 003 Apr 24, 2017 Apr NEWA AB AUROBINDO PHARMA LTD 5MG A 204798 001 Apr 24, 2017 Apr NEWA AB 20MG A 204798 002 Apr 24, 2017 Apr NEWA AB 40MG A 204798 003 Apr 24, 2017 Apr NEWA AB GLENMARK PHARMS LTD 5MG A 203281 001 May 25, 2017 May NEWA AB 20MG A 203281 002 May 25, 2017 May NEWA AB 40MG A 203281 003 May 25, 2017 May NEWA AB JUBILANT GENERICS 5MG A 205482 001 Apr 24, 2017 Apr NEWA AB 20MG A 205482 002 Apr 24, 2017 Apr NEWA AB 40MG A 205482 003 Apr 24, 2017 Apr NEWA AB LUPIN LTD 5MG A 206631 001 Apr 27, 2017 Apr NEWA AB 20MG A 206631 002 Apr 27, 2017 Apr NEWA AB 40MG A 206631 003 Apr 27, 2017 Apr NEWA AB MACLEODS PHARMS LTD 5MG A 204814 001 Apr 24, 2017 Apr NEWA AB 20MG A 204814 002 Apr 24, 2017 Apr NEWA AB 40MG A 204814 003 Apr 24, 2017 Apr NEWA AB TEVA PHARMS USA 5MG A 091079 001 Apr 24, 2017 Apr NEWA AB 20MG A 091079 002 Apr 24, 2017 Apr NEWA AB 40MG A 091079 003 Apr 24, 2017 Apr NEWA AB TORRENT PHARMS LTD 5MG A 202375 001 Apr 24, 2017 Apr NEWA AB 20MG A 202375 002 Apr 24, 2017 Apr NEWA AB 40MG A 202375 003 Apr 24, 2017 Apr NEWA AB ZYDUS PHARMS USA INC 5MG A 205192 001 Apr 24, 2017 Apr NEWA AB 20MG A 205192 002 Apr 24, 2017 Apr NEWA AB 40MG A 205192 003 Apr 24, 2017 Apr NEWA

OLOPATADINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC OLOPATADINE HYDROCHLORIDE >A> AT CIPLA LTD EQ 0.1% BASE A 206046 001 Jul 26, 2017 Jul NEWA AT WOCKHARDT LTD EQ 0.1% BASE A 200810 001 Jun 28, 2017 Jun NEWA SPRAY, METERED;NASAL OLOPATADINE HYDROCHLORIDE AB PERRIGO ISRAEL 0.665MG/SPRAY A 202853 001 Jan 31, 2017 Jan NEWA

OLSALAZINE SODIUM CAPSULE;ORAL DIPENTUM +! MYLAN SPECIALITY LP 250MG N 019715 001 Jul 31, 1990 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -83

OMACETAXINE MEPESUCCINATE POWDER;SUBCUTANEOUS SYNRIBO +! TEVA PHARMS INTL 3.5MG/VIAL N 203585 001 Oct 26, 2012 Apr CAHN

OMEGA-3-ACID ETHYL ESTERS CAPSULE;ORAL OMEGA-3-ACID ETHYL ESTERS AB AMNEAL PHARMS 1GM CONTAINS AT LEAST 900MG OF THE A 204940 001 Nov 27, 2015 May CAHN ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

OMEPRAZOLE CAPSULE, DELAYED REL PELLETS;ORAL OMEPRAZOLE AB AUROBINDO PHARMA LTD 10MG A 203270 001 Aug 19, 2015 Jan CAHN AB 20MG A 203270 002 Aug 19, 2015 Jan CAHN AB 40MG A 203270 003 Aug 19, 2015 Jan CAHN AB BRECKENRIDGE PHARM 10MG A 203481 001 Jul 03, 2017 Jun NEWA AB 20MG A 203481 002 Jul 03, 2017 Jun NEWA AB 40MG A 203481 003 Jul 03, 2017 Jun NEWA AB TEVA PHARMS USA 20MG A 204661 001 Jun 13, 2017 May NEWA AB 40MG A 204661 002 Jun 13, 2017 May NEWA

OMEPRAZOLE MAGNESIUM FOR SUSPENSION, DELAYED RELEASE;ORAL PRILOSEC + COVIS PHARMA BV EQ 2.5MG BASE/PACKET N 022056 001 Mar 20, 2008 May CAHN +! EQ 10MG BASE/PACKET N 022056 002 Mar 20, 2008 May CAHN

OMEPRAZOLE; SODIUM BICARBONATE FOR SUSPENSION;ORAL OMEPRAZOLE AND SODIUM BICARBONATE AB AJANTA PHARMA LTD 20MG/PACKET;1.68GM/PACKET A 205545 001 Jul 27, 2016 Jan CTEC AB 40MG/PACKET;1.68GM/PACKET A 205545 002 Jul 27, 2016 Jan CTEC AB PAR PHARM 20MG/PACKET;1.68GM/PACKET A 079182 001 Apr 19, 2013 Jan CMFD AB 40MG/PACKET;1.68GM/PACKET A 079182 002 Apr 19, 2013 Jan CMFD ZEGERID AB + SANTARUS INC 20MG/PACKET;1.68GM/PACKET N 021636 001 Jun 15, 2004 Jan CTEC AB +! 40MG/PACKET;1.68GM/PACKET N 021636 002 Dec 21, 2004 Jan CTEC

ONDANSETRON TABLET, ORALLY DISINTEGRATING;ORAL ONDANSETRON @ CHARTWELL MOLECULES 4MG A 076506 001 Dec 26, 2006 Mar CAHN @ 8MG A 076506 002 Dec 26, 2006 Mar CAHN @ 16MG A 077406 001 Dec 26, 2006 Mar CAHN @ 24MG A 077406 002 Dec 26, 2006 Mar CAHN

ONDANSETRON HYDROCHLORIDE INJECTABLE;INJECTION ONDANSETRON HYDROCHLORIDE >A> AP MYLAN LABS LTD EQ 2MG BASE/ML A 204906 001 Jul 31, 2017 Jul NEWA AP SANDOZ INC EQ 2MG BASE/ML A 077430 001 Jun 27, 2007 Mar CAHN AP WEST-WARD PHARMS INT EQ 2MG BASE/ML A 076967 001 Dec 26, 2006 Jan CAHN ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE AP SANDOZ INC EQ 2MG BASE/ML A 077551 001 Jun 27, 2007 Mar CAHN AP WEST-WARD PHARMS INT EQ 2MG BASE/ML A 077011 001 Dec 26, 2006 Jan CAHN AP EQ 2MG BASE/ML A 077541 001 Dec 26, 2006 Jan CAHN ZOFRAN + @ NOVARTIS PHARMS CORP EQ 2MG BASE/ML N 020007 001 Jan 04, 1991 Mar CRLD ZOFRAN PRESERVATIVE FREE + @ NOVARTIS PHARMS CORP EQ 2MG BASE/ML N 020007 003 Dec 10, 1993 Mar CRLD

ORPHENADRINE CITRATE INJECTABLE;INJECTION NORFLEX @ TELIGENT 30MG/ML N 013055 001 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -84

OSELTAMIVIR PHOSPHATE CAPSULE;ORAL OSELTAMIVIR PHOSPHATE AB AMNEAL PHARMS EQ 30MG BASE A 209093 001 May 17, 2017 May NEWA AB EQ 45MG BASE A 209093 002 May 17, 2017 May NEWA AB EQ 75MG BASE A 209093 003 May 17, 2017 May NEWA AB NESHER PHARMS EQ 30MG BASE A 208578 001 Feb 24, 2017 Feb NEWA AB EQ 45MG BASE A 208578 002 Feb 24, 2017 Feb NEWA AB EQ 75MG BASE A 208578 003 Feb 24, 2017 Feb NEWA

OSPEMIFENE TABLET;ORAL OSPHENA +! DUCHESNAY 60MG N 203505 001 Feb 26, 2013 Mar CAHN

OXACILLIN SODIUM INJECTABLE;INJECTION OXACILLIN SODIUM >A> AP WOCKHARDT BIO AG EQ 1GM BASE/VIAL A 207147 001 Jul 31, 2017 Jul NEWA >A> AP EQ 2GM BASE/VIAL A 207147 002 Jul 31, 2017 Jul NEWA

OXALIPLATIN INJECTABLE;IV (INFUSION) ELOXATIN + @ SANOFI AVENTIS US 200MG/40ML (5MG/ML) N 021759 003 Nov 17, 2006 Jan CRLD OXALIPLATIN AP ACCORD HLTHCARE 50MG/10ML (5MG/ML) A 207474 001 Mar 21, 2017 Mar NEWA AP 100MG/20ML (5MG/ML) A 207474 002 Mar 21, 2017 Mar NEWA AP 200MG/40ML (5MG/ML) A 207474 003 Mar 21, 2017 Mar NEWA AP CIPLA LTD 50MG/10ML (5MG/ML) A 208523 001 Feb 10, 2017 Jan NEWA AP 100MG/20ML (5MG/ML) A 208523 002 Feb 10, 2017 Jan NEWA AP FRESENIUS KABI USA 50MG/10ML (5MG/ML) A 090030 001 Jan 31, 2017 Jan NEWA AP 100MG/20ML (5MG/ML) A 090030 002 Jan 31, 2017 Jan NEWA AP 200MG/40ML (5MG/ML) A 090030 003 Jan 31, 2017 Jan NEWA AP GLAND PHARMA LTD 50MG/10ML (5MG/ML) A 207325 001 Feb 10, 2017 Jan NEWA AP 50MG/VIAL A 207385 001 May 23, 2017 May NEWA AP 100MG/20ML (5MG/ML) A 207325 002 Feb 10, 2017 Jan NEWA AP 100MG/VIAL A 207385 002 May 23, 2017 May NEWA AP LUITPOLD PHARMS INC 50MG/10ML (5MG/ML) A 204378 001 May 12, 2017 May NEWA AP 100MG/20ML (5MG/ML) A 204378 002 May 12, 2017 May NEWA AP ! QILU PHARM CO LTD 200MG/40ML (5MG/ML) A 204368 003 Jun 07, 2016 Jan CTEC

OXANDROLONE TABLET;ORAL OXANDROLONE AB UPSHER-SMITH LABS 2.5MG A 076761 001 Dec 01, 2006 Jun CAHN AB 10MG A 078033 001 Mar 22, 2007 Jun CAHN

OXAPROZIN TABLET;ORAL OXAPROZIN AB AMNEAL PHARMS CO 600MG A 208633 001 May 04, 2017 Apr NEWA

OXAZEPAM CAPSULE;ORAL OXAZEPAM AB ACTAVIS ELIZABETH 10MG A 072253 002 Apr 14, 1988 May CMS1 AB 15MG A 072253 003 Apr 14, 1988 May CMS1 @ WATSON LABS TEVA 10MG A 072952 001 Sep 28, 1990 May CAHN TABLET;ORAL OXAZEPAM @ SUN PHARM INDS 15MG A 070683 001 Jan 16, 1987 Jan CAHN

OXCARBAZEPINE TABLET;ORAL OXCARBAZEPINE AB GLENMARK PHARMS LTD 150MG A 077802 001 Oct 09, 2007 May CAHN AB 300MG A 077802 002 Oct 09, 2007 May CAHN AB 600MG A 077802 003 Oct 09, 2007 May CAHN AB JUBILANT CADISTA 150MG A 090239 001 Jan 25, 2010 Apr CAHN AB 300MG A 090239 002 Jan 25, 2010 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -85

TABLET;ORAL OXCARBAZEPINE AB 600MG A 090239 003 Jan 25, 2010 Apr CAHN

OXYBUTYNIN CHLORIDE SYRUP;ORAL DITROPAN + @ ORTHO MCNEIL JANSSEN 5MG/5ML N 018211 001 Jan CRLD OXYBUTYNIN CHLORIDE AA PHARM ASSOC 5MG/5ML A 075137 001 Dec 18, 1998 May CAHN TABLET;ORAL OXYBUTYNIN CHLORIDE AB USL PHARMA 5MG A 074625 001 Jul 31, 1996 Jun CAHN TABLET, EXTENDED RELEASE;ORAL OXYBUTYNIN CHLORIDE AB ZYDUS PHARMS USA INC 5MG A 202332 001 Jun 26, 2017 Jun NEWA AB 10MG A 202332 002 Jun 26, 2017 Jun NEWA AB 15MG A 202332 003 Jun 26, 2017 Jun NEWA

OXYCODONE HYDROCHLORIDE SOLUTION;ORAL OXYCODONE HYDROCHLORIDE >A> AA ABHAI LLC 5MG/5ML A 208593 001 Jul 21, 2017 Jul NEWA >A> AA 100MG/5ML A 208593 002 Jul 21, 2017 Jul NEWA >A> AA HI-TECH PHARMACAL 5MG/5ML A 208817 001 Aug 10, 2017 Jul NEWA >A> AA 100MG/5ML A 208795 001 Aug 07, 2017 Jul NEWA >A> AA PHARM ASSOC 100MG/5ML A 206822 001 Aug 15, 2017 Jul NEWA TABLET;ORAL OXYCODONE HYDROCHLORIDE >A> AB ASCENT PHARMS INC 15MG A 207418 001 Aug 07, 2017 Jul NEWA >A> AB 30MG A 207418 002 Aug 07, 2017 Jul NEWA AB EPIC PHARMA LLC 5MG A 090895 001 Aug 24, 2009 May CAHN AB 15MG A 090895 002 Aug 24, 2009 May CAHN AB 30MG A 090895 003 Aug 24, 2009 May CAHN AB NOVEL LABS INC 5MG A 204021 001 Jun 12, 2017 May NEWA AB 10MG A 204021 002 Jun 12, 2017 May NEWA AB 15MG A 204021 003 Jun 12, 2017 May NEWA AB 20MG A 204021 004 Jun 12, 2017 May NEWA AB 30MG A 204021 005 Jun 12, 2017 May NEWA ROXYBOND INSPIRION DELIVERY 5MG N 209777 001 Apr 20, 2017 Apr NEWA 15MG N 209777 002 Apr 20, 2017 Apr NEWA 30MG N 209777 003 Apr 20, 2017 Apr NEWA

OXYMETAZOLINE HYDROCHLORIDE CREAM;TOPICAL RHOFADE +! ALLERGAN INC 1% N 208552 001 Jan 18, 2017 Jan NEWA

OXYMETHOLONE TABLET;ORAL ANADROL-50 +! MYLAN SPECIALITY LP 50MG N 016848 001 Mar CAHN

OXYMORPHONE HYDROCHLORIDE TABLET;ORAL OXYMORPHONE HYDROCHLORIDE AB EPIC PHARMA LLC 5MG A 201187 001 Dec 15, 2014 May CAHN AB 10MG A 201187 002 Dec 15, 2014 May CAHN TABLET, EXTENDED RELEASE;ORAL OXYMORPHONE HYDROCHLORIDE AB ACTAVIS ELIZABETH 5MG A 079046 003 Jul 11, 2013 Apr CAHN AB 7.5MG A 079046 001 Dec 13, 2010 Apr CAHN AB 10MG A 079046 004 Jul 11, 2013 Apr CAHN AB 15MG A 079046 002 Dec 13, 2010 Apr CAHN AB 20MG A 079046 005 Jul 11, 2013 Apr CAHN AB 30MG A 079046 006 Jul 11, 2013 Apr CAHN AB 40MG A 079046 007 Jul 11, 2013 Apr CAHN @ PAR PHARM 5MG A 200792 001 Oct 24, 2014 May DISC @ 7.5MG A 200792 002 Oct 24, 2014 May DISC @ 10MG A 200792 003 Oct 24, 2014 May DISC @ 15MG A 200792 004 Oct 24, 2014 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -86

TABLET, EXTENDED RELEASE;ORAL OXYMORPHONE HYDROCHLORIDE @ 20MG A 200792 005 Oct 24, 2014 May DISC @ 30MG A 200792 006 Oct 24, 2014 May DISC @ 40MG A 200792 007 Oct 24, 2014 May DISC

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE OINTMENT;OPHTHALMIC TERRAMYCIN W/ POLYMYXIN B SULFATE >A> ! CASPER PHARMA LLC EQ 5MG BASE/GM;10,000 UNITS/GM A 061015 001 Jul CAHN >D> ! PFIZER EQ 5MG BASE/GM;10,000 UNITS/GM A 061015 001 Jul CAHN

PANTOPRAZOLE SODIUM POWDER;IV (INFUSION) PANTOPRAZOLE SODIUM EXELA PHARMA SCS LLC EQ 40MG BASE/VIAL N 209463 001 Jun 30, 2017 Jun NEWA TABLET, DELAYED RELEASE;ORAL PANTOPRAZOLE SODIUM AB SUN PHARM INDS LTD EQ 20MG BASE A 077058 001 Sep 10, 2007 Mar CAHN AB EQ 40MG BASE A 077058 002 Sep 10, 2007 Mar CAHN

PARICALCITOL CAPSULE;ORAL PARICALCITOL AB AMNEAL PHARMS 1MCG A 204327 001 Jan 13, 2016 May CAHN AB 2MCG A 204327 002 Jan 13, 2016 May CAHN AB 4MCG A 204327 003 Jan 13, 2016 May CAHN SOLUTION;INTRAVENOUS PARICALCITOL AP AMNEAL PHARMS CO 0.002MG/ML (0.002MG/ML) A 206699 001 Mar 09, 2017 Feb NEWA AP 0.005MG/ML (0.005MG/ML) A 206699 002 Mar 09, 2017 Feb NEWA AP 0.01MG/2ML (0.005MG/ML) A 206699 003 Mar 09, 2017 Feb NEWA AP SANDOZ INC 0.002MG/ML (0.002MG/ML) A 091108 001 Jul 27, 2011 Apr CAHN AP 0.005MG/ML (0.005MG/ML) A 091108 002 Jul 27, 2011 Apr CAHN AP 0.01MG/2ML (0.005MG/ML) A 091108 003 Jul 27, 2011 Apr CAHN

PAROXETINE HYDROCHLORIDE TABLET;ORAL PAROXETINE HYDROCHLORIDE @ MYLAN PHARMS INC EQ 10MG BASE A 075716 001 Mar 08, 2004 Apr DISC @ EQ 20MG BASE A 075716 002 Mar 08, 2004 Apr DISC @ EQ 30MG BASE A 075716 003 Mar 08, 2004 Apr DISC @ EQ 40MG BASE A 075716 004 Mar 08, 2004 Apr DISC @ UPSHER-SMITH LABS EQ 10MG BASE A 075566 001 Mar 08, 2004 Jun CAHN @ EQ 20MG BASE A 075566 002 Mar 08, 2004 Jun CAHN @ EQ 30MG BASE A 075566 003 Mar 08, 2004 Jun CAHN @ EQ 40MG BASE A 075566 004 Mar 08, 2004 Jun CAHN TABLET, EXTENDED RELEASE;ORAL PAROXETINE HYDROCHLORIDE AB LUPIN LTD EQ 12.5MG BASE A 204134 001 Jan 20, 2017 Jan NEWA AB EQ 25MG BASE A 204134 002 Jan 20, 2017 Jan NEWA AB EQ 37.5MG BASE A 204134 003 Jan 20, 2017 Jan NEWA

PAROXETINE MESYLATE CAPSULE;ORAL BRISDELLE AB +! SEBELA IRELAND LTD EQ 7.5MG BASE N 204516 001 Jun 28, 2013 Jun CFTG PAROXETINE MESYLATE AB ACTAVIS LABS FL INC EQ 7.5MG BASE A 207139 001 Jun 20, 2017 Jun NEWA

PENCICLOVIR CREAM;TOPICAL DENAVIR +! MYLAN PHARMS INC 1% N 020629 001 Sep 24, 1996 Jan CAHN

PENICILLAMINE TABLET;ORAL DEPEN +! MYLAN SPECIALITY LP 250MG N 019854 001 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -87

PENICILLIN G BENZATHINE INJECTABLE;INJECTION BICILLIN L-A +! KING PHARMS LLC 300,000 UNITS/ML N 050141 003 May CAHN BC +! 600,000 UNITS/ML N 050141 001 May CAHN PERMAPEN >A> BC CASPER PHARMA LLC 600,000 UNITS/ML A 060014 001 Jul CAHN >D> BC PFIZER 600,000 UNITS/ML A 060014 001 Jul CAHN

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE INJECTABLE;INJECTION BICILLIN C-R +! KING PHARMS LLC 150,000 UNITS/ML;150,000 UNITS/ML N 050138 002 Apr CAHN +! 300,000 UNITS/ML;300,000 UNITS/ML N 050138 001 Apr CAHN BICILLIN C-R 900/300 +! KING PHARMS LLC 900,000 UNITS/2ML;300,000 N 050138 003 Apr CAHN UNITS/2ML

PENICILLIN G PROCAINE INJECTABLE;INJECTION PENICILLIN G PROCAINE ! KING PHARMS LLC 300,000 UNITS/ML A 060101 002 Jun CAHN ! 600,000 UNITS/ML A 060101 001 Jun CAHN

PENTOBARBITAL SODIUM INJECTABLE;INJECTION PENTOBARBITAL SODIUM AP SAGENT PHARMS 50MG/ML A 206404 001 May 23, 2016 Apr CAHN

PENTOXIFYLLINE TABLET, EXTENDED RELEASE;ORAL PENTOXIL AB UPSHER-SMITH LABS 400MG A 074962 001 Mar 31, 1999 Jun CAHN TRENTAL + @ US PHARM HOLDINGS 400MG N 018631 001 Aug 30, 1984 Jan CRLD

PERINDOPRIL ERBUMINE TABLET;ORAL ACEON + @ SYMPLMED PHARMS LLC 2MG N 020184 001 Dec 30, 1993 May DISC + @ 4MG N 020184 002 Dec 30, 1993 May DISC + @ 8MG N 020184 003 Dec 30, 1993 May DISC PERINDOPRIL ERBUMINE AB ! AUROBINDO PHARMA 2MG A 079070 001 Nov 10, 2009 May CHRS AB ! 4MG A 079070 002 Nov 10, 2009 May CHRS AB ! 8MG A 079070 003 Nov 10, 2009 May CHRS

PERMETHRIN CREAM;TOPICAL ELIMITE AB +! MYLAN PHARMS INC 5% N 019855 001 Aug 25, 1989 Jan CAHN PERMETHRIN AB ACTAVIS LABS 5% A 074806 001 Jan 23, 1998 May CAHN

PERPHENAZINE TABLET;ORAL PERPHENAZINE AB MYLAN PHARMS INC 2MG A 206691 001 Apr 14, 2017 Apr NEWA AB 4MG A 206691 002 Apr 14, 2017 Apr NEWA AB 8MG A 206691 003 Apr 14, 2017 Apr NEWA AB 16MG A 206691 004 Apr 14, 2017 Apr NEWA

PHENDIMETRAZINE TARTRATE TABLET;ORAL PHENDIMETRAZINE TARTRATE @ USL PHARMA 35MG A 084399 001 Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -88

PHENOXYBENZAMINE HYDROCHLORIDE CAPSULE;ORAL PHENOXYBENZAMINE HYDROCHLORIDE AB PAR PHARM INC 10MG A 204522 001 Jan 24, 2017 Jan NEWA

PHENTERMINE HYDROCHLORIDE CAPSULE;ORAL PHENTERMINE HYDROCHLORIDE @ ELITE LABS INC 30MG A 040227 001 Jun 18, 1997 May CAHN @ 30MG A 040448 001 Jan 22, 2003 May CAHN AA 37.5MG A 040228 001 Jun 19, 1997 May CAHN @ UPSHER-SMITH LABS 30MG A 084487 001 Apr 09, 1982 Jun CAHN @ 30MG A 088430 001 Mar 27, 1984 Jun CAHN TABLET;ORAL PHENTERMINE HYDROCHLORIDE AA ELITE LABS INC 37.5MG A 040190 001 May 30, 1997 May CAHN AA KVK TECH INC 8MG A 203436 001 Mar 17, 2017 Mar NEWA AA PRINSTON INC 37.5MG A 040377 001 Jan 04, 2002 Feb CAHN TABLET, ORALLY DISINTEGRATING;ORAL PHENTERMINE HYDROCHLORIDE ZYDUS PHARMS USA INC 15MG A 204663 001 Jun 28, 2017 Jun NEWA 30MG A 204663 002 Jun 28, 2017 Jun NEWA 37.5MG A 204663 003 Jun 28, 2017 Jun NEWA

PHENTOLAMINE MESYLATE INJECTABLE;INJECTION PHENTOLAMINE MESYLATE >A> AP PRECISION DOSE INC 5MG/VIAL A 207686 001 Jul 14, 2017 Jul NEWA >D> ! WEST-WARD PHARMS INT 5MG/VIAL A 040235 001 Mar 11, 1998 Jul CTEC >A> AP ! 5MG/VIAL A 040235 001 Mar 11, 1998 Jul CTEC ! 5MG/VIAL A 040235 001 Mar 11, 1998 May CHRS REGITINE + @ NOVARTIS 5MG/VIAL N 008278 003 May DISC

PHENYLEPHRINE HYDROCHLORIDE SOLUTION;IV (INFUSION) VAZCULEP + AVADEL LEGACY 10MG/ML (10MG/ML) N 204300 001 Jun 27, 2014 Jan CAHN + 50MG/5ML (10MG/ML) N 204300 002 Jun 27, 2014 Jan CAHN +! 100MG/10ML (10MG/ML) N 204300 003 Jun 27, 2014 Jan CAHN

PHENYTOIN TABLET, CHEWABLE;ORAL DILANTIN AB ! PFIZER 50MG A 084427 001 Feb CAHN PHENYTOIN AB EPIC PHARMA LLC 50MG A 040884 001 Nov 28, 2014 May CAHN

PHENYTOIN SODIUM CAPSULE;ORAL DILANTIN AB ! PARKE-DAVIS 30MG EXTENDED A 084349 001 Feb CAHN AB ! 100MG EXTENDED A 084349 002 Feb CAHN INJECTABLE;INJECTION PHENYTOIN SODIUM AP ACELLA PHARMS LLC 50MG/ML A 040573 001 Sep 13, 2006 May CAHN @ HOSPIRA 50MG/ML A 089521 001 Mar 17, 1987 Mar DISC

PHYTONADIONE INJECTABLE;INJECTION AQUAMEPHYTON + @ TELIGENT 1MG/0.5ML N 012223 002 Apr CAHN + @ 10MG/ML N 012223 001 Apr CAHN

PILOCARPINE HYDROCHLORIDE TABLET;ORAL PILOCARPINE HYDROCHLORIDE AB ALLIED PHARMA INC 5MG A 076963 001 Dec 22, 2004 Mar CAHN AB 7.5MG A 076963 002 Feb 27, 2007 Mar CAHN AB PERRIGO PHARMA INTL 5MG A 076746 001 Nov 16, 2004 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -89

PINDOLOL TABLET;ORAL PINDOLOL AB IDT AUSTRALIA LTD 5MG A 073608 001 Mar 29, 1993 May CMFD AB 10MG A 073609 001 Mar 29, 1993 May CMFD

PIOGLITAZONE HYDROCHLORIDE TABLET;ORAL PIOGLITAZONE HYDROCHLORIDE AB CIPLA LTD EQ 15MG BASE A 076798 001 Oct 26, 2012 Jun CAHN AB EQ 30MG BASE A 076798 002 Oct 26, 2012 Jun CAHN AB EQ 45MG BASE A 076798 003 Oct 26, 2012 Jun CAHN AB WATSON LABS TEVA EQ 15MG BASE A 076798 001 Oct 26, 2012 May CAHN AB EQ 30MG BASE A 076798 002 Oct 26, 2012 May CAHN AB EQ 45MG BASE A 076798 003 Oct 26, 2012 May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM INJECTABLE;INJECTION PIPERACILLIN AND TAZOBACTAM AP APOLLO PHARMS INC EQ 2GM BASE/VIAL;EQ 250MG A 207847 001 Jan 13, 2017 Jan NEWA BASE/VIAL AP EQ 3GM BASE/VIAL;EQ 375MG A 207847 002 Jan 13, 2017 Jan NEWA BASE/VIAL AP EQ 36GM BASE/VIAL;EQ 4.5GM A 207848 002 Jan 13, 2017 Jan NEWA BASE/VIAL AP EQ 4GM BASE/VIAL;EQ 500MG A 207847 003 Jan 13, 2017 Jan NEWA BASE/VIAL AP WOCKHARDT BIO AG EQ 2GM BASE/VIAL;EQ 250MG A 206996 001 Mar 22, 2017 Mar NEWA BASE/VIAL AP EQ 3GM BASE/VIAL;EQ 375MG A 206996 002 Mar 22, 2017 Mar NEWA BASE/VIAL AP EQ 4GM BASE/VIAL;EQ 500MG A 206996 003 Mar 22, 2017 Mar NEWA BASE/VIAL AP EQ 4GM BASE/VIAL;EQ 500MG A 207146 001 Mar 17, 2017 Mar NEWA BASE/VIAL

PIRFENIDONE TABLET;ORAL ESBRIET + GENENTECH INC 267MG N 208780 001 Jan 11, 2017 Jan NEWA + @ 534MG N 208780 002 Jan 11, 2017 Jan DISC +! 801MG N 208780 003 Jan 11, 2017 Jan NEWA

PIROXICAM CAPSULE;ORAL PIROXICAM >A> AB HIKMA PHARMS 10MG A 209256 001 Aug 11, 2017 Jul NEWA >A> AB 20MG A 209256 002 Aug 11, 2017 Jul NEWA >D> AB MYLAN 10MG A 074102 001 Jul 31, 1992 Jul DISC >A> @ 10MG A 074102 001 Jul 31, 1992 Jul DISC >D> AB 20MG A 074102 002 Jul 31, 1992 Jul DISC >A> @ 20MG A 074102 002 Jul 31, 1992 Jul DISC AB PII 10MG A 206136 001 Jun 20, 2017 Jun NEWA AB 20MG A 206136 002 Jun 20, 2017 Jun NEWA AB UNICHEM LABS LTD 10MG A 208340 001 Apr 13, 2017 Apr NEWA AB 20MG A 208340 002 Apr 13, 2017 Apr NEWA

PITAVASTATIN CALCIUM TABLET;ORAL PITAVASTATIN CALCIUM AB ORIENT PHARMA CO LTD EQ 1MG BASE A 205932 001 Feb 03, 2017 Jan NEWA AB EQ 2MG BASE A 205932 002 Feb 03, 2017 Jan NEWA AB EQ 4MG BASE A 205932 003 Feb 03, 2017 Jan NEWA AB SAWAI USA EQ 1MG BASE A 205955 001 Feb 03, 2017 Jan NEWA AB EQ 2MG BASE A 205955 002 Feb 03, 2017 Jan NEWA AB EQ 4MG BASE A 205955 003 Feb 03, 2017 Jan NEWA

PITAVASTATIN MAGNESIUM TABLET;ORAL >A> ZYPITAMAG >A> + ZYDUS PHARMS USA INC EQ 1MG BASE N 208379 001 Jul 14, 2017 Jul NEWA >A> + EQ 2MG BASE N 208379 002 Jul 14, 2017 Jul NEWA >A> +! EQ 4MG BASE N 208379 003 Jul 14, 2017 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -90

PLECANATIDE TABLET;ORAL TRULANCE +! SYNERGY PHARMS 3MG N 208745 001 Jan 19, 2017 Jan NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE FOR SOLUTION;ORAL PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE @ MYLAN 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A 090409 001 Apr 02, 2010 Apr DISC .2GM/BOT AA STRIDES PHARMA 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A 204559 001 Apr 13, 2015 Apr CAHN .2GM/BOT PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AA BRECKENRIDGE PHARM 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A 202060 001 Mar 08, 2017 Mar CAHN .2GM/BOT AA BRECKENRIDGE PHARMS 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A 202060 001 Mar 08, 2017 Feb NEWA .2GM/BOT TRILYTE AA MYLAN PHARMS INC 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A 076491 001 Feb 05, 2004 Mar CAHN .2GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS FOR SOLUTION;ORAL COLYTE @ MYLAN SPECIALITY LP 120GM/PACKET;1.49GM/PACKET;3.36GM/ N 018983 005 Oct 26, 1984 Mar CAHN PACKET;2.92GM/PACKET;11.36GM/PACKE T @ 227.1GM/PACKET;2.82GM/PACKET;6.36G N 018983 004 Oct 26, 1984 Mar CAHN M/PACKET;5.53GM/PACKET;21.5GM/PACK ET @ 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; N 018983 010 Jan 31, 1989 Mar CAHN 5.53GM/BOT;21.5GM/BOT @ 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. N 018983 007 Jun 12, 1987 Mar CAHN 84GM/BOT;22.72GM/BOT @ 360GM/PACKET;4.47GM/PACKET;10.08GM N 018983 006 Oct 26, 1984 Mar CAHN /PACKET;8.76GM/PACKET;34.08GM/PACK ET COLYTE WITH FLAVOR PACKS AA MYLAN SPECIALITY LP 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. N 018983 012 Oct 08, 1998 Mar CAHN 84GM/BOT;22.72GM/BOT COLYTE-FLAVORED @ MYLAN SPECIALITY LP 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; N 018983 008 Nov 14, 1991 Mar CAHN 5.53GM/BOT;21.5GM/BOT @ 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. N 018983 009 Nov 14, 1991 Mar CAHN 84GM/BOT;22.72GM/BOT PEG 3350 AND ELECTROLYTES @ MYLAN 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5. A 090928 001 Jan 28, 2010 Apr DISC 86GM/BOT;22.74GM/BOT

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE SOLUTION/DROPS;OPHTHALMIC TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE AT SANDOZ INC 10,000 UNITS/ML;EQ 1MG BASE/ML A 064211 001 Apr 13, 1998 Feb CAHN

POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL KLOR-CON AB UPSHER-SMITH LABS 8MEQ A 203106 001 Jul 10, 2015 Jun CAHN AB 10MEQ A 203106 002 Jul 10, 2015 Jun CAHN POTASSIUM CHLORIDE AB ADARE PHARMS INC 8MEQ A 208864 001 Mar 17, 2017 Mar NEWA AB 10MEQ A 208864 002 Mar 17, 2017 Mar NEWA INJECTABLE;INJECTION POTASSIUM CHLORIDE @ BAXTER HLTHCARE 2MEQ/ML A 085499 001 Apr DISC POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER AP + ICU MEDICAL INC 14.9MG/ML N 020161 005 Nov 30, 1992 Feb CAHN AP + 745MG/100ML N 020161 001 Nov 30, 1992 Feb CAHN POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 29.8MG/ML N 020161 006 Aug 11, 1998 Feb CAHN AP + 1.49GM/100ML N 020161 002 Nov 30, 1992 Feb CAHN POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 2.24GM/100ML N 020161 003 Aug 11, 1998 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -91

INJECTABLE;INJECTION POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 2.98GM/100ML N 020161 004 Aug 11, 1998 Feb CAHN TABLET, EXTENDED RELEASE;ORAL KLOR-CON AB2 + UPSHER-SMITH LABS 8MEQ N 019123 001 Apr 17, 1986 Jun CAHN AB2 +! 10MEQ N 019123 002 Apr 17, 1986 Jun CAHN KLOR-CON M10 AB1 UPSHER-SMITH LABS 10MEQ A 074726 002 Aug 09, 2000 Jun CAHN KLOR-CON M15 UPSHER-SMITH LABS 15MEQ A 074726 003 Jun 06, 2003 Jun CAHN KLOR-CON M20 AB1 ! UPSHER-SMITH LABS 20MEQ A 074726 001 Nov 20, 1998 Jun CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE INJECTABLE;INJECTION POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP ICU MEDICAL INC 149MG/100ML;450MG/100ML A 078446 001 Sep 10, 2008 Feb CAHN POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 149MG/100ML;900MG/100ML N 019686 001 Oct 17, 1988 Feb CAHN POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ICU MEDICAL INC 298MG/100ML;900MG/100ML N 019686 002 Oct 17, 1988 Feb CAHN

POTASSIUM CITRATE TABLET, EXTENDED RELEASE;ORAL POTASSIUM CITRATE AB IMPAX LABS INC 5MEQ A 077440 001 Jun 09, 2006 Feb CAHN AB 10MEQ A 077440 002 Jun 09, 2006 Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE TABLET;ORAL PRAMIPEXOLE DIHYDROCHLORIDE @ ACTAVIS GRP PTC 0.125MG A 091254 001 Nov 30, 2010 Jan DISC @ 0.25MG A 091254 002 Nov 30, 2010 Jan DISC @ 0.5MG A 091254 003 Nov 30, 2010 Jan DISC @ 0.75MG A 091254 004 Nov 30, 2010 Jan DISC @ 1MG A 091254 005 Nov 30, 2010 Jan DISC @ 1.5MG A 091254 006 Nov 30, 2010 Jan DISC AB ALEMBIC PHARMS LTD 0.125MG A 078894 001 Oct 08, 2010 May CAHN AB 0.25MG A 078894 002 Oct 08, 2010 May CAHN AB 0.5MG A 078894 003 Oct 08, 2010 May CAHN AB 1MG A 078894 004 Oct 08, 2010 May CAHN AB 1.5MG A 078894 005 Oct 08, 2010 May CAHN TABLET, EXTENDED RELEASE;ORAL PRAMIPEXOLE DIHYDROCHLORIDE AB ACTAVIS ELIZABETH 2.25MG A 203615 001 Oct 14, 2016 Apr CAHN AB 3.75MG A 203615 002 Jan 03, 2017 Apr CAHN AB MACLEODS PHARMS LTD 3.75MG A 206156 007 Jan 23, 2017 Jan NEWA

PRASTERONE INSERT;VAGINAL INTRAROSA +! AMAG PHARMS INC 6.5MG N 208470 001 Nov 16, 2016 May CAHN

PRASUGREL HYDROCHLORIDE TABLET;ORAL EFFIENT AB + ELI LILLY AND CO EQ 5MG BASE N 022307 001 Jul 10, 2009 Jun CFTG AB +! EQ 10MG BASE N 022307 002 Jul 10, 2009 Jun CFTG PRASUGREL AB MYLAN PHARMS INC EQ 5MG BASE A 205927 001 Jul 12, 2017 Jun NEWA AB EQ 10MG BASE A 205927 002 Jul 12, 2017 Jun NEWA

PRAVASTATIN SODIUM TABLET;ORAL PRAVASTATIN SODIUM AB AUROBINDO PHARMA LTD 10MG A 203367 001 Feb 02, 2017 Jan NEWA AB 20MG A 203367 002 Feb 02, 2017 Jan NEWA AB 40MG A 203367 003 Feb 02, 2017 Jan NEWA AB 80MG A 203367 004 Feb 02, 2017 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -92

PRAZOSIN HYDROCHLORIDE CAPSULE;ORAL PRAZOSIN HYDROCHLORIDE IDT AUSTRALIA LTD EQ 1MG BASE A 072577 002 May 16, 1989 May CMS1 EQ 5MG BASE A 072577 003 May 16, 1989 May CMS1

PREDNISOLONE SYRUP;ORAL PREDNISOLONE AA PHARM ASSOC 15MG/5ML A 040399 001 Mar 05, 2003 May CAHN AA VISTAPHARM 15MG/5ML A 040323 001 May 13, 1999 Mar CAHN TABLET;ORAL PREDNISOLONE @ CHARTWELL RX 5MG A 084542 001 Apr CAHN

PREDNISOLONE SODIUM PHOSPHATE SOLUTION;ORAL PREDNISOLONE SODIUM PHOSPHATE @ AMNEAL PHARMS EQ 15MG BASE/5ML A 078345 001 Mar 10, 2009 May DISC AA CHARTWELL RX EQ 5MG BASE/5ML A 075988 001 May 25, 2004 Jun CAHN @ PHARM ASSOC EQ 5MG BASE/5ML A 076123 001 Dec 23, 2002 May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM SOLUTION/DROPS;OPHTHALMIC SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE AT ! BAUSCH AND LOMB EQ 0.23% PHOSPHATE;10% A 074449 001 Dec 29, 1995 Feb CAHN AT SANDOZ INC EQ 0.23% PHOSPHATE;10% A 073630 001 May 27, 1993 Feb CAHN

PREDNISONE TABLET;ORAL METICORTEN + @ SCHERING 1MG N 009766 002 Mar CMS1 + @ 5MG N 009766 001 Mar CMS1 PREDNISONE @ CHARTWELL RX 5MG A 083059 001 Apr CAHN @ CONTRACT PHARMACAL 5MG A 080209 001 Mar DISC AB MYLAN PHARMS INC 5MG A 080292 001 Jan CAHN AB 10MG A 088832 001 Dec 04, 1985 Jan CAHN AB 20MG A 083677 001 Jan CAHN AB SUN PHARM INDS 10MG A 089246 001 Dec 04, 1985 May CAHN @ UPSHER SMITH 5MG A 087471 001 Jun CAHN @ 20MG A 087470 001 Jun CAHN TABLET, DELAYED RELEASE;ORAL PREDNISONE AB ACTAVIS LABS FL INC 1MG A 204867 001 Apr 25, 2017 Apr NEWA AB 2MG A 204867 002 Apr 25, 2017 Apr NEWA AB 5MG A 204867 003 Apr 25, 2017 Apr NEWA RAYOS AB + HORIZON PHARMA 1MG N 202020 001 Jul 26, 2012 Apr CFTG AB + 2MG N 202020 002 Jul 26, 2012 Apr CFTG AB +! 5MG N 202020 003 Jul 26, 2012 Apr CFTG

PROBENECID TABLET;ORAL BENEMID + MERCK@ 500MG N 007898 004 Jan CRLD PROBENECID AB WATSON LABS TEVA 500MG A 084442 004 Mar 29, 1983 May CAHN

PROCAINAMIDE HYDROCHLORIDE INJECTABLE;INJECTION PROCAINAMIDE HYDROCHLORIDE @ WEST-WARD PHARMS INT 100MG/ML A 089029 001 Apr 17, 1986 Jan CAHN @ 500MG/ML A 089030 001 Apr 17, 1986 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -93

PROCARBAZINE HYDROCHLORIDE CAPSULE;ORAL MATULANE +! LEADIANT BIOSCI INC EQ 50MG BASE N 016785 001 Feb CAHN

PROCHLORPERAZINE EDISYLATE INJECTABLE;INJECTION PROCHLORPERAZINE EDISYLATE @ ATHENEX INC EQ 5MG BASE/ML A 040540 001 May 28, 2004 Mar CAHN @ WEST-WARD PHARMS INT EQ 5MG BASE/ML A 089523 001 May 03, 1988 Jan CAHN AP EQ 5MG BASE/ML A 089903 001 Aug 29, 1989 Jan CAHN

PROCYCLIDINE HYDROCHLORIDE TABLET;ORAL KEMADRIN @ MONARCH PHARMS 2MG N 009818 005 Apr CAHN @ 5MG N 009818 003 Apr CAHN

PROGESTERONE CAPSULE;ORAL PROGESTERONE AB DR REDDYS LABS INC 100MG A 208801 001 Feb 28, 2017 Feb NEWA AB 200MG A 208801 002 Feb 28, 2017 Feb NEWA INJECTABLE;INJECTION PROGESTERONE AO +! ACTAVIS LABS UT INC 50MG/ML N 017362 002 Feb CAHN

PROMETHAZINE HYDROCHLORIDE SUPPOSITORY;RECTAL PHENERGAN + @ MYLAN PHARMS INC 50MG N 011689 001 Jan CAHN TABLET;ORAL PROMETHAZINE HYDROCHLORIDE AB PRINSTON INC 12.5MG A 040622 001 Jul 18, 2006 Feb CAHN AB 25MG A 040622 002 Jul 18, 2006 Feb CAHN AB 50MG A 040622 003 Jul 18, 2006 Feb CAHN AB STRIDES PHARMA 12.5MG A 209177 001 Jun 30, 2017 Jun NEWA AB 25MG A 209177 002 Jun 30, 2017 Jun NEWA AB 50MG A 209177 003 Jun 30, 2017 Jun NEWA

PROPIOMAZINE HYDROCHLORIDE INJECTABLE;INJECTION LARGON @ WEST-WARD PHARMS INT 20MG/ML N 012382 002 Jan CAHN

PROPRANOLOL HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL INNOPRAN XL BX ANI PHARMS INC 80MG N 021438 001 Mar 12, 2003 Mar CAHN BX 120MG N 021438 002 Mar 12, 2003 Mar CAHN PROPRANOLOL HYDROCHLORIDE BX UPSHER SMITH 60MG A 078311 001 Mar 06, 2009 Apr CMFD @ 60MG A 078311 001 Mar 06, 2009 Feb DISC BX 80MG A 078311 002 Mar 06, 2009 Apr CMFD @ 80MG A 078311 002 Mar 06, 2009 Feb DISC BX 120MG A 078311 003 Mar 06, 2009 Apr CMFD @ 120MG A 078311 003 Mar 06, 2009 Feb DISC BX 160MG A 078311 004 Mar 06, 2009 Apr CMFD @ 160MG A 078311 004 Mar 06, 2009 Feb DISC BX UPSHER-SMITH LABS 60MG A 078311 001 Mar 06, 2009 Jun CAHN BX 80MG A 078311 002 Mar 06, 2009 Jun CAHN BX 120MG A 078311 003 Mar 06, 2009 Jun CAHN BX 160MG A 078311 004 Mar 06, 2009 Jun CAHN INJECTABLE;INJECTION PROPRANOLOL HYDROCHLORIDE AP ATHENEX INC 1MG/ML A 075792 001 Aug 29, 2000 Mar CAHN @ SANDOZ INC 1MG/ML A 076400 001 Feb 26, 2003 Mar CAHN TABLET;ORAL INDERAL + @ WYETH PHARMS INC 40MG N 016418 002 Jan CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -94

TABLET;ORAL PROPRANOLOL HYDROCHLORIDE @ WATSON LABS TEVA 10MG A 070548 001 Jul 10, 1986 May CAHN @ 20MG A 070549 001 Apr 11, 1986 May CAHN @ 40MG A 070550 001 Apr 11, 1986 May CAHN

PROPYLTHIOURACIL TABLET;ORAL PROPYLTHIOURACIL @ CHARTWELL RX 50MG A 084543 001 Apr CAHN

PROTAMINE SULFATE INJECTABLE;INJECTION PROTAMINE SULFATE @ WEST-WARD PHARMS INT 10MG/ML A 089474 001 Nov 05, 1986 Mar CAHN @ 10MG/ML A 089475 001 Nov 05, 1986 Jan CAHN

PYRIDOSTIGMINE BROMIDE INJECTABLE;INJECTION REGONOL AP SANDOZ INC 5MG/ML N 017398 001 May CAHN TABLET;ORAL PYRIDOSTIGMINE BROMIDE @ IMPAX LABS INC 60MG A 040457 001 Dec 26, 2002 Feb CAHN TABLET, EXTENDED RELEASE;ORAL PYRIDOSTIGMINE BROMIDE >A> AB KINEDEXE UK 180MG A 205464 001 Aug 15, 2017 Jul NEWA

PYRIMETHAMINE TABLET;ORAL DARAPRIM +! TURING PHARMS LLC 25MG N 008578 001 May CAHN

QUETIAPINE FUMARATE TABLET;ORAL QUETIAPINE FUMARATE @ MYLAN PHARMS INC EQ 25MG BASE A 090323 001 Mar 27, 2012 May DISC TABLET, EXTENDED RELEASE;ORAL QUETIAPINE FUMARATE AB ACCORD HLTHCARE EQ 150MG BASE A 090681 001 May 09, 2017 Apr NEWA AB EQ 200MG BASE A 090681 002 May 09, 2017 Apr NEWA AB EQ 300MG BASE A 090681 003 May 09, 2017 Apr NEWA AB EQ 400MG BASE A 090681 004 Nov 01, 2016 Mar CAHN AB INTELLIPHARMACEUTICS EQ 50MG BASE A 202939 001 May 09, 2017 Apr NEWA AB EQ 150MG BASE A 202939 002 May 09, 2017 Apr NEWA AB EQ 200MG BASE A 202939 003 May 09, 2017 Apr NEWA AB EQ 300MG BASE A 202939 004 May 09, 2017 Apr NEWA AB EQ 400MG BASE A 202939 005 May 09, 2017 Apr NEWA AB LUPIN LTD EQ 50MG BASE A 204203 001 May 17, 2017 May NEWA AB EQ 150MG BASE A 204203 002 May 17, 2017 May NEWA AB EQ 200MG BASE A 204203 003 May 17, 2017 May NEWA AB EQ 300MG BASE A 204203 004 May 17, 2017 May NEWA AB EQ 400MG BASE A 204203 005 May 17, 2017 May NEWA AB PAR PHARM EQ 50MG BASE A 090482 001 May 09, 2017 Apr NEWA AB EQ 150MG BASE A 090482 002 May 09, 2017 Apr NEWA AB EQ 200MG BASE A 090482 003 May 09, 2017 Apr NEWA AB EQ 300MG BASE A 090482 004 May 09, 2017 Apr NEWA AB EQ 400MG BASE A 090482 005 May 09, 2017 Apr NEWA AB PHARMADAX INC EQ 50MG BASE A 206260 001 May 09, 2017 Apr NEWA AB EQ 150MG BASE A 206260 002 May 09, 2017 Apr NEWA AB EQ 200MG BASE A 206260 003 May 09, 2017 Apr NEWA AB EQ 300MG BASE A 206260 004 May 09, 2017 Apr NEWA AB EQ 400MG BASE A 206260 005 May 09, 2017 Apr NEWA SEROQUEL XR AB + ASTRAZENECA EQ 50MG BASE N 022047 001 May 17, 2007 Apr CTEC AB + EQ 150MG BASE N 022047 005 Aug 11, 2008 Apr CTEC AB +! EQ 200MG BASE N 022047 002 May 17, 2007 Apr CTEC AB + EQ 300MG BASE N 022047 003 May 17, 2007 Apr CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -95

RABEPRAZOLE SODIUM TABLET, DELAYED RELEASE;ORAL RABEPRAZOLE SODIUM AB AUROBINDO PHARMA LTD 20MG A 205761 001 Feb 17, 2017 Feb NEWA AB KREMERS URBAN PHARMS 20MG A 090678 001 Nov 08, 2013 Jan CAHN

RALTEGRAVIR POTASSIUM TABLET;ORAL ISENTRESS HD + MERCK SHARP DOHME EQ 600MG BASE N 022145 002 May 26, 2017 May NEWA

RAMIPRIL CAPSULE;ORAL ALTACE >D> AB + KING PHARMS 1.25MG N 019901 001 Jan 28, 1991 Jul CAHN >D> AB + 2.5MG N 019901 002 Jan 28, 1991 Jul CAHN >D> AB + 5MG N 019901 003 Jan 28, 1991 Jul CAHN >D> AB +! 10MG N 019901 004 Jan 28, 1991 Jul CAHN >A> AB + KING PHARMS LLC 1.25MG N 019901 001 Jan 28, 1991 Jul CAHN >A> AB + 2.5MG N 019901 002 Jan 28, 1991 Jul CAHN >A> AB + 5MG N 019901 003 Jan 28, 1991 Jul CAHN >A> AB +! 10MG N 019901 004 Jan 28, 1991 Jul CAHN RAMIPRIL AB ACCORD HLTHCARE 1.25MG A 202392 001 Apr 15, 2014 Mar CAHN AB 2.5MG A 202392 002 Apr 15, 2014 Mar CAHN AB 5MG A 202392 003 Apr 15, 2014 Mar CAHN AB 10MG A 202392 004 Apr 15, 2014 Mar CAHN

RANITIDINE HYDROCHLORIDE INJECTABLE;INJECTION ZANTAC AP +! TELIGENT EQ 25MG BASE/ML N 019090 001 Oct 19, 1984 Apr CAHN AP +! TELIGENT PHARMA INC EQ 25MG BASE/ML N 019090 001 Oct 19, 1984 Jan CAHN ZANTAC IN PLASTIC CONTAINER @ TELIGENT EQ 1MG BASE/ML N 019593 002 Sep 27, 1991 May CAHN @ EQ 50MG BASE/100ML N 019593 001 Dec 17, 1986 May CAHN SYRUP;ORAL RANITIDINE HYDROCHLORIDE AA AUROBINDO PHARMA LTD EQ 15MG BASE/ML A 090623 001 Jul 28, 2010 Jan CAHN AA PHARM ASSOC EQ 15MG BASE/ML A 077405 001 Sep 21, 2007 May CAHN TABLET;ORAL RANITIDINE HYDROCHLORIDE AB GLENMARK PHARMS INC EQ 150MG BASE A 078542 001 Nov 19, 2008 May CAHN AB EQ 300MG BASE A 078542 002 Nov 19, 2008 May CAHN

RANOLAZINE TABLET, EXTENDED RELEASE;ORAL RANEXA + GILEAD 500MG N 021526 002 Jan 27, 2006 Feb CTEC +! 1GM N 021526 001 Feb 12, 2007 Feb CTEC RANOLAZINE @ LUPIN LTD 500MG A 201046 001 Jul 29, 2013 Feb DISC @ 1GM A 201046 002 Jul 29, 2013 Feb DISC

RASAGILINE MESYLATE TABLET;ORAL RASAGILINE MESYLATE >D> @ MYLAN PHARMS INC EQ 0.5MG BASE A 201971 001 May 15, 2017 Jul CMFD >A> AB EQ 0.5MG BASE A 201971 001 May 15, 2017 Jul CMFD @ EQ 0.5MG BASE A 201971 001 May 15, 2017 Jun DISC AB EQ 0.5MG BASE A 201971 001 May 15, 2017 May NEWA >D> @ EQ 1MG BASE A 201971 002 May 15, 2017 Jul CMFD >A> AB EQ 1MG BASE A 201971 002 May 15, 2017 Jul CMFD @ EQ 1MG BASE A 201971 002 May 15, 2017 Jun DISC AB EQ 1MG BASE A 201971 002 May 15, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -96

REPAGLINIDE TABLET;ORAL PRANDIN AB + GEMINI LABS LLC 0.5MG N 020741 001 Dec 22, 1997 Feb CAHN AB + 1MG N 020741 002 Dec 22, 1997 Feb CAHN AB +! 2MG N 020741 003 Dec 22, 1997 Feb CAHN REPAGLINIDE AB BOSCOGEN 0.5MG A 091517 001 Apr 24, 2015 Jun CAHN AB 1MG A 091517 002 Apr 24, 2015 Jun CAHN AB 2MG A 091517 003 Apr 24, 2015 Jun CAHN

RESERPINE TABLET;ORAL RESERPINE + @ SANDOZ 0.1MG N 009838 001 Apr DISC + @ 0.25MG N 009838 002 Apr DISC

RIBAVIRIN CAPSULE;ORAL RIBASPHERE AB KADMON PHARMS LLC 200MG A 076203 001 Apr 06, 2004 Jan CAHN TABLET;ORAL RIBAVIRIN AB KADMON PHARMS LLC 200MG A 077456 001 Dec 05, 2005 Jan CAHN AB 400MG A 077456 002 Dec 05, 2005 Jan CAHN AB ! 600MG A 077456 003 Dec 05, 2005 Jan CAHN

RIBOCICLIB SUCCINATE TABLET;ORAL KISQALI +! NOVARTIS PHARMS CORP EQ 200MG BASE N 209092 001 Mar 13, 2017 Mar NEWA

RIFAMPIN INJECTABLE;INJECTION RIFAMPIN AP WATSON PHARMS TEVA 600MG/VIAL A 206736 001 Jan 19, 2016 Feb CAHN AP WEST-WARD PHARMS INT 600MG/VIAL A 064217 001 Oct 29, 1999 Jan CAHN

RILUZOLE TABLET;ORAL RILUZOLE AB GLENMARK PHARMS LTD 50MG A 091394 001 Jun 18, 2013 May CAHN

RIMANTADINE HYDROCHLORIDE TABLET;ORAL RIMANTADINE HYDROCHLORIDE @ IMPAX LABS INC 100MG A 075916 001 Nov 02, 2001 Feb CAHN

RISPERIDONE TABLET;ORAL RISPERIDONE @ JUBILANT CADISTA 0.25MG A 078828 001 Mar 23, 2009 Apr CAHN @ 0.5MG A 078828 002 Mar 23, 2009 Apr CAHN @ 1MG A 078828 003 Mar 23, 2009 Apr CAHN @ 2MG A 078828 004 Mar 23, 2009 Apr CAHN @ 3MG A 078828 005 Mar 23, 2009 Apr CAHN @ 4MG A 078828 006 Mar 23, 2009 Apr CAHN AB PRINSTON INC 0.25MG A 078707 001 Dec 29, 2008 Feb CAHN AB 0.5MG A 078707 002 Dec 29, 2008 Feb CAHN AB 1MG A 078707 003 Dec 29, 2008 Feb CAHN AB 2MG A 078707 004 Dec 29, 2008 Feb CAHN AB 3MG A 078707 005 Dec 29, 2008 Feb CAHN AB 4MG A 078707 006 Dec 29, 2008 Feb CAHN

RITONAVIR POWDER;ORAL NORVIR +! ABBVIE INC 100MG/PACKET N 209512 001 Jun 07, 2017 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -97

RIVASTIGMINE TARTRATE CAPSULE;ORAL RIVASTIGMINE TARTRATE AB CADILA PHARMS LTD EQ 1.5MG BASE A 203844 001 Feb 13, 2017 Jan NEWA AB EQ 3MG BASE A 203844 002 Feb 13, 2017 Jan NEWA AB EQ 4.5MG BASE A 203844 003 Feb 13, 2017 Jan NEWA AB EQ 6MG BASE A 203844 004 Feb 13, 2017 Jan NEWA AB SUN PHARM INDS LTD EQ 1.5MG BASE A 077131 001 Oct 22, 2007 Mar CAHN AB EQ 3MG BASE A 077131 002 Oct 22, 2007 Mar CAHN AB EQ 4.5MG BASE A 077131 003 Oct 22, 2007 Mar CAHN AB EQ 6MG BASE A 077131 004 Oct 22, 2007 Mar CAHN

RIZATRIPTAN BENZOATE TABLET;ORAL RIZATRIPTAN BENZOATE AB ECI PHARMS LLC EQ 5MG BASE A 202047 001 Dec 31, 2012 Mar CAHN AB EQ 10MG BASE A 202047 002 Dec 31, 2012 Mar CAHN AB UNICHEM LABS LTD EQ 5MG BASE A 207836 001 Mar 07, 2017 Feb NEWA AB EQ 10MG BASE A 207836 002 Mar 07, 2017 Feb NEWA TABLET, ORALLY DISINTEGRATING;ORAL RIZATRIPTAN BENZOATE AB GLENMARK PHARMS LTD EQ 5MG BASE A 201914 001 Jul 01, 2013 May CAHN AB EQ 10MG BASE A 201914 002 Jul 01, 2013 May CAHN AB PANACEA BIOTEC LTD EQ 5MG BASE A 204722 001 Jan 11, 2017 Jan NEWA AB EQ 10MG BASE A 204722 002 Jan 11, 2017 Jan NEWA AB UNICHEM LABS LTD EQ 5MG BASE A 207835 001 Mar 07, 2017 Feb NEWA AB EQ 10MG BASE A 207835 002 Mar 07, 2017 Feb NEWA

ROCURONIUM BROMIDE INJECTABLE;INJECTION ROCURONIUM BROMIDE AP AUROBINDO PHARMA LTD 50MG/5ML (10MG/ML) A 206206 001 Apr 12, 2017 Mar NEWA AP 100MG/10ML (10MG/ML) A 206206 002 Apr 12, 2017 Mar NEWA AP ! SANDOZ INC 50MG/5ML (10MG/ML) A 079195 001 Dec 05, 2008 Mar CAHN AP ! 100MG/10ML (10MG/ML) A 079195 002 Dec 05, 2008 Mar CAHN AP WEST WARD PHARM CORP 50MG/5ML (10MG/ML) A 204679 001 Feb 28, 2017 Feb NEWA AP 100MG/10ML (10MG/ML) A 204679 002 Feb 28, 2017 Feb NEWA

ROPINIROLE HYDROCHLORIDE TABLET;ORAL ROPINIROLE HYDROCHLORIDE AB ACCORD HLTHCARE EQ 0.25MG BASE A 204022 001 Feb 28, 2017 Apr CAHN AB EQ 0.5MG BASE A 204022 002 Feb 28, 2017 Apr CAHN AB EQ 1MG BASE A 204022 003 Feb 28, 2017 Apr CAHN AB EQ 2MG BASE A 204022 004 Feb 28, 2017 Apr CAHN AB EQ 3MG BASE A 204022 005 Feb 28, 2017 Apr CAHN AB EQ 4MG BASE A 204022 006 Feb 28, 2017 Apr CAHN AB EQ 5MG BASE A 204022 007 Feb 28, 2017 Apr CAHN AB ACCORD HLTHCARE INC EQ 0.25MG BASE A 204022 001 Feb 28, 2017 Feb NEWA AB EQ 0.5MG BASE A 204022 002 Feb 28, 2017 Feb NEWA AB EQ 1MG BASE A 204022 003 Feb 28, 2017 Feb NEWA AB EQ 2MG BASE A 204022 004 Feb 28, 2017 Feb NEWA AB EQ 3MG BASE A 204022 005 Feb 28, 2017 Feb NEWA AB EQ 4MG BASE A 204022 006 Feb 28, 2017 Feb NEWA AB EQ 5MG BASE A 204022 007 Feb 28, 2017 Feb NEWA @ EPIC PHARMA LLC EQ 0.25MG BASE A 078230 001 May 20, 2008 May CAHN @ EQ 0.5MG BASE A 078230 002 May 20, 2008 May CAHN @ EQ 1MG BASE A 078230 003 May 20, 2008 May CAHN @ EQ 2MG BASE A 078230 004 May 20, 2008 May CAHN @ EQ 3MG BASE A 078230 005 May 20, 2008 May CAHN @ EQ 4MG BASE A 078230 006 May 20, 2008 May CAHN @ EQ 5MG BASE A 078230 007 May 20, 2008 May CAHN TABLET, EXTENDED RELEASE;ORAL ROPINIROLE HYDROCHLORIDE AB ALEMBIC PHARMS LTD EQ 2MG BASE A 202786 001 Apr 22, 2013 May CAHN AB EQ 4MG BASE A 202786 002 Apr 22, 2013 May CAHN AB EQ 6MG BASE A 202786 003 Apr 22, 2013 May CAHN AB EQ 8MG BASE A 202786 004 Apr 22, 2013 May CAHN AB EQ 12MG BASE A 202786 005 Apr 22, 2013 May CAHN @ MYLAN PHARMS INC EQ 3MG BASE A 200462 002 Oct 15, 2012 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -98

ROPIVACAINE HYDROCHLORIDE SOLUTION;INJECTION ROPIVACAINE HYDROCHLORIDE AP AKORN INC 150MG/30ML (5MG/ML) A 203955 001 Apr 11, 2016 Jun CDFR

ROSUVASTATIN CALCIUM TABLET;ORAL ROSUVASTATIN CALCIUM AB ACCORD HLTHCARE 5MG A 206434 001 Oct 31, 2016 Mar CAHN AB 10MG A 206434 002 Oct 31, 2016 Mar CAHN AB 20MG A 206434 003 Oct 31, 2016 Mar CAHN AB 40MG A 206434 004 Oct 31, 2016 Mar CAHN AB ALKEM LABS LTD 5MG A 206465 001 Mar 21, 2017 Mar NEWA AB 10MG A 206465 002 Mar 21, 2017 Mar NEWA AB 20MG A 206465 003 Mar 21, 2017 Mar NEWA AB 40MG A 206465 004 Mar 21, 2017 Mar NEWA >A> AB LUPIN LTD 5MG A 205587 001 Jul 31, 2017 Jul NEWA >A> AB 10MG A 205587 002 Jul 31, 2017 Jul NEWA >A> AB 20MG A 205587 003 Jul 31, 2017 Jul NEWA >A> AB 40MG A 205587 004 Jul 31, 2017 Jul NEWA AB TORRENT PHARMS LTD 5MG A 201619 001 Oct 31, 2016 Apr CAHN AB 10MG A 201619 002 Oct 31, 2016 Apr CAHN AB 20MG A 201619 003 Oct 31, 2016 Apr CAHN AB 40MG A 201619 004 Oct 31, 2016 Apr CAHN

RUCAPARIB CAMSYLATE TABLET;ORAL RUBRACA + CLOVIS ONCOLOGY INC EQ 250MG BASE N 209115 003 May 01, 2017 May NEWA

SAFINAMIDE MESYLATE TABLET;ORAL XADAGO + NEWRON PHARMS US INC 50MG N 207145 001 Mar 21, 2017 Mar NEWA +! 100MG N 207145 002 Mar 21, 2017 Mar NEWA + US WORLDMEDS LLC 50MG N 207145 001 Mar 21, 2017 Apr CAHN +! 100MG N 207145 002 Mar 21, 2017 Apr CAHN

SELEGILINE HYDROCHLORIDE TABLET;ORAL SELEGILINE HYDROCHLORIDE AB BOSCOGEN 5MG A 074912 001 Apr 30, 1998 May CAHN @ CHARTWELL MOLECULES 5MG A 074565 001 Aug 02, 1996 Jan CAHN @ 5MG A 074641 001 Aug 02, 1996 Jan CAHN

SERTRALINE HYDROCHLORIDE CONCENTRATE;ORAL SERTRALINE HYDROCHLORIDE @ ALLIED PHARMA INC EQ 20MG BASE/ML A 076934 001 Jun 30, 2006 Mar CAHN TABLET;ORAL SERTRALINE HYDROCHLORIDE @ ACI HEALTHCARE LTD EQ 25MG BASE A 076881 001 Feb 06, 2007 Jun CAHN @ EQ 50MG BASE A 076881 002 Feb 06, 2007 Jun CAHN @ EQ 100MG BASE A 076881 003 Feb 06, 2007 Jun CAHN @ ALLIED PHARMA INC EQ 25MG BASE A 076881 001 Feb 06, 2007 Mar CAHN @ EQ 50MG BASE A 076881 002 Feb 06, 2007 Mar CAHN @ EQ 100MG BASE A 076881 003 Feb 06, 2007 Mar CAHN @ MYLAN EQ 25MG BASE A 076671 001 Feb 06, 2007 Mar DISC @ EQ 50MG BASE A 076671 002 Feb 06, 2007 Mar DISC @ EQ 100MG BASE A 076671 003 Feb 06, 2007 Mar DISC @ WATSON LABS TEVA EQ 25MG BASE A 077663 001 Feb 06, 2007 May CAHN @ EQ 50MG BASE A 077663 002 Feb 06, 2007 May CAHN @ EQ 100MG BASE A 077663 003 Feb 06, 2007 May CAHN

SEVELAMER CARBONATE FOR SUSPENSION;ORAL RENVELA AB + GENZYME 800MG/PACKET N 022318 001 Aug 12, 2009 May CFTG AB +! 2.4GM/PACKET N 022318 002 Feb 18, 2009 May CFTG SEVELAMER CARBONATE AB AUROBINDO PHARMA LTD 800MG/PACKET A 207624 001 Jun 13, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -99

FOR SUSPENSION;ORAL SEVELAMER CARBONATE AB 2.4GM/PACKET A 207624 002 Jun 13, 2017 May NEWA TABLET;ORAL RENVELA >D> +! GENZYME 800MG N 022127 001 Oct 19, 2007 Jul CFTG >A> AB +! 800MG N 022127 001 Oct 19, 2007 Jul CFTG >A> SEVELAMER CARBONATE >A> AB AUROBINDO PHARMA LTD 800MG A 207179 001 Jul 17, 2017 Jul NEWA

SILDENAFIL CITRATE TABLET;ORAL VIAGRA + PFIZER INC EQ 25MG BASE N 020895 001 Mar 27, 1998 May CAHN + EQ 50MG BASE N 020895 002 Mar 27, 1998 May CAHN +! EQ 100MG BASE N 020895 003 Mar 27, 1998 May CAHN

SILODOSIN CAPSULE;ORAL RAPAFLO AB +! ALLERGAN SALES LLC 4MG N 022206 001 Oct 08, 2008 Mar CFTG AB + 8MG N 022206 002 Oct 08, 2008 Mar CFTG SILODOSIN AB SANDOZ INC 4MG A 204726 001 Mar 31, 2017 Mar NEWA AB 8MG A 204726 002 Mar 31, 2017 Mar NEWA

SIMVASTATIN SUSPENSION;ORAL SIMVASTATIN + TCG FLUENT PHARMA 20MG/5ML N 206679 001 Apr 21, 2016 Jan CAHN +! 40MG/5ML N 206679 002 Apr 21, 2016 Jan CAHN TABLET;ORAL SIMVASTATIN @ MYLAN PHARMS INC 5MG A 090868 001 Jun 08, 2010 May DISC @ 10MG A 090868 002 Jun 08, 2010 May DISC @ 20MG A 090868 003 Jun 08, 2010 May DISC @ 40MG A 090868 004 Jun 08, 2010 May DISC @ 80MG A 090868 005 Jun 08, 2010 May DISC AB WATSON LABS TEVA 5MG A 076685 001 Dec 20, 2006 May CAHN AB 10MG A 076685 002 Dec 20, 2006 May CAHN AB 20MG A 076685 003 Dec 20, 2006 May CAHN AB 40MG A 076685 004 Dec 20, 2006 May CAHN AB 80MG A 076685 005 Dec 20, 2006 May CAHN

SODIUM BENZOATE; SODIUM PHENYLACETATE SOLUTION;IV (INFUSION) SODIUM PHENYLACETATE AND SODIUM BENZOATE >A> AP AILEX PHARMS LLC 10%;10% (5GM/50ML;5GM/50ML) A 207096 001 Feb 24, 2016 Jul CAHN >D> AP AILEX PHARMS PVT LTD 10%;10% (5GM/50ML;5GM/50ML) A 207096 001 Feb 24, 2016 Jul CAHN

SODIUM BICARBONATE INJECTABLE;INJECTION SODIUM BICARBONATE AP ! HOSPIRA 0.9MEQ/ML A 077394 001 Nov 09, 2005 Feb CTEC AP ! 1MEQ/ML A 077394 002 Nov 09, 2005 Feb CTEC HOSPIRA INC 0.5MEQ/ML A 202679 001 Mar 07, 2017 Feb NEWA AP 0.9MEQ/ML A 202494 001 Mar 06, 2017 Feb NEWA 1MEQ/ML A 202495 001 Mar 06, 2017 Feb NEWA AP 1MEQ/ML A 202494 002 Mar 06, 2017 Feb NEWA

SODIUM CHLORIDE INJECTABLE;INJECTION SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 450MG/100ML N 018090 001 Feb CAHN SODIUM CHLORIDE 0.9% >A> AP SPECTRA MDCL DEVICES 9MG/ML A 206171 001 Jul 21, 2017 Jul NEWA AP WEST-WARD PHARMS INT 9MG/ML A 201850 001 Jan 20, 2012 Jan CAHN SODIUM CHLORIDE 0.9% WEST-WARD PHARMS INT 9MG/ML A 201833 001 Sep 24, 2013 Jan CAHN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 900MG/100ML N 016366 001 Feb CAHN AP LABORATORIOS GRIFOLS 900MG/100ML A 207956 001 May 25, 2017 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -100

INJECTABLE;INJECTION SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP ! TARO 9MG/ML A 077407 001 Aug 11, 2006 Apr CAHN SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER + @ ABRAXIS PHARM 234MG/ML N 019329 001 Apr 22, 1987 Jan CRLD SODIUM CHLORIDE 3% IN PLASTIC CONTAINER >D> @ B BRAUN 3GM/100ML N 019635 003 Mar 09, 1988 Jul CMFD >A> AP 3GM/100ML N 019635 003 Mar 09, 1988 Jul CMFD >D> +! BAXTER HLTHCARE 3GM/100ML N 019022 001 Nov 01, 1983 Jul CTEC >A> AP +! 3GM/100ML N 019022 001 Nov 01, 1983 Jul CTEC SODIUM CHLORIDE 5% IN PLASTIC CONTAINER >D> @ B BRAUN 5GM/100ML N 019635 004 Mar 09, 1988 Jul CMFD >A> AP 5GM/100ML N 019635 004 Mar 09, 1988 Jul CMFD >D> + BAXTER HLTHCARE 5GM/100ML N 019022 002 Nov 01, 1983 Jul CTEC >A> AP + 5GM/100ML N 019022 002 Nov 01, 1983 Jul CTEC SODIUM CHLORIDE IN PLASTIC CONTAINER + HOSPIRA 2.5MEQ/ML N 018897 001 Jul 20, 1984 Mar CRLD SOLUTION;IRRIGATION SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AT ICU MEDICAL INC 900MG/100ML N 017514 001 Feb CAHN AT 900MG/100ML N 018314 001 Feb CAHN

SODIUM NITROPRUSSIDE INJECTABLE;INJECTION SODIUM NITROPRUSSIDE AP AKORN 25MG/ML A 208635 001 May 04, 2017 Apr NEWA AP NEXUS PHARMS 25MG/ML A 207499 001 May 25, 2017 May NEWA SOLUTION;IV (INFUSION) NIPRIDE RTU IN SODIUM CHLORIDE 0.9% +! EXELA PHARMA SCS LLC 50MG/100ML (0.5MG/ML) N 209387 001 Mar 08, 2017 Mar NEWA

SODIUM OXYBATE SOLUTION;ORAL SODIUM OXYBATE AA WEST-WARD PHARMS INT 500MG/ML A 202090 001 Jan 17, 2017 Jan NEWA XYREM AA +! JAZZ PHARMS 500MG/ML N 021196 001 Jul 17, 2002 Jan CFTG

SODIUM PHENYLBUTYRATE TABLET;ORAL SODIUM PHENYLBUTYRATE AB ALVOGEN MALTA 500MG A 090910 001 Nov 18, 2011 Apr CAHN

SODIUM POLYSTYRENE SULFONATE POWDER;ORAL, RECTAL SODIUM POLYSTYRENE SULFONATE AA CMP PHARMA INC 454GM/BOT A 089910 001 Jan 19, 1989 Apr CAHN AA ECI PHARMS LLC 453.6GM/BOT A 090313 001 Dec 21, 2011 Mar CAHN SUSPENSION;ORAL, RECTAL SPS AA ! CMP PHARMA INC 15GM/60ML A 087859 001 Dec 08, 1982 Apr CAHN

>A> SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR >A> TABLET;ORAL >A> VOSEVI >A> +! GILEAD SCIENCES INC 400MG;100MG;100MG N 209195 001 Jul 18, 2017 Jul NEWA

SOMATROPIN RECOMBINANT INJECTABLE;INJECTION VALTROPIN BX LG CHEM LTD 5MG/VIAL N 021905 001 Apr 19, 2007 Jun CAHN

SONIDEGIB PHOSPHATE CAPSULE;ORAL ODOMZO +! SUN PHARM INDS INC EQ 200MG BASE N 205266 001 Jul 24, 2015 Mar CAHN +! SUN PHARMA GLOBAL EQ 200MG BASE N 205266 001 Jul 24, 2015 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -101

SOTALOL HYDROCHLORIDE TABLET;ORAL BETAPACE AB1 + COVIS PHARMA BV 80MG N 019865 001 Oct 30, 1992 May CAHN AB1 + 120MG N 019865 005 Apr 20, 1994 May CAHN AB1 +! 160MG N 019865 002 Oct 30, 1992 May CAHN AB1 + 240MG N 019865 003 Oct 30, 1992 May CAHN @ 320MG N 019865 004 Oct 30, 1992 May CAHN BETAPACE AF @ COVIS PHARMA BV 40MG N 021151 006 Apr 02, 2003 May CAHN @ 60MG N 021151 007 Apr 02, 2003 May CAHN AB2 + 80MG N 021151 001 Feb 22, 2000 May CAHN @ 100MG N 021151 005 Mar 14, 2003 May CAHN AB2 + 120MG N 021151 002 Feb 22, 2000 May CAHN AB2 +! 160MG N 021151 003 Feb 22, 2000 May CAHN SORINE AB1 UPSHER-SMITH LABS 80MG A 075500 001 Apr 27, 2001 Jun CAHN AB1 120MG A 075500 004 Apr 27, 2001 Jun CAHN AB1 160MG A 075500 002 Apr 27, 2001 Jun CAHN AB1 240MG A 075500 003 Apr 27, 2001 Jun CAHN SOTALOL HYDROCHLORIDE MY LAN@ MYLAN@ 80MG A 075237 001 May 01, 2000 Jun DISC @ 80MG A 075725 001 Dec 19, 2000 Jun DISC @ 120MG A 075237 002 May 01, 2000 Jun DISC @ 120MG A 075725 002 Dec 19, 2000 Jun DISC @ 160MG A 075237 003 May 01, 2000 Jun DISC @ 160MG A 075725 003 Dec 19, 2000 Jun DISC @ 240MG A 075237 004 May 01, 2000 Jun DISC @ 240MG A 075725 004 Dec 19, 2000 Jun DISC TE VA@ TEVA@ 80MG A 076883 001 Jul 26, 2004 Apr DISC @ 120MG A 076883 002 Jul 26, 2004 Apr DISC @ 160MG A 076883 003 Jul 26, 2004 Apr DISC AB1 UPSHER-SMITH LABS 80MG A 075366 001 May 01, 2000 Jun CAHN AB1 120MG A 075366 002 May 01, 2000 Jun CAHN AB1 160MG A 075366 003 May 01, 2000 Jun CAHN AB1 240MG A 075366 004 May 01, 2000 Jun CAHN

SPIRONOLACTONE TABLET;ORAL SPIRONOLACTONE AB ACCORD HLTHCARE 25MG A 203512 001 Sep 19, 2016 Mar CAHN AB 50MG A 203512 002 Sep 19, 2016 Mar CAHN AB 100MG A 203512 003 Sep 19, 2016 Mar CAHN AB AMNEAL PHARMS 25MG A 091426 001 Jul 02, 2010 May CAHN AB 25MG A 091426 001 Jul 02, 2010 May CMS1 AB 50MG A 091426 002 Jul 02, 2010 May CAHN AB 50MG A 091426 002 Jul 02, 2010 May CMS1 AB 100MG A 091426 003 Jul 02, 2010 May CAHN AB 100MG A 091426 003 Jul 02, 2010 May CMS1 @ UPSHER SMITH 25MG A 087554 001 Jun CAHN

STAVUDINE CAPSULE;ORAL STAVUDINE @ MYLAN LABS LTD 30MG A 078775 001 Jan 05, 2009 May DISC AB 30MG A 078775 001 Jan 05, 2009 Mar CAHN @ 40MG A 078775 002 Jan 05, 2009 May DISC AB 40MG A 078775 002 Jan 05, 2009 Mar CAHN FOR SOLUTION;ORAL STAVUDINE >D> AA AUROBINDO PHARMA 1MG/ML A 077774 001 Dec 29, 2008 Jul DISC >A> @ 1MG/ML A 077774 001 Dec 29, 2008 Jul DISC

STERILE WATER FOR INJECTION LIQUID;N/A STERILE WATER FOR INJECTION AP WEST-WARD PHARMS INT 100% A 206369 001 Sep 02, 2015 Jan CAHN STERILE WATER FOR INJECTION IN PLASTIC CONTAINER AP +! ICU MEDICAL INC 100% N 018233 001 Feb CAHN AP +! 100% N 019869 001 Dec 26, 1989 Apr CAHN AP TARO 100% A 077393 001 Aug 11, 2006 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -102

STERILE WATER FOR IRRIGATION LIQUID;IRRIGATION STERILE WATER IN PLASTIC CONTAINER AT ICU MEDICAL INC 100% N 017513 001 Feb CAHN AT 100% N 018313 001 Feb CAHN

SUCCINYLCHOLINE CHLORIDE INJECTABLE;INJECTION ANECTINE AP +! SANDOZ INC 20MG/ML N 008453 002 May CAHN @ 50MG/ML N 008453 003 May CAHN @ 500MG/VIAL N 008453 001 May CAHN @ 1GM/VIAL N 008453 004 May CAHN

SULFACETAMIDE SODIUM SOLUTION/DROPS;OPHTHALMIC SULFACETAMIDE SODIUM AT SANDOZ INC 10% A 089560 001 Oct 18, 1988 Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM TABLET;ORAL SEPTRA AB MONARCH PHARMS 400MG;80MG N 017376 001 May CAHN SEPTRA DS AB MONARCH PHARMS 800MG;160MG N 017376 002 May CAHN SULFAMETHOXAZOLE AND TRIMETHOPRIM AB CHARTWELL MOLECULES 400MG;80MG A 078060 002 Jan 25, 2007 Mar CAHN AB 800MG;160MG A 078060 001 Jan 25, 2007 Mar CAHN AB CHARTWELL PHARMS LLC 400MG;80MG A 078060 002 Jan 25, 2007 Jan CAHN AB 800MG;160MG A 078060 001 Jan 25, 2007 Jan CAHN

SULFANILAMIDE CREAM;VAGINAL AVC +! MYLAN SPECIALITY LP 15% N 006530 003 Jan 27, 1987 Mar CAHN SUPPOSITORY;VAGINAL AVC @ MYLAN SPECIALITY LP 1.05GM N 006530 004 Jan 27, 1987 Mar CAHN

SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS SUMATRIPTAN SUCCINATE @ SANDOZ INC EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A 078067 002 Feb 06, 2009 Mar CAHN @ EQ 6MG BASE/0.5ML (EQ 12MG A 078067 001 Feb 06, 2009 Mar CAHN BASE/ML) AP WEST-WARD PHARMS INT EQ 6MG BASE/0.5ML (EQ 12MG A 079123 001 Feb 06, 2009 Jan CAHN BASE/ML) SYSTEM;IONTOPHORESIS ZECUITY + @ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N 202278 001 Jan 17, 2013 Jan DISC

SUNITINIB MALATE CAPSULE;ORAL SUTENT + CPPI CV EQ 12.5MG BASE N 021938 001 Jan 26, 2006 Mar CTEC + EQ 25MG BASE N 021938 002 Jan 26, 2006 Mar CTEC + EQ 37.5MG BASE N 021938 004 Mar 31, 2009 Mar CTEC +! EQ 50MG BASE N 021938 003 Jan 26, 2006 Mar CTEC

TALC POWDER;INTRAPLEURAL STERITALC + NOVATECH SA 2GM/VIAL N 205555 001 May 01, 2017 Apr NEWA + 3GM/VIAL N 205555 002 May 01, 2017 Apr NEWA +! 4GM/VIAL N 205555 003 May 01, 2017 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -103

TAMSULOSIN HYDROCHLORIDE CAPSULE;ORAL TAMSULOSIN HYDROCHLORIDE AB MACLEODS PHARMS LTD 0.4MG A 204645 001 Jan 20, 2017 Jan NEWA TAMSULOSIN HYDROCHLORIDE >A> AB ALKEM LABS LTD 0.4MG A 207405 001 Aug 11, 2017 Jul NEWA

TAZAROTENE AEROSOL, FOAM;TOPICAL FABIOR +! MAYNE PHARMA 0.1% N 202428 001 May 11, 2012 Jan CAHN CREAM;TOPICAL AVAGE AB +! ALLERGAN 0.1% N 021184 003 Sep 30, 2002 Mar CFTG TAZAROTENE AB TARO 0.1% A 208258 001 Apr 03, 2017 Mar NEWA TAZORAC AB +! ALLERGAN 0.1% N 021184 002 Sep 29, 2000 Mar CFTG

TECHNETIUM TC-99M MEDRONATE KIT INJECTABLE;INJECTION MDP-BRACCO AP CARDINAL HEALTH 414 N/A N 018107 001 Apr CAHN

TECHNETIUM TC-99M SESTAMIBI KIT INJECTABLE;INJECTION TECHNETIUM TC 99M SESTAMIBI AP JUBILANT DRAXIMAGE N/A A 078806 001 Apr 29, 2009 Jun CAHN

TECHNETIUM TC-99M TETROFOSMIN KIT INJECTABLE;INJECTION >D> MYOVIEW >D> +! GE HEALTHCARE N/A N 020372 001 Feb 09, 1996 Jul DISC >A> + @ N/A N 020372 001 Feb 09, 1996 Jul DISC >D> MYOVIEW 30ML >D> +! GE HEALTHCARE N/A N 020372 002 Jul 07, 2005 Jul DISC >A> + @ N/A N 020372 002 Jul 07, 2005 Jul DISC

TECHNETIUM TC-99M TILMANOCEPT INJECTABLE;INJECTION LYMPHOSEEK KIT +! CARDINAL HLTH 414 N/A N 202207 001 Mar 13, 2013 Mar CAHN

TELAVANCIN HYDROCHLORIDE POWDER;IV (INFUSION) VIBATIV + THERAVANCE BIOPHARMA EQ 250MG BASE/VIAL N 022110 001 Sep 11, 2009 May CAHN +! EQ 750MG BASE/VIAL N 022110 002 Sep 11, 2009 May CAHN

TELMISARTAN TABLET;ORAL TELMISARTAN >A> AB CADILA PHARMS LTD 20MG A 208605 001 Jul 25, 2017 Jul NEWA >A> AB 40MG A 208605 002 Jul 25, 2017 Jul NEWA >A> AB 80MG A 208605 003 Jul 25, 2017 Jul NEWA AB GLENMARK PHARMS LTD 20MG A 090032 001 Jul 07, 2014 May CAHN AB 40MG A 090032 002 Jul 07, 2014 May CAHN AB 80MG A 090032 003 Jul 07, 2014 May CAHN AB PRINSTON INC 20MG A 207882 001 May 03, 2017 Apr NEWA AB 40MG A 207882 002 May 03, 2017 Apr NEWA AB 80MG A 207882 003 May 03, 2017 Apr NEWA

TELOTRISTAT ETIPRATE TABLET;ORAL XERMELO +! LEXICON PHARMS INC EQ 250MG BASE N 208794 001 Feb 28, 2017 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -104

TEMAZEPAM CAPSULE;ORAL TEMAZEPAM AB ACTAVIS ELIZABETH 15MG A 071620 002 Aug 07, 1987 May CMS1 AB PRINSTON INC 7.5MG A 201781 001 Jun 04, 2015 Feb CAHN AB 15MG A 201781 002 Jun 04, 2015 Feb CAHN AB 22.5MG A 201781 003 Jun 04, 2015 Feb CAHN AB 30MG A 201781 004 Jun 04, 2015 Feb CAHN

TEMOZOLOMIDE CAPSULE;ORAL TEMOZOLOMIDE AB ACCORD HLTHCARE 5MG A 201528 001 Feb 27, 2017 Feb NEWA AB 20MG A 201528 002 Feb 27, 2017 Feb NEWA AB 100MG A 201528 003 Feb 27, 2017 Feb NEWA AB 140MG A 201528 004 Feb 27, 2017 Feb NEWA AB 180MG A 201528 005 Feb 27, 2017 Feb NEWA AB 250MG A 201528 006 Feb 27, 2017 Feb NEWA AB DEVA HOLDING AS 5MG A 207658 001 Apr 26, 2017 Apr NEWA AB 20MG A 207658 002 Apr 26, 2017 Apr NEWA AB 100MG A 207658 003 Apr 26, 2017 Apr NEWA AB 140MG A 207658 004 Apr 26, 2017 Apr NEWA AB 180MG A 207658 005 Apr 26, 2017 Apr NEWA AB 250MG A 207658 006 Apr 26, 2017 Apr NEWA AB WATSON LABS TEVA 5MG A 203959 001 Apr 18, 2017 Apr NEWA AB 20MG A 203959 002 Apr 18, 2017 Apr NEWA AB 100MG A 203959 003 Apr 18, 2017 Apr NEWA AB 140MG A 203959 004 Apr 18, 2017 Apr NEWA AB 250MG A 203959 005 Apr 18, 2017 Apr NEWA >A> AB ZYDUS PHARMS USA INC 5MG A 206750 001 Jul 31, 2017 Jul NEWA >A> AB 20MG A 206750 002 Jul 31, 2017 Jul NEWA >A> AB 100MG A 206750 003 Jul 31, 2017 Jul NEWA >A> AB 140MG A 206750 004 Jul 31, 2017 Jul NEWA >A> AB 180MG A 206750 005 Jul 31, 2017 Jul NEWA >A> AB 250MG A 206750 006 Jul 31, 2017 Jul NEWA

TERAZOSIN HYDROCHLORIDE CAPSULE;ORAL TERAZOSIN HYDROCHLORIDE AB MYLAN PHARMS INC EQ 1MG BASE A 075140 002 Feb 11, 2000 Mar CAHN AB EQ 2MG BASE A 075140 003 Feb 11, 2000 Mar CAHN AB EQ 5MG BASE A 075140 001 Feb 11, 2000 Mar CAHN AB EQ 10MG BASE A 075140 004 Feb 11, 2000 Mar CAHN

TERBUTALINE SULFATE INJECTABLE;INJECTION TERBUTALINE SULFATE AP ! ATHENEX INC 1MG/ML A 076770 001 Apr 23, 2004 Mar CAHN TABLET;ORAL BRETHINE + @ ANI PHARMS INC 2.5MG N 017849 001 Feb CAHN + @ 5MG N 017849 002 Feb CAHN TERBUTALINE SULFATE ! LANNETT 5MG A 077152 002 Mar 25, 2005 Jan CHRS

TESTOSTERONE GEL;TRANSDERMAL ANDROGEL AB2 + ABBVIE 1.62% (20.25MG/1.25GM PACKET) N 022309 002 Sep 07, 2012 Jun CFTG AB2 +! 1.62% (40.5MG/2.5GM PACKET) N 022309 003 Sep 07, 2012 Jun CFTG TESTIM AB2 +! AUXILIUM PHARMS LLC 50MG/5GM PACKET N 021454 001 Oct 31, 2002 May CAHN TESTOSTERONE AB2 PERRIGO UK FINCO 1.62% (20.25MG/1.25GM PACKET) A 205781 001 Jul 12, 2017 Jun NEWA AB2 1.62% (40.5MG/2.5GM PACKET) A 205781 002 Jul 12, 2017 Jun NEWA VOGELXO AB2 UPSHER-SMITH LABS 50MG/5GM PACKET N 204399 002 Jun 04, 2014 Jun CAHN GEL, METERED;TRANSDERMAL TESTOSTERONE AB ACTAVIS LABS UT INC 10MG/0.5GM ACTUATION A 204571 001 Aug 05, 2015 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -105

GEL, METERED;TRANSDERMAL VOGELXO BX UPSHER-SMITH LABS 12.5MG/1.25GM ACTUATION N 204399 003 Jun 04, 2014 Jun CAHN SOLUTION, METERED;TRANSDERMAL AXIRON AT +! ELI LILLY AND CO 30MG/1.5ML ACTUATION N 022504 001 Nov 23, 2010 Feb CFTG TESTOSTERONE >A> AT ACTAVIS LABS UT INC 30MG/1.5ML ACTUATION A 205328 001 Aug 07, 2017 Jul NEWA AT PERRIGO ISRAEL 30MG/1.5ML ACTUATION A 204255 001 Feb 28, 2017 Feb NEWA TABLET, EXTENDED RELEASE;BUCCAL STRIANT +! AUXILIUM PHARMS LLC 30MG N 021543 001 Jun 19, 2003 May CAHN

TESTOSTERONE CYPIONATE INJECTABLE;INJECTION TESTOSTERONE CYPIONATE AO LUITPOLD PHARMS INC 200MG/ML A 207742 001 Jun 16, 2017 Jun NEWA AO SANDOZ INC 100MG/ML A 040615 001 Aug 10, 2006 Mar CAHN AO 200MG/ML A 040615 002 Aug 10, 2006 Mar CAHN AO WATSON PHARMS INC 200MG/ML A 086030 001 Feb CAHN AO WEST-WARD PHARMS INT 100MG/ML A 090387 001 Jul 15, 2010 Jan CAHN AO 200MG/ML A 090387 002 Jul 15, 2010 Jan CAHN

TESTOSTERONE ENANTHATE INJECTABLE;INJECTION TESTOSTERONE ENANTHATE AO WATSON PHARMS INC 200MG/ML A 085598 001 Feb CAHN

TETRABENAZINE TABLET;ORAL TETRABENAZINE AB ACTAVIS LABS FL INC 25MG A 206686 001 Jul 07, 2017 Jun NEWA AB APICORE US 12.5MG A 207682 001 Jan 31, 2017 Jan NEWA AB 25MG A 207682 002 Jan 31, 2017 Jan NEWA

TETRACYCLINE HYDROCHLORIDE CAPSULE;ORAL ACHROMYCIN V AB + HERITAGE PHARMA 250MG N 050278 003 Jan CAHN AB +! 500MG N 050278 001 Jan CAHN TETRACYCLINE HYDROCHLORIDE AB CHARTWELL TETRA 250MG A 062752 001 Aug 12, 1988 Apr CAHN AB 500MG A 062752 002 Aug 12, 1988 Apr CAHN >D> IMPAX LABS 100MG A 060469 002 Jul DISC >A> @ 100MG A 060469 002 Jul DISC >D> AB 250MG A 060469 001 Jul DISC >A> @ 250MG A 060469 001 Jul DISC >D> AB 500MG A 060469 003 Jul DISC >A> @ 500MG A 060469 003 Jul DISC

THEOPHYLLINE ELIXIR;ORAL THEOPHYLLINE @ CHARTWELL RX 80MG/15ML A 085952 001 Apr CAHN @ PHARM ASSOC 80MG/15ML A 086720 001 May CAHN TABLET, EXTENDED RELEASE;ORAL THEOCHRON AB NOSTRUM PHARMS LLC 100MG A 088320 001 Feb 21, 1985 May CAHN AB 200MG A 088321 001 Feb 21, 1985 May CAHN @ 300MG A 087400 002 Jan 11, 1983 May CAHN THEOPHYLLINE ! ALEMBIC LTD 450MG A 090430 002 Oct 27, 2010 Apr CHRS AB ALEMBIC PHARMS LTD 300MG A 090430 001 Oct 27, 2010 May CAHN ! 450MG A 090430 002 Oct 27, 2010 May CAHN

THIAMINE HYDROCHLORIDE INJECTABLE;INJECTION THIAMINE HYDROCHLORIDE @ WEST-WARD PHARMS INT 100MG/ML A 080575 001 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -106

THIORIDAZINE HYDROCHLORIDE CONCENTRATE;ORAL THIORIDAZINE HYDROCHLORIDE @ ANI PHARMS INC 30MG/ML A 089602 001 Nov 09, 1987 Jan CAHN @ PHARM ASSOC 30MG/ML A 040187 001 Aug 28, 1997 May CAHN @ 100MG/ML A 040213 001 May 29, 1998 May CAHN TABLET;ORAL THIORIDAZINE HYDROCHLORIDE @ WATSON LABS TEVA 15MG A 088477 001 Nov 08, 1983 May CAHN @ 25MG A 088567 001 May 11, 1984 May CAHN @ 200MG A 088872 001 Apr 26, 1985 May CAHN

THIOTEPA POWDER;IV (INFUSION) TEPADINA +! ADIENNE SA 15MG/VIAL N 208264 001 Jan 26, 2017 Jan NEWA +! 100MG/VIAL N 208264 002 Jan 26, 2017 Jan NEWA

TICAGRELOR TABLET;ORAL BRILINTA + ASTRAZENECA PHARMS 60MG N 022433 002 Sep 03, 2015 Jan CAHN +! 90MG N 022433 001 Jul 20, 2011 Jan CAHN

TIGECYCLINE POWDER;IV (INFUSION) TIGECYCLINE AP SANDOZ INC 50MG/VIAL A 091620 001 May 27, 2015 Feb CDFR TYGACIL AP +! PF PRISM CV 50MG/VIAL N 021821 001 Jun 15, 2005 Feb CDFR

TIMOLOL MALEATE SOLUTION, GEL FORMING/DROPS;OPHTHALMIC TIMOLOL MALEATE AB SANDOZ INC EQ 0.25% BASE N 020963 001 Oct 21, 1998 Feb CAHN AB EQ 0.5% BASE N 020963 002 Oct 21, 1998 Feb CAHN SOLUTION/DROPS;OPHTHALMIC TIMOLOL MALEATE AT ! ALCON RES LTD EQ 0.25% BASE A 074261 001 Apr 28, 1995 Jan CHRS AT1 ! EQ 0.5% BASE A 074262 001 Apr 28, 1995 Jan CHRS AT ! SANDOZ INC EQ 0.25% BASE A 074261 001 Apr 28, 1995 Feb CAHN AT1 ! EQ 0.5% BASE A 074262 001 Apr 28, 1995 Feb CAHN TIMOPTIC + @ ATON EQ 0.25% BASE N 018086 001 Jan DISC + @ EQ 0.5% BASE N 018086 002 Jan DISC

TINIDAZOLE TABLET;ORAL TINIDAZOLE AB UNIQUE PHARM LABS 250MG A 202489 001 Oct 09, 2013 Jan CTEC AB 500MG A 202489 002 Oct 09, 2013 Jan CTEC

TIZANIDINE HYDROCHLORIDE CAPSULE;ORAL TIZANIDINE HYDROCHLORIDE >A> AB JUBILANT GENERICS EQ 2MG BASE A 209605 001 Aug 04, 2017 Jul NEWA >A> AB EQ 4MG BASE A 209605 002 Aug 04, 2017 Jul NEWA >A> AB EQ 6MG BASE A 209605 003 Aug 04, 2017 Jul NEWA AB PAR PHARM INC EQ 2MG BASE A 207199 001 Mar 14, 2017 Feb NEWA AB EQ 4MG BASE A 207199 002 Mar 14, 2017 Feb NEWA AB EQ 6MG BASE A 207199 003 Mar 14, 2017 Feb NEWA AB ZYDUS PHARMS USA INC EQ 2MG BASE A 208622 001 Mar 03, 2017 Feb NEWA AB EQ 4MG BASE A 208622 002 Mar 03, 2017 Feb NEWA AB EQ 6MG BASE A 208622 003 Mar 03, 2017 Feb NEWA TABLET;ORAL TIZANIDINE HYDROCHLORIDE AB EPIC PHARMA LLC EQ 2MG BASE A 076347 001 Oct 11, 2002 May CAHN AB EQ 4MG BASE A 076347 002 Oct 11, 2002 May CAHN AB PAR PHARM INC EQ 2MG BASE A 207170 001 Jan 26, 2017 Jan NEWA AB EQ 4MG BASE A 207170 002 Jan 26, 2017 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -107

TOBRAMYCIN SOLUTION;INHALATION TOBRAMYCIN AN AMNEAL PHARMS 300MG/5ML A 205501 001 Jul 13, 2015 May CAHN AN LUPIN ATLANTIS 300MG/5ML A 208964 001 Mar 22, 2017 Mar NEWA SOLUTION/DROPS;OPHTHALMIC TOBRAMYCIN AT SOMERSET THERAPS LLC 0.3% A 207444 001 Jun 28, 2017 Jun NEWA TOBREX AT SANDOZ INC 0.3% A 062535 001 Dec 13, 1984 Feb CAHN

TOLMETIN SODIUM TABLET;ORAL TOLMETIN SODIUM @ SUN PHARM INDS EQ 200MG BASE A 073310 001 Nov 27, 1991 Apr DISC

TOPIRAMATE CAPSULE, EXTENDED RELEASE;ORAL QUDEXY XR + UPSHER-SMITH LABS 25MG N 205122 001 Mar 11, 2014 Jun CAHN + 50MG N 205122 002 Mar 11, 2014 Jun CAHN + 100MG N 205122 003 Mar 11, 2014 Jun CAHN + 150MG N 205122 004 Mar 11, 2014 Jun CAHN +! 200MG N 205122 005 Mar 11, 2014 Jun CAHN TABLET;ORAL TOPIRAMATE @ MYLAN 25MG A 076314 001 Mar 27, 2009 May DISC @ 50MG A 076314 002 Mar 27, 2009 May DISC @ 100MG A 076314 003 Mar 27, 2009 May DISC @ 200MG A 076314 004 Mar 27, 2009 May DISC AB UPSHER-SMITH LABS 25MG A 078499 001 Jan 07, 2010 Jun CAHN AB 50MG A 078499 002 Jan 07, 2010 Jun CAHN AB 100MG A 078499 003 Jan 07, 2010 Jun CAHN AB 200MG A 078499 004 Jan 07, 2010 Jun CAHN

TOPOTECAN HYDROCHLORIDE SOLUTION;INTRAVENOUS TOPOTECAN HYDROCHLORIDE AP ACCORD HLTHCARE EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 204406 001 Jul 06, 2017 Jun NEWA AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 204406 002 Jul 06, 2017 Jun NEWA

TOREMIFENE CITRATE TABLET;ORAL FARESTON +! KYOWA KIRIN EQ 60MG BASE N 020497 001 May 29, 1997 Jan CAHN

TORSEMIDE TABLET;ORAL DEMADEX AB + MYLAN SPECIALITY LP 5MG N 020136 001 Aug 23, 1993 Mar CAHN AB + 10MG N 020136 002 Aug 23, 1993 Mar CAHN AB +! 20MG N 020136 003 Aug 23, 1993 Mar CAHN AB + 100MG N 020136 004 Aug 23, 1993 Mar CAHN

TRAMADOL HYDROCHLORIDE TABLET;ORAL TRAMADOL HYDROCHLORIDE AB ACCORD HLTHCARE 50MG A 202390 001 May 16, 2013 Mar CAHN AB AMNEAL PHARMS 50MG A 076003 001 Jun 20, 2002 May CAHN TABLET, EXTENDED RELEASE;ORAL ULTRAM ER + @ VALEANT PHARMS 100MG N 021692 001 Sep 08, 2005 Mar CRLD + @ 200MG N 021692 002 Sep 08, 2005 Mar CRLD + @ 300MG N 021692 003 Sep 08, 2005 Mar CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -108

TRAMETINIB DIMETHYL SULFOXIDE TABLET;ORAL MEKINIST >D> + NOVARTIS PHARMS CORP EQ 1MG N 204114 002 May 29, 2013 Jul DISC >A> + @ EQ 1MG N 204114 002 May 29, 2013 Jul DISC

TRANDOLAPRIL TABLET;ORAL TRANDOLAPRIL @ EPIC PHARMA LLC 1MG A 077256 001 Jun 12, 2007 May CAHN @ 2MG A 077256 002 Jun 12, 2007 May CAHN @ 4MG A 077256 003 Jun 12, 2007 May CAHN @ INVAGEN PHARMS 1MG A 078320 001 Jun 12, 2007 Jun DISC BX 1MG A 078320 001 Jun 12, 2007 Apr CTEC @ 2MG A 078320 002 Jun 12, 2007 Jun DISC BX 2MG A 078320 002 Jun 12, 2007 Apr CTEC @ 4MG A 078320 003 Jun 12, 2007 Jun DISC BX 4MG A 078320 003 Jun 12, 2007 Apr CTEC @ MYLAN 1MG A 078346 001 Apr 28, 2008 May DISC @ 2MG A 078346 002 Apr 28, 2008 May DISC @ 4MG A 078346 003 Apr 28, 2008 May DISC

TRANEXAMIC ACID INJECTABLE;INJECTION TRANEXAMIC ACID AP AMNEAL PHARMS CO 100MG/ML A 208840 001 Feb 28, 2017 Feb NEWA AP GLAND PHARMA LTD 100MG/ML A 207239 001 Feb 13, 2017 Jan NEWA AP MICRO LABS 100MG/ML A 206713 001 Jun 27, 2017 Jun NEWA >A> AP ZYDUS PHARMS USA INC 100MG/ML A 205228 001 Jul 17, 2017 Jul NEWA

TRAVOPROST SOLUTION/DROPS;OPHTHALMIC TRAVOPROST AT MYLAN PHARMS INC 0.004% A 205050 001 Jul 07, 2017 Jun NEWA

TRAZODONE HYDROCHLORIDE TABLET;ORAL TRAZODONE HYDROCHLORIDE @ MYLAN PHARMS INC 50MG A 090514 001 Jun 02, 2009 May DISC @ 100MG A 090514 002 Jun 02, 2009 May DISC @ 150MG A 090514 003 Jun 02, 2009 May DISC @ 300MG A 090514 004 Jun 02, 2009 May DISC

TRETINOIN CAPSULE;ORAL TRETINOIN AB GLENMARK PHARMS LTD 10MG A 208279 001 Dec 23, 2016 Jun CAHN VESANOID + @ CHEPLAPHARM 10MG N 020438 001 Nov 22, 1995 May CAHN CREAM;TOPICAL TRETINOIN AB2 ZO SKIN HEALTH 0.05% A 076498 001 Sep 15, 2005 Feb CAHN GEL;TOPICAL TRETINOIN AB MYLAN PHARMS INC 0.04% A 202567 001 Jul 17, 2013 Jun CAHN AB 0.05% A 207955 001 Aug 13, 2015 Jun CAHN AB 0.1% A 202026 001 Jul 17, 2013 Jun CAHN

TRIAMCINOLONE ACETONIDE CREAM;TOPICAL TRIAMCINOLONE ACETONIDE AT LUPIN ATLANTIS 0.025% A 208763 001 Feb 01, 2017 Jan NEWA AT 0.1% A 208763 002 Feb 01, 2017 Jan NEWA AT 0.5% A 208763 003 Feb 01, 2017 Jan NEWA AT + MYLAN PHARMS INC 0.025% N 011601 003 Jan CAHN AT + 0.1% N 011601 006 Jan CAHN @ TARO 0.025% A 040038 001 Oct 26, 1994 Apr CAHN AT 0.1% A 040039 001 Nov 26, 1997 Apr CAHN AT 0.1% A 040039 001 Nov 26, 1997 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -109

INJECTABLE;INJECTION KENALOG-10 + APOTHECON 10MG/ML N 012041 001 Jun CRLD TRIAMCINOLONE ACETONIDE @ SANDOZ INC 10MG/ML A 090166 001 May 27, 2009 Apr CAHN @ 40MG/ML A 090164 001 Jun 01, 2009 Apr CAHN OINTMENT;TOPICAL KENALOG AT MYLAN PHARMS INC 0.025% N 011600 003 Jan CAHN AT 0.1% N 011600 001 Jan CAHN TRIAMCINOLONE ACETONIDE @ TARO 0.025% A 040040 001 Sep 30, 1994 Apr CAHN AT 0.1% A 040037 001 Sep 30, 1994 Apr CAHN AT TELIGENT PHARMA INC 0.5% A 208590 001 Mar 03, 2017 Feb NEWA TRIAMCINOLONE ACETONIDE IN ABSORBASE ! CMP PHARMA INC 0.05% A 089595 001 Mar 23, 1995 Apr CAHN PASTE;DENTAL TRIAMCINOLONE ACETONIDE AT G AND W LABS INC 0.1% A 205592 001 Jan 12, 2017 Jan NEWA SPRAY, METERED;NASAL TRIAMCINOLONE ACETONIDE @ PERRIGO ISRAEL 0.055MG/SPRAY A 078104 001 Jul 30, 2009 Jan CAHN

TRIAMCINOLONE DIACETATE INJECTABLE;INJECTION ARISTOCORT @ SANDOZ INC 25MG/ML N 011685 003 Jun CAHN + @ 40MG/ML N 012802 001 Jun CAHN

TRIAMCINOLONE HEXACETONIDE INJECTABLE;INJECTION ARISTOSPAN +! SANDOZ INC 5MG/ML N 016466 001 Jun CAHN +! 20MG/ML N 016466 002 Jun CAHN

TRIFLURIDINE SOLUTION/DROPS;OPHTHALMIC TRIFLURIDINE >A> AT HI-TECH PHARMACAL 1% A 205438 001 Jul 28, 2017 Jul NEWA AT SANDOZ INC 1% A 074311 001 Oct 06, 1995 Feb CAHN VIROPTIC AT +! MONARCH PHARMS 1% N 018299 001 Feb CAHN

TRIHEXYPHENIDYL HYDROCHLORIDE ELIXIR;ORAL TRIHEXYPHENIDYL HYDROCHLORIDE AA ! PHARM ASSOC 2MG/5ML A 040177 001 Apr 17, 1997 May CAHN TABLET;ORAL TRIHEXYPHENIDYL HYDROCHLORIDE AA VINTAGE PHARMS LLC 2MG A 040254 001 Dec 24, 1998 Mar CAHN AA 5MG A 040254 002 Dec 24, 1998 Mar CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE CAPSULE;ORAL TIGAN AB +! KING PHARMS LLC 300MG N 017531 006 Dec 13, 2001 May CAHN

TRIMIPRAMINE MALEATE CAPSULE;ORAL TRIMIPRAMINE MALEATE AB ELITE LABS INC EQ 25MG BASE A 077361 001 Aug 02, 2006 May CAHN AB EQ 50MG BASE A 077361 002 Aug 02, 2006 May CAHN AB EQ 100MG BASE A 077361 003 Aug 02, 2006 May CAHN

TRIPTORELIN PAMOATE FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR TRIPTODUR KIT +! ARBOR PHARMS LLC EQ 22.5MG BASE/VIAL N 208956 001 Jun 29, 2017 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -110

TROPICAMIDE SOLUTION/DROPS;OPHTHALMIC MYDRIACYL AT ! SANDOZ INC 0.5% A 084305 001 Feb CAHN

TROSPIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL TROSPIUM CHLORIDE @ UPSHER-SMITH LABS 60MG A 091635 001 Apr 29, 2015 Jun CAHN

ULIPRISTAL ACETATE TABLET;ORAL ELLA AB +! LAB HRA PHARMA 30MG N 022474 001 Aug 13, 2010 Jan CFTG LOGILIA AB TEVA PHARMS USA 30MG A 207952 001 Feb 13, 2017 Jan NEWA

URSODIOL CAPSULE;ORAL URSODIOL @ IMPAX LABS INC 300MG A 077895 001 Jul 27, 2006 May DISC BX 300MG A 077895 001 Jul 27, 2006 Apr CTEC AB 300MG A 077895 001 Jul 27, 2006 Feb CAHN

VALACYCLOVIR HYDROCHLORIDE TABLET;ORAL VALACYCLOVIR HYDROCHLORIDE @ MYLAN EQ 500MG BASE A 078070 001 May 24, 2010 Jun DISC @ EQ 1GM BASE A 078070 002 May 24, 2010 Jun DISC

VALBENAZINE TOSYLATE CAPSULE;ORAL INGREZZA +! NEUROCRINE 40MG N 209241 001 Apr 11, 2017 Apr NEWA

VALPROATE SODIUM INJECTABLE;INJECTION VALPROATE SODIUM AP ATHENEX INC EQ 100MG BASE/ML A 076295 001 Nov 14, 2002 Mar CAHN

VALPROIC ACID CAPSULE;ORAL VALPROIC ACID @ USL PHARMA 250MG A 070631 001 Jun 11, 1987 Jun CAHN SYRUP;ORAL VALPROIC ACID AA ECI PHARMS LLC 250MG/5ML A 090517 001 May 28, 2010 Mar CAHN AA PHARM ASSOC 250MG/5ML A 075379 001 Dec 15, 2000 May CAHN AA VISTAPHARM 250MG/5ML A 075782 001 Dec 22, 2000 Feb CAHN

VALSARTAN TABLET;ORAL VALSARTAN AB AMNEAL PHARMS 40MG A 204011 001 Jan 11, 2016 May CAHN AB 80MG A 204011 002 Jan 11, 2016 May CAHN AB 160MG A 204011 003 Jan 11, 2016 May CAHN AB 320MG A 204011 004 Jan 11, 2016 May CAHN AB MYLAN PHARMS INC 40MG A 090866 001 Jan 05, 2015 Feb CAHN AB 80MG A 090866 002 Jan 05, 2015 Feb CAHN AB 160MG A 090866 003 Jan 05, 2015 Feb CAHN AB 320MG A 090866 004 Jan 05, 2015 Feb CAHN

VARDENAFIL HYDROCHLORIDE TABLET, ORALLY DISINTEGRATING;ORAL STAXYN +! BAYER HLTHCARE 10MG N 200179 001 Jun 17, 2010 Jun CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -111

VASOPRESSIN SOLUTION;IV (INFUSION) VASOSTRICT +! PAR STERILE PRODUCTS 20UNITS/ML (20UNITS/ML) N 204485 001 Apr 17, 2014 May CMFD + @ 20UNITS/ML (20UNITS/ML) N 204485 001 Apr 17, 2014 Apr DISC +! 20UNITS/ML (20UNITS/ML) N 204485 002 Mar 18, 2016 Apr NEWA +! 200UNITS/10ML (20UNITS/ML) N 204485 002 Dec 17, 2016 May NEWA

VECURONIUM BROMIDE INJECTABLE;INJECTION VECURONIUM BROMIDE @ WEST-WARD PHARMS INT 10MG/VIAL A 075218 001 Aug 23, 1999 Mar CAHN AP 10MG/VIAL A 075549 001 Jun 13, 2000 Jan CAHN @ 20MG/VIAL A 075218 002 Aug 23, 1999 Mar CAHN AP 20MG/VIAL A 075549 002 Jun 13, 2000 Jan CAHN

VENLAFAXINE HYDROCHLORIDE TABLET;ORAL VENLAFAXINE HYDROCHLORIDE AB PRINSTON INC EQ 25MG BASE A 090027 001 Aug 04, 2010 Feb CAHN AB EQ 37.5MG BASE A 090027 002 Aug 04, 2010 Feb CAHN AB EQ 50MG BASE A 090027 003 Aug 04, 2010 Feb CAHN AB EQ 75MG BASE A 090027 004 Aug 04, 2010 Feb CAHN AB EQ 100MG BASE A 090027 005 Aug 04, 2010 Feb CAHN TABLET, EXTENDED RELEASE;ORAL VENLAFAXINE HYDROCHLORIDE AB NOSTRUM LABS INC EQ 150MG BASE A 205468 002 Mar 24, 2017 Mar NEWA AB EQ 225MG BASE A 205468 003 Mar 24, 2017 Mar NEWA AB + OSMOTICA PHARM EQ 225MG BASE N 022104 004 May 20, 2008 Mar CFTG

VERAPAMIL HYDROCHLORIDE INJECTABLE;INJECTION ISOPTIN + @ MT ADAMS 2.5MG/ML N 018485 001 Apr CRLD TABLET, EXTENDED RELEASE;ORAL CALAN SR + PFIZER@ 180MG N 019152 002 Dec 15, 1989 Jan CRLD COVERA-HS @ GD SEARLE LLC 180MG N 020552 001 Feb 26, 1996 Jan DISC @ 240MG N 020552 002 Feb 26, 1996 Jan DISC VERAPAMIL HYDROCHLORIDE AB CADILA PHARMS LTD 180MG A 206173 001 May 05, 2017 Apr NEWA AB 240MG A 206173 002 May 05, 2017 Apr NEWA

VIGABATRIN FOR SOLUTION;ORAL SABRIL AA +! LUNDBECK PHARMS LLC 500MG/PACKET N 022006 001 Aug 21, 2009 Apr CFTG +! 500MG/PACKET N 022006 001 Aug 21, 2009 Jan CAHN VIGABATRIN AA PAR PHARM INC 500MG/PACKET A 208218 001 Apr 27, 2017 Apr NEWA TABLET;ORAL SABRIL +! LUNDBECK PHARMS LLC 500MG N 020427 001 Aug 21, 2009 Jan CAHN

VINORELBINE TARTRATE INJECTABLE;INJECTION VINORELBINE TARTRATE AP WEST-WARD PHARMS INT EQ 10MG BASE/ML A 075992 001 Jun 10, 2003 Mar CAHN AP EQ 10MG BASE/ML A 076461 001 Dec 11, 2003 Jan CAHN

VORICONAZOLE POWDER;IV (INFUSION) VORICONAZOLE XELLIA PHARMS APS 200MG/VIAL N 208562 001 Mar 09, 2017 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -112

VORTIOXETINE HYDROBROMIDE TABLET;ORAL TRINTELLIX + @ TAKEDA PHARMS USA EQ 15MG BASE N 204447 003 Sep 30, 2013 Mar DISC

WARFARIN SODIUM TABLET;ORAL JANTOVEN AB USL PHARMA 1MG A 040416 001 Oct 02, 2003 Jun CAHN AB 2MG A 040416 002 Oct 02, 2003 Jun CAHN AB 2.5MG A 040416 003 Oct 02, 2003 Jun CAHN AB 3MG A 040416 004 Oct 02, 2003 Jun CAHN AB 4MG A 040416 005 Oct 02, 2003 Jun CAHN AB 5MG A 040416 006 Oct 02, 2003 Jun CAHN AB 6MG A 040416 007 Oct 02, 2003 Jun CAHN AB 7.5MG A 040416 008 Oct 02, 2003 Jun CAHN AB 10MG A 040416 009 Oct 02, 2003 Jun CAHN WARFARIN SODIUM MY LAN@ MYLAN@ 1MG A 040415 001 Sep 27, 2004 Apr DISC @ 2MG A 040415 002 Sep 27, 2004 Apr DISC @ 2.5MG A 040415 003 Sep 29, 2004 Apr DISC @ 3MG A 040415 004 Sep 27, 2004 Apr DISC @ 4MG A 040415 005 Sep 27, 2004 Apr DISC @ 5MG A 040415 006 Sep 27, 2004 Apr DISC @ 6MG A 040415 007 Sep 27, 2004 Apr DISC @ 7.5MG A 040415 008 Sep 27, 2004 Apr DISC @ 10MG A 040415 009 Sep 27, 2004 Apr DISC AB TARO PHARM 1MG A 040301 002 Jul 15, 1999 Mar CAHN AB 2MG A 040301 003 Jul 15, 1999 Mar CAHN AB 2.5MG A 040301 004 Jul 15, 1999 Mar CAHN AB 3MG A 040301 005 Jul 15, 1999 Mar CAHN AB 4MG A 040301 006 Jul 15, 1999 Mar CAHN AB 5MG A 040301 007 Jul 15, 1999 Mar CAHN AB 6MG A 040301 008 Jul 15, 1999 Mar CAHN AB 7.5MG A 040301 009 Jul 15, 1999 Mar CAHN AB 10MG A 040301 001 Jul 15, 1999 Mar CAHN

ZALEPLON CAPSULE;ORAL ZALEPLON >D> AB MYLAN 5MG A 077238 001 Jun 06, 2008 Jul DISC >A> @ 5MG A 077238 001 Jun 06, 2008 Jul DISC >D> AB 10MG A 077238 002 Jun 06, 2008 Jul DISC >A> @ 10MG A 077238 002 Jun 06, 2008 Jul DISC @ UPSHER-SMITH LABS 5MG A 078095 001 Jun 06, 2008 Jun CAHN @ 5MG A 078706 001 Jun 06, 2008 Jun CAHN @ 10MG A 078095 002 Jun 06, 2008 Jun CAHN @ 10MG A 078706 002 Jun 06, 2008 Jun CAHN

ZIDOVUDINE TABLET;ORAL ZIDOVUDINE @ HEC PHARM USA INC 300MG A 202058 001 Oct 07, 2011 May CAHN

ZILEUTON TABLET, EXTENDED RELEASE;ORAL ZILEUTON AB PACK PHARMS LLC 600MG A 204929 001 Mar 17, 2017 Mar NEWA AB RISING PHARMS INC 600MG A 204929 001 Mar 17, 2017 Mar CAHN ZYFLO CR AB +! CHIESI USA INC 600MG N 022052 001 May 30, 2007 Mar CFTG

ZIPRASIDONE HYDROCHLORIDE CAPSULE;ORAL ZIPRASIDONE HYDROCHLORIDE AB MACLEODS PHARMS LTD EQ 20MG BASE A 204375 001 Feb 17, 2017 Feb NEWA AB EQ 40MG BASE A 204375 002 Feb 17, 2017 Feb NEWA AB EQ 60MG BASE A 204375 003 Feb 17, 2017 Feb NEWA AB EQ 80MG BASE A 204375 004 Feb 17, 2017 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 1 -113

ZOLEDRONIC ACID INJECTABLE;IV (INFUSION) ZOLEDRONIC ACID AP MYLAN LABS LTD EQ 5MG BASE/100ML A 203841 001 Feb 14, 2017 Jan NEWA AP PII EQ 4MG BASE/5ML A 202571 001 May 07, 2013 May CAHN

ZOLMITRIPTAN TABLET;ORAL ZOLMITRIPTAN AB APPCO PHARMA LLC 2.5MG A 206973 001 Jun 30, 2017 Jun NEWA AB 5MG A 206973 002 Jun 30, 2017 Jun NEWA AB PLD ACQUISITIONS LLC 2.5MG A 207867 001 Feb 27, 2017 Feb NEWA AB 5MG A 207867 002 Feb 27, 2017 Feb NEWA

ZOLPIDEM TARTRATE TABLET;ORAL ZOLPIDEM TARTRATE AB ALLIED PHARMA INC 5MG A 077214 001 Apr 23, 2007 Mar CAHN AB 10MG A 077214 002 Apr 23, 2007 Mar CAHN TABLET;SUBLINGUAL EDLUAR AB + MYLAN SPECIALITY LP 5MG N 021997 001 Mar 13, 2009 Mar CAHN AB +! 10MG N 021997 002 Mar 13, 2009 Mar CAHN TABLET, EXTENDED RELEASE;ORAL ZOLPIDEM TARTRATE AB SUN PHARMA GLOBAL 6.25MG A 204170 001 Jan 24, 2017 Jan NEWA AB 12.5MG A 204170 002 Jan 24, 2017 Jan NEWA @ SYNTHON PHARMS 6.25MG A 078483 001 Apr 12, 2011 Apr DISC @ 12.5MG A 078483 002 Jun 06, 2011 Apr DISC

ZONISAMIDE CAPSULE;ORAL ZONISAMIDE @ EPIC PHARMA LLC 25MG A 077876 001 Feb 21, 2007 May CAHN @ 50MG A 077876 002 Feb 21, 2007 May CAHN @ 100MG A 077876 003 Feb 21, 2007 May CAHN @ MYLAN PHARMS INC 25MG A 077647 001 Dec 22, 2005 Jun DISC @ 50MG A 077647 002 Dec 22, 2005 Jun DISC @ 100MG A 077647 003 Dec 22, 2005 Jun DISC @ UPSHER-SMITH LABS 25MG A 077644 001 Dec 22, 2005 Jun CAHN @ 50MG A 077644 002 Dec 22, 2005 Jun CAHN @ 100MG A 077644 003 Dec 22, 2005 Jun CAHN OTC DRUG PRODUCT LIST - 37TH EDITION OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 2 -1

AVOBENZONE; OCTINOXATE; OXYBENZONE LOTION;TOPICAL SHADE UVAGUARD + @ BAYER HEALTHCARE LLC 3%;7.5%;3% N 020045 001 Dec 07, 1992 Jun DISC

CETIRIZINE HYDROCHLORIDE CAPSULE;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY >A> STRIDES PHARMA 10MG A 205291 001 Jul 21, 2017 Jul NEWA SYRUP;ORAL CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY ALLIED PHARMA INC 5MG/5ML A 091327 001 Oct 17, 2011 Apr CAHN CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF ALLIED PHARMA INC 5MG/5ML A 091327 002 Oct 17, 2011 Apr CAHN TABLET;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY JUBILANT CADISTA 5MG A 078933 001 Jun 15, 2010 Apr CAHN 10MG A 078933 002 Jun 15, 2010 Apr CAHN CETIRIZINE HYDROCHLORIDE HIVES JUBILANT CADISTA 5MG A 078933 003 Jun 15, 2010 Apr CAHN 10MG A 078933 004 Jun 15, 2010 Apr CAHN

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE TABLET;ORAL ADVIL MULTI-SYMPTOM COLD & FLU +! PFIZER 4MG;200MG;10MG N 022113 002 Apr 28, 2017 Apr NEWA

CIMETIDINE TABLET;ORAL CIMETIDINE L PERRIGO CO 200MG A 075285 001 Oct 29, 1998 Apr CAHN @ SANDOZ INC 100MG A 075122 001 Jun 19, 1998 Mar CAHN @ 200MG A 075122 002 Jun 19, 1998 Mar CAHN @ WATSON LABS TEVA 200MG A 075425 001 Jul 29, 1999 May CAHN

CLEMASTINE FUMARATE TABLET;ORAL CLEMASTINE FUMARATE L PERRIGO CO 1.34MG A 074512 001 Nov 22, 1995 Apr CAHN TAVIST-1 +! GLAXOSMITHKLINE CONS 1.34MG N 020925 001 Aug 21, 1992 Apr CAHN

CLOTRIMAZOLE CREAM;VAGINAL CLOTRIMAZOLE ! ACTAVIS MID ATLANTIC 1% A 074165 001 Jul 16, 1993 Jun CHRS TARO 1% A 072641 001 Dec 04, 1995 Apr CAHN GYNE-LOTRIMIN + @ BAYER HEALTHCARE LLC 1% N 018052 002 Nov 30, 1990 Jun DISC GYNE-LOTRIMIN 3 + @ BAYER HEALTHCARE LLC 2% N 020574 001 Nov 24, 1998 Jun DISC CREAM, TABLET;TOPICAL, VAGINAL GYNE-LOTRIMIN 3 COMBINATION PACK + @ BAYER HEALTHCARE LLC 1%,200MG N 020526 002 Jul 29, 1996 Jun DISC GYNE-LOTRIMIN COMBINATION PACK + @ BAYER HEALTHCARE LLC 1%,100MG N 020289 002 Apr 26, 1993 Jun DISC TABLET;VAGINAL GYNE-LOTRIMIN + @ BAYER HEALTHCARE LLC 100MG N 017717 002 Nov 30, 1990 Jun DISC GYNE-LOTRIMIN 3 + @ BAYER HEALTHCARE LLC 200MG N 020525 001 Jul 29, 1996 Jun DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE ACTAVIS LABS FL 30MG;600MG A 091070 001 Aug 31, 2015 Mar CAHN 60MG;1.2GM A 091070 002 Aug 31, 2015 Mar CAHN AUROBINDO PHARMA LTD 30MG;600MG A 206941 001 Mar 17, 2017 Mar NEWA 60MG;1.2GM A 206941 002 Mar 17, 2017 Mar NEWA OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 2 -2

DEXTROMETHORPHAN POLISTIREX SUSPENSION, EXTENDED RELEASE;ORAL DEXTROMETHORPHAN POLISTIREX >A> AMNEAL PHARMS LLC EQ 30MG HBR/5ML A 203133 001 Jul 28, 2017 Jul NEWA

FAMOTIDINE TABLET;ORAL FAMOTIDINE PERRIGO R AND D 20MG A 077351 001 Sep 25, 2006 Apr CAHN

FLUTICASONE FUROATE SPRAY, METERED;NASAL FLONASE SENSIMIST ALLERGY RELIEF +! GLAXOSMITHKLINE CONS 0.0275MG/SPRAY N 022051 002 Aug 02, 2016 Jun CAHN

GUAIFENESIN TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN ACTAVIS LABS FL 1.2GM A 091009 002 Sep 03, 2015 Mar CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE ACTAVIS LABS FL 600MG;60MG A 091071 001 May 27, 2015 Mar CAHN 1.2GM;120MG A 091071 002 May 27, 2015 Mar CAHN

IBUPROFEN CAPSULE;ORAL IBUPROFEN AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM A 202300 001 Dec 23, 2011 May CAHN SALT SUSPENSION;ORAL IBUPROFEN TARO 100MG/5ML A 209207 001 Jun 27, 2017 Jun NEWA SUSPENSION/DROPS;ORAL IBUPROFEN L PERRIGO CO 40MG/ML A 075217 001 Dec 16, 1998 Apr CAHN TABLET;ORAL IBUPROFEN AIPING PHARM INC 200MG A 207095 001 May 05, 2017 Apr NEWA AMNEAL PHARMS 200MG A 079233 001 Mar 18, 2014 Apr CAHN STRIDES PHARMA 200MG A 207052 001 May 30, 2017 Jun CMS2 200MG A 207052 001 May 30, 2017 May NEWA JUNIOR STRENGTH IBUPROFEN L PERRIGO CO 100MG A 075367 001 Apr 22, 1999 Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE SOLUTION;ORAL XYZAL ALLERGY 24HR + SANOFI-AVENTIS US 2.5MG/5ML (0.5MG/ML) N 209090 001 Jan 31, 2017 Feb CAHN + UCB INC 2.5MG/5ML (0.5MG/ML) N 209090 001 Jan 31, 2017 Jan NEWA TABLET;ORAL XYZAL ALLERGY 24HR + SANOFI-AVENTIS US 5MG N 209089 001 Jan 31, 2017 Feb CAHN + UCB INC 5MG N 209089 001 Jan 31, 2017 Jan NEWA

LEVONORGESTREL TABLET;ORAL LEVONORGESTREL RECKITT BENCKISER 1.5MG A 202246 001 Jun 05, 2015 Apr CAHN

LOPERAMIDE HYDROCHLORIDE SOLUTION;ORAL LOPERAMIDE HYDROCHLORIDE ALLIED PHARMA INC 1MG/5ML A 073079 001 Apr 30, 1992 Mar CAHN TABLET;ORAL LOPERAMIDE HYDROCHLORIDE L PERRIGO CO 2MG A 075232 001 Jan 06, 2000 Apr CAHN OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 2 -3

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE TABLET, CHEWABLE;ORAL LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE ! PERRIGO 2MG;125MG A 076029 001 Aug 30, 2002 Jan CHRS

LORATADINE SYRUP;ORAL LORATADINE TARO PHARM 1MG/ML A 201865 001 Jul 31, 2015 Mar CAHN

MICONAZOLE NITRATE CREAM;VAGINAL MICONAZOLE NITRATE TARO 2% A 074444 001 Jan 13, 1997 Apr CAHN CREAM, SUPPOSITORY;TOPICAL, VAGINAL M-ZOLE 3 COMBINATION PACK ACTAVIS MID ATLANTIC 2%,200MG A 074926 001 Apr 16, 1999 Jun CAHN SUPPOSITORY;VAGINAL MICONAZOLE NITRATE ACTAVIS PHARMA 100MG A 073507 001 Nov 19, 1993 May CAHN

MINOXIDIL AEROSOL, FOAM;TOPICAL MINOXIDIL (FOR MEN) WATSON LABS INC 5% A 208092 001 Feb 17, 2017 Feb NEWA MINOXIDIL (FOR WOMEN) >A> WATSON LABS INC 5% A 208092 002 Jul 27, 2017 Jul NEWA SOLUTION;TOPICAL MINOXIDIL (FOR MEN) L PERRIGO CO 2% A 075357 001 Jul 30, 1999 Apr CAHN MINOXIDIL (FOR WOMEN) L PERRIGO CO 2% A 075357 002 Jul 30, 1999 Apr CAHN

NAPROXEN SODIUM TABLET;ORAL NAPROXEN SODIUM LNK INTL INC EQ 200MG BASE A 204872 001 Jan 23, 2017 Jan NEWA

NICOTINE FILM, EXTENDED RELEASE;TRANSDERMAL HABITROL + DR REDDYS LABS SA 7MG/24HR N 020076 004 Nov 12, 1999 Jun CAHN + 14MG/24HR N 020076 005 Nov 12, 1999 Jun CAHN +! 21MG/24HR N 020076 006 Nov 12, 1999 Jun CAHN

NICOTINE POLACRILEX GUM, CHEWING;BUCCAL NICOTINE POLACRILEX L PERRIGO CO EQ 2MG BASE A 076775 001 Sep 16, 2004 Apr CAHN EQ 2MG BASE A 076776 001 Sep 16, 2004 Apr CAHN EQ 2MG BASE A 076777 001 Sep 16, 2004 Apr CAHN EQ 4MG BASE A 076778 001 Sep 16, 2004 Apr CAHN EQ 4MG BASE A 076779 001 Sep 16, 2004 Apr CAHN EQ 4MG BASE A 076789 001 Sep 16, 2004 Apr CAHN

OMEPRAZOLE >A> TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL >A> OMEPRAZOLE >A> + DEXCEL PHARMA 20MG N 209400 001 Jul 05, 2017 Jul NEWA

OXYMETAZOLINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC OCUCLEAR @ BAYER HEALTHCARE LLC 0.025% N 018471 001 May 30, 1986 May DISC OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 2 -4

PERMETHRIN LOTION;TOPICAL PERMETHRIN ACTAVIS MID ATLANTIC 1% A 075014 001 Mar 28, 2000 May CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL PSEUDOEPHEDRINE HYDROCHLORIDE AUROBINDO PHARMA LTD 120MG A 209008 001 Jun 09, 2017 May NEWA L PERRIGO CO 120MG A 075153 001 Feb 26, 1999 Apr CAHN

RANITIDINE HYDROCHLORIDE TABLET;ORAL RANITIDINE HYDROCHLORIDE STRIDES PHARMA EQ 150MG BASE A 200536 001 Jun 28, 2011 Jan CAHN ZANTAC 150 +! SANOFI US EQ 150MG BASE N 021698 001 Aug 31, 2004 Mar CAHN + EQ 150MG BASE N 021698 002 Mar 13, 2007 Mar CAHN ZANTAC 75 SANOFI US EQ 75MG BASE N 020520 001 Dec 19, 1995 Mar CAHN

TERBINAFINE HYDROCHLORIDE CREAM;TOPICAL LAMISIL >A> +! GLAXOSMITHKLINE 1% N 020980 001 Mar 09, 1999 Jul CAHN >D> +! NOVARTIS 1% N 020980 001 Mar 09, 1999 Jul CAHN

TIOCONAZOLE OINTMENT;VAGINAL VAGISTAT-1 >A> +! COMBE 6.5% N 020676 001 Feb 11, 1997 Jul CAHN >D> +! NOVARTIS 6.5% N 020676 001 Feb 11, 1997 Jul CAHN

TRIAMCINOLONE ACETONIDE SPRAY, METERED;NASAL TRIAMCINOLONE ACETONIDE PERRIGO ISRAEL 0.055MG/SPRAY A 078104 002 Nov 14, 2014 Jan CAHN

3-1

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2017

NO JULY 2017 APPROVALS

4-1

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at: http://www.fda.gov/orphan/designat/list.htm

5-1

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2017 ADDITIONS PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 37TH EDITION A - 1 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ABALOPARATIDE - TYMLOS N 208743 001 7803770 Mar 26, 2028 U-2009 NCE Apr 28, 2022 8148333 Nov 08, 2027 DP 8748382 Oct 03, 2027 U-2009

ACETAMINOPHEN - OFIRMEV N 022450 001 9610265 Nov 13, 2028 U-2000 M-196 Jan 27, 2020 PED Jul 27, 2020

ACETYLCYSTEINE - CETYLEV N 207916 001 9561204 May 08, 2032 U-1373

ACETYLCYSTEINE - CETYLEV N 207916 002 9561204 May 08, 2032 U-1373

ACLIDINIUM BROMIDE - TUDORZA PRESSAIR N 202450 001 RE46417 Sep 05, 2020 DS DP U-1263

ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE A 203790 001 >A> PC Jan 23, 2018

ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE N 207917 001 8445543 Dec 23, 2022 U-1078

AFATINIB DIMALEATE - GILOTRIF N 201292 001 9539258 Nov 09, 2026 U-1950

AFATINIB DIMALEATE - GILOTRIF N 201292 002 9539258 Nov 09, 2026 U-1950

AFATINIB DIMALEATE - GILOTRIF N 201292 003 9539258 Nov 09, 2026 U-1950

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT N 021747 001 8733341 Oct 16, 2030 DP

ALOGLIPTIN BENZOATE - NESINA N 022271 001 8173663 Dec 02, 2025 U-1338 8697125 Jun 16, 2029 DP

ALOGLIPTIN BENZOATE - NESINA N 022271 002 8173663 Dec 02, 2025 U-1338 8697125 Jun 16, 2029 DP

ALOGLIPTIN BENZOATE - NESINA N 022271 003 8173663 Dec 02, 2025 U-1338 8697125 Jun 16, 2029 DP

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO N 203414 001 8288539 Jun 24, 2025 DS

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO N 203414 002 8288539 Jun 24, 2025 DS

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI N 022426 005 6329404 Jun 19, 2021 DP U-1334 A - 2 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

AMBRISENTAN - LETAIRIS N 022081 001 9549926 Oct 14, 2031 U-1965

AMBRISENTAN - LETAIRIS N 022081 002 9549926 Oct 14, 2031 U-1965

AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN N 208630 001 ODE Jun 06, 2024

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA N 205003 001 NP Jan 21, 2018

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA N 205003 002 NP Jan 21, 2018

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA N 205003 003 NP Jan 21, 2018

AMPHETAMINE - DYANAVEL XR N 208147 001 9675703 Mar 15, 2027 DP

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS N 022063 001 6913768 May 24, 2023 DP U-2025 NP Jun 20, 2020 8846100 Aug 24, 2029 DP 9173857 May 12, 2026 U-2025 RE41148 Oct 21, 2018 DP RE42096 Oct 21, 2018 DP

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS N 022063 002 6913768 May 24, 2023 DP U-2025 NP Jun 20, 2020 8846100 Aug 24, 2029 DP 9173857 May 12, 2026 U-2025 RE41148 Oct 21, 2018 DP RE42096 Oct 21, 2018 DP

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS N 022063 003 6913768 May 24, 2023 DP U-2025 NP Jun 20, 2020 8846100 Aug 24, 2029 DP 9173857 May 12, 2026 U-2025 RE41148 Oct 21, 2018 DP RE42096 Oct 21, 2018 DP

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS N 022063 004 6913768 May 24, 2023 DP U-2025 NP Jun 20, 2020 8846100 Aug 24, 2029 DP 9173857 May 12, 2026 U-2025 RE41148 Oct 21, 2018 DP RE42096 Oct 21, 2018 DP

APIXABAN - ELIQUIS N 202155 001 6967208 Sep 17, 2022 DS DP U-1167 6967208 Sep 17, 2022 DS DP U-1200 6967208 Sep 17, 2022 DS DP U-1301 6967208 Sep 17, 2022 DS DP U-1302 6967208 Sep 17, 2022 DS DP U-1323 6967208 Sep 17, 2022 DS DP U-1501 6967208 Sep 17, 2022 DS DP U-1502 6967208 Sep 17, 2022 DS DP U-1729 6967208 Sep 17, 2022 DS DP U-1730 A - 3 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

APIXABAN - ELIQUIS N 202155 002 6967208 Sep 17, 2022 DS DP U-1200 6967208 Sep 17, 2022 DS DP U-1301 6967208 Sep 17, 2022 DS DP U-1302 6967208 Sep 17, 2022 DS DP U-1323

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 001 >A> I-746 Jul 27, 2020

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 002 >A> I-746 Jul 27, 2020

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 003 >A> I-746 Jul 27, 2020

ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 004 >A> I-746 Jul 27, 2020

ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 001 9526726 Mar 19, 2035 DP

ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 002 9526726 Mar 19, 2035 DP

ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 003 9526726 Mar 19, 2035 DP

ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 004 8431576 Oct 26, 2030 DS NCE Oct 05, 2020 8796276 Jun 24, 2030 U-543 9034867 Nov 07, 2032 DP U-543 9193685 Oct 24, 2033 DP U-543 9452131 Mar 19, 2035 U-543

ASENAPINE MALEATE - SAPHRIS N 022117 001 5763476 Jun 09, 2020 DP U-326 D-166 Jan 13, 2020 5763476 Jun 09, 2020 DP U-1960 I-597 Jan 13, 2020 5763476 Jun 09, 2020 DP U-1961 5763476 Jun 09, 2020 DP U-1962 5763476 Jun 09, 2020 DP U-1963 5763476*PED Dec 09, 2020 7741358 Apr 06, 2026 DS DP U-1064 7741358 Apr 06, 2026 DS DP U-1960 7741358 Apr 06, 2026 DS DP U-1961 7741358 Apr 06, 2026 DS DP U-1962 7741358 Apr 06, 2026 DS DP U-1963 7741358*PED Oct 06, 2026

ASENAPINE MALEATE - SAPHRIS N 022117 002 5763476 Jun 09, 2020 DP U-326 D-166 Jan 13, 2020 5763476 Jun 09, 2020 DP U-1960 I-597 Jan 13, 2020 5763476 Jun 09, 2020 DP U-1961 5763476 Jun 09, 2020 DP U-1962 5763476 Jun 09, 2020 DP U-1963 5763476*PED Dec 09, 2020 7741358 Apr 06, 2026 DS DP U-1064 7741358 Apr 06, 2026 DS DP U-1960 7741358 Apr 06, 2026 DS DP U-1961 7741358 Apr 06, 2026 DS DP U-1962 7741358 Apr 06, 2026 DS DP U-1963 7741358*PED Oct 06, 2026 A - 4 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ASENAPINE MALEATE - SAPHRIS N 022117 003 5763476 Jun 09, 2020 DP U-1893 D-166 Jan 13, 2020 5763476 Jun 09, 2020 DP U-1966 I-597 Jan 13, 2020 5763476*PED Dec 09, 2020 7741358 Apr 06, 2026 DS DP U-1893 7741358 Apr 06, 2026 DS DP U-1966 7741358*PED Oct 06, 2026

ASPIRIN; OMEPRAZOLE - YOSPRALA N 205103 001 9539214 Mar 13, 2033 U-1902

ASPIRIN; OMEPRAZOLE - YOSPRALA N 205103 002 9539214 Mar 13, 2033 U-1902

ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ N 206353 001 NCE Aug 27, 2017

ATORVASTATIN CALCIUM - LIPITOR N 020702 001 >A> M-204 Jun 23, 2020

ATORVASTATIN CALCIUM - LIPITOR N 020702 002 >A> M-204 Jun 23, 2020

ATORVASTATIN CALCIUM - LIPITOR N 020702 003 >A> M-204 Jun 23, 2020

ATORVASTATIN CALCIUM - LIPITOR N 020702 004 >A> M-204 Jun 23, 2020

AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ N 206494 001 9284314 Jun 15, 2032 DS >A> 9695122 Jun 15, 2032 DS

AXITINIB - INLYTA N 202324 001 8791140 Dec 14, 2030 DS

AXITINIB - INLYTA N 202324 002 8791140 Dec 14, 2030 DS

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE N 022247 001 5998402 Apr 04, 2018 DS DP U-594 NCE Oct 13, 2018

BEDAQUILINE FUMARATE - SIRTURO N 204384 001 7498343 Dec 01, 2026 DS DP U-1321

BENDAMUSTINE HYDROCHLORIDE - TREANDA N 022249 001 9533955 Mar 26, 2029 DP U-1949 9533955 Mar 26, 2029 DP U-1952

BENDAMUSTINE HYDROCHLORIDE - TREANDA N 022249 002 9533955 Mar 26, 2029 DP U-1949 9533955 Mar 26, 2029 DP U-1952

BENDAMUSTINE HYDROCHLORIDE - BENDEKA N 208194 001 9572796 Jan 28, 2031 DP U-1971 9572796 Jan 28, 2031 DP U-1972 9572797 Jan 28, 2031 U-1971 9572797 Jan 28, 2031 U-1972 9572887 Mar 15, 2033 U-1971 9572887 Mar 15, 2033 U-1972 9579384 Mar 15, 2033 U-1971 9579384 Mar 15, 2033 U-1972 A - 5 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BENDAMUSTINE HYDROCHLORIDE - BENDEKA N 208194 001 9597397 Mar 15, 2033 U-1971 9597397 Mar 15, 2033 U-1972 9597398 Mar 15, 2033 U-1971 9597399 Mar 15, 2033 U-1971 9597399 Mar 15, 2033 U-1972

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON N 050819 002 9561208 Jun 03, 2029 DP U-916

BETAMETHASONE DIPROPIONATE - SERNIVO N 208079 001 9655907 Aug 31, 2030 DP U-1858

BETRIXABAN - BEVYXXA N 208383 001 >A> 6376515 Sep 15, 2020 DS DP U-1167 NCE Jun 23, 2022 >A> 6376515 Sep 15, 2020 DS DP U-1502 >A> 6376515 Sep 15, 2020 DS DP U-2029 >A> 6376515 Sep 15, 2020 DS DP U-2030 >A> 6835739 Sep 15, 2020 DS DP >A> 7598276 Nov 08, 2026 DS >A> 8404724 Mar 29, 2031 DP U-2034 >A> 8518977 Sep 15, 2020 DS >A> 8557852 Sep 08, 2028 U-1167 >A> 8557852 Sep 08, 2028 U-2030 >A> 8691847 Sep 15, 2020 DS DP U-2029 >A> 8691847 Sep 15, 2020 DS DP U-2035 >A> 8987463 Dec 28, 2030 DP >A> 9555023 Nov 07, 2026 U-1502 >A> 9629831 Sep 15, 2020 U-1167 >A> 9629831 Sep 15, 2020 U-1502 >A> 9629831 Sep 15, 2020 U-2030 >A> 9629831 Sep 15, 2020 U-2035

BETRIXABAN - BEVYXXA N 208383 002 >A> 6376515 Sep 15, 2020 DS DP U-1167 NCE Jun 23, 2022 >A> 6376515 Sep 15, 2020 DS DP U-1502 >A> 6376515 Sep 15, 2020 DS DP U-2029 >A> 6376515 Sep 15, 2020 DS DP U-2030 >A> 6835739 Sep 15, 2020 DS DP >A> 7598276 Nov 08, 2026 DS >A> 8404724 Mar 29, 2031 DP U-2034 >A> 8518977 Sep 15, 2020 DS >A> 8557852 Sep 08, 2028 U-1167 >A> 8557852 Sep 08, 2028 U-2030 >A> 8691847 Sep 15, 2020 DS DP U-2029 >A> 8691847 Sep 15, 2020 DS DP U-2035 >A> 8987463 Dec 28, 2030 DP >A> 9555023 Nov 07, 2026 U-1502 >A> 9629831 Sep 15, 2020 U-1167 >A> 9629831 Sep 15, 2020 U-1502 >A> 9629831 Sep 15, 2020 U-2030 >A> 9629831 Sep 15, 2020 U-2035

BIMATOPROST - LATISSE N 022369 001 9579270 Jan 31, 2021 U-1975

BRIGATINIB - ALUNBRIG N 208772 001 9012462 Feb 06, 2031 DS NCE Apr 28, 2022 9273077 May 21, 2029 U-1927 ODE Apr 28, 2024 9611283 Apr 10, 2034 U-1927

BRIGATINIB - ALUNBRIG N 208772 002 9012462 Feb 06, 2031 DS NCE Apr 28, 2022 9273077 May 21, 2029 U-1927 ODE Apr 28, 2024 9611283 Apr 10, 2034 U-1927 A - 6 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BRIGATINIB - ALUNBRIG N 208772 002 9012462 Feb 06, 2031 DS NCE Apr 28, 2022 9273077 May 21, 2029 U-1927 ODE Apr 28, 2024 9611283 Apr 10, 2034 U-1927

BRIMONIDINE TARTRATE - ALPHAGAN P N 021770 001 9687443 Jul 10, 2021 DP

BROMFENAC SODIUM - PROLENSA N 203168 001 9517220 Nov 11, 2033 U-1933 9561277 Jan 16, 2024 U-1933

BROMOCRIPTINE MESYLATE - CYCLOSET N 020866 001 9522117 Apr 30, 2032 DP U-976 9522117 Apr 30, 2032 DP U-1939

BUDESONIDE - UCERIS N 203634 001 9532954 Jun 09, 2020 DP U-1325

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT N 021929 001 6123924 Sep 26, 2017 DP NPP Jan 27, 2020 7367333 Nov 11, 2018 DP PED Jul 27, 2020 7367333*PED May 11, 2019 7587988 Apr 10, 2026 DP 7587988*PED Oct 10, 2026 7759328 Jan 29, 2023 DP U-2001 7759328 Jan 29, 2023 DP U-2002 7759328*PED Jul 29, 2023 7967011 Aug 11, 2021 DP 7967011*PED Feb 11, 2022 8143239 Jan 29, 2023 DP U-2001 8143239 Jan 29, 2023 DP U-2002 8143239*PED Jul 29, 2023 8387615 Nov 10, 2024 DP 8387615*PED May 10, 2025 8528545 Oct 16, 2028 DP 8528545*PED Apr 16, 2029 8575137 Jan 29, 2023 DP U-2001 8575137 Jan 29, 2023 DP U-2002 8575137*PED Jul 29, 2023 8616196 Apr 07, 2029 DP 8616196*PED Oct 07, 2029 8875699 Nov 10, 2024 DP 8875699*PED May 10, 2025

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT N 021929 002 6123924 Sep 26, 2017 DP 7367333 Nov 11, 2018 DP 7367333*PED May 11, 2019 7587988 Apr 10, 2026 DP 7587988*PED Oct 10, 2026 7759328 Jan 29, 2023 DP U-2001 7759328 Jan 29, 2023 DP U-2002 7759328*PED Jul 29, 2023 7897646 Sep 09, 2018 U-2002 7897646*PED Mar 09, 2019 7967011 Aug 11, 2021 DP 7967011*PED Feb 11, 2022 8143239 Jan 29, 2023 DP U-2001 8143239 Jan 29, 2023 DP U-2002 8143239*PED Jul 29, 2023 8387615 Nov 10, 2024 DP 8387615*PED May 10, 2025 8461211 Sep 09, 2018 U-2002 8461211*PED Mar 09, 2019 A - 7 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT N 021929 002 8528545 Oct 16, 2028 DP 8528545*PED Apr 16, 2029 8575137 Jan 29, 2023 DP U-2001 8575137 Jan 29, 2023 DP U-2002 8575137*PED Jul 29, 2023 8616196 Apr 07, 2029 DP 8616196*PED Oct 07, 2029 8875699 Nov 10, 2024 DP 8875699*PED May 10, 2025

BUPIVACAINE - EXPAREL N 022496 001 9585838 Dec 24, 2021 DP

BUPIVACAINE - EXPAREL N 022496 002 9585838 Dec 24, 2021 DP

BUPRENORPHINE - BUTRANS N 021306 001 9642850 Sep 29, 2017 U-1556

BUPRENORPHINE - BUTRANS N 021306 002 9642850 Sep 29, 2017 U-1556

BUPRENORPHINE - BUTRANS N 021306 003 9642850 Sep 29, 2017 U-1556

BUPRENORPHINE - BUTRANS N 021306 004 9642850 Sep 29, 2017 U-1556

BUPRENORPHINE - BUTRANS N 021306 005 9642850 Sep 29, 2017 U-1556

BUPRENORPHINE HYDROCHLORIDE - BELBUCA N 207932 001 9655843 Jul 23, 2027 DP U-1556

BUPRENORPHINE HYDROCHLORIDE - BELBUCA N 207932 002 9655843 Jul 23, 2027 DP U-1556

BUPRENORPHINE HYDROCHLORIDE - BELBUCA N 207932 003 9655843 Jul 23, 2027 DP U-1556

BUPRENORPHINE HYDROCHLORIDE - BELBUCA N 207932 004 9655843 Jul 23, 2027 DP U-1556

BUPRENORPHINE HYDROCHLORIDE - BELBUCA N 207932 005 9655843 Jul 23, 2027 DP U-1556

BUPRENORPHINE HYDROCHLORIDE - BELBUCA N 207932 006 9655843 Jul 23, 2027 DP U-1556

BUPRENORPHINE HYDROCHLORIDE - BELBUCA N 207932 007 9655843 Jul 23, 2027 DP U-1556

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 001 >A> 9687454 Aug 07, 2029 DP U-1464

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 002 >A> 9687454 Aug 07, 2029 DP U-1464 A - 8 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 003 >A> 9687454 Aug 07, 2029 DP U-1464

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 004 >A> 9687454 Aug 07, 2029 DP U-1464

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL N 205637 001 9655843 Jul 23, 2027 DP U-2017

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL N 205637 002 9655843 Jul 23, 2027 DP U-2017

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL N 205637 003 9655843 Jul 23, 2027 DP U-2017

CABAZITAXEL - JEVTANA KIT N 201023 001 5847170 Mar 26, 2021 DS DP M-201 May 17, 2020 5847170*PED Sep 26, 2021 PED Nov 17, 2020 7241907 Dec 10, 2025 DS 7241907*PED Jun 10, 2026 8927592 Oct 27, 2030 U-1630 8927592*PED Apr 27, 2031

CANAGLIFLOZIN - INVOKANA N 204042 001 M-197 Feb 01, 2020

CANAGLIFLOZIN - INVOKANA N 204042 002 M-197 Feb 01, 2020

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET N 204353 001 M-197 Feb 01, 2020

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET N 204353 002 M-197 Feb 01, 2020

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET N 204353 003 M-197 Feb 01, 2020

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET N 204353 004 M-197 Feb 01, 2020

CANGRELOR - KENGREAL N 204958 001 >A> 9700575 Jul 10, 2035 DP

CARBAMAZEPINE - CARNEXIV N 206030 001 9493582 Feb 27, 2033 DP 9629797 Nov 10, 2028 U-2004 9629797 Nov 10, 2028 U-2005 9629797 Nov 10, 2028 U-2006

CARBIDOPA; LEVODOPA - RYTARY N 203312 001 9533046 Dec 26, 2028 DP U-219

CARBIDOPA; LEVODOPA - RYTARY N 203312 002 9533046 Dec 26, 2028 DP U-219

CARBIDOPA; LEVODOPA - RYTARY N 203312 003 9533046 Dec 26, 2028 DP U-219 A - 9 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

CARBIDOPA; LEVODOPA - RYTARY N 203312 004 9533046 Dec 26, 2028 DP U-219

CARBINOXAMINE MALEATE - KARBINAL ER N 022556 001 9522191 Jun 15, 2027 DP

CARFILZOMIB - KYPROLIS N 202714 001 9493582 Feb 27, 2033 DP

CARFILZOMIB - KYPROLIS N 202714 002 9493582 Feb 27, 2033 DP

CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE N 206110 001 9636407 Dec 21, 2032 DP

CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE N 206110 002 9636407 Dec 21, 2032 DP

CEFTAROLINE FOSAMIL - TEFLARO N 200327 001 9629861 Sep 21, 2030 DP

CEFTAROLINE FOSAMIL - TEFLARO N 200327 002 9629861 Sep 21, 2030 DP

CERITINIB - ZYKADIA N 205755 001 8188276 Jan 31, 2023 DS DP M-199 May 26, 2020 8399450 Nov 20, 2027 DS DP ODE May 26, 2024 8835430 Jan 31, 2023 DS DP 9018204 Jan 31, 2023 DS DP 9416112 Jan 31, 2023 DS DP

CETIRIZINE HYDROCHLORIDE - ZERVIATE N 208694 001 8829005 Mar 15, 2030 U-1680 NDF May 30, 2020 8829005*PED Sep 15, 2030 PED Nov 30, 2020 9254286 Jul 09, 2032 DP 9254286*PED Jan 09, 2033

CINACALCET HYDROCHLORIDE - SENSIPAR N 021688 001 M-200 May 23, 2020

CINACALCET HYDROCHLORIDE - SENSIPAR N 021688 002 M-200 May 23, 2020

CINACALCET HYDROCHLORIDE - SENSIPAR N 021688 003 M-200 May 23, 2020

CLOFARABINE - CLOFARABINE A 204029 001 >A> PC Nov 05, 2017

COBICISTAT - TYBOST N 203094 001 NCE Aug 27, 2017

COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX N 205395 001 NCE Aug 27, 2017

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA N 207561 001 7176220 Aug 27, 2026 DS DP U-257 NCE Aug 27, 2017 NCE Nov 05, 2020 A - 10 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD N 203100 001 7176220 Aug 27, 2026 DS DP U-257 NCE Aug 27, 2017 NPP Jan 27, 2020

COLCHICINE - MITIGARE N 204820 001 9555029 Aug 22, 2033 U-1020 9675613 Aug 22, 2033 U-1020

CRISABOROLE - EUCRISA N 207695 001 8039451 Jun 11, 2026 DS DP NCE Dec 14, 2021 8168614 Jan 20, 2030 U-1932 8501712 Feb 16, 2027 U-1932 >A> 9682092 Feb 16, 2027 U-1932

CROFELEMER - FULYZAQ N 202292 001 >A> 9585868 Oct 31, 2031 DS U-1319

CYCLOSPORINE - RESTASIS MULTIDOSE N 050790 002 8292129 Feb 25, 2031 DP 8561859 Apr 16, 2032 DP 9669974 May 11, 2034 DP 9676525 Feb 07, 2034 DP

DABRAFENIB MESYLATE - TAFINLAR N 202806 001 >A> 7994185 Jan 20, 2030 DS DP U-1406 I-745 Jun 22, 2020 >A> 7994185 Jan 20, 2030 DS DP U-2031 >A> ODE Jun 22, 2024 >A> 7994185 Jan 20, 2030 DS DP U-2032 >A> 8415345 Jan 20, 2030 DS DP U-1406 >A> 8415345 Jan 20, 2030 DS DP U-2031 >A> 8415345 Jan 20, 2030 DS DP U-2032 >A> 8835443 Sep 13, 2025 U-2026 >A> 8835443 Sep 13, 2025 U-2027 >A> 8952018 Oct 15, 2030 U-2027

DABRAFENIB MESYLATE - TAFINLAR N 202806 002 >A> 7994185 Jan 20, 2030 DS DP U-1406 I-745 Jun 22, 2020 >A> 7994185 Jan 20, 2030 DS DP U-2031 >A> ODE Jun 22, 2024 >A> 7994185 Jan 20, 2030 DS DP U-2032 >A> 8415345 Jan 20, 2030 DS DP U-1406 >A> 8415345 Jan 20, 2030 DS DP U-2031 >A> 8415345 Jan 20, 2030 DS DP U-2032 >A> 8835443 Sep 13, 2025 U-2026 >A> 8835443 Sep 13, 2025 U-2027 >A> 8952018 Oct 15, 2030 U-2027

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN N 209091 001 6414126 Oct 04, 2020 DS DP U-1976 M-175 Apr 05, 2019 6414126 Oct 04, 2020 DS DP U-1977 NC Feb 27, 2020 6515117 Oct 04, 2020 DS DP U-1976 NCE Jan 08, 2019 6515117 Oct 04, 2020 DS DP U-1977 6936590 Oct 04, 2020 U-1976 6936590 Oct 04, 2020 U-1977 7919598 Dec 16, 2029 DS 8221786 Mar 21, 2028 DP 8361972 Mar 21, 2028 U-1976 8361972 Mar 21, 2028 U-1977 8501698 Jun 20, 2027 DP U-1976 8501698 Jun 20, 2027 DP U-1977 8628799 Jul 13, 2025 DP 8716251 Mar 21, 2028 DP 9198925 Oct 04, 2020 U-1976 9198925 Oct 04, 2020 U-1977 RE44186 Jul 31, 2023 DS DP U-1976 RE44186 Jul 31, 2023 DS DP U-1977 A - 11 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DAPTOMYCIN - CUBICIN N 021572 002 NPP Mar 29, 2020

DAPTOMYCIN - CUBICIN RF N 021572 003 NPP Mar 29, 2020

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED) N 206619 001 9629841 Oct 18, 2033 DP U-1753

DEFERASIROX - JADENU SPRINKLE N 207968 001 6465504 Apr 05, 2019 DS DP

DEFERASIROX - JADENU SPRINKLE N 207968 002 6465504 Apr 05, 2019 DS DP

DEFERASIROX - JADENU SPRINKLE N 207968 003 6465504 Apr 05, 2019 DS DP

DEFLAZACORT - EMFLAZA N 208684 001 NCE Feb 09, 2022 ODE Feb 09, 2024

DEFLAZACORT - EMFLAZA N 208684 002 NCE Feb 09, 2022 ODE Feb 09, 2024

DEFLAZACORT - EMFLAZA N 208684 003 NCE Feb 09, 2022 ODE Feb 09, 2024

DEFLAZACORT - EMFLAZA N 208684 004 NCE Feb 09, 2022 ODE Feb 09, 2024

DEFLAZACORT - EMFLAZA N 208685 001 NCE Feb 09, 2022 ODE Feb 09, 2024

DEGARELIX ACETATE - FIRMAGON N 022201 001 9579359 Feb 10, 2029 U-1978 A - 12 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DEGARELIX ACETATE - FIRMAGON N 022201 002 9579359 Feb 10, 2029 U-1978

DELAFLOXACIN MEGLUMINE - BAXDELA N 208610 001 >A> 7728143 Nov 20, 2027 DS NCE Jun 19, 2022 >A> 8252813 Oct 02, 2026 DP U-2028 GAIN Jun 19, 2027 >A> 8273892 Aug 06, 2026 DS >A> 8497378 Dec 28, 2029 DS >A> 8648093 Oct 07, 2025 DP U-2028 >A> 8871938 Sep 23, 2029 DS >A> 8969569 Oct 07, 2025 DP U-2028 >A> 9539250 Oct 07, 2025 DS DP U-2028

DELAFLOXACIN MEGLUMINE - BAXDELA N 208611 001 >A> 7728143 Nov 20, 2027 DS NCE Jun 19, 2022 >A> 8252813 Oct 02, 2026 DP U-2028 GAIN Jun 19, 2027 >A> 8273892 Aug 06, 2026 DS >A> 8497378 Dec 28, 2029 DS >A> 8648093 Oct 07, 2025 DP U-2028 >A> 8871938 Sep 23, 2029 DS >A> 9539250 Oct 07, 2025 DS DP U-2028

DEOXYCHOLIC ACID - KYBELLA N 206333 001 9522155 Feb 21, 2028 DP U-1940

DESMOPRESSIN ACETATE - NOCTIVA N 201656 001 7405203 May 06, 2023 U-1980 NP Mar 03, 2020 7579321 May 06, 2023 U-1980 7799761 Sep 26, 2024 DP 9539302 Jun 15, 2030 DP

DESMOPRESSIN ACETATE - NOCTIVA N 201656 002 7405203 May 06, 2023 U-1980 NP Mar 03, 2020 7579321 May 06, 2023 U-1980 7799761 Sep 26, 2024 DP 9539302 Jun 15, 2030 DP

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204003 001 PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204003 002 PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204028 001 PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204028 002 PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204065 001 >A> PC Jan 25, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204065 002 >A> PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204065 003 >A> PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204082 001 PC Aug 28, 2017 A - 13 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204083 001 PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204095 001 PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204095 002 PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204172 001 PC Aug 28, 2017

DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE A 204172 002 PC Aug 28, 2017

DEUTETRABENAZINE - AUSTEDO N 208082 001 8524733 Mar 27, 2031 DS DP NCE Apr 03, 2022 9233959 Sep 18, 2033 DP ODE Apr 03, 2024 9296739 Sep 18, 2033 DP 9550780 Sep 18, 2033 DS DP U-1846

DEUTETRABENAZINE - AUSTEDO N 208082 002 8524733 Mar 27, 2031 DS DP NCE Apr 03, 2022 9233959 Sep 18, 2033 DP ODE Apr 03, 2024 9296739 Sep 18, 2033 DP 9550780 Sep 18, 2033 DS DP U-1846

DEUTETRABENAZINE - AUSTEDO N 208082 003 8524733 Mar 27, 2031 DS DP NCE Apr 03, 2022 9233959 Sep 18, 2033 DP ODE Apr 03, 2024 9296739 Sep 18, 2033 DP 9550780 Sep 18, 2033 DS DP U-1846

DEXAMETHASONE - OZURDEX N 022315 001 9592242 Oct 20, 2020 U-1989 9592242 Oct 20, 2020 U-1990

DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX N 021038 002 9616049 Jan 04, 2032 DP 9616049*PED Jul 04, 2032

DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX N 021038 003 9616049 Jan 04, 2032 DP 9616049*PED Jul 04, 2032

DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX N 021038 004 9616049 Jan 04, 2032 DP 9616049*PED Jul 04, 2032

DICLOFENAC POTASSIUM - ZIPSOR N 022202 001 9561200 Feb 24, 2029 U-1482

DICLOFENAC SODIUM - PENNSAID N 204623 001 9539335 Oct 17, 2027 U-1614

DOXEPIN HYDROCHLORIDE - SILENOR N 022036 001 9532971 Jun 01, 2029 DP 9572814 Jul 20, 2027 U-620 A - 14 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DOXEPIN HYDROCHLORIDE - SILENOR N 022036 002 9532971 Jun 01, 2029 DP 9572814 Jul 20, 2027 U-620

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA N 209661 001 >A> 7560122 Jan 25, 2019 DP 9089489 Feb 18, 2033 DP U-1382 9375404 Feb 18, 2033 DP U-1382 9526703 Feb 18, 2033 DP U-1382

DRONABINOL - SYNDROS N 205525 001 8222292 Aug 06, 2028 DS DP 9345771 Aug 06, 2028 DS DP

EDARAVONE - RADICAVA N 209176 001 6933310 Nov 13, 2020 U-2013 NCE May 05, 2022 ODE May 05, 2024

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA N 021937 001 8598185 Apr 28, 2029 DP 9545414 Jun 13, 2026 DP U-750 9545414 Jun 13, 2026 DP U-1170

EFINACONAZOLE - JUBLIA N 203567 001 9566272 Jan 03, 2028 U-1969 9662394 Oct 02, 2034 DP

ELTROMBOPAG OLAMINE - PROMACTA N 207027 001 6280959 Oct 30, 2018 DS DP U-1736 ODE Aug 26, 2021 6280959*PED Apr 30, 2019 PED Feb 26, 2022 7160870 Nov 20, 2022 DS DP U-1736 7160870*PED May 20, 2023 7332481 May 24, 2021 U-1736 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-1736 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-1736 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-1736 7790704*PED Nov 24, 2021 7795293 May 24, 2023 U-1736 7795293*PED Nov 24, 2023

ELUXADOLINE - VIBERZI N 206940 001 8772325 Mar 14, 2025 U-1709

ELUXADOLINE - VIBERZI N 206940 002 8772325 Mar 14, 2025 U-1709

ELVITEGRAVIR - VITEKTA N 203093 001 7176220 Aug 27, 2026 DS DP U-257 NCE Aug 27, 2017

ELVITEGRAVIR - VITEKTA N 203093 002 7176220 Aug 27, 2026 DS DP U-257 NCE Aug 27, 2017

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA N 021752 002 5914331 Jul 02, 2017 DS 5914331*PED Jan 02, 2018 6642245 Nov 04, 2020 U-248 6642245 Nov 04, 2020 U-541 6642245 Nov 04, 2020 U-1170 A - 15 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA N 021752 002 6642245*PED May 04, 2021

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA N 021752 003 5914331 Jul 02, 2017 DS 5914331*PED Jan 02, 2018 6642245 Nov 04, 2020 U-248 6642245 Nov 04, 2020 U-541 6642245 Nov 04, 2020 U-1170 6642245*PED May 04, 2021

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA N 021752 004 5914331 Jul 02, 2017 DS 5914331*PED Jan 02, 2018 6642245 Nov 04, 2020 U-248 6642245 Nov 04, 2020 U-541 6642245 Nov 04, 2020 U-1170 6642245*PED May 04, 2021

ENALAPRIL MALEATE - EPANED N 208686 001 9669008 Mar 25, 2036 DP

ENZALUTAMIDE - XTANDI N 203415 001 8183274 Aug 24, 2026 U-1281 8183274 Aug 24, 2026 U-1588

EPINEPHRINE - EPIPEN N 019430 001 9586010 Sep 11, 2025 DP

EPINEPHRINE - EPIPEN JR. N 019430 002 9586010 Sep 11, 2025 DP

EPINEPHRINE - ADRENACLICK N 020800 003 7905352 Apr 12, 2027 DP

EPINEPHRINE - ADRENACLICK N 020800 004 7905352 Apr 12, 2027 DP

EPINEPHRINE - ADRENALIN N 204200 001 9295657 Mar 13, 2035 U-1829

ESLICARBAZEPINE ACETATE - APTIOM N 022416 001 >A> 5753646 Jun 27, 2021 DS DP U-2041 9566244 Oct 23, 2028 DP 9643929 Apr 21, 2026 DP

ESLICARBAZEPINE ACETATE - APTIOM N 022416 002 >A> 5753646 Jun 27, 2021 DS DP U-2041 9566244 Oct 23, 2028 DP 9643929 Apr 21, 2026 DP

ESLICARBAZEPINE ACETATE - APTIOM N 022416 003 >A> 5753646 Jun 27, 2021 DS DP U-2041 9566244 Oct 23, 2028 DP 9643929 Apr 21, 2026 DP

ESLICARBAZEPINE ACETATE - APTIOM N 022416 004 >A> 5753646 Jun 27, 2021 DS DP U-2041 9566244 Oct 23, 2028 DP 9643929 Apr 21, 2026 DP A - 16 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO N 022511 001 >A> NPP Jul 06, 2020

ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO N 022511 002 >A> NPP Jul 06, 2020

ESTRADIOL - ESTRADIOL A 205256 001 PC Apr 15, 2017

ETELCALCETIDE - PARSABIV N 208325 001 8377880 Jul 29, 2030 DS DP NCE Feb 07, 2022 8999932 Jul 29, 2030 DS DP U-2014 9278995 Jul 29, 2030 DS >A> 9701712 Jul 29, 2030 DS DP U-2014

ETELCALCETIDE - PARSABIV N 208325 002 8377880 Jul 29, 2030 DS DP NCE Feb 07, 2022 8999932 Jul 29, 2030 DS DP U-2014 9278995 Jul 29, 2030 DS >A> 9701712 Jul 29, 2030 DS DP U-2014

ETELCALCETIDE - PARSABIV N 208325 003 8377880 Jul 29, 2030 DS DP NCE Feb 07, 2022 8999932 Jul 29, 2030 DS DP U-2014 9278995 Jul 29, 2030 DS >A> 9701712 Jul 29, 2030 DS DP U-2014

ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM A 205943 001 PC Sep 30, 2017

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE A 206287 001 PC Sep 11, 2017

EVEROLIMUS - ZORTRESS N 021560 001 >A> 6239124 Jul 29, 2017 U-1049 >A> 6239124*PED Jan 29, 2018

EVEROLIMUS - ZORTRESS N 021560 002 >A> 6239124 Jul 29, 2017 U-1049 >A> 6239124*PED Jan 29, 2018

EVEROLIMUS - ZORTRESS N 021560 003 >A> 6239124 Jul 29, 2017 U-1049 >A> 6239124*PED Jan 29, 2018

EVEROLIMUS - AFINITOR N 022334 001 ODE Feb 26, 2023

EVEROLIMUS - AFINITOR N 022334 002 ODE Feb 26, 2023

EVEROLIMUS - AFINITOR N 022334 003 ODE Feb 26, 2023

EVEROLIMUS - AFINITOR N 022334 004 ODE Feb 26, 2023

FENTANYL - SUBSYS N 202788 001 9289387 Jan 25, 2027 DP U-55 9642797 Jan 25, 2027 DP U-55 9642844 Jan 25, 2027 DP A - 17 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

FENTANYL - SUBSYS N 202788 001 9289387 Jan 25, 2027 DP U-55 9642797 Jan 25, 2027 DP U-55 9642844 Jan 25, 2027 DP

FENTANYL - SUBSYS N 202788 002 9289387 Jan 25, 2027 DP U-55 9642797 Jan 25, 2027 DP U-55 9642844 Jan 25, 2027 DP

FENTANYL - SUBSYS N 202788 003 9289387 Jan 25, 2027 DP U-55 9642797 Jan 25, 2027 DP U-55 9642844 Jan 25, 2027 DP

FENTANYL - SUBSYS N 202788 004 9289387 Jan 25, 2027 DP U-55 9642797 Jan 25, 2027 DP U-55 9642844 Jan 25, 2027 DP

FENTANYL - SUBSYS N 202788 005 9289387 Jan 25, 2027 DP U-55 9642797 Jan 25, 2027 DP U-55 9642844 Jan 25, 2027 DP

FENTANYL - SUBSYS N 202788 006 9289387 Jan 25, 2027 DP U-55 9642797 Jan 25, 2027 DP U-55 9642844 Jan 25, 2027 DP

FENTANYL - SUBSYS N 202788 007 9289387 Jan 25, 2027 DP U-55 9642797 Jan 25, 2027 DP U-55 9642844 Jan 25, 2027 DP

FENTANYL CITRATE - ONSOLIS N 022266 001 9597288 Jul 23, 2027 DP U-767

FENTANYL CITRATE - ONSOLIS N 022266 002 9597288 Jul 23, 2027 DP U-767

FENTANYL CITRATE - ONSOLIS N 022266 003 9597288 Jul 23, 2027 DP U-767

FENTANYL CITRATE - ONSOLIS N 022266 004 9597288 Jul 23, 2027 DP U-767

FENTANYL CITRATE - ONSOLIS N 022266 005 9597288 Jul 23, 2027 DP U-767

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20% N 207648 001 NCE Jul 13, 2021

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20% N 207648 002 NCE Jul 13, 2021

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20% N 207648 003 NCE Jul 13, 2021 A - 18 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA N 204275 001 M-202 May 15, 2020 NCE May 10, 2018

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA N 204275 002 M-202 May 15, 2020 NCE May 10, 2018

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 001 6446627 Dec 18, 2017 DP NP Jan 27, 2020 6701917 Jun 23, 2021 DP 6718972 Jun 23, 2021 DP 6748947 Jun 23, 2021 DP 6871646 Jun 23, 2021 DP 7540282 May 06, 2023 DP 8006690 Jun 23, 2021 DP 8651103 Mar 26, 2028 DP 8714149 Feb 25, 2032 DP 8978966 Jan 13, 2032 DP 9216260 Jun 28, 2031 DP 9463288 May 19, 2025 DP 9616024 Sep 01, 2024 DP

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 002 6446627 Dec 18, 2017 DP NP Jan 27, 2020 6701917 Jun 23, 2021 DP 6718972 Jun 23, 2021 DP 6748947 Jun 23, 2021 DP 6871646 Jun 23, 2021 DP 7540282 May 06, 2023 DP 8006690 Jun 23, 2021 DP 8651103 Mar 26, 2028 DP 8714149 Feb 25, 2032 DP 8978966 Jan 13, 2032 DP 9216260 Jun 28, 2031 DP 9463288 May 19, 2025 DP 9616024 Sep 01, 2024 DP

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 003 6446627 Dec 18, 2017 DP NP Jan 27, 2020 6701917 Jun 23, 2021 DP 6718972 Jun 23, 2021 DP 6748947 Jun 23, 2021 DP 6871646 Jun 23, 2021 DP 7540282 May 06, 2023 DP 8006690 Jun 23, 2021 DP 8651103 Mar 26, 2028 DP 8714149 Feb 25, 2032 DP 8978966 Jan 13, 2032 DP 9216260 Jun 28, 2031 DP 9463288 May 19, 2025 DP 9616024 Sep 01, 2024 DP

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 001 6446627 Dec 18, 2017 DP NP Jan 27, 2020 6701917 Jun 23, 2021 DP 6718972 Jun 23, 2021 DP 6748947 Jun 23, 2021 DP 6871646 Jun 23, 2021 DP 7540282 May 06, 2023 DP 8006690 Jun 23, 2021 DP 8651103 Mar 26, 2028 DP 8714149 Feb 25, 2032 DP 8978966 Jan 13, 2032 DP 9066957 Oct 06, 2034 DP U-645 9216260 Jun 28, 2031 DP A - 19 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 001 9415008 Oct 06, 2034 DP U-645 9463288 May 19, 2025 DP 9616024 Sep 01, 2024 DP

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 002 6446627 Dec 18, 2017 DP NP Jan 27, 2020 6701917 Jun 23, 2021 DP 6718972 Jun 23, 2021 DP 6748947 Jun 23, 2021 DP 6871646 Jun 23, 2021 DP 7540282 May 06, 2023 DP 8006690 Jun 23, 2021 DP 8651103 Mar 26, 2028 DP 8714149 Feb 25, 2032 DP 8978966 Jan 13, 2032 DP 9066957 Oct 06, 2034 DP U-645 9216260 Jun 28, 2031 DP 9463288 May 19, 2025 DP 9616024 Sep 01, 2024 DP

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 003 6446627 Dec 18, 2017 DP NP Jan 27, 2020 6701917 Jun 23, 2021 DP 6718972 Jun 23, 2021 DP 6748947 Jun 23, 2021 DP 6871646 Jun 23, 2021 DP 7540282 May 06, 2023 DP 8006690 Jun 23, 2021 DP 8651103 Mar 26, 2028 DP 8714149 Feb 25, 2032 DP 8978966 Jan 13, 2032 DP 9066957 Oct 06, 2034 DP U-645 9216260 Jun 28, 2031 DP 9463288 May 19, 2025 DP 9616024 Sep 01, 2024 DP

GANCICLOVIR - GANCICLOVIR N 209347 001 9486530 Sep 02, 2034 DP

GLYCEROL PHENYLBUTYRATE - RAVICTI N 203284 001 9561197 Sep 22, 2030 U-1383 NPP Apr 28, 2020

GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON N 205474 001 9549907 Nov 13, 2035 DS DP U-2023

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 001 9486451 Sep 12, 2034 U-55 9610286 Jul 25, 2033 U-1810

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 002 9486451 Sep 12, 2034 U-55 9610286 Jul 25, 2033 U-1810

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 003 9486451 Sep 12, 2034 U-55 9610286 Jul 25, 2033 U-1810

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 004 9486451 Sep 12, 2034 U-55 9610286 Jul 25, 2033 U-1810 A - 20 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 005 9486451 Sep 12, 2034 U-55 9610286 Jul 25, 2033 U-1810

HYDROCODONE BITARTRATE - ZOHYDRO ER N 202880 006 9486451 Sep 12, 2034 U-55 9610286 Jul 25, 2033 U-1810

HYDROCODONE BITARTRATE - HYSINGLA N 206627 001 9023401 Oct 30, 2020 DP 9056052 Oct 30, 2020 DP 9060940 Oct 30, 2020 U-1556 9198863 Oct 30, 2020 DP 9205056 Oct 30, 2020 DP 9289391 Oct 30, 2020 DP 9517236 Oct 30, 2020 DP 9545380 Aug 24, 2027 U-1556 9572779 Dec 21, 2031 DP 9572804 Oct 30, 2020 DP 9669023 Oct 30, 2020 DP 9669024 Oct 30, 2020 DP >A> 9675610 Jun 16, 2023 DP 9675611 Oct 30, 2020 U-1556 9682077 Oct 30, 2020 U-1556

HYDROCODONE BITARTRATE - HYSINGLA N 206627 002 9023401 Oct 30, 2020 DP 9056052 Oct 30, 2020 DP 9060940 Oct 30, 2020 U-1556 9198863 Oct 30, 2020 DP 9205056 Oct 30, 2020 DP 9289391 Oct 30, 2020 DP 9517236 Oct 30, 2020 DP 9545380 Aug 24, 2027 U-1556 9572779 Dec 21, 2031 DP 9572804 Oct 30, 2020 DP 9669023 Oct 30, 2020 DP 9669024 Oct 30, 2020 DP >A> 9675610 Jun 16, 2023 DP 9675611 Oct 30, 2020 U-1556 9682077 Oct 30, 2020 U-1556

HYDROCODONE BITARTRATE - HYSINGLA N 206627 003 9023401 Oct 30, 2020 DP 9056052 Oct 30, 2020 DP 9060940 Oct 30, 2020 U-1556 9198863 Oct 30, 2020 DP 9205056 Oct 30, 2020 DP 9289391 Oct 30, 2020 DP 9517236 Oct 30, 2020 DP 9545380 Aug 24, 2027 U-1556 9572779 Dec 21, 2031 DP 9572804 Oct 30, 2020 DP 9669023 Oct 30, 2020 DP 9669024 Oct 30, 2020 DP >A> 9675610 Jun 16, 2023 DP 9675611 Oct 30, 2020 U-1556 9682077 Oct 30, 2020 U-1556

HYDROCODONE BITARTRATE - HYSINGLA N 206627 004 9023401 Oct 30, 2020 DP 9056052 Oct 30, 2020 DP 9060940 Oct 30, 2020 U-1556 9198863 Oct 30, 2020 DP 9205056 Oct 30, 2020 DP 9289391 Oct 30, 2020 DP A - 21 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

HYDROCODONE BITARTRATE - HYSINGLA N 206627 004 9517236 Oct 30, 2020 DP 9545380 Aug 24, 2027 U-1556 9572779 Dec 21, 2031 DP 9572804 Oct 30, 2020 DP 9669023 Oct 30, 2020 DP 9669024 Oct 30, 2020 DP >A> 9675610 Jun 16, 2023 DP 9675611 Oct 30, 2020 U-1556 9682077 Oct 30, 2020 U-1556

HYDROCODONE BITARTRATE - HYSINGLA N 206627 005 9056052 Oct 30, 2020 DP 9060940 Oct 30, 2020 U-1556 9198863 Oct 30, 2020 DP 9205056 Oct 30, 2020 DP 9289391 Oct 30, 2020 DP 9517236 Oct 30, 2020 DP 9545380 Aug 24, 2027 U-1556 9572779 Dec 21, 2031 DP 9572804 Oct 30, 2020 DP 9669023 Oct 30, 2020 DP 9669024 Oct 30, 2020 DP >A> 9675610 Jun 16, 2023 DP 9675611 Oct 30, 2020 U-1556 9682077 Oct 30, 2020 U-1556

HYDROCODONE BITARTRATE - HYSINGLA N 206627 006 9056052 Oct 30, 2020 DP 9060940 Oct 30, 2020 U-1556 9198863 Oct 30, 2020 DP 9205056 Oct 30, 2020 DP 9289391 Oct 30, 2020 DP 9517236 Oct 30, 2020 DP 9545380 Aug 24, 2027 U-1556 9572779 Dec 21, 2031 DP 9572804 Oct 30, 2020 DP 9669023 Oct 30, 2020 DP 9669024 Oct 30, 2020 DP >A> 9675610 Jun 16, 2023 DP 9675611 Oct 30, 2020 U-1556 9682077 Oct 30, 2020 U-1556

HYDROCODONE BITARTRATE - HYSINGLA N 206627 007 9056052 Oct 30, 2020 DP 9060940 Oct 30, 2020 U-1556 9198863 Oct 30, 2020 DP 9205056 Oct 30, 2020 DP 9289391 Oct 30, 2020 DP 9517236 Oct 30, 2020 DP 9545380 Aug 24, 2027 U-1556 9572779 Dec 21, 2031 DP 9572804 Oct 30, 2021 DP 9669023 Oct 30, 2020 DP 9669024 Oct 30, 2020 DP >A> 9675610 Jun 16, 2023 DP 9675611 Oct 30, 2020 U-1556 9682077 Oct 30, 2020 U-1556

HYDROCODONE BITARTRATE - VANTRELA ER N 207975 001 8445018 Jul 31, 2029 DP 9216176 Sep 13, 2027 DP 9572803 Sep 13, 2027 DP A - 22 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

HYDROCODONE BITARTRATE - VANTRELA ER N 207975 002 8445018 Jul 31, 2029 DP 9216176 Sep 13, 2027 DP 9572803 Sep 13, 2027 DP

HYDROCODONE BITARTRATE - VANTRELA ER N 207975 003 8445018 Jul 31, 2029 DP 9216176 Sep 13, 2027 DP 9572803 Sep 13, 2027 DP

HYDROCODONE BITARTRATE - VANTRELA ER N 207975 004 8445018 Jul 31, 2029 DP 9216176 Sep 13, 2027 DP 9572803 Sep 13, 2027 DP

HYDROCODONE BITARTRATE - VANTRELA ER N 207975 005 8445018 Jul 31, 2029 DP 9216176 Sep 13, 2027 DP 9572803 Sep 13, 2027 DP

IBRUTINIB - IMBRUVICA N 205552 001 8476284 Dec 28, 2026 U-1456 I-741 Jan 18, 2020 8476284 Dec 28, 2026 U-1491 ODE Jan 18, 2024 8476284 Dec 28, 2026 U-1947 8497277 Dec 28, 2026 U-1456 8497277 Dec 28, 2026 U-1491 8497277 Dec 28, 2026 U-1650 8497277 Dec 28, 2026 U-1947 9540382 Aug 18, 2033 U-1456 9540382 Aug 18, 2033 U-1650 9540382 Aug 18, 2033 U-1684 9540382 Aug 18, 2033 U-1946 9540382 Aug 18, 2033 U-1947

IBUPROFEN - CALDOLOR N 022348 002 9649284 Sep 30, 2029 U-2018

ICOSAPENT ETHYL - VASCEPA N 202057 002 8188146 Jan 27, 2020 DS DP NCE Jul 26, 2017 8293727 Feb 09, 2030 U-1287 8293728 Feb 09, 2030 U-1287 8298554 Apr 29, 2030 DP 8314086 Feb 09, 2030 U-1287 8318715 Feb 09, 2030 U-1287 8357677 Feb 09, 2030 U-1287 8367652 Feb 09, 2030 U-1287 8377920 Feb 09, 2030 U-1287 8399446 Feb 09, 2030 U-1287 8415335 Feb 09, 2030 U-1287 8426399 Feb 09, 2030 U-1287 8440650 Feb 09, 2030 U-1287 8445003 Apr 29, 2030 U-1287 8445013 Apr 29, 2030 U-1287 8501225 Apr 29, 2030 U-1287 8518929 Apr 29, 2030 U-1287 8524698 Apr 29, 2030 U-1287 8546372 Apr 29, 2030 U-1287 8551521 Apr 29, 2030 U-1287 8563608 Apr 29, 2030 U-1287 8617593 Apr 29, 2030 U-1287 8617594 Apr 29, 2030 U-1287 8623406 Apr 29, 2030 U-1287 A - 23 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH N 020986 005 RE46363 Aug 03, 2026 DP

INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30 N 203313 001 RE46363 Aug 03, 2026 DP

INSULIN DEGLUDEC - TRESIBA N 203314 001 RE46363 Aug 03, 2026 DP

INSULIN DEGLUDEC - TRESIBA N 203314 002 RE46363 Aug 03, 2026 DP

INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6 N 208583 001 RE46363 Aug 03, 2026 DP

INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH N 021536 005 RE46363 Aug 03, 2026 DP

INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR N 021081 002 9561331 Aug 28, 2024 DP 9604008 Mar 02, 2024 DP 9604009 Aug 16, 2024 DP 9610409 Mar 02, 2024 DP 9623189 Aug 19, 2024 DP

INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR N 206538 001 9561331 Aug 28, 2024 DP 9604008 Mar 02, 2024 DP 9604009 Aug 16, 2024 DP 9610409 Mar 02, 2024 DP 9623189 Aug 19, 2024 DP

INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33 N 208673 001 9526764 Oct 09, 2029 DP 9561331 Aug 28, 2024 DP 9604008 Mar 02, 2024 DP 9604009 Aug 16, 2024 DP 9610409 Mar 02, 2024 DP 9623189 Aug 19, 2024 DP >A> 9707176 Nov 11, 2030 DP

INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR N 021629 003 9561331 Aug 28, 2024 DP 9604008 Mar 02, 2024 DP 9610409 Mar 02, 2024 DP 9623189 Aug 19, 2024 DP

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 001 9597374 Oct 08, 2031 U-1987 9662461 Jun 12, 2029 DP U-2019

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 002 9597374 Oct 08, 2031 U-1987 9662461 Jun 12, 2029 DP U-2019

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 003 9597374 Oct 08, 2031 U-1987 9662461 Jun 12, 2029 DP U-2019

IVACAFTOR - KALYDECO N 203188 001 9670163 Dec 28, 2026 DP U-1311 A - 24 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

IVACAFTOR - KALYDECO N 207925 001 9670163 Dec 28, 2026 DP U-1311

IVACAFTOR - KALYDECO N 207925 002 9670163 Dec 28, 2026 DP U-1311

IVACAFTOR; LUMACAFTOR - ORKAMBI N 206038 001 7973038 Nov 08, 2026 U-1973 9670163 Dec 28, 2026 DP U-1911

IVACAFTOR; LUMACAFTOR - ORKAMBI N 206038 002 7973038 Nov 08, 2026 U-1973 9670163 Dec 28, 2026 DP U-1911

L-GLUTAMINE - ENDARI N 208587 001 >A> I-748 Jul 07, 2020 >A> ODE Jul 07, 2024

LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS N 206510 001 >A> 7169780 Oct 03, 2023 DS DP >A> 7169780*PED Apr 03, 2024 >A> 7217713 Oct 21, 2022 U-1663 >A> 7217713*PED Apr 21, 2023 >A> 7435734 Oct 21, 2022 U-1663 >A> 7435734*PED Apr 21, 2023 >A> 7754731 Mar 11, 2029 DS DP U-1663 >A> 7754731*PED Sep 11, 2029

LEDIPASVIR; SOFOSBUVIR - HARVONI N 205834 001 NPP Apr 07, 2020 ODE Apr 07, 2024

LENALIDOMIDE - REVLIMID N 021880 001 5635517 Oct 04, 2019 DS ODE Feb 22, 2024

LENALIDOMIDE - REVLIMID N 021880 002 5635517 Oct 04, 2019 DS ODE Feb 22, 2024

LENALIDOMIDE - REVLIMID N 021880 003 5635517 Oct 04, 2019 DS ODE Feb 22, 2024

LENALIDOMIDE - REVLIMID N 021880 004 5635517 Oct 04, 2019 DS ODE Feb 22, 2024

LENALIDOMIDE - REVLIMID N 021880 005 5635517 Oct 04, 2019 DS ODE Feb 22, 2024

LENALIDOMIDE - REVLIMID N 021880 006 5635517 Oct 04, 2019 DS ODE Feb 22, 2024

LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED) N 209935 001 8324225 Jun 17, 2028 DS DP NCE Mar 13, 2022 8415355 Feb 19, 2031 DS DP 8685980 May 25, 2030 DS DP 8962630 Dec 09, 2029 U-1981 9193732 Nov 09, 2031 DS DP 9416136 Aug 20, 2029 U-1981

LEUPROLIDE ACETATE - ELIGARD N 021343 001 9254307 Oct 28, 2018 DS DP A - 25 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LEUPROLIDE ACETATE - ELIGARD N 021379 001 8470359 Oct 15, 2023 DS DP U-621 8486455 Oct 28, 2018 DS DP 8840916 Nov 13, 2020 DP 9539333 Nov 13, 2020 DS DP U-621

LEUPROLIDE ACETATE - ELIGARD N 021488 001 8470359 Oct 15, 2023 DS DP U-621 8486455 Oct 28, 2018 DS DP 8840916 Nov 13, 2020 DP 9539333 Nov 13, 2020 DS DP U-621

LEUPROLIDE ACETATE - ELIGARD N 021731 001 8470359 Oct 15, 2023 DS DP U-621 8486455 Oct 28, 2018 DS DP 8840916 Nov 13, 2020 DP 9539333 Nov 13, 2020 DS DP U-621

LEVETIRACETAM - SPRITAM N 207958 001 >A> 9339489 Mar 14, 2034 DP U-1850 9669009 Mar 14, 2034 U-1850 9669009 Mar 14, 2034 U-2021 9669009 Mar 14, 2034 U-2022

LEVETIRACETAM - SPRITAM N 207958 002 9669009 Mar 14, 2034 U-1850 9669009 Mar 14, 2034 U-2021 9669009 Mar 14, 2034 U-2022

LEVETIRACETAM - SPRITAM N 207958 003 9669009 Mar 14, 2034 U-1850 9669009 Mar 14, 2034 U-2021 9669009 Mar 14, 2034 U-2022

LEVETIRACETAM - SPRITAM N 207958 004 9669009 Mar 14, 2034 U-1850 9669009 Mar 14, 2034 U-2021 9669009 Mar 14, 2034 U-2022

LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR N 209090 001 8633194 Oct 16, 2027 DP

LEVONORGESTREL - MIRENA N 021225 001 9615965 Sep 16, 2029 DP U-2003 9668912 Apr 01, 2031 DP

LEVONORGESTREL - SKYLA N 203159 001 9615965 Sep 16, 2029 DP U-2003 9668912 Apr 01, 2031 DP

LEVONORGESTREL - KYLEENA N 208224 001 9615965 Sep 16, 2029 DP U-2003 9668912 Apr 01, 2031 DP

LINACLOTIDE - LINZESS N 202811 001 >A> 9708371 Aug 16, 2033 DP U-1515 >A> 9708371 Aug 16, 2033 DP U-1516

LINACLOTIDE - LINZESS N 202811 002 >A> 9708371 Aug 16, 2033 DP U-1515 A - 26 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LINACLOTIDE - LINZESS N 202811 003 7304036 Aug 30, 2026 DS DP U-1516 NCE Aug 30, 2017 7371727 Jan 28, 2024 DS NS Jan 25, 2020 7704947 Jan 28, 2024 DS DP 7745409 Jan 28, 2024 DS DP 8080526 Jan 28, 2024 DS DP 8110553 Jan 28, 2024 U-1516 8933030 Feb 17, 2031 DP U-1516 >A> 9708371 Aug 16, 2033 DP U-1516

LINAGLIPTIN - TRADJENTA N 201280 001 8846695 Jun 04, 2030 U-1503 Y

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 001 8846695 Jun 04, 2030 U-1503

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 002 8846695 Jun 04, 2030 U-1503

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 003 8846695 Jun 04, 2030 U-1503 Y

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR N 208026 001 9555001 Mar 06, 2033 DP U-1967 9555001 Mar 06, 2033 DP U-1968

LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR N 208026 002 9555001 Mar 06, 2033 DP U-1967 9555001 Mar 06, 2033 DP U-1968

LIRAGLUTIDE RECOMBINANT - SAXENDA N 206321 001 RE46363 Aug 03, 2026 DP

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 001 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 7223735 Feb 24, 2023 DP M-188 Oct 14, 2019 7655630 Feb 24, 2023 DS DP 7659253 Feb 24, 2023 DS DP U-727 7659254 Feb 24, 2023 U-727 7662787 Feb 24, 2023 DS 7662788 Feb 24, 2023 U-727 7671030 Feb 24, 2023 DP U-727 7671031 Feb 24, 2023 U-727 7674774 Feb 24, 2023 DP U-727 7678770 Feb 24, 2023 U-727 7678771 Feb 24, 2023 DP U-727 7687466 Feb 24, 2023 DP 7687467 Feb 24, 2023 DP U-727 7713936 Feb 24, 2023 U-727 7718619 Feb 24, 2023 DP U-727 7723305 Feb 24, 2023 DP U-727

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 002 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 7223735 Feb 24, 2023 DP M-188 Oct 14, 2019 7655630 Feb 24, 2023 DS DP 7659253 Feb 24, 2023 DS DP U-727 7659254 Feb 24, 2023 U-727 7662787 Feb 24, 2023 DS 7662788 Feb 24, 2023 U-727 7671030 Feb 24, 2023 DP U-727 7671031 Feb 24, 2023 U-727 7674774 Feb 24, 2023 DP U-727 7678770 Feb 24, 2023 U-727 A - 27 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 002 7678771 Feb 24, 2023 DP U-727 7687466 Feb 24, 2023 DP 7687467 Feb 24, 2023 DP U-727 7713936 Feb 24, 2023 U-727 7718619 Feb 24, 2023 DP U-727 7723305 Feb 24, 2023 DP U-727

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 003 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 7223735 Feb 24, 2023 DP M-188 Oct 14, 2019 7655630 Feb 24, 2023 DS DP 7659253 Feb 24, 2023 DS DP U-727 7659254 Feb 24, 2023 U-727 7662787 Feb 24, 2023 DS 7662788 Feb 24, 2023 U-727 7671030 Feb 24, 2023 DP U-727 7671031 Feb 24, 2023 U-727 7674774 Feb 24, 2023 DP U-727 7678770 Feb 24, 2023 U-727 7678771 Feb 24, 2023 DP U-727 7687466 Feb 24, 2023 DP 7687467 Feb 24, 2023 DP U-727 7713936 Feb 24, 2023 U-727 7718619 Feb 24, 2023 DP U-727 7723305 Feb 24, 2023 DP U-727

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 004 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 7223735 Feb 24, 2023 DP M-188 Oct 14, 2019 7655630 Feb 24, 2023 DS DP 7659253 Feb 24, 2023 DS DP U-727 7659254 Feb 24, 2023 U-727 7662787 Feb 24, 2023 DS 7662788 Feb 24, 2023 U-727 7671030 Feb 24, 2023 DP U-727 7671031 Feb 24, 2023 U-727 7674774 Feb 24, 2023 DP U-727 7678770 Feb 24, 2023 U-727 7678771 Feb 24, 2023 DP U-727 7687466 Feb 24, 2023 DP 7687467 Feb 24, 2023 DP U-727 7713936 Feb 24, 2023 U-727 7718619 Feb 24, 2023 DP U-727 7723305 Feb 24, 2023 DP U-727

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 005 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 7223735 Feb 24, 2023 DP M-188 Oct 14, 2019 7655630 Feb 24, 2023 DS DP 7659253 Feb 24, 2023 DS DP U-727 7659254 Feb 24, 2023 U-727 7662787 Feb 24, 2023 DS 7662788 Feb 24, 2023 U-727 7671030 Feb 24, 2023 DP U-727 7671031 Feb 24, 2023 U-727 7674774 Feb 24, 2023 DP U-727 7678770 Feb 24, 2023 U-727 7678771 Feb 24, 2023 DP U-727 7687466 Feb 24, 2023 DP 7687467 Feb 24, 2023 DP U-727 7713936 Feb 24, 2023 U-727 7718619 Feb 24, 2023 DP U-727 7723305 Feb 24, 2023 DP U-727 A - 28 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 006 7105486 Feb 24, 2023 U-727 I-703 Jan 30, 2018 7223735 Feb 24, 2023 DP M-188 Oct 14, 2019 7655630 Feb 24, 2023 DS DP 7659253 Feb 24, 2023 DS DP U-727 7659254 Feb 24, 2023 U-727 7662787 Feb 24, 2023 DS 7662788 Feb 24, 2023 U-727 7671030 Feb 24, 2023 DP U-727 7671031 Feb 24, 2023 U-727 7674774 Feb 24, 2023 DP U-727 7678770 Feb 24, 2023 U-727 7678771 Feb 24, 2023 DP U-727 7687466 Feb 24, 2023 DP 7687467 Feb 24, 2023 DP U-727 7713936 Feb 24, 2023 U-727 7718619 Feb 24, 2023 DP U-727 7723305 Feb 24, 2023 DP U-727

LISINOPRIL - QBRELIS N 208401 001 9616096 Nov 06, 2035 U-3 9616096 Nov 06, 2035 U-8 9616096 Nov 06, 2035 U-71 9616096 Nov 06, 2035 U-185 9616096 Nov 06, 2035 U-1723 9616096 Nov 06, 2035 U-1864 9616096 Nov 06, 2035 U-1991

LIXISENATIDE - ADLYXIN N 208471 001 >A> 9707176 Nov 11, 2030 DP

LIXISENATIDE - ADLYXIN N 208471 002 >A> 9707176 Nov 11, 2030 DP

LOXAPINE - ADASUVE N 022549 001 >A> 9687487 Oct 26, 2021 DS DP

LULICONAZOLE - LUZU N 204153 001 >A> 5900488 Jan 18, 2020 DS DP

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 001 9555027 May 26, 2026 DP U-543 M-195 Jan 27, 2020 NPP Jan 27, 2020 PED Jul 27, 2020 PED Jul 27, 2020

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 002 9555027 May 26, 2026 DP U-543 NPP Jan 27, 2020 PED Jul 27, 2020

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 003 9555027 May 26, 2026 DP U-543 M-195 Jan 27, 2020 NPP Jan 27, 2020 PED Jul 27, 2020 PED Jul 27, 2020

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 004 9555027 May 26, 2026 DP U-543

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 005 9555027 May 26, 2026 DP U-543 M-195 Jan 27, 2020 NPP Jan 27, 2020 PED Jul 27, 2020 PED Jul 27, 2020 A - 29 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LURASIDONE HYDROCHLORIDE - LATUDA N 200603 005 9555027 May 26, 2026 DP U-543 M-195 Jan 27, 2020 NPP Jan 27, 2020 PED Jul 27, 2020 PED Jul 27, 2020

MARAVIROC - SELZENTRY N 022128 001 NPP Nov 04, 2019 NS Nov 04, 2019

MARAVIROC - SELZENTRY N 022128 002 NPP Nov 04, 2019 NS Nov 04, 2019

MARAVIROC - SELZENTRY N 022128 003 6586430 Dec 01, 2019 DS DP U-824 NPP Nov 04, 2019 6667314 Aug 06, 2021 DS DP U-824 NS Nov 04, 2019 7368460 Nov 25, 2022 U-824 7576097 May 25, 2021 DS

MARAVIROC - SELZENTRY N 022128 004 6586430 Dec 01, 2019 DS DP U-824 NPP Nov 04, 2019 6667314 Aug 06, 2021 DS DP U-824 NS Nov 04, 2019 7368460 Nov 25, 2022 U-824 7576097 May 25, 2021 DS

MARAVIROC - SELZENTRY N 208984 001 NP Nov 04, 2019

MELOXICAM - VIVLODEX N 207233 001 9649318 Mar 31, 2035 DP

MELOXICAM - VIVLODEX N 207233 002 9649318 Mar 31, 2035 DP

MELPHALAN HYDROCHLORIDE - EVOMELA N 207155 001 9493582 Feb 27, 2033 DP

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR N 200678 001 M-198 Feb 27, 2020

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR N 200678 002 9339472 Jul 13, 2025 DP M-198 Feb 27, 2020

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR N 200678 003 9339472 Jul 13, 2025 DP M-198 Feb 27, 2020

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET N 022044 001 6303661 Apr 24, 2017 U-1996 6890898 Feb 02, 2019 U-1996 7078381 Feb 02, 2019 U-1996 7459428 Feb 02, 2019 U-1996

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET N 022044 002 6303661 Apr 24, 2017 U-1996 6890898 Feb 02, 2019 U-1996 7078381 Feb 02, 2019 U-1996 7459428 Feb 02, 2019 U-1996

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR N 202270 001 6303661 Apr 24, 2017 U-1996 6890898 Feb 02, 2019 U-1996 A - 30 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR N 202270 001 7078381 Feb 02, 2019 U-1996 7459428 Feb 02, 2019 U-1996

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR N 202270 002 6303661 Apr 24, 2017 U-1996 6890898 Feb 02, 2019 U-1996 7078381 Feb 02, 2019 U-1996 7459428 Feb 02, 2019 U-1996

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR N 202270 003 6303661 Apr 24, 2017 U-1996 6890898 Feb 02, 2019 U-1996 7078381 Feb 02, 2019 U-1996 7459428 Feb 02, 2019 U-1996

METHOTREXATE - OTREXUP N 204824 001 9533102 Jan 24, 2026 DP 9629959 Jan 24, 2026 DP

METHOTREXATE - OTREXUP N 204824 002 9533102 Jan 24, 2026 DP 9629959 Jan 24, 2026 DP

METHOTREXATE - OTREXUP N 204824 003 9533102 Jan 24, 2026 DP 9629959 Jan 24, 2026 DP

METHOTREXATE - OTREXUP N 204824 004 9533102 Jan 24, 2026 DP 9629959 Jan 24, 2026 DP

METHOTREXATE - OTREXUP N 204824 005 9533102 Jan 24, 2026 DP 9629959 Jan 24, 2026 DP

METHOTREXATE - OTREXUP N 204824 006 9533102 Jan 24, 2026 DP 9629959 Jan 24, 2026 DP

METHOTREXATE - OTREXUP N 204824 007 9533102 Jan 24, 2026 DP 9629959 Jan 24, 2026 DP

METHOTREXATE - OTREXUP N 204824 008 9533102 Jan 24, 2026 DP 9629959 Jan 24, 2026 DP

METHOTREXATE SODIUM - XATMEP N 208400 001 9259427 Jan 02, 2033 DP >A> ODE Apr 25, 2024 >A> ODE Apr 25, 2024

METHYLNALTREXONE BROMIDE - RELISTOR N 021964 001 9669096 Apr 08, 2024 DP

METHYLNALTREXONE BROMIDE - RELISTOR N 021964 002 9669096 Apr 08, 2024 DP

METHYLNALTREXONE BROMIDE - RELISTOR N 021964 003 9669096 Apr 08, 2024 DP A - 31 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

METHYLNALTREXONE BROMIDE - RELISTOR N 208271 001 >A> 9724343 Sep 30, 2029 DP U-1185

METHYLPHENIDATE - DAYTRANA N 021514 001 9668981 Oct 07, 2025 U-2024

METHYLPHENIDATE - DAYTRANA N 021514 002 9668981 Oct 07, 2025 U-2024

METHYLPHENIDATE - DAYTRANA N 021514 003 9668981 Oct 07, 2025 U-2024

METHYLPHENIDATE - DAYTRANA N 021514 004 9668981 Oct 07, 2025 U-2024

METHYLPHENIDATE - COTEMPLA XR-ODT N 205489 001 >A> 8840924 Jun 05, 2026 DP NP Jun 19, 2020 >A> 9072680 Jun 28, 2032 DP >A> 9089496 Jun 28, 2032 DP

METHYLPHENIDATE - COTEMPLA XR-ODT N 205489 002 >A> 8840924 Jun 05, 2026 DP NP Jun 19, 2020 >A> 9072680 Jun 28, 2032 DP >A> 9089496 Jun 28, 2032 DP

METHYLPHENIDATE - COTEMPLA XR-ODT N 205489 003 >A> 8840924 Jun 05, 2026 DP NP Jun 19, 2020 >A> 9072680 Jun 28, 2032 DP >A> 9089496 Jun 28, 2032 DP

METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 001 9545399 Aug 14, 2033 DP U-1827

METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 002 9545399 Aug 14, 2033 DP U-1827

METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 003 9545399 Aug 14, 2033 DP U-1827

MIDOSTAURIN - RYDAPT N 207997 001 7973031 Oct 17, 2024 U-2007 NCE Apr 28, 2022 8222244 Oct 29, 2022 U-2007 ODE Apr 28, 2024 8575146 Dec 02, 2030 U-2008 ODE Apr 28, 2024

MORPHINE SULFATE - ARYMO ER N 208603 001 9044402 Jul 01, 2033 DP U-1556 9549899 Jul 01, 2033 DP U-1556

MORPHINE SULFATE - ARYMO ER N 208603 002 9044402 Jul 01, 2033 DP U-1556 9549899 Jul 01, 2033 DP U-1556

MORPHINE SULFATE - ARYMO ER N 208603 003 9044402 Jul 01, 2033 DP U-1556 9549899 Jul 01, 2033 DP U-1556

NALDEMEDINE TOSYLATE - SYMPROIC N 208854 001 9108975 Nov 11, 2031 DS DP NCE Mar 23, 2022 RE46365 Jan 11, 2028 DS DP RE46375 Oct 05, 2026 DS DP U-1185 A - 32 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

NALOXONE HYDROCHLORIDE - NARCAN N 208411 001 9211253 Mar 16, 2035 DP 9561177 Mar 16, 2035 DP U-1903 9629965 Mar 16, 2035 DP U-1903

NALOXONE HYDROCHLORIDE - NARCAN N 208411 002 9480644 Mar 16, 2035 DP U-1903 >A> 9707226 Mar 16, 2035 DP U-1903

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ N 205777 001 9555000 Apr 04, 2023 DP U-1556

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ N 205777 002 9555000 Apr 04, 2023 DP U-1556

NEPAFENAC - ILEVRO N 203491 001 9662398 Dec 01, 2030 DP

NERATINIB MALEATE - NERLYNX N 208051 001 >A> 6288082 Sep 24, 2019 DS DP U-2043 >A> NCE Jul 17, 2022 >A> 7399865 Dec 29, 2025 DS DP >A> 7982043 Oct 08, 2025 U-2043 >A> 8518446 Nov 20, 2030 DP U-2043 >A> 8790708 Nov 05, 2030 DP U-2043 >A> 9139558 Oct 15, 2028 U-2043 >A> 9211291 Mar 24, 2030 U-2043 >A> 9630946 Oct 15, 2028 U-2043

NIRAPARIB TOSYLATE - ZEJULA N 208447 001 8071623 Mar 22, 2030 DS DP NCE Mar 27, 2022 8436185 Apr 24, 2029 DS ODE Mar 27, 2024

NUSINERSEN SODIUM - SPINRAZA N 209531 001 6166197 Dec 26, 2017 DS ODE Dec 23, 2023 6210892 Oct 07, 2018 U-1942 7101993 Sep 05, 2023 DS 7838657 Jul 11, 2027 DS 8110560 Dec 05, 2025 U-1942 8110560 Dec 05, 2025 U-1943 8110560 Dec 05, 2025 U-1944 8361977 May 27, 2030 DS DP 8980853 Nov 24, 2030 U-1941

OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT N 203108 001 8733341 Oct 16, 2030 DP

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT N 206756 001 6149054 Dec 19, 2016 DP 6149054*PED Jun 19, 2017 6846413 Aug 28, 2018 DP 6846413*PED Feb 28, 2019 6977042 Aug 28, 2018 DP 6977042*PED Feb 28, 2019 6988496 Feb 23, 2020 DP 6988496*PED Aug 23, 2020 7284474 Aug 26, 2024 DP 7284474*PED Feb 26, 2025 7396341 Oct 10, 2026 DP 7396341*PED Apr 10, 2027 7802568 Feb 26, 2019 DP 7802568*PED Aug 26, 2019 7837235 Mar 13, 2028 DP 7837235*PED Sep 13, 2028 8733341 Oct 16, 2030 DP A - 33 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE A 090848 001 PC Dec 05, 2017

OLOPATADINE HYDROCHLORIDE - PAZEO N 206276 001 9533053 May 19, 2032 DP

OMACETAXINE MEPESUCCINATE - SYNRIBO N 203585 001 6987103 Oct 26, 2026 U-1300

OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE N 207931 001 I-743 Jul 24, 2018

OMEGA-3-CARBOXYLIC ACIDS - EPANOVA N 205060 001 5792795 May 13, 2018 DP 5948818 May 13, 2018 DP

ORITAVANCIN DIPHOSPHATE - ORBACTIV N 206334 001 9649352 Jul 16, 2035 DP >A> 9682061 Apr 26, 2030 U-1569

OSPEMIFENE - OSPHENA N 203505 001 6245819 Jul 21, 2020 U-1370 9566252 Jul 21, 2020 U-1370

OXYCODONE - XTAMPZA ER N 208090 001 9592200 Jul 07, 2023 DP 9682075 Dec 10, 2030 DP U-1556

OXYCODONE - XTAMPZA ER N 208090 002 9592200 Jul 07, 2023 DP 9682075 Dec 10, 2030 DP U-1556

OXYCODONE - XTAMPZA ER N 208090 003 9592200 Jul 07, 2023 DP 9682075 Dec 10, 2030 DP U-1556

OXYCODONE - XTAMPZA ER N 208090 004 9592200 Jul 07, 2023 DP 9682075 Dec 10, 2030 DP U-1556

OXYCODONE - XTAMPZA ER N 208090 005 9592200 Jul 07, 2023 DP 9682075 Dec 10, 2030 DP U-1556 A - 34 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

OXYCODONE - XTAMPZA ER N 208090 005 9592200 Jul 07, 2023 DP 9682075 Dec 10, 2030 DP U-1556

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 001 >A> 9675610 Jun 16, 2023 DP

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 002 >A> 9675610 Jun 16, 2023 DP

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 003 >A> 9675610 Jun 16, 2023 DP

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 004 >A> 9675610 Jun 16, 2023 DP

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 005 >A> 9675610 Jun 16, 2023 DP

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 006 >A> 9675610 Jun 16, 2023 DP

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 007 >A> 9675610 Jun 16, 2023 DP

OXYCODONE HYDROCHLORIDE - OXAYDO N 202080 001 9492443 May 26, 2024 DP

OXYCODONE HYDROCHLORIDE - OXAYDO N 202080 002 9492443 May 26, 2024 DP

OXYCODONE HYDROCHLORIDE - ROXYBOND N 209777 001 7955619 Aug 12, 2028 DP

OXYCODONE HYDROCHLORIDE - ROXYBOND N 209777 002 7955619 Aug 12, 2028 DP

OXYCODONE HYDROCHLORIDE - ROXYBOND N 209777 003 7955619 Aug 12, 2028 DP

OXYMETAZOLINE HYDROCHLORIDE - RHOFADE N 208552 001 7812049 May 02, 2028 U-1959 NP Jan 18, 2020 8420688 Aug 02, 2024 U-1959 8883838 Dec 01, 2031 DP

PACLITAXEL - ABRAXANE N 021660 001 9393318 Mar 04, 2032 U-1290 9511046 Jan 12, 2034 U-1434 9597409 Mar 04, 2032 U-1290

PALBOCICLIB - IBRANCE N 207103 001 7456168 Jan 16, 2023 U-1998

PALBOCICLIB - IBRANCE N 207103 002 7456168 Jan 16, 2023 U-1998

PALBOCICLIB - IBRANCE N 207103 003 7456168 Jan 16, 2023 U-1998 A - 35 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

PALONOSETRON HYDROCHLORIDE - ALOXI N 021372 001 9439854 Jan 30, 2024 DP 9439854*PED Jul 30, 2024

PALONOSETRON HYDROCHLORIDE - ALOXI N 021372 002 9439854 Jan 30, 2024 DP 9439854*PED Jul 30, 2024

PERFLUTREN - DEFINITY N 021064 001 9545457 Jan 13, 2019 U-665

PIMAVANSERIN TARTRATE - NUPLAZID N 207318 001 9566271 Jan 15, 2024 U-1974

PIRFENIDONE - ESBRIET N 208780 001 >A> 7566729 Apr 22, 2029 U-2077 NCE Oct 16, 2019 >A> 7566729 Apr 22, 2029 U-2078 ODE Oct 15, 2021 >A> 7635707 Apr 22, 2029 U-2072 >A> 7635707 Apr 22, 2029 U-2073 >A> 7635707 Apr 22, 2029 U-2074 >A> 7635707 Apr 22, 2029 U-2075 >A> 7635707 Apr 22, 2029 U-2076 >A> 7635707 Apr 22, 2029 U-2083 >A> 7767700 Dec 18, 2027 U-2080 >A> 7816383 Jan 08, 2030 U-2042 >A> 7816383 Jan 08, 2030 U-2050 >A> 7910610 Jan 08, 2030 U-2048 >A> 7910610 Jan 08, 2030 U-2049 >A> 8013002 Jan 08, 2030 U-2047 >A> 8013002 Jan 08, 2030 U-2082 >A> 8084475 Jan 08, 2030 U-2052 >A> 8084475 Jan 08, 2030 U-2054 >A> 8318780 Jan 08, 2030 U-2046 >A> 8318780 Jan 08, 2030 U-2081 >A> 8383150 Sep 22, 2026 DP U-1607 >A> 8420674 Dec 18, 2017 U-2079 >A> 8592462 Apr 22, 2029 U-2055 >A> 8592462 Apr 22, 2029 U-2056 >A> 8592462 Apr 22, 2029 U-2057 >A> 8592462 Apr 22, 2029 U-2058 >A> 8592462 Apr 22, 2029 U-2059 >A> 8592462 Apr 22, 2029 U-2060 >A> 8592462 Apr 22, 2029 U-2061 >A> 8592462 Apr 22, 2029 U-2062 >A> 8592462 Apr 22, 2029 U-2063 >A> 8609701 Apr 22, 2029 U-2064 >A> 8609701 Apr 22, 2029 U-2065 >A> 8609701 Apr 22, 2029 U-2066 >A> 8609701 Apr 22, 2029 U-2067 >A> 8609701 Apr 22, 2029 U-2068 >A> 8609701 Apr 22, 2029 U-2069 >A> 8609701 Apr 22, 2029 U-2070 >A> 8648098 Jan 08, 2030 U-2051 >A> 8648098 Jan 08, 2030 U-2052 >A> 8754109 Jan 08, 2030 U-2053 >A> 8778947 Aug 30, 2033 U-2044 >A> 8778947 Aug 30, 2033 U-2045 >A> 9561217 Jan 25, 2022 DP

PIRFENIDONE - ESBRIET N 208780 002 NCE Oct 16, 2019 ODE Oct 15, 2021 A - 36 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

PIRFENIDONE - ESBRIET N 208780 003 >A> 7566729 Apr 22, 2029 U-2077 NCE Oct 16, 2019 >A> 7566729 Apr 22, 2029 U-2078 ODE Oct 15, 2021 >A> 7635707 Apr 22, 2029 U-2072 >A> 7635707 Apr 22, 2029 U-2073 >A> 7635707 Apr 22, 2029 U-2074 >A> 7635707 Apr 22, 2029 U-2075 >A> 7635707 Apr 22, 2029 U-2076 >A> 7635707 Apr 22, 2029 U-2083 >A> 7767700 Dec 18, 2027 U-2080 >A> 7816383 Jan 08, 2030 U-2042 >A> 7816383 Jan 08, 2030 U-2050 >A> 7910610 Jan 08, 2030 U-2048 >A> 7910610 Jan 08, 2030 U-2049 >A> 8013002 Jan 08, 2030 U-2047 >A> 8013002 Jan 08, 2030 U-2082 >A> 8084475 Jan 08, 2030 U-2052 >A> 8084475 Jan 08, 2030 U-2054 >A> 8318780 Jan 08, 2030 U-2046 >A> 8318780 Jan 08, 2030 U-2081 >A> 8383150 Sep 22, 2026 DP U-1607 >A> 8420674 Dec 18, 2017 U-2079 >A> 8592462 Apr 22, 2029 U-2055 >A> 8592462 Apr 22, 2029 U-2056 >A> 8592462 Apr 22, 2029 U-2057 >A> 8592462 Apr 22, 2029 U-2058 >A> 8592462 Apr 22, 2029 U-2059 >A> 8592462 Apr 22, 2029 U-2060 >A> 8592462 Apr 22, 2029 U-2061 >A> 8592462 Apr 22, 2029 U-2062 >A> 8592462 Apr 22, 2029 U-2063 >A> 8609701 Apr 22, 2029 U-2064 >A> 8609701 Apr 22, 2029 U-2065 >A> 8609701 Apr 22, 2029 U-2066 >A> 8609701 Apr 22, 2029 U-2067 >A> 8609701 Apr 22, 2029 U-2068 >A> 8609701 Apr 22, 2029 U-2069 >A> 8609701 Apr 22, 2029 U-2070 >A> 8648098 Jan 08, 2030 U-2051 >A> 8648098 Jan 08, 2030 U-2052 >A> 8754109 Jan 08, 2030 U-2053 >A> 8778947 Aug 30, 2033 U-2044 >A> 8778947 Aug 30, 2033 U-2045 >A> 9561217 Jan 25, 2022 DP

PLECANATIDE - TRULANCE N 208745 001 7041786 Mar 25, 2023 DS NCE Jan 19, 2022 7799897 Jun 09, 2022 DS 8637451 Mar 28, 2022 U-1964 9610321 Sep 11, 2031 U-1999 9616097 Jul 02, 2032 DP

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 001 9493470 Dec 12, 2033 DS DP U-1700 9493470 Dec 12, 2033 DS DP U-1948

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 002 9493470 Dec 12, 2033 DS DP U-1700 9493470 Dec 12, 2033 DS DP U-1948

PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 003 8114874 Dec 22, 2026 DS DP 9493470 Dec 12, 2033 DS DP U-1700 9493470 Dec 12, 2033 DS DP U-1948 A - 37 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

PREDNISONE - RAYOS N 202020 001 9504699 Aug 03, 2027 U-1362

PREDNISONE - RAYOS N 202020 002 9504699 Aug 03, 2027 U-1362

RALTEGRAVIR POTASSIUM - ISENTRESS N 022145 001 >A> 7169780 Oct 03, 2023 DS DP >A> D-167 May 26, 2020 >A> 7169780*PED Apr 03, 2024 >A> PED Nov 26, 2020 >A> 7217713 Oct 21, 2022 U-257 >A> 7217713*PED Apr 21, 2023 >A> 7435734 Oct 21, 2022 U-257 >A> 7435734 Oct 21, 2022 U-900 >A> 7435734*PED Apr 21, 2023 >A> 7754731 Mar 11, 2029 DS DP U-257 >A> 7754731*PED Sep 11, 2029

RALTEGRAVIR POTASSIUM - ISENTRESS HD N 022145 002 >A> 7169780 Oct 03, 2023 DS DP >A> NS May 26, 2020 >A> 7169780*PED Apr 03, 2024 >A> PED Nov 26, 2020 >A> 7217713 Oct 21, 2022 U-257 >A> 7217713*PED Apr 21, 2023 >A> 7435734 Oct 21, 2022 U-257 >A> 7435734 Oct 21, 2022 U-900 >A> 7435734*PED Apr 21, 2023 >A> 7754731 Mar 11, 2029 DS DP U-257 >A> 7754731*PED Sep 11, 2029 >A> 9649311 Oct 21, 2030 DP >A> 9649311*PED Apr 21, 2031

RALTEGRAVIR POTASSIUM - ISENTRESS N 203045 001 >A> 7169780 Oct 03, 2023 DS DP >A> 7169780*PED Apr 03, 2024 >A> 7217713 Oct 21, 2022 U-257 >A> 7217713*PED Apr 21, 2023 >A> 7435734 Oct 21, 2022 U-257 >A> 7435734*PED Apr 21, 2023 >A> 7754731 Mar 11, 2029 DS DP U-257 >A> 7754731*PED Sep 11, 2029

RALTEGRAVIR POTASSIUM - ISENTRESS N 203045 002 >A> 7169780 Oct 03, 2023 DS DP >A> 7169780*PED Apr 03, 2024 >A> 7217713 Oct 21, 2022 U-257 >A> 7217713*PED Apr 21, 2023 >A> 7435734 Oct 21, 2022 U-257 >A> 7435734*PED Apr 21, 2023 >A> 7754731 Mar 11, 2029 DS DP U-257 >A> 7754731*PED Sep 11, 2029

RALTEGRAVIR POTASSIUM - ISENTRESS N 205786 001 >A> 7169780 Oct 03, 2023 DS DP >A> 7169780*PED Apr 03, 2024 >A> 7217713 Oct 21, 2022 U-257 >A> 7217713*PED Apr 21, 2023 >A> 7435734 Oct 21, 2022 U-257 >A> 7435734*PED Apr 21, 2023 >A> 7754731 Mar 11, 2029 DS DP U-257 >A> 7754731*PED Sep 11, 2029

RASAGILINE MESYLATE - RASAGILINE MESYLATE A 201823 001 PC Jul 01, 2017 A - 38 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

RASAGILINE MESYLATE - RASAGILINE MESYLATE A 201823 002 PC Jul 01, 2017

RASAGILINE MESYLATE - RASAGILINE MESYLATE A 201950 001 PC Jul 01, 2017

RASAGILINE MESYLATE - RASAGILINE MESYLATE A 201950 002 PC Jul 01, 2017

REGADENOSON - LEXISCAN N 022161 001 M-194 Jan 17, 2020

REGORAFENIB - STIVARGA N 203085 001 7351834 Jun 28, 2022 DS I-744 Apr 27, 2020 ODE Apr 27, 2024

RIBOCICLIB SUCCINATE - KISQALI N 209092 001 8324225 Jun 17, 2028 DS DP NCE Mar 13, 2022 8415355 Feb 19, 2031 DS DP 8685980 May 25, 2030 DS DP 8962630 Dec 09, 2029 U-1981 9193732 Nov 09, 2031 DS DP 9416136 Aug 20, 2029 U-1981

RIFAXIMIN - XIFAXAN N 022554 001 9629828 Jul 24, 2029 U-1994

RIVAROXABAN - XARELTO N 022406 001 9539218 Feb 17, 2034 U-1953 9539218 Feb 17, 2034 U-1954 9539218 Feb 17, 2034 U-1955 9539218 Feb 17, 2034 U-1956 9539218 Feb 17, 2034 U-1957

RIVAROXABAN - XARELTO N 022406 002 9539218 Feb 17, 2034 U-1953 9539218 Feb 17, 2034 U-1954 9539218 Feb 17, 2034 U-1955 9539218 Feb 17, 2034 U-1956 9539218 Feb 17, 2034 U-1957

RIVAROXABAN - XARELTO N 022406 003 9539218 Feb 17, 2034 U-1953 9539218 Feb 17, 2034 U-1954 9539218 Feb 17, 2034 U-1955 9539218 Feb 17, 2034 U-1957

ROLAPITANT HYDROCHLORIDE - VARUBI N 206500 001 8404702 Apr 04, 2027 U-1741

ROPINIROLE HYDROCHLORIDE - REQUIP XL N 022008 001 M-203 Mar 23, 2020

ROPINIROLE HYDROCHLORIDE - REQUIP XL N 022008 002 M-203 Mar 23, 2020

ROPINIROLE HYDROCHLORIDE - REQUIP XL N 022008 003 M-203 Mar 23, 2020

ROPINIROLE HYDROCHLORIDE - REQUIP XL N 022008 004 M-203 Mar 23, 2020 A - 39 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ROPINIROLE HYDROCHLORIDE - REQUIP XL N 022008 005 M-203 Mar 23, 2020

ROPINIROLE HYDROCHLORIDE - REQUIP XL N 022008 006 M-203 Mar 23, 2020

RUCAPARIB CAMSYLATE - RUBRACA N 209115 001 7351701 Jul 23, 2024 U-2012 ODE Dec 19, 2023 7531530 Jul 23, 2024 U-2012 8071579 Aug 12, 2027 U-2012 8143241 Aug 12, 2027 U-2012 8859562 Aug 04, 2031 U-2012

RUCAPARIB CAMSYLATE - RUBRACA N 209115 002 7351701 Jul 23, 2024 U-2012 ODE Dec 19, 2023 7531530 Jul 23, 2024 U-2012 8071579 Aug 12, 2027 U-2012 8143241 Aug 12, 2027 U-2012 8859562 Aug 04, 2031 U-2012

RUCAPARIB CAMSYLATE - RUBRACA N 209115 003 6495541 Jan 10, 2020 DS DP 7351701 Jul 23, 2024 U-2012 7531530 Jul 23, 2024 U-2012 8071579 Aug 12, 2027 U-2012 8143241 Aug 12, 2027 U-2012 8754072 Feb 10, 2031 DS DP 8859562 Aug 04, 2031 U-2012 9045487 Feb 10, 2031 DS DP

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 001 9662335 Dec 12, 2026 DS

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 002 9662335 Dec 12, 2026 DS

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 003 9662335 Dec 12, 2026 DS

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 004 9662335 Dec 12, 2026 DS

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 005 9662335 Dec 12, 2026 DS

SACROSIDASE - SUCRAID N 020772 001 9469847 Feb 07, 2034 DS DP

SAFINAMIDE MESYLATE - XADAGO N 207145 001 8076515 Dec 10, 2028 DS DP U-1993 NCE Mar 21, 2022 8278485 Jun 08, 2027 DS U-1993 8283380 Sep 01, 2027 U-1993

SAFINAMIDE MESYLATE - XADAGO N 207145 002 8076515 Dec 10, 2028 DS DP U-1993 NCE Mar 21, 2022 8278485 Jun 08, 2027 DS U-1993 8283380 Sep 01, 2027 U-1993

SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA N 022350 001 M-198 Feb 27, 2020 A - 40 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA N 022350 002 M-198 Feb 27, 2020

SIMEPREVIR SODIUM - OLYSIO N 205123 001 9623022 Jul 28, 2026 U-1467

SIMVASTATIN - SIMVASTATIN N 206679 001 9597289 Feb 23, 2030 DP

SIMVASTATIN - SIMVASTATIN N 206679 002 9597289 Feb 23, 2030 DP

SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 001 6303661 Apr 24, 2017 U-1996 6890898 Feb 02, 2019 U-1997 7078381 Feb 02, 2019 U-1997 7459428 Feb 02, 2019 U-1945

SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 002 6303661 Apr 24, 2017 U-1996 6890898 Feb 02, 2019 U-1997 7078381 Feb 02, 2019 U-1997 7459428 Feb 02, 2019 U-1945

SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 003 6303661 Apr 24, 2017 U-1996 6890898 Feb 02, 2019 U-1997 7078381 Feb 02, 2019 U-1997 7459428 Feb 02, 2019 U-1945

SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE N 201444 001 9345724 Mar 29, 2031 DS DP U-2015 9585912 Mar 29, 2031 DS DP

SODIUM OXYBATE - XYREM N 021196 001 9539330 Dec 22, 2019 DP

SODIUM THIOSULFATE - SODIUM THIOSULFATE N 203923 001 9345724 Mar 29, 2031 DS DP U-2015 9585912 Mar 29, 2031 DS DP

SOFOSBUVIR - SOVALDI N 204671 001 9549941 Mar 26, 2029 U-1958 NPP Apr 07, 2020 ODE Apr 07, 2024

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI N 209195 001 >A> 7964580 Mar 26, 2029 DS DP U-2039 >A> NCE Dec 06, 2018 >A> 7964580 Mar 26, 2029 DS DP U-2040 >A> NCE Jun 28, 2021 >A> 8334270 Mar 21, 2028 DS DP U-2039 >A> NCE Jul 18, 2022 >A> 8334270 Mar 21, 2028 DS DP U-2040 >A> 8575135 Nov 05, 2033 DS DP U-2039 >A> 8575135 Nov 05, 2033 DS DP U-2040 >A> 8580765 Mar 21, 2028 DS DP U-2039 >A> 8580765 Mar 21, 2028 DS DP U-2040 >A> 8618076 Dec 11, 2030 DS DP U-2039 >A> 8618076 Dec 11, 2030 DS DP U-2040 >A> 8633309 Mar 26, 2029 DS DP U-2039 >A> 8633309 Mar 26, 2029 DS DP U-2040 >A> 8735372 Mar 21, 2028 DS DP U-2039 >A> 8735372 Mar 21, 2028 DS DP U-2040 >A> 8889159 Mar 26, 2029 DS DP U-2039 >A> 8889159 Mar 26, 2029 DS DP U-2040 >A> 8921341 Nov 16, 2032 DS DP U-2039 A - 41 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI N 209195 001 >A> 8921341 Nov 16, 2032 DS DP U-2040 >A> 8940718 Nov 16, 2032 DS DP U-2039 >A> 8940718 Nov 16, 2032 DS DP U-2040 >A> 9085573 Mar 21, 2028 DS DP U-2039 >A> 9085573 Mar 21, 2028 DS DP U-2040 >A> 9284342 Sep 13, 2030 DS DP U-2039 >A> 9284342 Sep 13, 2030 DS DP U-2040 >A> 9296782 Jul 17, 2034 DS DP >A> 9585906 Mar 21, 2028 DS DP U-2039 >A> 9585906 Mar 21, 2028 DS DP U-2040

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 008 RE46363 Aug 03, 2026 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 009 RE46363 Aug 03, 2026 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 010 RE46363 Aug 03, 2026 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 011 RE46363 Aug 03, 2026 DP

SUCROFERRIC OXYHYDROXIDE - VELPHORO N 205109 001 9561251 Jan 23, 2030 DP U-1468

SUMATRIPTAN SUCCINATE - ONZETRA XSAIL N 206099 001 9649456 Oct 21, 2030 DP U-1719 9649456 Oct 21, 2030 DP U-2010 9649456 Oct 21, 2030 DP U-2011

TACROLIMUS - ENVARSUS XR N 206406 001 9549918 May 30, 2028 DP

TACROLIMUS - ENVARSUS XR N 206406 002 9549918 May 30, 2028 DP

TACROLIMUS - ENVARSUS XR N 206406 003 9549918 May 30, 2028 DP

TALC - STERITALC N 205555 001 >A> ODE May 01, 2024

TALC - STERITALC N 205555 002 >A> ODE May 01, 2024

TALC - STERITALC N 205555 003 >A> ODE May 01, 2024

TASIMELTEON - HETLIOZ N 205677 001 9539234 Jan 25, 2033 U-1934 9549913 Jan 25, 2033 U-1486

TAVABOROLE - KERYDIN N 204427 001 7582621 May 26, 2027 U-2016 9549938 Feb 16, 2026 U-1951 9566289 Feb 16, 2026 DP 9566290 Feb 16, 2026 U-1970 9572823 Feb 16, 2026 U-1970 A - 42 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TEDUGLUTIDE RECOMBINANT - GATTEX KIT N 203441 001 9539310 Nov 01, 2025 U-1320 9545434 Nov 01, 2025 U-1320 9545435 Nov 01, 2025 U-1320 9555079 Nov 01, 2025 U-1320 9572867 Nov 01, 2025 U-1320 9592273 Nov 01, 2025 U-1320 9592274 Nov 01, 2025 U-1320

TELOTRISTAT ETIPRATE - XERMELO N 208794 001 7553840 Dec 11, 2027 DS NCE Feb 28, 2022 7709493 Dec 11, 2027 DS U-1979 ODE Feb 28, 2024 7968559 Dec 11, 2027 U-1979 8193204 Feb 27, 2031 DS 8653094 Dec 19, 2028 U-1979

TESTOSTERONE - VOGELXO N 204399 002 >A> 9662340 Feb 11, 2034 DP U-1531

TESTOSTERONE - VOGELXO N 204399 003 >A> 9662340 Feb 11, 2034 DP U-1531

THIOTEPA - TEPADINA N 208264 001 >A> I-747 Jan 26, 2020 ODE Jan 26, 2024

THIOTEPA - TEPADINA N 208264 002 >A> I-747 Jan 26, 2020 ODE Jan 26, 2024

TICAGRELOR - BRILINTA N 022433 001 6525060 Dec 02, 2019 DS DP U-1171 Y 6525060 Dec 02, 2019 DS DP U-1860 Y 6525060 Dec 02, 2019 DS DP U-1862 Y 6525060 Dec 02, 2019 DS DP U-1863 Y >A> RE46276 Oct 30, 2024 DS DP U-1935 >A> RE46276 Oct 30, 2024 DS DP U-1936 >A> RE46276 Oct 30, 2024 DS DP U-1937 >A> RE46276 Oct 30, 2024 DS DP U-1938

TICAGRELOR - BRILINTA N 022433 002 6525060 Dec 02, 2019 DS DP U-1171 Y 6525060 Dec 02, 2019 DS DP U-1860 Y 6525060 Dec 02, 2019 DS DP U-1862 Y 6525060 Dec 02, 2019 DS DP U-1863 Y >A> RE46276 Oct 30, 2024 DS DP U-1935 >A> RE46276 Oct 30, 2024 DS DP U-1936 >A> RE46276 Oct 30, 2024 DS DP U-1937 >A> RE46276 Oct 30, 2024 DS DP U-1938

TIGECYCLINE - TYGACIL N 021821 001 >A> 9694078 Mar 13, 2026 DP

TIOTROPIUM BROMIDE - SPIRIVA N 021395 001 6777423 Sep 24, 2021 DS DP 6777423*PED Mar 24, 2022 6908928 Sep 24, 2021 DS DP U-566 6908928 Sep 24, 2021 DS DP U-762 6908928*PED Mar 24, 2022 7070800 Jan 22, 2022 DP U-566 7070800*PED Jul 22, 2022 7309707 Sep 24, 2021 DS DP 7309707*PED Mar 24, 2022 7642268 Sep 24, 2021 DS DP A - 43 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TIOTROPIUM BROMIDE - SPIRIVA N 021395 001 7642268*PED Mar 24, 2022 7694676 Mar 12, 2027 DP 7694676*PED Sep 12, 2027 8022082 Jan 19, 2026 DP U-1186 8022082*PED Jul 19, 2026 9010323 Apr 19, 2030 DP RE38912 Oct 11, 2021 DP RE38912*PED Apr 11, 2022 RE39820 Jan 30, 2018 DS DP U-566 RE39820*PED Jul 30, 2018

TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT N 021936 001 5964416 Oct 04, 2016 DP NPP Feb 15, 2020 5964416*PED Apr 04, 2017 PED Aug 15, 2020 6149054 Dec 16, 2016 DP 6149054*PED Jun 16, 2017 6176442*PED Dec 01, 2016 6453795 Dec 05, 2016 DP 6453795*PED Jun 05, 2017 6726124 Oct 04, 2016 DP 6726124*PED Apr 04, 2017 6846413 Aug 28, 2018 DP 6846413*PED Feb 28, 2019 6977042 Aug 28, 2018 DP 6977042*PED Feb 28, 2019 6988496 Feb 23, 2020 DP 6988496*PED Aug 23, 2020 7104470 Oct 04, 2016 DP 7104470*PED Apr 04, 2017 7246615*PED Dec 01, 2016 7284474 Aug 26, 2024 DP 7284474*PED Feb 26, 2025 7396341 Oct 10, 2026 DP 7396341*PED Apr 10, 2027 7802568 Feb 26, 2019 DP 7802568*PED Aug 26, 2019 7837235 Mar 13, 2028 DP 7837235*PED Sep 13, 2028 7896264 May 26, 2025 DP 7896264*PED Nov 26, 2025 7988001 Aug 04, 2021 DP 7988001*PED Feb 04, 2022 8733341 Oct 16, 2030 DP 8733341*PED Apr 16, 2031 RE39820 Jan 30, 2018 DS DP U-1593 RE39820*PED Jul 30, 2018

TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT N 021936 002 5964416 Oct 04, 2016 DP NPP Feb 15, 2020 6149054 Dec 16, 2016 DP PED Aug 15, 2020 6149054*PED Jun 16, 2017 6453795 Dec 05, 2016 DP 6726124 Oct 04, 2016 DP 6846413 Aug 28, 2018 DP 6846413*PED Feb 28, 2019 6977042 Aug 28, 2018 DP 6977042*PED Feb 28, 2019 6988496 Feb 23, 2020 DP 6988496*PED Aug 23, 2020 7104470 Oct 04, 2016 DP 7284474 Aug 26, 2024 DP 7284474*PED Feb 26, 2025 7396341 Oct 10, 2026 DP 7396341*PED Apr 10, 2027 7802568 Feb 26, 2019 DP 7802568*PED Aug 26, 2019 A - 44 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT N 021936 002 7837235 Mar 13, 2028 DP 7837235*PED Sep 13, 2028 7896264 May 26, 2025 DP 7896264*PED Nov 26, 2025 7988001 Aug 04, 2021 DP 7988001*PED Feb 04, 2022 8733341 Oct 16, 2030 DP 8733341*PED Apr 16, 2031 RE39820 Jan 30, 2018 DS DP RE39820*PED Jul 30, 2018

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 001 9527833 Jun 17, 2034 DS DP RE46284 Dec 16, 2026 U-1751

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 002 9527833 Jun 17, 2034 DS DP RE46284 Dec 16, 2026 U-1751

TOFACITINIB CITRATE - XELJANZ N 203214 001 RE41783 Dec 08, 2025 DS

TOFACITINIB CITRATE - XELJANZ XR N 208246 001 RE41783 Dec 08, 2025 DS

TOPIRAMATE - TROKENDI XR N 201635 001 8298576 Apr 04, 2028 DP U-106 8298576 Apr 04, 2028 DP U-1992 8298580 Nov 16, 2027 DP U-106 8298580 Nov 16, 2027 DP U-1992 8663683 Nov 16, 2027 DP U-106 8663683 Nov 16, 2027 DP U-1992 8877248 Nov 16, 2027 DP U-106 8877248 Nov 16, 2027 DP U-1992 8889191 Nov 16, 2027 U-106 8889191 Nov 16, 2027 U-1992 8992989 Nov 16, 2027 DP U-1675 8992989 Nov 16, 2027 DP U-1992 9549940 Nov 16, 2027 DP U-1675 9549940 Nov 16, 2027 DP U-1992 9555004 Nov 16, 2027 DP U-1675 9555004 Nov 16, 2027 DP U-1992 9622983 Nov 16, 2027 DP U-1675 9622983 Nov 16, 2027 DP U-1992

TOPIRAMATE - TROKENDI XR N 201635 002 8298576 Apr 04, 2028 DP U-106 8298576 Apr 04, 2028 DP U-1992 8298580 Nov 16, 2027 DP U-106 8298580 Nov 16, 2027 DP U-1992 8663683 Nov 16, 2027 DP U-106 8663683 Nov 16, 2027 DP U-1992 8877248 Nov 16, 2027 DP U-106 8877248 Nov 16, 2027 DP U-1992 8889191 Nov 16, 2027 U-106 8889191 Nov 16, 2027 U-1992 8992989 Nov 16, 2027 DP U-1675 8992989 Nov 16, 2027 DP U-1992 9549940 Nov 16, 2027 DP U-1675 9549940 Nov 16, 2027 DP U-1992 9555004 Nov 16, 2027 DP U-1675 9555004 Nov 16, 2027 DP U-1992 9622983 Nov 16, 2027 DP U-1675 9622983 Nov 16, 2027 DP U-1992 A - 45 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TOPIRAMATE - TROKENDI XR N 201635 003 8298576 Apr 04, 2028 DP U-106 8298576 Apr 04, 2028 DP U-1992 8298580 Nov 16, 2027 DP U-106 8298580 Nov 16, 2027 DP U-1992 8663683 Nov 16, 2027 DP U-106 8663683 Nov 16, 2027 DP U-1992 8877248 Nov 16, 2027 DP U-106 8877248 Nov 16, 2027 DP U-1992 8889191 Nov 16, 2027 U-106 8889191 Nov 16, 2027 U-1992 8992989 Nov 16, 2027 DP U-1675 8992989 Nov 16, 2027 DP U-1992 9549940 Nov 16, 2027 DP U-1675 9549940 Nov 16, 2027 DP U-1992 9555004 Nov 16, 2027 DP U-1675 9555004 Nov 16, 2027 DP U-1992 9622983 Nov 16, 2027 DP U-1675 9622983 Nov 16, 2027 DP U-1992

TOPIRAMATE - TROKENDI XR N 201635 004 8298576 Apr 04, 2028 DP U-106 8298576 Apr 04, 2028 DP U-1992 8298580 Nov 16, 2027 DP U-106 8298580 Nov 16, 2027 DP U-1992 8663683 Nov 16, 2027 DP U-106 8663683 Nov 16, 2027 DP U-1992 8877248 Nov 16, 2027 DP U-106 8877248 Nov 16, 2027 DP U-1992 8889191 Nov 16, 2027 U-106 8889191 Nov 16, 2027 U-1992 8992989 Nov 16, 2027 DP U-1675 8992989 Nov 16, 2027 DP U-1992 9549940 Nov 16, 2027 DP U-1675 9549940 Nov 16, 2027 DP U-1992 9555004 Nov 16, 2027 DP U-1675 9555004 Nov 16, 2027 DP U-1992 9622983 Nov 16, 2027 DP U-1675 9622983 Nov 16, 2027 DP U-1992

TOPIRAMATE - QUDEXY XR N 205122 001 9555005 Mar 19, 2033 DP

TOPIRAMATE - QUDEXY XR N 205122 002 9555005 Mar 19, 2033 DP A - 46 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TOPIRAMATE - QUDEXY XR N 205122 003 9555005 Mar 19, 2033 DP

TOPIRAMATE - QUDEXY XR N 205122 004 9555005 Mar 19, 2033 DP

TOPIRAMATE - QUDEXY XR N 205122 005 9555005 Mar 19, 2033 DP

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 001 >A> 8703781 Oct 15, 2030 DS DP U-1712 I-745 Jun 22, 2020 >A> 8703781 Oct 15, 2030 DS DP U-2033 >A> ODE Jun 22, 2024 >A> 8835443 Sep 13, 2025 U-1581 >A> 8835443 Sep 13, 2025 U-1582 >A> 8835443 Sep 13, 2025 U-2020 >A> 8835443 Sep 13, 2025 U-2037 >A> 8952018 Oct 15, 2030 U-2020

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 002 >A> 8703781 Oct 15, 2030 DS DP U-1712 I-745 Jun 22, 2020 >A> 8703781 Oct 15, 2030 DS DP U-2033 >A> ODE Jun 22, 2024 >A> 8835443 Sep 13, 2025 U-1581 >A> 8835443 Sep 13, 2025 U-1582 >A> 8835443 Sep 13, 2025 U-2020 >A> 8835443 Sep 13, 2025 U-2037 >A> 8952018 Oct 15, 2030 U-2020 >A> 9155706 Jan 28, 2032 DP >A> 9271941 Jan 28, 2032 DP

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 003 >A> 8703781 Oct 15, 2030 DS DP U-1712 I-745 Jun 22, 2020 >A> 8703781 Oct 15, 2030 DS DP U-2033 >A> ODE Jun 22, 2024 >A> 8835443 Sep 13, 2025 U-1581 >A> 8835443 Sep 13, 2025 U-1582 >A> 8835443 Sep 13, 2025 U-2020 >A> 8835443 Sep 13, 2025 U-2037 >A> 8952018 Oct 15, 2030 U-2020

TREPROSTINIL - REMODULIN N 021272 001 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS >A> 9713599 Dec 16, 2024 U-2036

TREPROSTINIL - REMODULIN N 021272 002 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS >A> 9713599 Dec 16, 2024 U-2036

TREPROSTINIL - REMODULIN N 021272 003 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS >A> 9713599 Dec 16, 2024 U-2036

TREPROSTINIL - REMODULIN N 021272 004 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS >A> 9713599 Dec 16, 2024 U-2036

TREPROSTINIL - TYVASO N 022387 001 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS A - 47 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 001 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 002 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 003 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 004 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS

TREPROSTINIL DIOLAMINE - ORENITRAM N 203496 005 6765117 Oct 24, 2017 DS D-156 Jan 28, 2019 7417070 Jul 30, 2026 DS D-157 Jan 28, 2019 7544713 Jul 14, 2024 U-1475 8252839 May 24, 2024 DP 8349892 Jan 22, 2031 DP 8410169 Feb 13, 2030 DP 8497393 Dec 15, 2028 DS 8747897 Oct 08, 2029 DP 9050311 May 24, 2024 DS DP 9278901 May 24, 2024 U-1475 9393203 Apr 27, 2026 DP U-1877 9422223 May 24, 2024 DP 9593066 Dec 15, 2028 DS 9604901 Dec 15, 2028 DS

TRIPTORELIN PAMOATE - TRIPTODUR KIT N 208956 001 NP Jun 29, 2020 >A> ODE Jun 29, 2024

UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA N 205382 001 NCE Dec 18, 2018

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA N 203975 001 NCE May 10, 2018 NCE Dec 18, 2018

VALBENAZINE TOSYLATE - INGREZZA N 209241 001 8039627 Oct 06, 2029 DS DP NCE Apr 11, 2022 8357697 Nov 08, 2027 U-1995

VALGANCICLOVIR HYDROCHLORIDE - VALCYTE N 022257 001 9642911 Dec 11, 2027 DP

VASOPRESSIN - VASOSTRICT N 204485 001 9687526 Jan 30, 2035 U-1857

VASOPRESSIN - VASOSTRICT N 204485 002 9375478 Jan 30, 2035 U-1857 9687526 Jan 30, 2035 U-1857

ZICONOTIDE ACETATE - PRIALT N 021060 001 >A> 9707270 Oct 01, 2024 U-2084 A - 48 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2017 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ZICONOTIDE ACETATE - PRIALT N 021060 002 >A> 9707270 Oct 01, 2024 U-2084

ZICONOTIDE ACETATE - PRIALT N 021060 003 >A> 9707270 Oct 01, 2024 U-2084

ZICONOTIDE ACETATE - PRIALT N 021060 004 >A> 9707270 Oct 01, 2024 U-2084

ZOLPIDEM TARTRATE - EDLUAR N 021997 001 9265720 Feb 25, 2031 U-674 9597281 Apr 06, 2027 U-674

ZOLPIDEM TARTRATE - EDLUAR N 021997 002 9265720 Feb 25, 2031 U-674 9597281 Apr 06, 2027 U-674

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

B-1

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, APPROVED DRUG abbreviations and references have been developed.th Refer to the PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37 Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm